ID   ANKE1_HUMAN             Reviewed;         776 AA.
AC   Q9NU02; B3KUQ0; Q9H6Y9;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 2.
DT   22-FEB-2023, entry version 166.
DE   RecName: Full=Ankyrin repeat and EF-hand domain-containing protein 1;
DE   AltName: Full=Ankyrin repeat domain-containing protein 5;
GN   Name=ANKEF1; Synonyms=ANKRD5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-694.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- INTERACTION:
CC       Q9NU02; P55212: CASP6; NbExp=3; IntAct=EBI-8464238, EBI-718729;
CC       Q9NU02; P06307: CCK; NbExp=3; IntAct=EBI-8464238, EBI-6624398;
CC       Q9NU02; Q8N2M8: CLASRP; NbExp=3; IntAct=EBI-8464238, EBI-751069;
CC       Q9NU02; Q8NI60: COQ8A; NbExp=3; IntAct=EBI-8464238, EBI-745535;
CC       Q9NU02; P13473-2: LAMP2; NbExp=3; IntAct=EBI-8464238, EBI-21591415;
CC       Q9NU02; P07237: P4HB; NbExp=3; IntAct=EBI-8464238, EBI-395883;
CC       Q9NU02; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-8464238, EBI-5280197;
CC       Q9NU02; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-8464238, EBI-2623095;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15111.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK025322; BAB15111.1; ALT_INIT; mRNA.
DR   EMBL; AK097689; BAG53512.1; -; mRNA.
DR   EMBL; AL109754; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10355.1; -; Genomic_DNA.
DR   CCDS; CCDS13108.1; -.
DR   RefSeq; NP_001290401.1; NM_001303472.1.
DR   RefSeq; NP_071379.3; NM_022096.5.
DR   RefSeq; NP_942093.1; NM_198798.2.
DR   AlphaFoldDB; Q9NU02; -.
DR   SMR; Q9NU02; -.
DR   BioGRID; 121995; 13.
DR   IntAct; Q9NU02; 13.
DR   MINT; Q9NU02; -.
DR   STRING; 9606.ENSP00000367631; -.
DR   iPTMnet; Q9NU02; -.
DR   PhosphoSitePlus; Q9NU02; -.
DR   BioMuta; ANKEF1; -.
DR   DMDM; 20137528; -.
DR   MassIVE; Q9NU02; -.
DR   MaxQB; Q9NU02; -.
DR   PaxDb; Q9NU02; -.
DR   PeptideAtlas; Q9NU02; -.
DR   ProteomicsDB; 82647; -.
DR   Antibodypedia; 35178; 100 antibodies from 15 providers.
DR   DNASU; 63926; -.
DR   Ensembl; ENST00000378380.4; ENSP00000367631.3; ENSG00000132623.16.
DR   Ensembl; ENST00000378392.6; ENSP00000367644.1; ENSG00000132623.16.
DR   GeneID; 63926; -.
DR   KEGG; hsa:63926; -.
DR   MANE-Select; ENST00000378392.6; ENSP00000367644.1; NM_022096.6; NP_071379.3.
DR   UCSC; uc002wno.4; human.
DR   AGR; HGNC:15803; -.
DR   CTD; 63926; -.
DR   DisGeNET; 63926; -.
DR   GeneCards; ANKEF1; -.
DR   HGNC; HGNC:15803; ANKEF1.
DR   HPA; ENSG00000132623; Tissue enhanced (pancreas, testis).
DR   neXtProt; NX_Q9NU02; -.
DR   OpenTargets; ENSG00000132623; -.
DR   PharmGKB; PA24806; -.
DR   VEuPathDB; HostDB:ENSG00000132623; -.
DR   eggNOG; KOG4177; Eukaryota.
DR   GeneTree; ENSGT00940000156852; -.
DR   HOGENOM; CLU_020261_0_0_1; -.
DR   InParanoid; Q9NU02; -.
DR   OMA; EHKTPRA; -.
DR   OrthoDB; 3075304at2759; -.
DR   PhylomeDB; Q9NU02; -.
DR   TreeFam; TF351260; -.
DR   PathwayCommons; Q9NU02; -.
DR   SignaLink; Q9NU02; -.
DR   BioGRID-ORCS; 63926; 12 hits in 1150 CRISPR screens.
DR   GenomeRNAi; 63926; -.
DR   Pharos; Q9NU02; Tdark.
DR   PRO; PR:Q9NU02; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9NU02; protein.
DR   Bgee; ENSG00000132623; Expressed in sperm and 155 other tissues.
DR   Genevisible; Q9NU02; HS.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 3.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR002048; EF_hand_dom.
DR   PANTHER; PTHR24127; ANKYRIN REPEAT AND EF-HAND DOMAIN-CONTAINING PROTEIN 1; 1.
DR   PANTHER; PTHR24127:SF1; ANKYRIN REPEAT AND EF-HAND DOMAIN-CONTAINING PROTEIN 1; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF13637; Ank_4; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 11.
DR   SUPFAM; SSF48403; Ankyrin repeat; 2.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 6.
DR   PROSITE; PS50222; EF_HAND_2; 1.
PE   1: Evidence at protein level;
KW   ANK repeat; Reference proteome; Repeat.
FT   CHAIN           1..776
FT                   /note="Ankyrin repeat and EF-hand domain-containing protein
FT                   1"
FT                   /id="PRO_0000066899"
FT   REPEAT          47..76
FT                   /note="ANK 1"
FT   REPEAT          184..213
FT                   /note="ANK 2"
FT   REPEAT          217..246
FT                   /note="ANK 3"
FT   REPEAT          250..279
FT                   /note="ANK 4"
FT   DOMAIN          335..369
FT                   /note="EF-hand"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REPEAT          524..553
FT                   /note="ANK 5"
FT   REPEAT          557..586
FT                   /note="ANK 6"
FT   REPEAT          590..619
FT                   /note="ANK 7"
FT   REPEAT          623..652
FT                   /note="ANK 8"
FT   VARIANT         74
FT                   /note="P -> T (in dbSNP:rs7260784)"
FT                   /id="VAR_033500"
FT   VARIANT         324
FT                   /note="L -> Q (in dbSNP:rs652633)"
FT                   /id="VAR_024172"
FT   VARIANT         412
FT                   /note="G -> E (in dbSNP:rs524625)"
FT                   /id="VAR_033501"
FT   VARIANT         694
FT                   /note="K -> N (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035609"
FT   VARIANT         742
FT                   /note="R -> Q (in dbSNP:rs6087119)"
FT                   /id="VAR_033502"
SQ   SEQUENCE   776 AA;  86664 MW;  2F71F35AC4D337B6 CRC64;
     MALADKRLEN LQIYKVLQCV RNKDKKQIEK LTKLGYPELI NYTEPINGLS ALHLASVSND
     IDMVSFLLDL GAHPDVQDRM GCTPTMRAAE LGHELSMEIL AKAKADMTIV DNEGKGVLFY
     CILPTKRHYR CALIALEHGA DVNNSTYEGK PIFLRACEDA HDVKDVCLTF LEKGANPNAI
     NSSTGRTALM EASREGVVEI VRGILERGGE VNAFDNDRHH AAHFAAKGGF FDILKLLFAY
     NGDVGLISIN GNTPLHYAAM GGFADCCKYI AQRGCDLKWK NLDHKTPRAV AKEGGFKAAS
     KEIRRAERIA NKLARPGAKN PNPLWALRLH DWSVEREAFL REAFAVLDRG DGSISKNDFV
     MVLEERQDYA SSEQLAAIAH LHEKTRGGGV NINEFFKGTR YLNKSFVLGS YGPKKKEKGM
     GKKGKKGKFV LPLPICVIPE YAFPRRQDGG PPYYMIETYK NVTDSSRFNR DHPPEHPIQD
     DSVWYIDDSE KVFSNINIIT KAGDLASLKK AFESGIPVDM KDNYYKTPLM TACASGNIDV
     VKFLLEKGAN VNATDNFLWT PLHFACHAGQ QDIVELLVES GALIDAASIN NSTPLNRAIE
     SCRLDTVKYL LDIGAKFQLE NRKGHSAMDV AKAYADYRII DLIKEKLDNL PKPAENQKLK
     GKTPPILKTE GPEIKKEEEL LSSIYGVPTT SEGKKVQKGN VVHLNSLITS GYTKKVDITF
     IPRRIWSPEA TTAELIRKRE LRRERFTHEV DFDDFMMPFQ KNITEKARAL EAALKT
//
ID   BTBD3_HUMAN             Reviewed;         522 AA.
AC   Q9Y2F9; D3DW19; Q5JY73;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   22-FEB-2023, entry version 167.
DE   RecName: Full=BTB/POZ domain-containing protein 3;
GN   Name=BTBD3; Synonyms=KIAA0952;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Acts as a key regulator of dendritic field orientation during
CC       development of sensory cortex. Also directs dendrites toward active
CC       axon terminals when ectopically expressed (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9Y2F9; Q9Y2F9: BTBD3; NbExp=3; IntAct=EBI-311155, EBI-311155;
CC       Q9Y2F9; Q96KE9-2: BTBD6; NbExp=3; IntAct=EBI-311155, EBI-12012762;
CC       Q9Y2F9; Q16543: CDC37; NbExp=3; IntAct=EBI-311155, EBI-295634;
CC       Q9Y2F9; Q13618: CUL3; NbExp=3; IntAct=EBI-311155, EBI-456129;
CC       Q9Y2F9; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-311155, EBI-739467;
CC       Q9Y2F9; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-311155, EBI-16439278;
CC       Q9Y2F9; P78317: RNF4; NbExp=3; IntAct=EBI-311155, EBI-2340927;
CC       Q9Y2F9; P63165: SUMO1; NbExp=3; IntAct=EBI-311155, EBI-80140;
CC       Q9Y2F9; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-311155, EBI-11139477;
CC       Q9Y2F9; Q7KZS0: UBE2I; NbExp=5; IntAct=EBI-311155, EBI-10180829;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Note=Translocates from the cytosol to the nucleus in
CC       response to neuronal activity. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y2F9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y2F9-2; Sequence=VSP_041215;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76796.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB023169; BAA76796.2; ALT_INIT; mRNA.
DR   EMBL; AL035448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10327.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10328.1; -; Genomic_DNA.
DR   EMBL; BC101527; AAI01528.1; -; mRNA.
DR   EMBL; BC109315; AAI09316.1; -; mRNA.
DR   EMBL; BC109316; AAI09317.1; -; mRNA.
DR   CCDS; CCDS13113.1; -. [Q9Y2F9-1]
DR   CCDS; CCDS13114.1; -. [Q9Y2F9-2]
DR   RefSeq; NP_001269479.1; NM_001282550.1. [Q9Y2F9-2]
DR   RefSeq; NP_001269480.1; NM_001282551.1. [Q9Y2F9-2]
DR   RefSeq; NP_055777.1; NM_014962.3. [Q9Y2F9-1]
DR   RefSeq; NP_852108.2; NM_181443.3. [Q9Y2F9-2]
DR   RefSeq; XP_016883217.1; XM_017027728.1. [Q9Y2F9-2]
DR   RefSeq; XP_016883218.1; XM_017027729.1.
DR   AlphaFoldDB; Q9Y2F9; -.
DR   SMR; Q9Y2F9; -.
DR   BioGRID; 116567; 23.
DR   IntAct; Q9Y2F9; 18.
DR   STRING; 9606.ENSP00000384545; -.
DR   iPTMnet; Q9Y2F9; -.
DR   PhosphoSitePlus; Q9Y2F9; -.
DR   BioMuta; BTBD3; -.
DR   DMDM; 20137580; -.
DR   EPD; Q9Y2F9; -.
DR   jPOST; Q9Y2F9; -.
DR   MassIVE; Q9Y2F9; -.
DR   MaxQB; Q9Y2F9; -.
DR   PaxDb; Q9Y2F9; -.
DR   PeptideAtlas; Q9Y2F9; -.
DR   ProteomicsDB; 85754; -. [Q9Y2F9-1]
DR   ProteomicsDB; 85755; -. [Q9Y2F9-2]
DR   Antibodypedia; 8935; 144 antibodies from 23 providers.
DR   DNASU; 22903; -.
DR   Ensembl; ENST00000254977.7; ENSP00000254977.3; ENSG00000132640.15. [Q9Y2F9-2]
DR   Ensembl; ENST00000378226.7; ENSP00000367471.2; ENSG00000132640.15. [Q9Y2F9-1]
DR   Ensembl; ENST00000399006.6; ENSP00000381971.2; ENSG00000132640.15. [Q9Y2F9-2]
DR   Ensembl; ENST00000405977.5; ENSP00000384545.1; ENSG00000132640.15. [Q9Y2F9-1]
DR   Ensembl; ENST00000618296.4; ENSP00000477589.1; ENSG00000132640.15. [Q9Y2F9-2]
DR   Ensembl; ENST00000618918.4; ENSP00000483520.1; ENSG00000132640.15. [Q9Y2F9-2]
DR   GeneID; 22903; -.
DR   KEGG; hsa:22903; -.
DR   MANE-Select; ENST00000378226.7; ENSP00000367471.2; NM_014962.4; NP_055777.1.
DR   UCSC; uc002wny.5; human. [Q9Y2F9-1]
DR   AGR; HGNC:15854; -.
DR   CTD; 22903; -.
DR   DisGeNET; 22903; -.
DR   GeneCards; BTBD3; -.
DR   HGNC; HGNC:15854; BTBD3.
DR   HPA; ENSG00000132640; Tissue enhanced (brain).
DR   MIM; 615566; gene.
DR   neXtProt; NX_Q9Y2F9; -.
DR   OpenTargets; ENSG00000132640; -.
DR   PharmGKB; PA25440; -.
DR   VEuPathDB; HostDB:ENSG00000132640; -.
DR   eggNOG; KOG2075; Eukaryota.
DR   GeneTree; ENSGT00940000156461; -.
DR   HOGENOM; CLU_015899_2_1_1; -.
DR   InParanoid; Q9Y2F9; -.
DR   OMA; ELQFACQ; -.
DR   OrthoDB; 354786at2759; -.
DR   PhylomeDB; Q9Y2F9; -.
DR   TreeFam; TF106482; -.
DR   PathwayCommons; Q9Y2F9; -.
DR   SignaLink; Q9Y2F9; -.
DR   BioGRID-ORCS; 22903; 19 hits in 1194 CRISPR screens.
DR   ChiTaRS; BTBD3; human.
DR   GenomeRNAi; 22903; -.
DR   Pharos; Q9Y2F9; Tbio.
DR   PRO; PR:Q9Y2F9; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9Y2F9; protein.
DR   Bgee; ENSG00000132640; Expressed in cerebellar vermis and 206 other tissues.
DR   ExpressionAtlas; Q9Y2F9; baseline and differential.
DR   Genevisible; Q9Y2F9; HS.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB.
DR   GO; GO:0048813; P:dendrite morphogenesis; ISS:UniProtKB.
DR   GO; GO:0022008; P:neurogenesis; IBA:GO_Central.
DR   CDD; cd18524; BACK_BTBD3; 1.
DR   CDD; cd18348; BTB_POZ_BTBD3; 1.
DR   Gene3D; 1.25.40.420; -; 1.
DR   Gene3D; 2.60.120.820; PHR domain; 1.
DR   InterPro; IPR011705; BACK.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR012983; PHR.
DR   InterPro; IPR038648; PHR_sf.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   PANTHER; PTHR45774; BTB/POZ DOMAIN-CONTAINING; 1.
DR   PANTHER; PTHR45774:SF2; BTB/POZ DOMAIN-CONTAINING PROTEIN 3; 1.
DR   Pfam; PF07707; BACK; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF08005; PHR; 1.
DR   SMART; SM00875; BACK; 1.
DR   SMART; SM00225; BTB; 1.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasm; Neurogenesis; Nucleus; Reference proteome.
FT   CHAIN           1..522
FT                   /note="BTB/POZ domain-containing protein 3"
FT                   /id="PRO_0000186211"
FT   DOMAIN          120..190
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   DOMAIN          235..300
FT                   /note="BACK"
FT   REGION          25..44
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         1..61
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041215"
SQ   SEQUENCE   522 AA;  58420 MW;  A5E1359C96FF8919 CRC64;
     MVDDKEKNMK CLTFFLMLPE TVKNRSKKSS KKANTSSSSS NSSKLPPVCY EIITLKTKKK
     KMAADIFPRK KPANSSSTSV QQYHQQNLSN NNLIPAPNWQ GLYPTIRERN AMMFNNDLMA
     DVHFVVGPPG GTQRLPGHKY VLAVGSSVFH AMFYGELAED KDEIRIPDVE PAAFLAMLKY
     IYCDEIDLAA DTVLATLYAA KKYIVPHLAR ACVNFLETSL SAKNACVLLS QSCLFEEPDL
     TQRCWEVIDA QAELALKSEG FCDIDFQTLE SILRRETLNA KEIVVFEAAL NWAEVECQRQ
     DLALSIENKR KVLGKALYLI RIPTMALDDF ANGAAQSGVL TLNETNDIFL WYTAAKKPEL
     QFVSKARKGL VPQRCHRFQS CAYRSNQWRY RGRCDSIQFA VDKRVFIAGF GLYGSSCGSA
     EYSAKIELKR QGVVLGQNLS KYFSDGSSNT FPVWFEYPVQ IEPDTFYTAS VILDGNELSY
     FGQEGMTEVQ CGKVTVQFQC SSDSTNGTGV QGGQIPELIF YA
//
ID   CASP6_HUMAN             Reviewed;         293 AA.
AC   P55212; Q9BQE7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2002, sequence version 2.
DT   22-FEB-2023, entry version 223.
DE   RecName: Full=Caspase-6 {ECO:0000303|PubMed:11953316};
DE            Short=CASP-6;
DE            Short=CSP-6 {ECO:0000303|PubMed:16123779};
DE            EC=3.4.22.59 {ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:19694615, ECO:0000269|PubMed:20890311, ECO:0000269|PubMed:30420425, ECO:0000269|PubMed:32029622};
DE   AltName: Full=Apoptotic protease Mch-2 {ECO:0000303|PubMed:7796396};
DE   Contains:
DE     RecName: Full=Caspase-6 subunit p18 {ECO:0000303|PubMed:8900201};
DE     AltName: Full=Caspase-6 subunit p20 {ECO:0000303|PubMed:19133298};
DE   Contains:
DE     RecName: Full=Caspase-6 subunit p11 {ECO:0000303|PubMed:8900201};
DE     AltName: Full=Caspase-6 subunit p10 {ECO:0000303|PubMed:19133298};
DE   Flags: Precursor;
GN   Name=CASP6 {ECO:0000312|HGNC:HGNC:1507};
GN   Synonyms=MCH2 {ECO:0000303|PubMed:7796396};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA).
RC   TISSUE=T-cell;
RX   PubMed=7796396;
RA   Fernandes-Alnemri T., Litwack G., Alnemri E.S.;
RT   "Mch2, a new member of the apoptotic Ced-3/Ice cysteine protease gene
RT   family.";
RL   Cancer Res. 55:2737-2742(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-182.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEOLYTIC PROCESSING.
RC   TISSUE=Lymphocyte;
RX   PubMed=8900201; DOI=10.1074/jbc.271.43.27099;
RA   Srinivasula S.M., Fernandes-Alnemri T., Zangrilli J., Robertson N.,
RA   Armstrong R.C., Wang L., Trapani J.A., Tomaselli K.J., Litwack G.,
RA   Alnemri E.S.;
RT   "The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the
RT   lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator
RT   CPP32.";
RL   J. Biol. Chem. 271:27099-27106(1996).
RN   [5]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=8663580; DOI=10.1074/jbc.271.28.16720;
RA   Orth K., Chinnaiyan A.M., Garg M., Froelich C.J., Dixit V.M.;
RT   "The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves
RT   the death substrate lamin A.";
RL   J. Biol. Chem. 271:16443-16446(1996).
RN   [6]
RP   FUNCTION, ACTIVITY REGULATION, AND CLEAVAGE BY CASP8 AND CASP3.
RX   PubMed=9463409; DOI=10.1084/jem.187.4.587;
RA   Hirata H., Takahashi A., Kobayashi S., Yonehara S., Sawai H., Okazaki T.,
RA   Yamamoto K., Sasada M.;
RT   "Caspases are activated in a branched protease cascade and control distinct
RT   downstream processes in Fas-induced apoptosis.";
RL   J. Exp. Med. 187:587-600(1998).
RN   [7]
RP   FUNCTION.
RX   PubMed=10559921; DOI=10.1038/12050;
RA   Levkau B., Scatena M., Giachelli C.M., Ross R., Raines E.W.;
RT   "Apoptosis overrides survival signals through a caspase-mediated dominant-
RT   negative NF-kappa B loop.";
RL   Nat. Cell Biol. 1:227-233(1999).
RN   [8]
RP   FUNCTION.
RX   PubMed=11953316; DOI=10.1093/emboj/21.8.1967;
RA   Ruchaud S., Korfali N., Villa P., Kottke T.J., Dingwall C., Kaufmann S.H.,
RA   Earnshaw W.C.;
RT   "Caspase-6 gene disruption reveals a requirement for lamin A cleavage in
RT   apoptotic chromatin condensation.";
RL   EMBO J. 21:1967-1977(2002).
RN   [9]
RP   FUNCTION.
RX   PubMed=14657026; DOI=10.1093/emboj/cdg615;
RA   Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P.,
RA   Boutillier A.L.;
RT   "Critical loss of CBP/p300 histone acetylase activity by caspase-6 during
RT   neurodegeneration.";
RL   EMBO J. 22:6537-6549(2003).
RN   [10]
RP   INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=15200957; DOI=10.1016/j.molcel.2004.05.018;
RA   Bartke T., Pohl C., Pyrowolakis G., Jentsch S.;
RT   "Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin
RT   ligase.";
RL   Mol. Cell 14:801-811(2004).
RN   [11]
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT SER-257, AND MUTAGENESIS OF
RP   SER-257.
RX   PubMed=15273717; DOI=10.1038/sj.onc.1207963;
RA   Suzuki A., Kusakai G., Kishimoto A., Shimojo Y., Miyamoto S., Ogura T.,
RA   Ochiai A., Esumi H.;
RT   "Regulation of caspase-6 and FLIP by the AMPK family member ARK5.";
RL   Oncogene 23:7067-7075(2004).
RN   [12]
RP   ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, ACTIVE SITE, AND MUTAGENESIS
RP   OF CYS-163.
RX   PubMed=16123779; DOI=10.1038/sj.cdd.4401753;
RA   Guo H., Petrin D., Zhang Y., Bergeron C., Goodyer C.G., LeBlanc A.C.;
RT   "Caspase-1 activation of caspase-6 in human apoptotic neurons.";
RL   Cell Death Differ. 13:285-292(2006).
RN   [13]
RP   FUNCTION.
RX   PubMed=17401638; DOI=10.1007/s11373-007-9165-3;
RA   Lin H.H., Hsu H.L., Yeh N.H.;
RT   "Apoptotic cleavage of NuMA at the C-terminal end is related to nuclear
RT   disruption and death amplification.";
RL   J. Biomed. Sci. 14:681-694(2007).
RN   [14]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=18155731; DOI=10.1016/j.jmb.2007.11.081;
RA   Diemer C., Schneider M., Seebach J., Quaas J., Froesner G., Schaetzl H.M.,
RA   Gilch S.;
RT   "Cell type-specific cleavage of nucleocapsid protein by effector caspases
RT   during SARS coronavirus infection.";
RL   J. Mol. Biol. 376:23-34(2008).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PROTEOLYTIC PROCESSING,
RP   SUBUNIT, DOMAIN, ACTIVE SITE, AND MUTAGENESIS OF ASP-23; CYS-163; ASP-179
RP   AND ASP-193.
RX   PubMed=19133298; DOI=10.1016/j.bbamcr.2008.12.004;
RA   Klaiman G., Champagne N., LeBlanc A.C.;
RT   "Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation
RT   does not induce cell death in HEK293T cells.";
RL   Biochim. Biophys. Acta 1793:592-601(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION.
RX   PubMed=22858542; DOI=10.1038/cdd.2012.98;
RA   van Raam B.J., Ehrnhoefer D.E., Hayden M.R., Salvesen G.S.;
RT   "Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase-
RT   6.";
RL   Cell Death Differ. 20:86-96(2013).
RN   [18]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=27032039; DOI=10.1021/acschembio.5b00971;
RA   Hill M.E., MacPherson D.J., Wu P., Julien O., Wells J.A., Hardy J.A.;
RT   "Reprogramming caspase-7 specificity by regio-specific mutations and
RT   selection provides alternate solutions for substrate recognition.";
RL   ACS Chem. Biol. 11:1603-1612(2016).
RN   [19]
RP   PALMITOYLATION AT CYS-264 AND CYS-277, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF CYS-264 AND CYS-277.
RX   PubMed=27911442; DOI=10.1038/cdd.2016.139;
RA   Skotte N.H., Sanders S.S., Singaraja R.R., Ehrnhoefer D.E., Vaid K.,
RA   Qiu X., Kannan S., Verma C., Hayden M.R.;
RT   "Palmitoylation of caspase-6 by HIP14 regulates its activation.";
RL   Cell Death Differ. 24:433-444(2017).
RN   [20]
RP   DOMAIN, AND MUTAGENESIS OF GLU-135.
RX   PubMed=28154009; DOI=10.1074/jbc.m116.773499;
RA   Dagbay K.B., Bolik-Coulon N., Savinov S.N., Hardy J.A.;
RT   "Caspase-6 undergoes a distinct helix-strand interconversion upon substrate
RT   binding.";
RL   J. Biol. Chem. 292:4885-4897(2017).
RN   [21]
RP   FUNCTION, ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, ACTIVE SITE, AND
RP   MUTAGENESIS OF ASP-23; CYS-163; ASP-179 AND ASP-193.
RX   PubMed=28864531; DOI=10.1073/pnas.1704640114;
RA   Dagbay K.B., Hardy J.A.;
RT   "Multiple proteolytic events in caspase-6 self-activation impact
RT   conformations of discrete structural regions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E7977-E7986(2017).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITES, AND MUTAGENESIS OF
RP   42-ARG--ARG-44; HIS-121 AND CYS-163.
RX   PubMed=30420425; DOI=10.1074/jbc.ra118.005914;
RA   MacPherson D.J., Mills C.L., Ondrechen M.J., Hardy J.A.;
RT   "Tri-arginine exosite patch of caspase-6 recruits substrates for
RT   hydrolysis.";
RL   J. Biol. Chem. 294:71-88(2019).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH RIPK3.
RX   PubMed=32298652; DOI=10.1016/j.cell.2020.03.040;
RA   Zheng M., Karki R., Vogel P., Kanneganti T.D.;
RT   "Caspase-6 is a key regulator of innate immunity, inflammasome activation,
RT   and host defense.";
RL   Cell 181:674-687(2020).
RN   [24]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT
RP   SER-257, AND MUTAGENESIS OF SER-257.
RX   PubMed=32029622; DOI=10.1126/science.aay0542;
RA   Zhao P., Sun X., Chaggan C., Liao Z., In Wong K., He F., Singh S.,
RA   Loomba R., Karin M., Witztum J.L., Saltiel A.R.;
RT   "An AMPK-caspase-6 axis controls liver damage in nonalcoholic
RT   steatohepatitis.";
RL   Science 367:652-660(2020).
RN   [25]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   "Coronaviruses exploit a host cysteine-aspartic protease for replication.";
RL   Nature 0:0-0(2022).
RN   [26] {ECO:0007744|PDB:2WDP}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS), CATALYTIC ACTIVITY, SUBUNIT, ACTIVE
RP   SITE, AND MUTAGENESIS OF CYS-163.
RX   PubMed=19694615; DOI=10.1042/bj20090540;
RA   Baumgartner R., Meder G., Briand C., Decock A., D'arcy A., Hassiepen U.,
RA   Morse R., Renatus M.;
RT   "The crystal structure of caspase-6, a selective effector of axonal
RT   degeneration.";
RL   Biochem. J. 423:429-439(2009).
RN   [27] {ECO:0007744|PDB:3NR2, ECO:0007744|PDB:3OD5}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 24-293, CATALYTIC ACTIVITY,
RP   ACTIVE SITE, SUBUNIT, ACTIVITY REGULATION, AND MUTAGENESIS OF CYS-163.
RX   PubMed=20890311; DOI=10.1038/embor.2010.141;
RA   Wang X.J., Cao Q., Liu X., Wang K.T., Mi W., Zhang Y., Li L.F.,
RA   LeBlanc A.C., Su X.D.;
RT   "Crystal structures of human caspase 6 reveal a new mechanism for
RT   intramolecular cleavage self-activation.";
RL   EMBO Rep. 11:841-847(2010).
RN   [28] {ECO:0007744|PDB:3V6L, ECO:0007744|PDB:3V6M}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 21-293, ACTIVITY REGULATION, AND
RP   MUTAGENESIS OF SER-257.
RX   PubMed=22433863; DOI=10.1074/jbc.m112.351213;
RA   Cao Q., Wang X.J., Liu C.W., Liu D.F., Li L.F., Gao Y.Q., Su X.D.;
RT   "Inhibitory mechanism of caspase-6 phosphorylation revealed by crystal
RT   structures, molecular dynamics simulations, and biochemical assays.";
RL   J. Biol. Chem. 287:15371-15379(2012).
RN   [29] {ECO:0007744|PDB:4HVA}
RP   X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS) OF 24-293, AND ACTIVITY REGULATION.
RX   PubMed=23227217; DOI=10.1371/journal.pone.0050864;
RA   Heise C.E., Murray J., Augustyn K.E., Bravo B., Chugha P., Cohen F.,
RA   Giannetti A.M., Gibbons P., Hannoush R.N., Hearn B.R., Jaishankar P.,
RA   Ly C.Q., Shah K., Stanger K., Steffek M., Tang Y., Zhao X., Lewcock J.W.,
RA   Renslo A.R., Flygare J., Arkin M.R.;
RT   "Mechanistic and structural understanding of uncompetitive inhibitors of
RT   caspase-6.";
RL   PLoS ONE 7:e50864-e50864(2012).
RN   [30] {ECO:0007744|PDB:3S8E}
RP   X-RAY CRYSTALLOGRAPHY (2.88 ANGSTROMS) OF 24-293, PHOSPHORYLATION AT
RP   SER-257, MUTAGENESIS OF SER-257, AND ACTIVITY REGULATION.
RX   PubMed=22483120; DOI=10.1016/j.str.2012.02.003;
RA   Velazquez-Delgado E.M., Hardy J.A.;
RT   "Phosphorylation regulates assembly of the caspase-6 substrate-binding
RT   groove.";
RL   Structure 20:742-751(2012).
CC   -!- FUNCTION: Cysteine protease that plays essential roles in programmed
CC       cell death, axonal degeneration, development and innate immunity
CC       (PubMed:8663580, PubMed:19133298, PubMed:22858542, PubMed:27032039,
CC       PubMed:28864531, PubMed:30420425, PubMed:32298652). Acts as a non-
CC       canonical executioner caspase during apoptosis: localizes in the
CC       nucleus and cleaves the nuclear structural protein NUMA1 and lamin
CC       A/LMNA thereby inducing nuclear shrinkage and fragmentation
CC       (PubMed:8663580, PubMed:9463409, PubMed:11953316, PubMed:17401638).
CC       Lamin-A/LMNA cleavage is required for chromatin condensation and
CC       nuclear disassembly during apoptotic execution (PubMed:11953316). Acts
CC       as a regulator of liver damage by promoting hepatocyte apoptosis: in
CC       absence of phosphorylation by AMP-activated protein kinase (AMPK),
CC       catalyzes cleavage of BID, leading to cytochrome c release, thereby
CC       participating in nonalcoholic steatohepatitis (PubMed:32029622).
CC       Cleaves PARK7/DJ-1 in cells undergoing apoptosis (By similarity).
CC       Involved in intrinsic apoptosis by mediating cleavage of RIPK1
CC       (PubMed:22858542). Furthermore, cleaves many transcription factors such
CC       as NF-kappa-B and cAMP response element-binding protein/CREBBP
CC       (PubMed:10559921, PubMed:14657026). Cleaves phospholipid scramblase
CC       proteins XKR4 and XKR9 (By similarity). In addition to apoptosis,
CC       involved in different forms of programmed cell death (PubMed:32298652).
CC       Plays an essential role in defense against viruses by acting as a
CC       central mediator of the ZBP1-mediated pyroptosis, apoptosis, and
CC       necroptosis (PANoptosis), independently of its cysteine protease
CC       activity (PubMed:32298652). PANoptosis is a unique inflammatory
CC       programmed cell death, which provides a molecular scaffold that allows
CC       the interactions and activation of machinery required for
CC       inflammasome/pyroptosis, apoptosis and necroptosis (PubMed:32298652).
CC       Mechanistically, interacts with RIPK3 and enhances the interaction
CC       between RIPK3 and ZBP1, leading to ZBP1-mediated inflammasome
CC       activation and cell death (PubMed:32298652). Plays an essential role in
CC       axon degeneration during axon pruning which is the remodeling of axons
CC       during neurogenesis but not apoptosis (By similarity). Regulates B-cell
CC       programs both during early development and after antigen stimulation
CC       (By similarity). {ECO:0000250|UniProtKB:O08738,
CC       ECO:0000269|PubMed:10559921, ECO:0000269|PubMed:11953316,
CC       ECO:0000269|PubMed:14657026, ECO:0000269|PubMed:17401638,
CC       ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:22858542,
CC       ECO:0000269|PubMed:27032039, ECO:0000269|PubMed:28864531,
CC       ECO:0000269|PubMed:30420425, ECO:0000269|PubMed:32029622,
CC       ECO:0000269|PubMed:32298652, ECO:0000269|PubMed:8663580,
CC       ECO:0000269|PubMed:9463409}.
CC   -!- FUNCTION: (Microbial infection) Proteolytically cleaves the N protein
CC       of coronoviruses such as MERS-CoV and SARS-CoV (PubMed:35922005,
CC       PubMed:18155731). The cleavage of MERS-CoV N-protein leads to two
CC       fragments and modulates coronavirus replication by regulating IFN
CC       signaling. The two fragments produced by the cleavage interact with
CC       IRF3 inhibiting its nuclear translocation after activation and reduce
CC       the expression of IFNB and IFN-stimulated genes (PubMed:35922005). The
CC       same mechanism seems to be used by other coronaviruses such as SARS-CoV
CC       and SARS-CoV-2 to enhance their replication (PubMed:35922005).
CC       {ECO:0000269|PubMed:18155731, ECO:0000269|PubMed:35922005}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Strict requirement for Asp at position P1 and has a preferred
CC         cleavage sequence of Val-Glu-His-Asp-|-.; EC=3.4.22.59;
CC         Evidence={ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:19694615,
CC         ECO:0000269|PubMed:27032039, ECO:0000269|PubMed:30420425,
CC         ECO:0000269|PubMed:32029622};
CC   -!- ACTIVITY REGULATION: During activation, the N-terminal disordered
CC       prodomain is removed by cleavage (PubMed:8900201, PubMed:8663580,
CC       PubMed:19133298, PubMed:28864531). Concomitantly, double cleavage gives
CC       rise to a large 18-kDa and a small 11-kDa subunit (PubMed:8663580,
CC       PubMed:19133298). The two large and two small subunits then assemble to
CC       form the active CASP6 complex (PubMed:8663580). Can be cleaved and
CC       activated by different caspases, depending on the context
CC       (PubMed:9463409, PubMed:19133298). Cleaved and activated by caspase-8
CC       (CASP8) and subsequently by caspase-3 (CASP3) (PubMed:9463409). Can
CC       also undergo autoactivation by mediating autocleavage at Asp-179 and
CC       Asp-193, while it is not able to cleave its N-terminal disordered
CC       prodomain (PubMed:19133298, PubMed:28864531). Intramolecular cleavage
CC       at Asp-193 is a prerequisite for CASP6 self-activation
CC       (PubMed:20890311, PubMed:28864531). Cleaved and activated by CASP1 in
CC       neurons, possibly in the context of inflammation (PubMed:16123779).
CC       Phosphorylation at Ser-257 inhibits autocleavage, preventing caspase
CC       activation (PubMed:15273717, PubMed:32029622, PubMed:22433863,
CC       PubMed:22483120). Specifically inhibited by compound 3
CC       (benzyloxycarbonyl (Z)-VEID-tetrafluorophenoxymethyl ketone)
CC       (PubMed:23227217). {ECO:0000269|PubMed:15273717,
CC       ECO:0000269|PubMed:16123779, ECO:0000269|PubMed:19133298,
CC       ECO:0000269|PubMed:20890311, ECO:0000269|PubMed:22433863,
CC       ECO:0000269|PubMed:22483120, ECO:0000269|PubMed:23227217,
CC       ECO:0000269|PubMed:28864531, ECO:0000269|PubMed:32029622,
CC       ECO:0000269|PubMed:8663580, ECO:0000269|PubMed:8900201,
CC       ECO:0000269|PubMed:9463409}.
CC   -!- SUBUNIT: Heterotetramer that consists of two anti-parallel arranged
CC       heterodimers, each one formed by a 18 kDa (p18) and a 11 kDa (p11)
CC       subunits (PubMed:19133298, PubMed:19694615, PubMed:20890311). Interacts
CC       with BIRC6/bruce (PubMed:15200957). Interacts with RIPK3
CC       (PubMed:32298652). {ECO:0000269|PubMed:15200957,
CC       ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:19694615,
CC       ECO:0000269|PubMed:20890311, ECO:0000269|PubMed:32298652}.
CC   -!- SUBUNIT: [Caspase-6 subunit p18]: Heterotetramer that consists of two
CC       anti-parallel arranged heterodimers, each one formed by a 18 kDa
CC       (Caspase-6 subunit p18) and a 11 kDa (Caspase-6 subunit p11) subunit.
CC       {ECO:0000269|PubMed:19694615, ECO:0000269|PubMed:20890311}.
CC   -!- SUBUNIT: [Caspase-6 subunit p11]: Heterotetramer that consists of two
CC       anti-parallel arranged heterodimers, each one formed by a 18 kDa
CC       (Caspase-6 subunit p18) and a 11 kDa (Caspase-6 subunit p11) subunit.
CC       {ECO:0000269|PubMed:19694615, ECO:0000269|PubMed:20890311}.
CC   -!- INTERACTION:
CC       P55212; Q9Y614: ACTL7B; NbExp=3; IntAct=EBI-718729, EBI-25835070;
CC       P55212; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-718729, EBI-18899653;
CC       P55212; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-718729, EBI-10173507;
CC       P55212; Q96MA6: AK8; NbExp=3; IntAct=EBI-718729, EBI-8466265;
CC       P55212; Q5T2L2: AKR1C8; NbExp=3; IntAct=EBI-718729, EBI-22006248;
CC       P55212; Q96Q83-2: ALKBH3; NbExp=3; IntAct=EBI-718729, EBI-9089544;
CC       P55212; Q9Y303-2: AMDHD2; NbExp=3; IntAct=EBI-718729, EBI-12323557;
CC       P55212; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-718729, EBI-8464238;
CC       P55212; P09525: ANXA4; NbExp=3; IntAct=EBI-718729, EBI-2556852;
CC       P55212; P06727: APOA4; NbExp=3; IntAct=EBI-718729, EBI-1222447;
CC       P55212; Q8WW27: APOBEC4; NbExp=3; IntAct=EBI-718729, EBI-25836284;
CC       P55212; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-718729, EBI-5280499;
CC       P55212; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-718729, EBI-10254793;
CC       P55212; P18848: ATF4; NbExp=3; IntAct=EBI-718729, EBI-492498;
CC       P55212; Q9H0Y0: ATG10; NbExp=3; IntAct=EBI-718729, EBI-1048913;
CC       P55212; Q14032: BAAT; NbExp=3; IntAct=EBI-718729, EBI-8994378;
CC       P55212; P54687-4: BCAT1; NbExp=3; IntAct=EBI-718729, EBI-25834445;
CC       P55212; P06276: BCHE; NbExp=3; IntAct=EBI-718729, EBI-7936069;
CC       P55212; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-718729, EBI-10693038;
CC       P55212; Q96Q07-2: BTBD9; NbExp=3; IntAct=EBI-718729, EBI-22006737;
CC       P55212; Q9H0W9-3: C11orf54; NbExp=3; IntAct=EBI-718729, EBI-12108466;
CC       P55212; Q9NQ89: C12orf4; NbExp=3; IntAct=EBI-718729, EBI-11090973;
CC       P55212; Q13901: C1D; NbExp=3; IntAct=EBI-718729, EBI-3844053;
CC       P55212; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-718729, EBI-18036948;
CC       P55212; Q8N1A6: C4orf33; NbExp=3; IntAct=EBI-718729, EBI-10264911;
CC       P55212; P17655: CAPN2; NbExp=3; IntAct=EBI-718729, EBI-1028956;
CC       P55212; P20807-4: CAPN3; NbExp=3; IntAct=EBI-718729, EBI-11532021;
CC       P55212; P42574: CASP3; NbExp=2; IntAct=EBI-718729, EBI-524064;
CC       P55212; P55212: CASP6; NbExp=8; IntAct=EBI-718729, EBI-718729;
CC       P55212; Q5JTY5: CBWD3; NbExp=3; IntAct=EBI-718729, EBI-723434;
CC       P55212; O00257-3: CBX4; NbExp=3; IntAct=EBI-718729, EBI-4392727;
CC       P55212; P24863: CCNC; NbExp=3; IntAct=EBI-718729, EBI-395261;
CC       P55212; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-718729, EBI-12300031;
CC       P55212; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-718729, EBI-396137;
CC       P55212; P42773: CDKN2C; NbExp=3; IntAct=EBI-718729, EBI-711290;
CC       P55212; O95674: CDS2; NbExp=3; IntAct=EBI-718729, EBI-3913685;
CC       P55212; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-718729, EBI-11953200;
CC       P55212; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-718729, EBI-749253;
CC       P55212; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-718729, EBI-744045;
CC       P55212; Q8N365: CIART; NbExp=3; IntAct=EBI-718729, EBI-10265133;
CC       P55212; Q99966: CITED1; NbExp=3; IntAct=EBI-718729, EBI-2624951;
CC       P55212; P09496-2: CLTA; NbExp=3; IntAct=EBI-718729, EBI-4401010;
CC       P55212; Q6PJW8-3: CNST; NbExp=3; IntAct=EBI-718729, EBI-25836090;
CC       P55212; Q96BR5: COA7; NbExp=3; IntAct=EBI-718729, EBI-6269632;
CC       P55212; P02458-1: COL2A1; NbExp=3; IntAct=EBI-718729, EBI-12375799;
CC       P55212; Q9UGL9: CRCT1; NbExp=3; IntAct=EBI-718729, EBI-713677;
CC       P55212; Q9UKG9-2: CROT; NbExp=3; IntAct=EBI-718729, EBI-25835363;
CC       P55212; P26998: CRYBB3; NbExp=3; IntAct=EBI-718729, EBI-1965681;
CC       P55212; P35222: CTNNB1; NbExp=3; IntAct=EBI-718729, EBI-491549;
CC       P55212; Q53TN4: CYBRD1; NbExp=3; IntAct=EBI-718729, EBI-8637742;
CC       P55212; P61962: DCAF7; NbExp=3; IntAct=EBI-718729, EBI-359808;
CC       P55212; O60479: DLX3; NbExp=3; IntAct=EBI-718729, EBI-3908248;
CC       P55212; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-718729, EBI-11526226;
CC       P55212; Q92782-2: DPF1; NbExp=3; IntAct=EBI-718729, EBI-23669343;
CC       P55212; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-718729, EBI-724653;
CC       P55212; A0AVK6: E2F8; NbExp=3; IntAct=EBI-718729, EBI-7779316;
CC       P55212; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-718729, EBI-10248874;
CC       P55212; O00303: EIF3F; NbExp=3; IntAct=EBI-718729, EBI-711990;
CC       P55212; Q13347: EIF3I; NbExp=3; IntAct=EBI-718729, EBI-354047;
CC       P55212; O00472: ELL2; NbExp=3; IntAct=EBI-718729, EBI-395274;
CC       P55212; O00423: EML1; NbExp=3; IntAct=EBI-718729, EBI-751327;
CC       P55212; Q6NXG1-3: ESRP1; NbExp=3; IntAct=EBI-718729, EBI-21567429;
CC       P55212; Q49AJ0-4: FAM135B; NbExp=3; IntAct=EBI-718729, EBI-25835236;
CC       P55212; Q8N128-2: FAM177A1; NbExp=3; IntAct=EBI-718729, EBI-12201693;
CC       P55212; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-718729, EBI-8468186;
CC       P55212; Q6ZNL6: FGD5; NbExp=3; IntAct=EBI-718729, EBI-7962481;
CC       P55212; Q9NSA1: FGF21; NbExp=3; IntAct=EBI-718729, EBI-3909329;
CC       P55212; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-718729, EBI-9088619;
CC       P55212; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-718729, EBI-12143817;
CC       P55212; Q9HAV0: GNB4; NbExp=3; IntAct=EBI-718729, EBI-358539;
CC       P55212; Q6NXT2: H3-5; NbExp=3; IntAct=EBI-718729, EBI-2868501;
CC       P55212; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-718729, EBI-2558143;
CC       P55212; Q9NRZ9-6: HELLS; NbExp=3; IntAct=EBI-718729, EBI-12003732;
CC       P55212; Q96EW2-2: HSPBAP1; NbExp=3; IntAct=EBI-718729, EBI-25835621;
CC       P55212; P42858: HTT; NbExp=15; IntAct=EBI-718729, EBI-466029;
CC       P55212; Q8N6M8-2: IQCF1; NbExp=3; IntAct=EBI-718729, EBI-21771049;
CC       P55212; Q92613: JADE3; NbExp=3; IntAct=EBI-718729, EBI-10278909;
CC       P55212; P0C870: JMJD7; NbExp=3; IntAct=EBI-718729, EBI-9090173;
CC       P55212; Q9UK76: JPT1; NbExp=3; IntAct=EBI-718729, EBI-720411;
CC       P55212; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-718729, EBI-743960;
CC       P55212; Q8TBB5-2: KLHDC4; NbExp=3; IntAct=EBI-718729, EBI-21838933;
CC       P55212; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-718729, EBI-8524663;
CC       P55212; Q8N4N3-2: KLHL36; NbExp=3; IntAct=EBI-718729, EBI-10973851;
CC       P55212; Q5JUW0-3: KRBOX4; NbExp=3; IntAct=EBI-718729, EBI-12893625;
CC       P55212; Q8N1A0: KRT222; NbExp=3; IntAct=EBI-718729, EBI-8473062;
CC       P55212; P13473-2: LAMP2; NbExp=3; IntAct=EBI-718729, EBI-21591415;
CC       P55212; Q6DKI2: LGALS9C; NbExp=3; IntAct=EBI-718729, EBI-9088829;
CC       P55212; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-718729, EBI-25835523;
CC       P55212; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-718729, EBI-10264791;
CC       P55212; Q9Y234: LIPT1; NbExp=3; IntAct=EBI-718729, EBI-727376;
CC       P55212; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-718729, EBI-739832;
CC       P55212; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-718729, EBI-2510853;
CC       P55212; Q96JB6: LOXL4; NbExp=3; IntAct=EBI-718729, EBI-749562;
CC       P55212; Q16609: LPAL2; NbExp=3; IntAct=EBI-718729, EBI-10238012;
CC       P55212; Q8IYG6: LRRC56; NbExp=3; IntAct=EBI-718729, EBI-14752528;
CC       P55212; P0DP58-2: LYNX1; NbExp=3; IntAct=EBI-718729, EBI-21916939;
CC       P55212; Q969L2: MAL2; NbExp=3; IntAct=EBI-718729, EBI-944295;
CC       P55212; P27338: MAOB; NbExp=3; IntAct=EBI-718729, EBI-3911344;
CC       P55212; A6NJ78-4: METTL15; NbExp=3; IntAct=EBI-718729, EBI-10174029;
CC       P55212; Q96C03-3: MIEF2; NbExp=3; IntAct=EBI-718729, EBI-11988931;
CC       P55212; Q8N5J2-3: MINDY1; NbExp=3; IntAct=EBI-718729, EBI-12382151;
CC       P55212; A0A0A0MR05: MLST8; NbExp=3; IntAct=EBI-718729, EBI-25835557;
CC       P55212; P34949-2: MPI; NbExp=3; IntAct=EBI-718729, EBI-21823432;
CC       P55212; Q9BV20: MRI1; NbExp=3; IntAct=EBI-718729, EBI-747381;
CC       P55212; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-718729, EBI-25835707;
CC       P55212; A2RUH7: MYBPHL; NbExp=3; IntAct=EBI-718729, EBI-9088235;
CC       P55212; P01106: MYC; NbExp=3; IntAct=EBI-718729, EBI-447544;
CC       P55212; Q9H7X0: NAA60; NbExp=3; IntAct=EBI-718729, EBI-12260336;
CC       P55212; Q15742-2: NAB2; NbExp=3; IntAct=EBI-718729, EBI-25834665;
CC       P55212; Q9UJ70-2: NAGK; NbExp=3; IntAct=EBI-718729, EBI-11526455;
CC       P55212; Q8NDH3-5: NPEPL1; NbExp=3; IntAct=EBI-718729, EBI-12329915;
CC       P55212; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-718729, EBI-741158;
CC       P55212; P36639-4: NUDT1; NbExp=3; IntAct=EBI-718729, EBI-25834643;
CC       P55212; Q8NFH4: NUP37; NbExp=3; IntAct=EBI-718729, EBI-2563158;
CC       P55212; Q8NFH3: NUP43; NbExp=3; IntAct=EBI-718729, EBI-1059321;
CC       P55212; Q7Z3B4: NUP54; NbExp=3; IntAct=EBI-718729, EBI-741048;
CC       P55212; Q3SX64: ODF3L2; NbExp=3; IntAct=EBI-718729, EBI-6660184;
CC       P55212; Q6N063-2: OGFOD2; NbExp=3; IntAct=EBI-718729, EBI-22006224;
CC       P55212; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-718729, EBI-25830200;
CC       P55212; Q9H8K7: PAAT; NbExp=3; IntAct=EBI-718729, EBI-714785;
CC       P55212; Q99447: PCYT2; NbExp=3; IntAct=EBI-718729, EBI-750317;
CC       P55212; P27815-4: PDE4A; NbExp=3; IntAct=EBI-718729, EBI-12080840;
CC       P55212; O15534: PER1; NbExp=3; IntAct=EBI-718729, EBI-2557276;
CC       P55212; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-718729, EBI-722852;
CC       P55212; Q00169: PITPNA; NbExp=3; IntAct=EBI-718729, EBI-1042490;
CC       P55212; P48739: PITPNB; NbExp=3; IntAct=EBI-718729, EBI-1047143;
CC       P55212; P61925: PKIA; NbExp=3; IntAct=EBI-718729, EBI-2682139;
CC       P55212; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-718729, EBI-21503705;
CC       P55212; O60664: PLIN3; NbExp=3; IntAct=EBI-718729, EBI-725795;
CC       P55212; Q14181: POLA2; NbExp=3; IntAct=EBI-718729, EBI-712752;
CC       P55212; P0DPB6: POLR1D; NbExp=3; IntAct=EBI-718729, EBI-359498;
CC       P55212; P36954: POLR2I; NbExp=3; IntAct=EBI-718729, EBI-395202;
CC       P55212; Q07869: PPARA; NbExp=3; IntAct=EBI-718729, EBI-78615;
CC       P55212; O60927: PPP1R11; NbExp=3; IntAct=EBI-718729, EBI-1048104;
CC       P55212; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-718729, EBI-25835994;
CC       P55212; P54619: PRKAG1; NbExp=3; IntAct=EBI-718729, EBI-1181439;
CC       P55212; Q8NCQ7-2: PROCA1; NbExp=3; IntAct=EBI-718729, EBI-25836043;
CC       P55212; P41222: PTGDS; NbExp=3; IntAct=EBI-718729, EBI-948821;
CC       P55212; P29074: PTPN4; NbExp=3; IntAct=EBI-718729, EBI-710431;
CC       P55212; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-718729, EBI-25835884;
CC       P55212; Q5R372-9: RABGAP1L; NbExp=3; IntAct=EBI-718729, EBI-10699389;
CC       P55212; Q9HD47-3: RANGRF; NbExp=3; IntAct=EBI-718729, EBI-9089733;
CC       P55212; Q09028: RBBP4; NbExp=3; IntAct=EBI-718729, EBI-620823;
CC       P55212; Q04206: RELA; NbExp=3; IntAct=EBI-718729, EBI-73886;
CC       P55212; P47804-3: RGR; NbExp=3; IntAct=EBI-718729, EBI-25834767;
CC       P55212; Q15382: RHEB; NbExp=3; IntAct=EBI-718729, EBI-1055287;
CC       P55212; Q06587: RING1; NbExp=3; IntAct=EBI-718729, EBI-752313;
CC       P55212; Q8N5U6: RNF10; NbExp=3; IntAct=EBI-718729, EBI-714023;
CC       P55212; P62701: RPS4X; NbExp=3; IntAct=EBI-718729, EBI-354303;
CC       P55212; Q66K80: RUSC1-AS1; NbExp=3; IntAct=EBI-718729, EBI-10248967;
CC       P55212; Q01826: SATB1; NbExp=2; IntAct=EBI-718729, EBI-743747;
CC       P55212; O15126: SCAMP1; NbExp=3; IntAct=EBI-718729, EBI-954338;
CC       P55212; P22307-3: SCP2; NbExp=3; IntAct=EBI-718729, EBI-25834804;
CC       P55212; Q9BRK5: SDF4; NbExp=3; IntAct=EBI-718729, EBI-1389808;
CC       P55212; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-718729, EBI-9089805;
CC       P55212; P01011: SERPINA3; NbExp=3; IntAct=EBI-718729, EBI-296557;
CC       P55212; Q15393: SF3B3; NbExp=3; IntAct=EBI-718729, EBI-346977;
CC       P55212; Q9NR46: SH3GLB2; NbExp=3; IntAct=EBI-718729, EBI-749607;
CC       P55212; Q9BZQ2: SHCBP1L; NbExp=3; IntAct=EBI-718729, EBI-10818532;
CC       P55212; O60902-3: SHOX2; NbExp=3; IntAct=EBI-718729, EBI-9092164;
CC       P55212; Q86US8: SMG6; NbExp=3; IntAct=EBI-718729, EBI-3232100;
CC       P55212; P37840: SNCA; NbExp=3; IntAct=EBI-718729, EBI-985879;
CC       P55212; Q96H20: SNF8; NbExp=3; IntAct=EBI-718729, EBI-747719;
CC       P55212; Q13573: SNW1; NbExp=3; IntAct=EBI-718729, EBI-632715;
CC       P55212; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-718729, EBI-10696971;
CC       P55212; Q496A3: SPATS1; NbExp=3; IntAct=EBI-718729, EBI-3923692;
CC       P55212; Q9C004: SPRY4; NbExp=3; IntAct=EBI-718729, EBI-354861;
CC       P55212; Q5W111-2: SPRYD7; NbExp=3; IntAct=EBI-718729, EBI-12408727;
CC       P55212; Q96BD6: SPSB1; NbExp=3; IntAct=EBI-718729, EBI-2659201;
CC       P55212; Q92797-2: SYMPK; NbExp=3; IntAct=EBI-718729, EBI-21560407;
CC       P55212; O60506-4: SYNCRIP; NbExp=3; IntAct=EBI-718729, EBI-11123832;
CC       P55212; O15273: TCAP; NbExp=3; IntAct=EBI-718729, EBI-954089;
CC       P55212; Q86WV5: TEN1; NbExp=3; IntAct=EBI-718729, EBI-2562799;
CC       P55212; Q96A09: TENT5B; NbExp=3; IntAct=EBI-718729, EBI-752030;
CC       P55212; P54274-2: TERF1; NbExp=3; IntAct=EBI-718729, EBI-711018;
CC       P55212; P22735: TGM1; NbExp=3; IntAct=EBI-718729, EBI-2562368;
CC       P55212; O43548: TGM5; NbExp=3; IntAct=EBI-718729, EBI-12027348;
CC       P55212; Q9NQ88: TIGAR; NbExp=3; IntAct=EBI-718729, EBI-3920747;
CC       P55212; Q9UIK5-2: TMEFF2; NbExp=3; IntAct=EBI-718729, EBI-25835153;
CC       P55212; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-718729, EBI-10242677;
CC       P55212; P04637: TP53; NbExp=3; IntAct=EBI-718729, EBI-366083;
CC       P55212; Q12888: TP53BP1; NbExp=3; IntAct=EBI-718729, EBI-396540;
CC       P55212; P36406: TRIM23; NbExp=3; IntAct=EBI-718729, EBI-740098;
CC       P55212; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-718729, EBI-11525489;
CC       P55212; Q13885: TUBB2A; NbExp=3; IntAct=EBI-718729, EBI-711595;
CC       P55212; P49459: UBE2A; NbExp=3; IntAct=EBI-718729, EBI-2339348;
CC       P55212; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-718729, EBI-25835297;
CC       P55212; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-718729, EBI-10316321;
CC       P55212; Q8NA23-2: WDR31; NbExp=3; IntAct=EBI-718729, EBI-25835937;
CC       P55212; Q9BQA1: WDR77; NbExp=3; IntAct=EBI-718729, EBI-1237307;
CC       P55212; O00755: WNT7A; NbExp=3; IntAct=EBI-718729, EBI-727198;
CC       P55212; O95070: YIF1A; NbExp=3; IntAct=EBI-718729, EBI-2799703;
CC       P55212; O43829: ZBTB14; NbExp=3; IntAct=EBI-718729, EBI-10176632;
CC       P55212; Q8IWT0-2: ZBTB8OS; NbExp=3; IntAct=EBI-718729, EBI-12956041;
CC       P55212; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-718729, EBI-14104088;
CC       P55212; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-718729, EBI-25835471;
CC       P55212; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-718729, EBI-25835852;
CC       P55212; Q96LX8: ZNF597; NbExp=3; IntAct=EBI-718729, EBI-9091553;
CC       P55212; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-718729, EBI-18036029;
CC       P55212; A0A384MDV8; NbExp=3; IntAct=EBI-718729, EBI-25834468;
CC       P55212; B7Z3E8; NbExp=3; IntAct=EBI-718729, EBI-25831617;
CC       P55212; Q86V28; NbExp=3; IntAct=EBI-718729, EBI-10259496;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:27911442}. Nucleus
CC       {ECO:0000269|PubMed:27911442}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha;
CC         IsoId=P55212-1; Sequence=Displayed;
CC       Name=Beta;
CC         IsoId=P55212-2; Sequence=VSP_000805;
CC   -!- DOMAIN: The N-terminal disordered prodomain is required to prevent
CC       self-activation. {ECO:0000269|PubMed:19133298}.
CC   -!- DOMAIN: The Tri-arginine exosite is required to recruit substrates for
CC       hydrolysis. {ECO:0000269|PubMed:30420425}.
CC   -!- DOMAIN: Undergoes helix-strand structural transitions upon substrate-
CC       binding: the 130's region interconverts between an inactive helical
CC       state and the canonically active strand state (PubMed:28154009). Other
CC       caspases rest constitutively in the strand conformation before and
CC       after substrate-binding (PubMed:28154009).
CC       {ECO:0000269|PubMed:28154009}.
CC   -!- PTM: Phosphorylated by NUAK1; phosphorylation inhibits self-activation
CC       (PubMed:15273717, PubMed:22483120). Phosphorylation at Ser-257 by AMP-
CC       activated protein kinase (PRKAA1 or PRKAA2) inhibits autocleavage,
CC       preventing caspase activation, thereby preventing hepatocyte apoptosis
CC       (PubMed:32029622). {ECO:0000269|PubMed:15273717,
CC       ECO:0000269|PubMed:22483120, ECO:0000269|PubMed:32029622}.
CC   -!- PTM: Palmitoylation by ZDHHC17 blocks dimerization and subsequent
CC       activation, leading to inhibit the cysteine protease activity.
CC       {ECO:0000269|PubMed:27911442}.
CC   -!- PTM: Can be cleaved and activated by different caspases, depending on
CC       the context (PubMed:19133298, PubMed:28864531). Cleaved and activated
CC       by caspase-8 (CASP8) and subsequently by caspase-3 (CASP3)
CC       (PubMed:9463409). Can also undergo autoactivation by mediating
CC       autocleavage at Asp-179 and Asp-193, while it is not able to cleave its
CC       N-terminal disordered prodomain (PubMed:19133298, PubMed:28864531).
CC       Cleaved and activated by CASP1, possibly in the context of inflammation
CC       (PubMed:16123779). {ECO:0000269|PubMed:16123779,
CC       ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:28864531,
CC       ECO:0000269|PubMed:9463409}.
CC   -!- SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/casp6/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U20536; AAC50168.1; -; mRNA.
DR   EMBL; U20537; AAC50169.1; -; mRNA.
DR   EMBL; AY254046; AAO63494.1; -; Genomic_DNA.
DR   EMBL; BC000305; AAH00305.1; -; mRNA.
DR   EMBL; BC004460; AAH04460.1; -; mRNA.
DR   CCDS; CCDS3684.1; -. [P55212-1]
DR   CCDS; CCDS3685.1; -. [P55212-2]
DR   RefSeq; NP_001217.2; NM_001226.3. [P55212-1]
DR   RefSeq; NP_116787.1; NM_032992.2. [P55212-2]
DR   PDB; 2WDP; X-ray; 1.95 A; A/B/C/D=1-293.
DR   PDB; 3K7E; X-ray; 3.00 A; A/B/C/D=24-293.
DR   PDB; 3NKF; X-ray; 2.90 A; A/B/C/D=24-293.
DR   PDB; 3NR2; X-ray; 2.90 A; A/B=24-293.
DR   PDB; 3OD5; X-ray; 1.60 A; A/B=24-293.
DR   PDB; 3P45; X-ray; 2.53 A; A/C/E/G/I/K/M/O=1-179, B/D/F/H/J/L/N/P=193-293.
DR   PDB; 3P4U; X-ray; 1.90 A; A/C=23-179, B/D=193-293.
DR   PDB; 3QNW; X-ray; 2.65 A; A/C/E/G=24-179, B/D/F/H=194-293.
DR   PDB; 3S70; X-ray; 1.62 A; A/C=24-293.
DR   PDB; 3S8E; X-ray; 2.88 A; A/B/C/D/E/F/G/H=24-293.
DR   PDB; 3V6L; X-ray; 2.20 A; A/B=21-293.
DR   PDB; 3V6M; X-ray; 2.69 A; A/B/C/D/F/G/I/J=24-293.
DR   PDB; 4EJF; X-ray; 2.65 A; A/B/C/D=24-293.
DR   PDB; 4FXO; X-ray; 2.85 A; A/B/C/D=1-293.
DR   PDB; 4HVA; X-ray; 2.07 A; A/B=24-293.
DR   PDB; 4IYR; X-ray; 2.70 A; A/B=1-293.
DR   PDB; 4N5D; X-ray; 2.06 A; A/B=24-293.
DR   PDB; 4N6G; X-ray; 2.14 A; A/B=24-293.
DR   PDB; 4N7J; X-ray; 1.67 A; A/B=24-293.
DR   PDB; 4N7M; X-ray; 2.12 A; A/B=24-293.
DR   PDB; 4NBK; X-ray; 1.94 A; A/B=24-293.
DR   PDB; 4NBL; X-ray; 1.76 A; A/B=24-293.
DR   PDB; 4NBN; X-ray; 1.75 A; A/B=24-293.
DR   PDB; 6DEU; X-ray; 2.80 A; A/B=2-293.
DR   PDB; 6DEV; X-ray; 2.35 A; A/B/C/D=2-293.
DR   PDBsum; 2WDP; -.
DR   PDBsum; 3K7E; -.
DR   PDBsum; 3NKF; -.
DR   PDBsum; 3NR2; -.
DR   PDBsum; 3OD5; -.
DR   PDBsum; 3P45; -.
DR   PDBsum; 3P4U; -.
DR   PDBsum; 3QNW; -.
DR   PDBsum; 3S70; -.
DR   PDBsum; 3S8E; -.
DR   PDBsum; 3V6L; -.
DR   PDBsum; 3V6M; -.
DR   PDBsum; 4EJF; -.
DR   PDBsum; 4FXO; -.
DR   PDBsum; 4HVA; -.
DR   PDBsum; 4IYR; -.
DR   PDBsum; 4N5D; -.
DR   PDBsum; 4N6G; -.
DR   PDBsum; 4N7J; -.
DR   PDBsum; 4N7M; -.
DR   PDBsum; 4NBK; -.
DR   PDBsum; 4NBL; -.
DR   PDBsum; 4NBN; -.
DR   PDBsum; 6DEU; -.
DR   PDBsum; 6DEV; -.
DR   AlphaFoldDB; P55212; -.
DR   SMR; P55212; -.
DR   BioGRID; 107289; 39.
DR   ComplexPortal; CPX-971; Caspase-6 complex.
DR   DIP; DIP-44649N; -.
DR   ELM; P55212; -.
DR   IntAct; P55212; 213.
DR   MINT; P55212; -.
DR   STRING; 9606.ENSP00000265164; -.
DR   BindingDB; P55212; -.
DR   ChEMBL; CHEMBL3308; -.
DR   GuidetoPHARMACOLOGY; 1622; -.
DR   MEROPS; C14.005; -.
DR   GlyCosmos; P55212; 1 site, 2 glycans.
DR   GlyGen; P55212; 1 site, 2 O-linked glycans (1 site).
DR   iPTMnet; P55212; -.
DR   PhosphoSitePlus; P55212; -.
DR   SwissPalm; P55212; -.
DR   BioMuta; CASP6; -.
DR   DMDM; 26006981; -.
DR   OGP; P55212; -.
DR   EPD; P55212; -.
DR   jPOST; P55212; -.
DR   MassIVE; P55212; -.
DR   MaxQB; P55212; -.
DR   PaxDb; P55212; -.
DR   PeptideAtlas; P55212; -.
DR   ProteomicsDB; 56817; -. [P55212-1]
DR   ProteomicsDB; 56818; -. [P55212-2]
DR   Antibodypedia; 1733; 1161 antibodies from 43 providers.
DR   DNASU; 839; -.
DR   Ensembl; ENST00000265164.7; ENSP00000265164.2; ENSG00000138794.10. [P55212-1]
DR   Ensembl; ENST00000352981.7; ENSP00000285333.3; ENSG00000138794.10. [P55212-2]
DR   GeneID; 839; -.
DR   KEGG; hsa:839; -.
DR   MANE-Select; ENST00000265164.7; ENSP00000265164.2; NM_001226.4; NP_001217.2.
DR   UCSC; uc003hzn.2; human. [P55212-1]
DR   AGR; HGNC:1507; -.
DR   CTD; 839; -.
DR   DisGeNET; 839; -.
DR   GeneCards; CASP6; -.
DR   HGNC; HGNC:1507; CASP6.
DR   HPA; ENSG00000138794; Tissue enhanced (intestine).
DR   MIM; 601532; gene.
DR   neXtProt; NX_P55212; -.
DR   OpenTargets; ENSG00000138794; -.
DR   PharmGKB; PA26090; -.
DR   VEuPathDB; HostDB:ENSG00000138794; -.
DR   eggNOG; KOG3573; Eukaryota.
DR   GeneTree; ENSGT00940000155140; -.
DR   HOGENOM; CLU_036904_2_2_1; -.
DR   InParanoid; P55212; -.
DR   OMA; PAEEYRM; -.
DR   OrthoDB; 2873736at2759; -.
DR   PhylomeDB; P55212; -.
DR   TreeFam; TF102023; -.
DR   BRENDA; 3.4.22.59; 2681.
DR   PathwayCommons; P55212; -.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-264870; Caspase-mediated cleavage of cytoskeletal proteins.
DR   Reactome; R-HSA-352238; Breakdown of the nuclear lamina.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   SABIO-RK; P55212; -.
DR   SignaLink; P55212; -.
DR   SIGNOR; P55212; -.
DR   BioGRID-ORCS; 839; 14 hits in 1166 CRISPR screens.
DR   ChiTaRS; CASP6; human.
DR   EvolutionaryTrace; P55212; -.
DR   GeneWiki; Caspase_6; -.
DR   GenomeRNAi; 839; -.
DR   Pharos; P55212; Tchem.
DR   PRO; PR:P55212; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P55212; protein.
DR   Bgee; ENSG00000138794; Expressed in rectum and 168 other tissues.
DR   ExpressionAtlas; P55212; baseline and differential.
DR   Genevisible; P55212; HS.
DR   GO; GO:0008303; C:caspase complex; IPI:ComplexPortal.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005730; C:nucleolus; IDA:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0097153; F:cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0097200; F:cysteine-type endopeptidase activity involved in execution phase of apoptosis; IMP:CAFA.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0097202; P:activation of cysteine-type endopeptidase activity; IDA:ComplexPortal.
DR   GO; GO:0002218; P:activation of innate immune response; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IBA:GO_Central.
DR   GO; GO:0072734; P:cellular response to staurosporine; IMP:CAFA.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:ComplexPortal.
DR   GO; GO:0060545; P:positive regulation of necroptotic process; IDA:UniProtKB.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0070269; P:pyroptosis; IDA:UniProtKB.
DR   GO; GO:1901028; P:regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; NAS:ComplexPortal.
DR   CDD; cd00032; CASc; 1.
DR   Gene3D; 3.40.50.1460; -; 1.
DR   InterPro; IPR029030; Caspase-like_dom_sf.
DR   InterPro; IPR033139; Caspase_cys_AS.
DR   InterPro; IPR016129; Caspase_his_AS.
DR   InterPro; IPR002398; Pept_C14.
DR   InterPro; IPR011600; Pept_C14_caspase.
DR   InterPro; IPR002138; Pept_C14_p10.
DR   InterPro; IPR001309; Pept_C14_p20.
DR   InterPro; IPR015917; Pept_C14A.
DR   PANTHER; PTHR10454; CASPASE; 1.
DR   PANTHER; PTHR10454:SF206; CASPASE-6; 1.
DR   Pfam; PF00656; Peptidase_C14; 1.
DR   PRINTS; PR00376; IL1BCENZYME.
DR   SMART; SM00115; CASc; 1.
DR   SUPFAM; SSF52129; Caspase-like; 1.
DR   PROSITE; PS01122; CASPASE_CYS; 1.
DR   PROSITE; PS01121; CASPASE_HIS; 1.
DR   PROSITE; PS50207; CASPASE_P10; 1.
DR   PROSITE; PS50208; CASPASE_P20; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Autocatalytic cleavage;
KW   Cytoplasm; Hydrolase; Lipoprotein; Nucleus; Palmitate; Phosphoprotein;
KW   Protease; Reference proteome; Thiol protease; Zymogen.
FT   PROPEP          1..23
FT                   /evidence="ECO:0000305|PubMed:19133298,
FT                   ECO:0000305|PubMed:8900201, ECO:0000305|PubMed:9463409"
FT                   /id="PRO_0000004608"
FT   CHAIN           24..179
FT                   /note="Caspase-6 subunit p18"
FT                   /evidence="ECO:0000305|PubMed:19133298,
FT                   ECO:0000305|PubMed:8900201, ECO:0000305|PubMed:9463409"
FT                   /id="PRO_0000004609"
FT   PROPEP          180..193
FT                   /evidence="ECO:0000305|PubMed:19133298,
FT                   ECO:0000305|PubMed:8900201, ECO:0000305|PubMed:9463409"
FT                   /id="PRO_0000004610"
FT   CHAIN           194..293
FT                   /note="Caspase-6 subunit p11"
FT                   /evidence="ECO:0000305|PubMed:19133298,
FT                   ECO:0000305|PubMed:8900201, ECO:0000305|PubMed:9463409"
FT                   /id="PRO_0000004611"
FT   REGION          1..20
FT                   /note="Disordered"
FT                   /evidence="ECO:0000269|PubMed:28864531,
FT                   ECO:0000305|PubMed:30420425"
FT   REGION          42..44
FT                   /note="Tri-arginine exosite"
FT                   /evidence="ECO:0000269|PubMed:30420425"
FT   REGION          125..142
FT                   /note="130's region"
FT                   /evidence="ECO:0000269|PubMed:28154009"
FT   ACT_SITE        121
FT                   /evidence="ECO:0000269|PubMed:30420425"
FT   ACT_SITE        163
FT                   /evidence="ECO:0000269|PubMed:16123779,
FT                   ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:19694615,
FT                   ECO:0000269|PubMed:20890311, ECO:0000269|PubMed:28864531,
FT                   ECO:0000269|PubMed:30420425"
FT   MOD_RES         79
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08738"
FT   MOD_RES         257
FT                   /note="Phosphoserine; by NUAK1 and AMPK"
FT                   /evidence="ECO:0000269|PubMed:15273717,
FT                   ECO:0000269|PubMed:22483120, ECO:0000269|PubMed:32029622"
FT   LIPID           264
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27911442"
FT   LIPID           277
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27911442"
FT   VAR_SEQ         14..102
FT                   /note="Missing (in isoform Beta)"
FT                   /evidence="ECO:0000303|PubMed:7796396"
FT                   /id="VSP_000805"
FT   VARIANT         35
FT                   /note="E -> K (in dbSNP:rs11574697)"
FT                   /id="VAR_029242"
FT   VARIANT         109
FT                   /note="A -> T (in dbSNP:rs5030674)"
FT                   /id="VAR_016130"
FT   VARIANT         182
FT                   /note="T -> S (in dbSNP:rs5030593)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_020126"
FT   MUTAGEN         23
FT                   /note="D->A: Abolished activation due to the presence of
FT                   the N-terminal disordered prodomain. Abolished processing
FT                   and subsequent activation; when associated with A-179 and
FT                   A-193."
FT                   /evidence="ECO:0000269|PubMed:19133298,
FT                   ECO:0000269|PubMed:28864531"
FT   MUTAGEN         42..44
FT                   /note="RRR->AAA: Decreased ability to hydrolyze
FT                   substrates."
FT                   /evidence="ECO:0000269|PubMed:30420425"
FT   MUTAGEN         121
FT                   /note="H->A: Catalytically inactive active-site mutant."
FT                   /evidence="ECO:0000269|PubMed:30420425"
FT   MUTAGEN         135
FT                   /note="E->Q: Increased stability."
FT                   /evidence="ECO:0000269|PubMed:28154009"
FT   MUTAGEN         163
FT                   /note="C->A,S: Catalytically inactive active-site mutant."
FT                   /evidence="ECO:0000269|PubMed:16123779,
FT                   ECO:0000269|PubMed:19133298, ECO:0000269|PubMed:19694615,
FT                   ECO:0000269|PubMed:20890311, ECO:0000269|PubMed:28864531,
FT                   ECO:0000269|PubMed:30420425"
FT   MUTAGEN         179
FT                   /note="D->A: Abolished processing and subsequent
FT                   activation; when associated with A-23 and A-193."
FT                   /evidence="ECO:0000269|PubMed:19133298,
FT                   ECO:0000269|PubMed:28864531"
FT   MUTAGEN         193
FT                   /note="D->A: Abolished processing and subsequent
FT                   activation; when associated with A-23 and A-179."
FT                   /evidence="ECO:0000269|PubMed:19133298,
FT                   ECO:0000269|PubMed:28864531"
FT   MUTAGEN         257
FT                   /note="S->A: Abolished phosphorylation, leading to caspase-
FT                   6 activation."
FT                   /evidence="ECO:0000269|PubMed:15273717,
FT                   ECO:0000269|PubMed:32029622"
FT   MUTAGEN         257
FT                   /note="S->D: Phospho-mimetic mutant; prevents caspase-6
FT                   autoactivation."
FT                   /evidence="ECO:0000269|PubMed:22483120,
FT                   ECO:0000269|PubMed:32029622"
FT   MUTAGEN         257
FT                   /note="S->E: Phospho-mimetic mutant; loss of self-
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:22433863,
FT                   ECO:0000269|PubMed:32029622"
FT   MUTAGEN         264
FT                   /note="C->S: Reduced palmitoylation, leading to increased
FT                   cysteine protease activity."
FT                   /evidence="ECO:0000269|PubMed:27911442"
FT   MUTAGEN         277
FT                   /note="C->S: Reduced palmitoylation, leading to increased
FT                   cysteine protease activity."
FT                   /evidence="ECO:0000269|PubMed:27911442"
FT   CONFLICT        66
FT                   /note="G -> R (in Ref. 1; AAC50168)"
FT                   /evidence="ECO:0000305"
FT   STRAND          41..43
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          46..51
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           67..80
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          84..90
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           93..105
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          114..120
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:4N7J"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          130..135
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           136..141
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   TURN            145..147
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          156..162
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          190..194
FT                   /evidence="ECO:0007829|PDB:4N7J"
FT   STRAND          197..199
FT                   /evidence="ECO:0007829|PDB:3S8E"
FT   TURN            202..205
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          206..212
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   TURN            222..224
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           227..239
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   TURN            240..242
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   HELIX           245..258
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          263..265
FT                   /evidence="ECO:0007829|PDB:4N7J"
FT   HELIX           267..269
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:3S8E"
FT   STRAND          277..280
FT                   /evidence="ECO:0007829|PDB:3OD5"
FT   STRAND          283..285
FT                   /evidence="ECO:0007829|PDB:3QNW"
SQ   SEQUENCE   293 AA;  33310 MW;  0738AE4F9791EBD7 CRC64;
     MSSASGLRRG HPAGGEENMT ETDAFYKREM FDPAEKYKMD HRRRGIALIF NHERFFWHLT
     LPERRGTCAD RDNLTRRFSD LGFEVKCFND LKAEELLLKI HEVSTVSHAD ADCFVCVFLS
     HGEGNHIYAY DAKIEIQTLT GLFKGDKCHS LVGKPKIFII QACRGNQHDV PVIPLDVVDN
     QTEKLDTNIT EVDAASVYTL PAGADFLMCY SVAEGYYSHR ETVNGSWYIQ DLCEMLGKYG
     SSLEFTELLT LVNRKVSQRR VDFCKDPSAI GKKQVPCFAS MLTKKLHFFP KSN
//
ID   CCKN_HUMAN              Reviewed;         115 AA.
AC   P06307;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   22-FEB-2023, entry version 185.
DE   RecName: Full=Cholecystokinin;
DE            Short=CCK;
DE   Contains:
DE     RecName: Full=Cholecystokinin-58;
DE              Short=CCK58;
DE   Contains:
DE     RecName: Full=Cholecystokinin-58 desnonopeptide;
DE     AltName: Full=(1-49)-CCK58;
DE   Contains:
DE     RecName: Full=Cholecystokinin-39;
DE              Short=CCK39;
DE   Contains:
DE     RecName: Full=Cholecystokinin-33;
DE              Short=CCK33;
DE   Contains:
DE     RecName: Full=Cholecystokinin-25;
DE              Short=CCK25;
DE   Contains:
DE     RecName: Full=Cholecystokinin-18;
DE              Short=CCK18;
DE   Contains:
DE     RecName: Full=Cholecystokinin-12;
DE              Short=CCK12;
DE   Contains:
DE     RecName: Full=Cholecystokinin-8;
DE              Short=CCK8;
DE   Contains:
DE     RecName: Full=Cholecystokinin-7;
DE              Short=CCK7;
DE   Contains:
DE     RecName: Full=Cholecystokinin-5;
DE              Short=CCK5;
DE   Flags: Precursor;
GN   Name=CCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Kato K., Takahashi Y., Matsubara K.;
RT   "Molecular cloning of the human cholecystokinin gene.";
RL   Ann. N. Y. Acad. Sci. 448:613-615(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND AMIDATION AT PHE-103.
RX   PubMed=3856870; DOI=10.1073/pnas.82.7.1931;
RA   Takahashi Y., Kato K., Hayashizaki Y., Wakabayashi T., Ohtsuka E.,
RA   Matsuki S., Ikehara M., Matsubara K.;
RT   "Molecular cloning of the human cholecystokinin gene by use of a synthetic
RT   probe containing deoxyinosine.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1931-1935(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-32.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEOLYTIC CLEAVAGE (CHOLECYSTOKININ-5).
RX   PubMed=9371719; DOI=10.1042/bj3280587;
RA   Isaac R.E., Williams T.A., Sajid M., Corvol P., Coates D.;
RT   "Cleavage of arginyl-arginine and lysyl-arginine from the C-terminus of
RT   pro-hormone peptides by human germinal angiotensin I-converting enzyme
RT   (ACE) and the C-domain of human somatic ACE.";
RL   Biochem. J. 328:587-591(1997).
RN   [7]
RP   PROTEOLYTIC CLEAVAGE (CHOLECYSTOKININ-5).
RX   PubMed=10336644; DOI=10.1046/j.1432-1327.1999.00419.x;
RA   Isaac R.E., Michaud A., Keen J.N., Williams T.A., Coates D., Wetsel W.C.,
RA   Corvol P.;
RT   "Hydrolysis by somatic angiotensin-I converting enzyme of basic dipeptides
RT   from a cholecystokinin/gastrin and a LH-RH peptide extended at the C-
RT   terminus with gly-Arg/Lys-arg, but not from diarginyl insulin.";
RL   Eur. J. Biochem. 262:569-574(1999).
RN   [8]
RP   MUTAGENESIS OF TYR-97, AND SULFATION AT TYR-97.
RX   PubMed=11076522; DOI=10.1021/bi0011072;
RA   Vishnuvardhan D., Beinfeld M.C.;
RT   "Role of tyrosine sulfation and serine phosphorylation in the processing of
RT   procholecystokinin to amidated cholecystokinin and its secretion in
RT   transfected AtT-20 cells.";
RL   Biochemistry 39:13825-13830(2000).
CC   -!- FUNCTION: This peptide hormone induces gall bladder contraction and the
CC       release of pancreatic enzymes in the gut. Its function in the brain is
CC       not clear. Binding to CCK-A receptors stimulates amylase release from
CC       the pancreas, binding to CCK-B receptors stimulates gastric acid
CC       secretion. {ECO:0000250|UniProtKB:Q9TS44}.
CC   -!- SUBUNIT: Binds to CCK-A receptors in the pancreas and CCK-B receptors
CC       in the brain. {ECO:0000250|UniProtKB:Q9TS44}.
CC   -!- INTERACTION:
CC       P06307; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-6624398, EBI-18899653;
CC       P06307; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-6624398, EBI-10173507;
CC       P06307; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-6624398, EBI-8464238;
CC       P06307; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-6624398, EBI-5280499;
CC       P06307; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-6624398, EBI-10254793;
CC       P06307; C1IDX9: ATG12; NbExp=3; IntAct=EBI-6624398, EBI-25836940;
CC       P06307; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-6624398, EBI-10693038;
CC       P06307; O00257-3: CBX4; NbExp=3; IntAct=EBI-6624398, EBI-4392727;
CC       P06307; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-6624398, EBI-11953200;
CC       P06307; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-6624398, EBI-749253;
CC       P06307; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-6624398, EBI-744045;
CC       P06307; Q99966: CITED1; NbExp=3; IntAct=EBI-6624398, EBI-2624951;
CC       P06307; O95278-6: EPM2A; NbExp=3; IntAct=EBI-6624398, EBI-25836908;
CC       P06307; Q6NXG1-3: ESRP1; NbExp=3; IntAct=EBI-6624398, EBI-21567429;
CC       P06307; P06241: FYN; NbExp=3; IntAct=EBI-6624398, EBI-515315;
CC       P06307; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-6624398, EBI-9088619;
CC       P06307; O75409: H2AP; NbExp=3; IntAct=EBI-6624398, EBI-6447217;
CC       P06307; Q6NXT2: H3-5; NbExp=3; IntAct=EBI-6624398, EBI-2868501;
CC       P06307; P53701: HCCS; NbExp=3; IntAct=EBI-6624398, EBI-10763431;
CC       P06307; Q9NRZ9-6: HELLS; NbExp=3; IntAct=EBI-6624398, EBI-12003732;
CC       P06307; Q9UK76: JPT1; NbExp=3; IntAct=EBI-6624398, EBI-720411;
CC       P06307; Q8N1A0: KRT222; NbExp=3; IntAct=EBI-6624398, EBI-8473062;
CC       P06307; Q6DKI2: LGALS9C; NbExp=3; IntAct=EBI-6624398, EBI-9088829;
CC       P06307; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-6624398, EBI-25835523;
CC       P06307; Q16609: LPAL2; NbExp=3; IntAct=EBI-6624398, EBI-10238012;
CC       P06307; Q8NI22: MCFD2; NbExp=3; IntAct=EBI-6624398, EBI-2689785;
CC       P06307; P01106: MYC; NbExp=3; IntAct=EBI-6624398, EBI-447544;
CC       P06307; Q9UJ70-2: NAGK; NbExp=3; IntAct=EBI-6624398, EBI-11526455;
CC       P06307; P25208: NFYB; NbExp=3; IntAct=EBI-6624398, EBI-389728;
CC       P06307; Q8NFH3: NUP43; NbExp=3; IntAct=EBI-6624398, EBI-1059321;
CC       P06307; Q7Z3B4: NUP54; NbExp=3; IntAct=EBI-6624398, EBI-741048;
CC       P06307; Q07869: PPARA; NbExp=3; IntAct=EBI-6624398, EBI-78615;
CC       P06307; P02775: PPBP; NbExp=3; IntAct=EBI-6624398, EBI-718973;
CC       P06307; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-6624398, EBI-25835994;
CC       P06307; P23942: PRPH2; NbExp=3; IntAct=EBI-6624398, EBI-25836834;
CC       P06307; P29074: PTPN4; NbExp=3; IntAct=EBI-6624398, EBI-710431;
CC       P06307; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-6624398, EBI-14065960;
CC       P06307; Q04206: RELA; NbExp=3; IntAct=EBI-6624398, EBI-73886;
CC       P06307; P47804-3: RGR; NbExp=3; IntAct=EBI-6624398, EBI-25834767;
CC       P06307; Q15382: RHEB; NbExp=3; IntAct=EBI-6624398, EBI-1055287;
CC       P06307; P62701: RPS4X; NbExp=3; IntAct=EBI-6624398, EBI-354303;
CC       P06307; Q66K80: RUSC1-AS1; NbExp=3; IntAct=EBI-6624398, EBI-10248967;
CC       P06307; Q7L8J4: SH3BP5L; NbExp=3; IntAct=EBI-6624398, EBI-747389;
CC       P06307; Q8IYM2: SLFN12; NbExp=3; IntAct=EBI-6624398, EBI-2822550;
CC       P06307; Q9C004: SPRY4; NbExp=3; IntAct=EBI-6624398, EBI-354861;
CC       P06307; Q5W111-2: SPRYD7; NbExp=3; IntAct=EBI-6624398, EBI-12408727;
CC       P06307; Q96BD6: SPSB1; NbExp=3; IntAct=EBI-6624398, EBI-2659201;
CC       P06307; Q92797-2: SYMPK; NbExp=3; IntAct=EBI-6624398, EBI-21560407;
CC       P06307; P62253: UBE2G1; NbExp=3; IntAct=EBI-6624398, EBI-2340619;
CC       P06307; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-6624398, EBI-947187;
CC       P06307; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-6624398, EBI-25835297;
CC       P06307; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-6624398, EBI-10316321;
CC       P06307; Q8IWT0-2: ZBTB8OS; NbExp=3; IntAct=EBI-6624398, EBI-12956041;
CC       P06307; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-6624398, EBI-14104088;
CC       P06307; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-6624398, EBI-25835852;
CC       PRO_0000010542; P32239: CCKBR; NbExp=2; IntAct=EBI-6624436, EBI-1753137;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P09240}.
CC   -!- PTM: The precursor is cleaved by proteases to produce a number of
CC       active cholecystokinins.
CC   -!- PTM: [Cholecystokinin-5]: The precursor is cleaved by ACE, which
CC       removes the Gly-Arg-Arg peptide at the C-terminus, leading to mature
CC       hormone. {ECO:0000269|PubMed:10336644, ECO:0000269|PubMed:9371719}.
CC   -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cck/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cholecystokinin entry;
CC       URL="https://en.wikipedia.org/wiki/Cholecystokinin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L00354; AAA53094.1; -; Genomic_DNA.
DR   EMBL; BT006991; AAP35637.1; -; mRNA.
DR   EMBL; AY514491; AAR89908.1; -; Genomic_DNA.
DR   EMBL; BC008283; AAH08283.1; -; mRNA.
DR   CCDS; CCDS2696.1; -.
DR   PIR; A01623; GMHUCP.
DR   RefSeq; NP_000720.1; NM_000729.5.
DR   RefSeq; NP_001167609.1; NM_001174138.2.
DR   PDB; 7EZH; EM; 3.20 A; P=96-103.
DR   PDB; 7EZK; EM; 3.10 A; P=96-103.
DR   PDB; 7EZM; EM; 2.90 A; P=96-103.
DR   PDB; 7MBX; EM; 1.95 A; P=96-103.
DR   PDB; 7MBY; EM; 2.44 A; P=96-103.
DR   PDBsum; 7EZH; -.
DR   PDBsum; 7EZK; -.
DR   PDBsum; 7EZM; -.
DR   PDBsum; 7MBX; -.
DR   PDBsum; 7MBY; -.
DR   AlphaFoldDB; P06307; -.
DR   SMR; P06307; -.
DR   BioGRID; 107327; 13.
DR   IntAct; P06307; 56.
DR   STRING; 9606.ENSP00000379472; -.
DR   BindingDB; P06307; -.
DR   ChEMBL; CHEMBL1649050; -.
DR   DrugBank; DB13729; Camostat.
DR   iPTMnet; P06307; -.
DR   PhosphoSitePlus; P06307; -.
DR   BioMuta; CCK; -.
DR   DMDM; 115945; -.
DR   MassIVE; P06307; -.
DR   PaxDb; P06307; -.
DR   PeptideAtlas; P06307; -.
DR   ProteomicsDB; 51882; -.
DR   Antibodypedia; 29187; 275 antibodies from 34 providers.
DR   DNASU; 885; -.
DR   Ensembl; ENST00000334681.9; ENSP00000335657.5; ENSG00000187094.12.
DR   Ensembl; ENST00000396169.7; ENSP00000379472.2; ENSG00000187094.12.
DR   Ensembl; ENST00000434608.1; ENSP00000409124.1; ENSG00000187094.12.
DR   GeneID; 885; -.
DR   KEGG; hsa:885; -.
DR   MANE-Select; ENST00000396169.7; ENSP00000379472.2; NM_000729.6; NP_000720.1.
DR   AGR; HGNC:1569; -.
DR   CTD; 885; -.
DR   DisGeNET; 885; -.
DR   GeneCards; CCK; -.
DR   HGNC; HGNC:1569; CCK.
DR   HPA; ENSG00000187094; Group enriched (brain, choroid plexus, intestine).
DR   MIM; 118440; gene.
DR   neXtProt; NX_P06307; -.
DR   OpenTargets; ENSG00000187094; -.
DR   PharmGKB; PA26141; -.
DR   VEuPathDB; HostDB:ENSG00000187094; -.
DR   eggNOG; ENOG502S472; Eukaryota.
DR   GeneTree; ENSGT00390000003571; -.
DR   HOGENOM; CLU_169783_0_0_1; -.
DR   InParanoid; P06307; -.
DR   OMA; YSGLCIC; -.
DR   OrthoDB; 5293435at2759; -.
DR   PhylomeDB; P06307; -.
DR   TreeFam; TF333419; -.
DR   PathwayCommons; P06307; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P06307; -.
DR   SIGNOR; P06307; -.
DR   BioGRID-ORCS; 885; 15 hits in 1146 CRISPR screens.
DR   ChiTaRS; CCK; human.
DR   GeneWiki; Cholecystokinin; -.
DR   GenomeRNAi; 885; -.
DR   Pharos; P06307; Tbio.
DR   PRO; PR:P06307; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P06307; protein.
DR   Bgee; ENSG00000187094; Expressed in frontal pole and 123 other tissues.
DR   ExpressionAtlas; P06307; baseline and differential.
DR   Genevisible; P06307; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0005179; F:hormone activity; TAS:ProtInc.
DR   GO; GO:0005184; F:neuropeptide hormone activity; ISS:UniProtKB.
DR   GO; GO:0051428; F:peptide hormone receptor binding; IPI:GO_Central.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0007586; P:digestion; IBA:GO_Central.
DR   GO; GO:0042755; P:eating behavior; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR015499; CCK-like.
DR   InterPro; IPR001651; Gastrin/CCK.
DR   InterPro; IPR013152; Gastrin/cholecystokinin_CS.
DR   PANTHER; PTHR10786; CHOLECYSTOKININ; 1.
DR   PANTHER; PTHR10786:SF0; CHOLECYSTOKININ; 1.
DR   Pfam; PF00918; Gastrin; 1.
DR   SMART; SM00029; GASTRIN; 1.
DR   PROSITE; PS00259; GASTRIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amidation; Cleavage on pair of basic residues; Hormone;
KW   Reference proteome; Secreted; Signal; Sulfation.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..115
FT                   /note="Cholecystokinin"
FT                   /id="PRO_0000010536"
FT   PROPEP          21..44
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000010537"
FT   PEPTIDE         46..103
FT                   /note="Cholecystokinin-58"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000010538"
FT   PEPTIDE         46..94
FT                   /note="Cholecystokinin-58 desnonopeptide"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000306304"
FT   PEPTIDE         65..103
FT                   /note="Cholecystokinin-39"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000010539"
FT   PEPTIDE         71..103
FT                   /note="Cholecystokinin-33"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000010540"
FT   PEPTIDE         79..103
FT                   /note="Cholecystokinin-25"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000306305"
FT   PEPTIDE         86..103
FT                   /note="Cholecystokinin-18"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000306306"
FT   PEPTIDE         92..103
FT                   /note="Cholecystokinin-12"
FT                   /evidence="ECO:0000250|UniProtKB:P01356"
FT                   /id="PRO_0000010541"
FT   PEPTIDE         96..103
FT                   /note="Cholecystokinin-8"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000010542"
FT   PEPTIDE         97..103
FT                   /note="Cholecystokinin-7"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000306307"
FT   PEPTIDE         99..103
FT                   /note="Cholecystokinin-5"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT                   /id="PRO_0000306308"
FT   PROPEP          107..115
FT                   /id="PRO_0000010543"
FT   REGION          22..52
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        38..52
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         97
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11076522"
FT   MOD_RES         103
FT                   /note="Phenylalanine amide"
FT                   /evidence="ECO:0000269|PubMed:3856870"
FT   MOD_RES         111
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT   MOD_RES         113
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9TS44"
FT   VARIANT         32
FT                   /note="G -> E (in dbSNP:rs11571848)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_018818"
FT   VARIANT         95
FT                   /note="R -> W (in dbSNP:rs3774395)"
FT                   /id="VAR_024452"
FT   MUTAGEN         97
FT                   /note="Y->F: Reduces the quantity of secreted CCK8 by 50%."
FT                   /evidence="ECO:0000269|PubMed:11076522"
SQ   SEQUENCE   115 AA;  12669 MW;  8A3EE6442FAEAF4B CRC64;
     MNSGVCLCVL MAVLAAGALT QPVPPADPAG SGLQRAEEAP RRQLRVSQRT DGESRAHLGA
     LLARYIQQAR KAPSGRMSIV KNLQNLDPSH RISDRDYMGW MDFGRRSAEE YEYPS
//
ID   CLASR_HUMAN             Reviewed;         674 AA.
AC   Q8N2M8; B4DDT8; F8WAG9; O96026; Q6UW71; Q96DX2;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 4.
DT   22-FEB-2023, entry version 160.
DE   RecName: Full=CLK4-associating serine/arginine rich protein;
DE   AltName: Full=Splicing factor, arginine/serine-rich 16;
DE   AltName: Full=Suppressor of white-apricot homolog 2;
GN   Name=CLASRP; Synonyms=SFRS16, SWAP2; ORFNames=UNQ2428/PRO4988;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLU-174.
RA   Yoshiura K., Murray J.C.;
RT   "A transcriptional map in the region of 19q13 derived using direct
RT   sequencing and exon trapping.";
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLU-174.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT GLU-174.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLU-174.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-547, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-285; THR-327; SER-331 AND
RP   SER-335, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-331 AND SER-335, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-547, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-285 AND SER-547, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-285; SER-294;
RP   SER-547 AND THR-573, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-285 AND SER-547, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-213.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Probably functions as an alternative splicing regulator. May
CC       regulate the mRNA splicing of genes such as CLK1. May act by regulating
CC       members of the CLK kinase family (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Probably interacts with CLK4. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q8N2M8; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-751069, EBI-8464238;
CC       Q8N2M8; Q9Y6A4: CFAP20; NbExp=4; IntAct=EBI-751069, EBI-1046872;
CC       Q8N2M8; P49759-3: CLK1; NbExp=3; IntAct=EBI-751069, EBI-11981867;
CC       Q8N2M8; P49760: CLK2; NbExp=3; IntAct=EBI-751069, EBI-750020;
CC       Q8N2M8; P49761: CLK3; NbExp=4; IntAct=EBI-751069, EBI-745579;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8N2M8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N2M8-3; Sequence=VSP_013894, VSP_013895;
CC       Name=3;
CC         IsoId=Q8N2M8-4; Sequence=VSP_055717;
CC   -!- PTM: Phosphorylated in vitro by CLK4. {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the splicing factor SR family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-16 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC82339.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC82340.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH80554.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF042800; AAC82339.1; ALT_INIT; mRNA.
DR   EMBL; AF042810; AAC82340.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF042802; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042803; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042804; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042805; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042806; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042807; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042808; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AF042809; AAC82340.1; JOINED; Genomic_DNA.
DR   EMBL; AY358944; AAQ89303.1; -; mRNA.
DR   EMBL; AK293333; BAG56849.1; -; mRNA.
DR   EMBL; AC011489; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC080554; AAH80554.1; ALT_INIT; mRNA.
DR   CCDS; CCDS12652.2; -. [Q8N2M8-1]
DR   CCDS; CCDS62710.1; -. [Q8N2M8-4]
DR   RefSeq; NP_001265368.1; NM_001278439.1.
DR   RefSeq; NP_008987.2; NM_007056.2.
DR   AlphaFoldDB; Q8N2M8; -.
DR   SMR; Q8N2M8; -.
DR   BioGRID; 116302; 85.
DR   IntAct; Q8N2M8; 32.
DR   STRING; 9606.ENSP00000221455; -.
DR   GlyCosmos; Q8N2M8; 1 site, 1 glycan.
DR   GlyGen; Q8N2M8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8N2M8; -.
DR   PhosphoSitePlus; Q8N2M8; -.
DR   BioMuta; CLASRP; -.
DR   DMDM; 226694202; -.
DR   EPD; Q8N2M8; -.
DR   jPOST; Q8N2M8; -.
DR   MassIVE; Q8N2M8; -.
DR   MaxQB; Q8N2M8; -.
DR   PaxDb; Q8N2M8; -.
DR   PeptideAtlas; Q8N2M8; -.
DR   ProteomicsDB; 30495; -.
DR   ProteomicsDB; 71717; -. [Q8N2M8-1]
DR   ProteomicsDB; 71718; -. [Q8N2M8-3]
DR   Antibodypedia; 54055; 73 antibodies from 19 providers.
DR   DNASU; 11129; -.
DR   Ensembl; ENST00000391952.7; ENSP00000375814.2; ENSG00000104859.15.
DR   Ensembl; ENST00000391953.8; ENSP00000375815.3; ENSG00000104859.15.
DR   GeneID; 11129; -.
DR   KEGG; hsa:11129; -.
DR   UCSC; uc010xxh.3; human. [Q8N2M8-1]
DR   AGR; HGNC:17731; -.
DR   CTD; 11129; -.
DR   DisGeNET; 11129; -.
DR   GeneCards; CLASRP; -.
DR   HGNC; HGNC:17731; CLASRP.
DR   HPA; ENSG00000104859; Low tissue specificity.
DR   MIM; 618532; gene.
DR   neXtProt; NX_Q8N2M8; -.
DR   PharmGKB; PA134961731; -.
DR   VEuPathDB; HostDB:ENSG00000104859; -.
DR   eggNOG; KOG2548; Eukaryota.
DR   InParanoid; Q8N2M8; -.
DR   OrthoDB; 1330734at2759; -.
DR   PhylomeDB; Q8N2M8; -.
DR   TreeFam; TF351621; -.
DR   PathwayCommons; Q8N2M8; -.
DR   SignaLink; Q8N2M8; -.
DR   BioGRID-ORCS; 11129; 391 hits in 1173 CRISPR screens.
DR   ChiTaRS; CLASRP; human.
DR   GeneWiki; SFRS16; -.
DR   GenomeRNAi; 11129; -.
DR   Pharos; Q8N2M8; Tbio.
DR   PRO; PR:Q8N2M8; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8N2M8; protein.
DR   Bgee; ENSG00000104859; Expressed in adenohypophysis and 190 other tissues.
DR   ExpressionAtlas; Q8N2M8; baseline and differential.
DR   Genevisible; Q8N2M8; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   InterPro; IPR040397; SWAP.
DR   InterPro; IPR019147; SWAP_N_domain.
DR   PANTHER; PTHR13161:SF4; CLK4-ASSOCIATING SERINE/ARGININE RICH PROTEIN; 1.
DR   PANTHER; PTHR13161; SPLICING FACTOR SUPPRESSOR OF WHITE APRICOT; 1.
DR   Pfam; PF09750; DRY_EERY; 1.
DR   SMART; SM01141; DRY_EERY; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; mRNA processing; mRNA splicing; Nucleus;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN           1..674
FT                   /note="CLK4-associating serine/arginine rich protein"
FT                   /id="PRO_0000081945"
FT   REGION          172..232
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          257..674
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          585..647
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        185..214
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        295..309
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        372..405
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        407..441
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        442..456
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        461..491
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        492..537
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        574..642
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         285
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         327
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         335
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         547
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         573
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         42..103
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055717"
FT   VAR_SEQ         570..594
FT                   /note="PKLTPQEKLKLRMQKALNRQFKADK -> VTQADASGEAETEDAEGAEQAVQ
FT                   GG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12975309"
FT                   /id="VSP_013894"
FT   VAR_SEQ         595..674
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12975309"
FT                   /id="VSP_013895"
FT   VARIANT         174
FT                   /note="K -> E (in dbSNP:rs4803794)"
FT                   /evidence="ECO:0000269|PubMed:12975309,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|Ref.1"
FT                   /id="VAR_016809"
FT   VARIANT         213
FT                   /note="L -> S (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035490"
SQ   SEQUENCE   674 AA;  77161 MW;  454F935EBDD96541 CRC64;
     MWHEARKHER KLRGMMVDYK KRAERRREYY EKIKKDPAQF LQVHGRACKV HLDSAVALAA
     ESPVNMMPWQ GDTNNMIDRF DVRAHLDHIP DYTPPLLTTI SPEQESDERK CNYERYRGLV
     QNDFAGISEE QCLYQIYIDE LYGGLQRPSE DEKKKLAEKK ASIGYTYEDS TVAKVEKAAE
     KPEEEESAAE EESNSDEDEV IPDIDVEVDV DELNQEQVAD LNKQATTYGM ADGDFVRMLR
     KDKEEAEAIK HAKALEEEKA MYSGRRSRRQ RREFREKRLR GRKISPPSYA RRDSPTYDPY
     KRSPSESSSE SRSRSRSPTP GREEKITFIT SFGGSDEEAA AAAAAAAASG VTTGKPPAPP
     QPGGPAPGRN ASARRRSSSS SSSSSASRTS SSRSSSRSSS RSRRGGGYYR SGRHARSRSR
     SWSRSRSRSR RYSRSRSRGR RHSGGGSRDG HRYSRSPARR GGYGPRRRSR SRSHSGDRYR
     RGGRGLRHHS SSRSRSSWSL SPSRSRSLTR SRSHSPSPSQ SRSRSRSRSQ SPSPSPAREK
     LTRPAASPAV GEKLKKTEPA AGKETGAAKP KLTPQEKLKL RMQKALNRQF KADKKAAQEK
     MIQQEHERQE REDELRAMAR KIRMKERERR EKEREEWERQ YSRQSRSPSP RYSREYSSSR
     RRSRSRSRSP HYRH
//
ID   COQ8A_HUMAN             Reviewed;         647 AA.
AC   Q8NI60; Q5T7A5; Q63HK0; Q8NCJ6; Q9HBQ1; Q9NQ67;
DT   27-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   22-FEB-2023, entry version 174.
DE   RecName: Full=Atypical kinase COQ8A, mitochondrial {ECO:0000305};
DE            EC=2.7.-.- {ECO:0000269|PubMed:25498144};
DE   AltName: Full=Chaperone activity of bc1 complex-like {ECO:0000303|PubMed:11888884};
DE            Short=Chaperone-ABC1-like {ECO:0000303|PubMed:11888884};
DE   AltName: Full=Coenzyme Q protein 8A {ECO:0000305};
DE   AltName: Full=aarF domain-containing protein kinase 3 {ECO:0000312|HGNC:HGNC:16812};
DE   Flags: Precursor;
GN   Name=COQ8A {ECO:0000303|PubMed:27499294, ECO:0000312|HGNC:HGNC:16812};
GN   Synonyms=ADCK3 {ECO:0000312|HGNC:HGNC:16812},
GN   CABC1 {ECO:0000303|PubMed:11888884}; ORFNames=PP265;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   INDUCTION.
RX   PubMed=11888884;
RA   Iiizumi M., Arakawa H., Mori T., Ando A., Nakamura Y.;
RT   "Isolation of a novel gene, CABC1, encoding a mitochondrial protein that is
RT   highly homologous to yeast activity of bc1 complex.";
RL   Cancer Res. 62:1246-1250(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Skeletal muscle;
RA   Ievolella C., Stanchi F., Bertocco E., Millino C., Faulkner G., Valle G.,
RA   Lanfranchi G.;
RT   "Full length sequencing of some human and murine muscular transcript
RT   (Telethon Italy project B41).";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X.,
RA   Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X.,
RA   Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF N-TERMINUS, X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) OF
RP   256-647, FUNCTION, SUBCELLULAR LOCATION, PATHWAY, DOMAIN, ACTIVITY
RP   REGULATION, MUTAGENESIS OF LYS-276; GLN-279; ALA-339; LYS-358; GLU-405;
RP   GLU-411; ASP-488; ASN-493; ASP-507 AND ARG-611, AND CHARACTERIZATION OF
RP   VARIANTS COQ10D4 TRP-299; CYS-429; SER-549 AND LYS-551.
RX   PubMed=25498144; DOI=10.1016/j.molcel.2014.11.002;
RA   Stefely J.A., Reidenbach A.G., Ulbrich A., Oruganty K., Floyd B.J.,
RA   Jochem A., Saunders J.M., Johnson I.E., Minogue C.E., Wrobel R.L.,
RA   Barber G.E., Lee D., Li S., Kannan N., Coon J.J., Bingman C.A.,
RA   Pagliarini D.J.;
RT   "Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable
RT   coenzyme Q biosynthesis.";
RL   Mol. Cell 57:83-94(2015).
RN   [9]
RP   INVOLVEMENT IN COQ10D4.
RX   PubMed=20580948; DOI=10.1016/j.mito.2010.05.008;
RA   Gerards M., van den Bosch B., Calis C., Schoonderwoerd K., van Engelen K.,
RA   Tijssen M., de Coo R., van der Kooi A., Smeets H.;
RT   "Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and
RT   atrophy.";
RL   Mitochondrion 10:510-515(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   FUNCTION.
RX   PubMed=21296186; DOI=10.1016/j.bbalip.2011.01.009;
RA   Xie L.X., Hsieh E.J., Watanabe S., Allan C.M., Chen J.Y., Tran U.C.,
RA   Clarke C.F.;
RT   "Expression of the human atypical kinase ADCK3 rescues coenzyme Q
RT   biosynthesis and phosphorylation of Coq polypeptides in yeast coq8
RT   mutants.";
RL   Biochim. Biophys. Acta 1811:348-360(2011).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=24270420; DOI=10.1172/jci69000;
RA   Ashraf S., Gee H.Y., Woerner S., Xie L.X., Vega-Warner V., Lovric S.,
RA   Fang H., Song X., Cattran D.C., Avila-Casado C., Paterson A.D.,
RA   Nitschke P., Bole-Feysot C., Cochat P., Esteve-Rudd J., Haberberger B.,
RA   Allen S.J., Zhou W., Airik R., Otto E.A., Barua M., Al-Hamed M.H.,
RA   Kari J.A., Evans J., Bierzynska A., Saleem M.A., Bockenhauer D., Kleta R.,
RA   El Desoky S., Hacihamdioglu D.O., Gok F., Washburn J., Wiggins R.C.,
RA   Choi M., Lifton R.P., Levy S., Han Z., Salviati L., Prokisch H.,
RA   Williams D.S., Pollak M., Clarke C.F., Pei Y., Antignac C., Hildebrandt F.;
RT   "ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10
RT   biosynthesis disruption.";
RL   J. Clin. Invest. 123:5179-5189(2013).
RN   [13]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-214; ALA-215;
RP   ASN-216; PHE-217; GLY-218; GLY-219; LEU-220; ALA-221; VAL-222; GLY-223;
RP   LEU-224; GLY-225; PHE-226; GLY-227; ALA-228; LEU-229 AND ALA-230.
RX   PubMed=25216398; DOI=10.1021/ja505017f;
RA   Khadria A.S., Mueller B.K., Stefely J.A., Tan C.H., Pagliarini D.J.,
RA   Senes A.;
RT   "A Gly-zipper motif mediates homodimerization of the transmembrane domain
RT   of the mitochondrial kinase ADCK3.";
RL   J. Am. Chem. Soc. 136:14068-14077(2014).
RN   [14]
RP   INVOLVEMENT IN COQ10D4.
RX   PubMed=24218524; DOI=10.1136/jnnp-2013-306483;
RA   Liu Y.T., Hersheson J., Plagnol V., Fawcett K., Duberley K.E., Preza E.,
RA   Hargreaves I.P., Chalasani A., Laura M., Wood N.W., Reilly M.M.,
RA   Houlden H.;
RT   "Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation
RT   that elongates the protein: clinical, genetic and biochemical
RT   characterisation.";
RL   J. Neurol. Neurosurg. Psych. 85:493-498(2014).
RN   [15]
RP   FUNCTION.
RX   PubMed=25540914; DOI=10.1016/j.pep.2014.12.008;
RA   Wheeler B., Jia Z.;
RT   "Preparation and characterization of human ADCK3, a putative atypical
RT   kinase.";
RL   Protein Expr. Purif. 108:13-17(2015).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   FUNCTION, INTERACTION WITH THE COQ ENZYME COMPLEX, DOMAIN, X-RAY
RP   CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 256-647 IN COMPLEX WITH ANP NUCLEOTIDE,
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF LYS-276 AND ASP-507.
RX   PubMed=27499294; DOI=10.1016/j.molcel.2016.06.030;
RA   Stefely J.A., Licitra F., Laredj L., Reidenbach A.G., Kemmerer Z.A.,
RA   Grangeray A., Jaeg-Ehret T., Minogue C.E., Ulbrich A., Hutchins P.D.,
RA   Wilkerson E.M., Ruan Z., Aydin D., Hebert A.S., Guo X., Freiberger E.C.,
RA   Reutenauer L., Jochem A., Chergova M., Johnson I.E., Lohman D.C.,
RA   Rush M.J., Kwiecien N.W., Singh P.K., Schlagowski A.I., Floyd B.J.,
RA   Forsman U., Sindelar P.J., Westphall M.S., Pierrel F., Zoll J.,
RA   Dal Peraro M., Kannan N., Bingman C.A., Coon J.J., Isope P., Puccio H.,
RA   Pagliarini D.J.;
RT   "Cerebellar ataxia and coenzyme Q deficiency through loss of unorthodox
RT   kinase activity.";
RL   Mol. Cell 63:608-620(2016).
RN   [18]
RP   INTERACTION WITH THE COQ ENZYME COMPLEX.
RX   PubMed=27499296; DOI=10.1016/j.molcel.2016.06.033;
RA   Floyd B.J., Wilkerson E.M., Veling M.T., Minogue C.E., Xia C., Beebe E.T.,
RA   Wrobel R.L., Cho H., Kremer L.S., Alston C.L., Gromek K.A., Dolan B.K.,
RA   Ulbrich A., Stefely J.A., Bohl S.L., Werner K.M., Jochem A.,
RA   Westphall M.S., Rensvold J.W., Taylor R.W., Prokisch H., Kim J.J.,
RA   Coon J.J., Pagliarini D.J.;
RT   "Mitochondrial protein interaction mapping identifies regulators of
RT   respiratory chain function.";
RL   Mol. Cell 63:621-632(2016).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-341.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [20]
RP   VARIANTS COQ10D4 TRP-213; VAL-272; ASP-272 AND LYS-551.
RX   PubMed=18319072; DOI=10.1016/j.ajhg.2007.12.022;
RA   Mollet J., Delahodde A., Serre V., Chretien D., Schlemmer D., Lombes A.,
RA   Boddaert N., Desguerre I., de Lonlay P., de Baulny H.O., Munnich A.,
RA   Roetig A.;
RT   "CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia
RT   and seizures.";
RL   Am. J. Hum. Genet. 82:623-630(2008).
RN   [21]
RP   VARIANTS COQ10D4 CYS-514; SER-549 AND THR-584 DEL.
RX   PubMed=18319074; DOI=10.1016/j.ajhg.2007.12.024;
RA   Lagier-Tourenne C., Tazir M., Lopez L.C., Quinzii C.M., Assoum M.,
RA   Drouot N., Busso C., Makri S., Ali-Pacha L., Benhassine T., Anheim M.,
RA   Lynch D.R., Thibault C., Plewniak F., Bianchetti L., Tranchant C., Poch O.,
RA   DiMauro S., Mandel J.-L., Barros M.H., Hirano M., Koenig M.;
RT   "ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia
RT   associated with coenzyme Q10 deficiency.";
RL   Am. J. Hum. Genet. 82:661-672(2008).
RN   [22]
RP   VARIANTS COQ10D4 TRP-213; CYS-271; ASP-272; VAL-272; TRP-299; THR-304;
RP   VAL-304; CYS-429; SER-549 AND LYS-551.
RX   PubMed=22036850; DOI=10.1136/jnnp-2011-301258;
RA   Horvath R., Czermin B., Gulati S., Demuth S., Houge G., Pyle A.,
RA   Dineiger C., Blakely E.L., Hassani A., Foley C., Brodhun M., Storm K.,
RA   Kirschner J., Gorman G.S., Lochmuller H., Holinski-Feder E., Taylor R.W.,
RA   Chinnery P.F.;
RT   "Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3.";
RL   J. Neurol. Neurosurg. Psych. 83:174-178(2012).
RN   [23]
RP   VARIANT COQ10D4 ARG-602.
RX   PubMed=24048965; DOI=10.1007/8904_2013_251;
RA   Blumkin L., Leshinsky-Silver E., Zerem A., Yosovich K., Lerman-Sagie T.,
RA   Lev D.;
RT   "Heterozygous mutations in the ADCK3 gene in siblings with cerebellar
RT   atrophy and extreme phenotypic variability.";
RL   JIMD Rep. 12:103-107(2014).
RN   [24]
RP   INVOLVEMENT IN COQ10D4.
RX   PubMed=26818466; DOI=10.1111/cge.12742;
RA   Barca E., Musumeci O., Montagnese F., Marino S., Granata F., Nunnari D.,
RA   Peverelli L., DiMauro S., Quinzii C.M., Toscano A.;
RT   "Cerebellar ataxia and severe muscle CoQ10 deficiency in a patient with a
RT   novel mutation in ADCK3.";
RL   Clin. Genet. 90:156-160(2016).
RN   [25]
RP   VARIANTS COQ10D4 TRP-299 AND VAL-578.
RX   PubMed=27106809; DOI=10.1111/ene.13003;
RA   Hikmat O., Tzoulis C., Knappskog P.M., Johansson S., Boman H.,
RA   Sztromwasser P., Lien E., Brodtkorb E., Ghezzi D., Bindoff L.A.;
RT   "ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG
RT   mimic?";
RL   Eur. J. Neurol. 23:1188-1194(2016).
CC   -!- FUNCTION: Atypical kinase involved in the biosynthesis of coenzyme Q,
CC       also named ubiquinone, an essential lipid-soluble electron transporter
CC       for aerobic cellular respiration (PubMed:25498144, PubMed:21296186,
CC       PubMed:25540914, PubMed:27499294). Its substrate specificity is
CC       unclear: does not show any protein kinase activity (PubMed:25498144,
CC       PubMed:27499294). Probably acts as a small molecule kinase, possibly a
CC       lipid kinase that phosphorylates a prenyl lipid in the ubiquinone
CC       biosynthesis pathway, as suggested by its ability to bind coenzyme Q
CC       lipid intermediates (PubMed:25498144, PubMed:27499294). Shows an
CC       unusual selectivity for binding ADP over ATP (PubMed:25498144).
CC       {ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27499294,
CC       ECO:0000305|PubMed:21296186, ECO:0000305|PubMed:25540914}.
CC   -!- ACTIVITY REGULATION: Autoinhibited by the N-terminal domain, containing
CC       the KxGQ motif, that completely occludes the typical substrate binding
CC       pocket. Nucleotide-binding relieves inhibition (PubMed:27499294).
CC       {ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27499294}.
CC   -!- PATHWAY: Cofactor biosynthesis; ubiquinone biosynthesis.
CC       {ECO:0000269|PubMed:25498144}.
CC   -!- SUBUNIT: Homodimer; homodimerizes via its transmembrane region
CC       (PubMed:25216398). Interacts with the multi-subunit COQ enzyme complex,
CC       composed of at least COQ3, COQ4, COQ5, COQ6, COQ7 and COQ9
CC       (PubMed:27499294, PubMed:27499296). {ECO:0000269|PubMed:25216398,
CC       ECO:0000269|PubMed:27499294, ECO:0000269|PubMed:27499296}.
CC   -!- INTERACTION:
CC       Q8NI60; Q8WTS1: ABHD5; NbExp=3; IntAct=EBI-745535, EBI-2813554;
CC       Q8NI60; Q6RW13: AGTRAP; NbExp=4; IntAct=EBI-745535, EBI-741181;
CC       Q8NI60; Q6RW13-2: AGTRAP; NbExp=6; IntAct=EBI-745535, EBI-11522760;
CC       Q8NI60; Q5T2L2: AKR1C8; NbExp=3; IntAct=EBI-745535, EBI-22006248;
CC       Q8NI60; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-745535, EBI-8464238;
CC       Q8NI60; Q9H0Y0: ATG10; NbExp=3; IntAct=EBI-745535, EBI-1048913;
CC       Q8NI60; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-745535, EBI-18036948;
CC       Q8NI60; Q96HJ3-2: CCDC34; NbExp=3; IntAct=EBI-745535, EBI-17641690;
CC       Q8NI60; P09496-2: CLTA; NbExp=3; IntAct=EBI-745535, EBI-4401010;
CC       Q8NI60; Q8IZR5-2: CMTM4; NbExp=3; IntAct=EBI-745535, EBI-17278014;
CC       Q8NI60; Q96DZ9-2: CMTM5; NbExp=6; IntAct=EBI-745535, EBI-11522780;
CC       Q8NI60; Q9NX76: CMTM6; NbExp=3; IntAct=EBI-745535, EBI-1054315;
CC       Q8NI60; P02458-1: COL2A1; NbExp=3; IntAct=EBI-745535, EBI-12375799;
CC       Q8NI60; O75208: COQ9; NbExp=11; IntAct=EBI-745535, EBI-724524;
CC       Q8NI60; Q9BSY9: DESI2; NbExp=3; IntAct=EBI-745535, EBI-12878374;
CC       Q8NI60; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-745535, EBI-724653;
CC       Q8NI60; Q86UW9: DTX2; NbExp=3; IntAct=EBI-745535, EBI-740376;
CC       Q8NI60; Q96KS9: FAM167A; NbExp=3; IntAct=EBI-745535, EBI-10290462;
CC       Q8NI60; Q6ZNL6: FGD5; NbExp=3; IntAct=EBI-745535, EBI-7962481;
CC       Q8NI60; Q8TAC2: JOSD2; NbExp=3; IntAct=EBI-745535, EBI-12205593;
CC       Q8NI60; P13473-2: LAMP2; NbExp=3; IntAct=EBI-745535, EBI-21591415;
CC       Q8NI60; Q96B96: LDAF1; NbExp=8; IntAct=EBI-745535, EBI-7055862;
CC       Q8NI60; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-745535, EBI-25835523;
CC       Q8NI60; Q99732: LITAF; NbExp=3; IntAct=EBI-745535, EBI-725647;
CC       Q8NI60; P0DP58-2: LYNX1; NbExp=3; IntAct=EBI-745535, EBI-21916939;
CC       Q8NI60; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-745535, EBI-741835;
CC       Q8NI60; Q969L2: MAL2; NbExp=5; IntAct=EBI-745535, EBI-944295;
CC       Q8NI60; P27338: MAOB; NbExp=3; IntAct=EBI-745535, EBI-3911344;
CC       Q8NI60; Q6IN84: MRM1; NbExp=3; IntAct=EBI-745535, EBI-5454865;
CC       Q8NI60; Q9H2K0: MTIF3; NbExp=3; IntAct=EBI-745535, EBI-3923617;
CC       Q8NI60; Q69YL0: NCBP2AS2; NbExp=3; IntAct=EBI-745535, EBI-10986258;
CC       Q8NI60; Q6N063-2: OGFOD2; NbExp=3; IntAct=EBI-745535, EBI-22006224;
CC       Q8NI60; Q8N138: ORMDL3; NbExp=3; IntAct=EBI-745535, EBI-721750;
CC       Q8NI60; Q96AL5: PBX3; NbExp=3; IntAct=EBI-745535, EBI-741171;
CC       Q8NI60; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-745535, EBI-21503705;
CC       Q8NI60; Q9UI14: RABAC1; NbExp=12; IntAct=EBI-745535, EBI-712367;
CC       Q8NI60; Q96HR9: REEP6; NbExp=9; IntAct=EBI-745535, EBI-750345;
CC       Q8NI60; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-745535, EBI-14065960;
CC       Q8NI60; P47804-3: RGR; NbExp=3; IntAct=EBI-745535, EBI-25834767;
CC       Q8NI60; Q8N5U6: RNF10; NbExp=3; IntAct=EBI-745535, EBI-714023;
CC       Q8NI60; Q9NS64: RPRM; NbExp=3; IntAct=EBI-745535, EBI-1052363;
CC       Q8NI60; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-745535, EBI-9089805;
CC       Q8NI60; Q9Y371: SH3GLB1; NbExp=11; IntAct=EBI-745535, EBI-2623095;
CC       Q8NI60; O60902-3: SHOX2; NbExp=3; IntAct=EBI-745535, EBI-9092164;
CC       Q8NI60; O60906: SMPD2; NbExp=3; IntAct=EBI-745535, EBI-12828299;
CC       Q8NI60; Q9C004: SPRY4; NbExp=3; IntAct=EBI-745535, EBI-354861;
CC       Q8NI60; O60499-2: STX10; NbExp=3; IntAct=EBI-745535, EBI-12094584;
CC       Q8NI60; Q9UBB9: TFIP11; NbExp=13; IntAct=EBI-745535, EBI-1105213;
CC       Q8NI60; Q7Z6W1: TMCO2; NbExp=3; IntAct=EBI-745535, EBI-12807858;
CC       Q8NI60; Q8WW34: TMEM239; NbExp=5; IntAct=EBI-745535, EBI-9675724;
CC       Q8NI60; Q8WW34-2: TMEM239; NbExp=3; IntAct=EBI-745535, EBI-11528917;
CC       Q8NI60; O43399: TPD52L2; NbExp=3; IntAct=EBI-745535, EBI-782604;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:11888884,
CC       ECO:0000269|PubMed:25498144}. Membrane {ECO:0000255}; Single-pass
CC       membrane protein {ECO:0000255, ECO:0000305|PubMed:25216398}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8NI60-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NI60-2; Sequence=VSP_022351;
CC       Name=3;
CC         IsoId=Q8NI60-3; Sequence=VSP_022353;
CC       Name=4;
CC         IsoId=Q8NI60-4; Sequence=VSP_022352;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in adrenal
CC       gland, heart, pancreas, nasal mucosa, stomach, uterus and skeletal
CC       muscle. {ECO:0000269|PubMed:24270420}.
CC   -!- INDUCTION: By p53/TP53. {ECO:0000269|PubMed:11888884}.
CC   -!- DOMAIN: Adopts an atypical protein kinase-like fold: while it adopts a
CC       core fold similar to that of well-characterized protein kinase-like
CC       domains, a number of features are positioned to inhibit the kinase
CC       activity: (1) an atypical AAAS motif in an alanine-rich (A-rich) loop
CC       that replaces the canonical glycine-rich (G-rich) nucleotide-binding
CC       loop and limits ATP binding by establishing an unusual selectivity for
CC       ADP and (2) an N-terminal domain, containing the KxGQ motif, that
CC       completely occludes the typical substrate binding pocket
CC       (PubMed:25498144). Nucleotide-binding opens the substrate binding
CC       pocket and flips the active site from inside the hydrophobic core into
CC       a catalytically competent, solvent-exposed posture (PubMed:27499294).
CC       {ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27499294}.
CC   -!- DISEASE: Coenzyme Q10 deficiency, primary, 4 (COQ10D4) [MIM:612016]: An
CC       autosomal recessive disorder characterized by childhood-onset of
CC       cerebellar ataxia and exercise intolerance. Patient manifest gait
CC       ataxia and cerebellar atrophy with slow progression. Additional
CC       features include brisk tendon reflexes and Hoffmann sign, variable
CC       psychomotor retardation and variable seizures.
CC       {ECO:0000269|PubMed:18319072, ECO:0000269|PubMed:18319074,
CC       ECO:0000269|PubMed:20580948, ECO:0000269|PubMed:22036850,
CC       ECO:0000269|PubMed:24048965, ECO:0000269|PubMed:24218524,
CC       ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:26818466,
CC       ECO:0000269|PubMed:27106809}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. ADCK protein
CC       kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB073905; BAB91363.1; -; mRNA.
DR   EMBL; AJ278126; CAC00482.1; -; mRNA.
DR   EMBL; AF218003; AAG17245.1; -; mRNA.
DR   EMBL; AK074693; BAC11143.1; -; mRNA.
DR   EMBL; BX648860; CAH56132.1; -; mRNA.
DR   EMBL; AL353689; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC005171; AAH05171.2; -; mRNA.
DR   CCDS; CCDS1557.1; -. [Q8NI60-1]
DR   RefSeq; NP_064632.2; NM_020247.4. [Q8NI60-1]
DR   RefSeq; XP_005273258.1; XM_005273201.1. [Q8NI60-1]
DR   RefSeq; XP_011542540.1; XM_011544238.1. [Q8NI60-1]
DR   RefSeq; XP_011542541.1; XM_011544239.2. [Q8NI60-1]
DR   RefSeq; XP_011542542.1; XM_011544240.2.
DR   RefSeq; XP_011542543.1; XM_011544241.2. [Q8NI60-1]
DR   RefSeq; XP_016857341.1; XM_017001852.1. [Q8NI60-1]
DR   PDB; 4PED; X-ray; 1.64 A; A=256-647.
DR   PDB; 5I35; X-ray; 2.30 A; A=256-647.
DR   PDBsum; 4PED; -.
DR   PDBsum; 5I35; -.
DR   AlphaFoldDB; Q8NI60; -.
DR   SMR; Q8NI60; -.
DR   BioGRID; 121312; 114.
DR   IntAct; Q8NI60; 211.
DR   MINT; Q8NI60; -.
DR   STRING; 9606.ENSP00000355741; -.
DR   BindingDB; Q8NI60; -.
DR   ChEMBL; CHEMBL5550; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q8NI60; -.
DR   iPTMnet; Q8NI60; -.
DR   PhosphoSitePlus; Q8NI60; -.
DR   SwissPalm; Q8NI60; -.
DR   BioMuta; COQ8A; -.
DR   DMDM; 27923741; -.
DR   EPD; Q8NI60; -.
DR   jPOST; Q8NI60; -.
DR   MassIVE; Q8NI60; -.
DR   MaxQB; Q8NI60; -.
DR   PaxDb; Q8NI60; -.
DR   PeptideAtlas; Q8NI60; -.
DR   ProteomicsDB; 73833; -. [Q8NI60-1]
DR   ProteomicsDB; 73834; -. [Q8NI60-2]
DR   ProteomicsDB; 73835; -. [Q8NI60-3]
DR   ProteomicsDB; 73836; -. [Q8NI60-4]
DR   Antibodypedia; 20768; 334 antibodies from 30 providers.
DR   DNASU; 56997; -.
DR   Ensembl; ENST00000366777.4; ENSP00000355739.3; ENSG00000163050.18. [Q8NI60-1]
DR   Ensembl; ENST00000366778.5; ENSP00000355740.1; ENSG00000163050.18. [Q8NI60-3]
DR   GeneID; 56997; -.
DR   KEGG; hsa:56997; -.
DR   MANE-Select; ENST00000366777.4; ENSP00000355739.3; NM_020247.5; NP_064632.2.
DR   UCSC; uc001hqm.2; human. [Q8NI60-1]
DR   AGR; HGNC:16812; -.
DR   CTD; 56997; -.
DR   DisGeNET; 56997; -.
DR   GeneCards; COQ8A; -.
DR   GeneReviews; COQ8A; -.
DR   HGNC; HGNC:16812; COQ8A.
DR   HPA; ENSG00000163050; Group enriched (skeletal muscle, tongue).
DR   MalaCards; COQ8A; -.
DR   MIM; 606980; gene.
DR   MIM; 612016; phenotype.
DR   neXtProt; NX_Q8NI60; -.
DR   OpenTargets; ENSG00000163050; -.
DR   Orphanet; 139485; Autosomal recessive ataxia due to ubiquinone deficiency.
DR   PharmGKB; PA25999; -.
DR   VEuPathDB; HostDB:ENSG00000163050; -.
DR   VEuPathDB; HostDB:ENSG00000288674; -.
DR   eggNOG; KOG1234; Eukaryota.
DR   GeneTree; ENSGT00940000156810; -.
DR   HOGENOM; CLU_006533_9_1_1; -.
DR   InParanoid; Q8NI60; -.
DR   OMA; QVERVMN; -.
DR   OrthoDB; 668390at2759; -.
DR   PhylomeDB; Q8NI60; -.
DR   TreeFam; TF300630; -.
DR   PathwayCommons; Q8NI60; -.
DR   SignaLink; Q8NI60; -.
DR   UniPathway; UPA00232; -.
DR   BioGRID-ORCS; 56997; 9 hits in 1192 CRISPR screens.
DR   ChiTaRS; COQ8A; human.
DR   GeneWiki; CABC1; -.
DR   GenomeRNAi; 56997; -.
DR   Pharos; Q8NI60; Tbio.
DR   PRO; PR:Q8NI60; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q8NI60; protein.
DR   Bgee; ENSG00000163050; Expressed in gastrocnemius and 100 other tissues.
DR   Genevisible; Q8NI60; HS.
DR   GO; GO:0031314; C:extrinsic component of mitochondrial inner membrane; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043531; F:ADP binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006744; P:ubiquinone biosynthetic process; IMP:UniProtKB.
DR   CDD; cd13970; ABC1_ADCK3; 1.
DR   InterPro; IPR004147; ABC1_dom.
DR   InterPro; IPR034646; ADCK3_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   PANTHER; PTHR43851; -; 1.
DR   PANTHER; PTHR43851:SF1; ATYPICAL KINASE COQ8A, MITOCHONDRIAL; 1.
DR   Pfam; PF03109; ABC1; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Direct protein sequencing;
KW   Disease variant; Kinase; Membrane; Mitochondrion; Neurodegeneration;
KW   Nucleotide-binding; Primary mitochondrial disease; Reference proteome;
KW   Transferase; Transit peptide; Transmembrane; Transmembrane helix;
KW   Ubiquinone biosynthesis.
FT   TRANSIT         1..162
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   CHAIN           163..647
FT                   /note="Atypical kinase COQ8A, mitochondrial"
FT                   /id="PRO_0000000262"
FT   TRANSMEM        214..230
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:25216398"
FT   DOMAIN          329..518
FT                   /note="Protein kinase"
FT   REGION          90..117
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          182..203
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           276..279
FT                   /note="KxGQ motif"
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MOTIF           337..340
FT                   /note="AAAS motif"
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   ACT_SITE        488
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:27499294"
FT   BINDING         340
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27499294,
FT                   ECO:0000305|PubMed:25498144, ECO:0000312|PDB:5I35"
FT   BINDING         358
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27499294,
FT                   ECO:0000312|PDB:5I35"
FT   BINDING         445..448
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27499294,
FT                   ECO:0000312|PDB:5I35"
FT   BINDING         493
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27499294,
FT                   ECO:0000312|PDB:5I35"
FT   BINDING         507
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27499294,
FT                   ECO:0000312|PDB:5I35"
FT   VAR_SEQ         1..484
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15498874"
FT                   /id="VSP_022351"
FT   VAR_SEQ         1..279
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_022352"
FT   VAR_SEQ         1..52
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_022353"
FT   VARIANT         85
FT                   /note="H -> Q (in dbSNP:rs2297411)"
FT                   /id="VAR_020319"
FT   VARIANT         213
FT                   /note="R -> W (in COQ10D4; dbSNP:rs119468005)"
FT                   /evidence="ECO:0000269|PubMed:18319072,
FT                   ECO:0000269|PubMed:22036850"
FT                   /id="VAR_044402"
FT   VARIANT         271
FT                   /note="R -> C (in COQ10D4; dbSNP:rs145034527)"
FT                   /evidence="ECO:0000269|PubMed:22036850"
FT                   /id="VAR_072622"
FT   VARIANT         272
FT                   /note="G -> D (in COQ10D4; dbSNP:rs119468006)"
FT                   /evidence="ECO:0000269|PubMed:18319072,
FT                   ECO:0000269|PubMed:22036850"
FT                   /id="VAR_044403"
FT   VARIANT         272
FT                   /note="G -> V (in COQ10D4; dbSNP:rs119468006)"
FT                   /evidence="ECO:0000269|PubMed:18319072,
FT                   ECO:0000269|PubMed:22036850"
FT                   /id="VAR_044404"
FT   VARIANT         299
FT                   /note="R -> W (in COQ10D4; decreased stability;
FT                   dbSNP:rs201908721)"
FT                   /evidence="ECO:0000269|PubMed:22036850,
FT                   ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:27106809"
FT                   /id="VAR_072623"
FT   VARIANT         304
FT                   /note="A -> T (in COQ10D4; dbSNP:rs778798354)"
FT                   /evidence="ECO:0000269|PubMed:22036850"
FT                   /id="VAR_072624"
FT   VARIANT         304
FT                   /note="A -> V (in COQ10D4; dbSNP:rs748118737)"
FT                   /evidence="ECO:0000269|PubMed:22036850"
FT                   /id="VAR_072625"
FT   VARIANT         341
FT                   /note="I -> T (in dbSNP:rs55798516)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_045576"
FT   VARIANT         429
FT                   /note="Y -> C (in COQ10D4; decreased stability;
FT                   dbSNP:rs144147839)"
FT                   /evidence="ECO:0000269|PubMed:22036850,
FT                   ECO:0000269|PubMed:25498144"
FT                   /id="VAR_072626"
FT   VARIANT         514
FT                   /note="Y -> C (in COQ10D4; dbSNP:rs119468008)"
FT                   /evidence="ECO:0000269|PubMed:18319074"
FT                   /id="VAR_044405"
FT   VARIANT         549
FT                   /note="G -> S (in COQ10D4; decreased stability;
FT                   dbSNP:rs119468009)"
FT                   /evidence="ECO:0000269|PubMed:18319074,
FT                   ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:25498144"
FT                   /id="VAR_044406"
FT   VARIANT         551
FT                   /note="E -> K (in COQ10D4; decreased stability;
FT                   dbSNP:rs119468004)"
FT                   /evidence="ECO:0000269|PubMed:18319072,
FT                   ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:25498144"
FT                   /id="VAR_044407"
FT   VARIANT         578
FT                   /note="F -> V (in COQ10D4; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:27106809"
FT                   /id="VAR_076860"
FT   VARIANT         584
FT                   /note="Missing (in COQ10D4; dbSNP:rs387906299)"
FT                   /evidence="ECO:0000269|PubMed:18319074"
FT                   /id="VAR_044408"
FT   VARIANT         602
FT                   /note="P -> R (in COQ10D4; dbSNP:rs61995958)"
FT                   /evidence="ECO:0000269|PubMed:24048965"
FT                   /id="VAR_072627"
FT   MUTAGEN         214
FT                   /note="L->A,I,L,F: Strongly impairs homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         214
FT                   /note="L->I,F,G,V: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         215
FT                   /note="A->I,L,G: Does not impair homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         216
FT                   /note="N->A,L,F,M: Does not impair homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         217
FT                   /note="F->A: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         218
FT                   /note="G->I,L,F: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         219
FT                   /note="G->A,F: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         219
FT                   /note="G->I: Strongly impairs homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         220
FT                   /note="L->G: Impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         221
FT                   /note="A->L: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         222
FT                   /note="V->A: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         223
FT                   /note="G->A,I,L,F: Strongly impairs homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         224
FT                   /note="L->V: Impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         225
FT                   /note="G->L: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         226
FT                   /note="F->A: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         227
FT                   /note="G->V,F,L,I: Strongly impairs homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         228
FT                   /note="A->I,L,F: Does not impair homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         229
FT                   /note="L->A: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         230
FT                   /note="A->I: Slightly impaired homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25216398"
FT   MUTAGEN         276
FT                   /note="K->R,H: Does not affect selectivity for binding ADP
FT                   or ATP. Impaired multi-subunit COQ enzyme complex."
FT                   /evidence="ECO:0000269|PubMed:25498144,
FT                   ECO:0000269|PubMed:27499294"
FT   MUTAGEN         279
FT                   /note="Q->R,H: Does not affect selectivity for binding ADP
FT                   or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         339
FT                   /note="A->G: Enables autophosphorylation but inhibits
FT                   coenzyme Q biosynthesis in vivo."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         358
FT                   /note="K->R: Abolishes binding ADP or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         405
FT                   /note="E->A,Q: Slightly affects selectivity for binding ADP
FT                   or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         411
FT                   /note="E->Q: Impaired binding ADP or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         488
FT                   /note="D->N: Impaired binding ADP or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         493
FT                   /note="N->A: Impaired binding ADP or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   MUTAGEN         507
FT                   /note="D->N: Strongly impairs binding ADP or ATP. Impaired
FT                   multi-subunit COQ enzyme complex."
FT                   /evidence="ECO:0000269|PubMed:25498144,
FT                   ECO:0000269|PubMed:27499294"
FT   MUTAGEN         611
FT                   /note="R->A,Q: Does not affect selectivity for binding ADP
FT                   or ATP."
FT                   /evidence="ECO:0000269|PubMed:25498144"
FT   CONFLICT        283..284
FT                   /note="IQ -> VR (in Ref. 4; BAC11143)"
FT                   /evidence="ECO:0000305"
FT   HELIX           260..269
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           271..281
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          284..289
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           291..302
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           303..306
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           309..320
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          328..331
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          336..339
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          342..349
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          354..360
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   TURN            362..364
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           365..367
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           368..382
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          387..389
FT                   /evidence="ECO:0007829|PDB:5I35"
FT   HELIX           391..393
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           395..405
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           408..421
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   TURN            422..424
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          426..429
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           435..437
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          442..446
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          450..452
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           453..455
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           461..480
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          484..488
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           491..493
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          494..497
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   TURN            498..501
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          502..505
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           508..510
FT                   /evidence="ECO:0007829|PDB:5I35"
FT   STRAND          511..513
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           516..530
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           534..543
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           553..571
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           581..588
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           589..594
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   STRAND          596..600
FT                   /evidence="ECO:0007829|PDB:5I35"
FT   HELIX           604..622
FT                   /evidence="ECO:0007829|PDB:4PED"
FT   HELIX           630..643
FT                   /evidence="ECO:0007829|PDB:4PED"
SQ   SEQUENCE   647 AA;  71950 MW;  DEF8F022027BF6CC CRC64;
     MAAILGDTIM VAKGLVKLTQ AAVETHLQHL GIGGELIMAA RALQSTAVEQ IGMFLGKVQG
     QDKHEEYFAE NFGGPEGEFH FSVPHAAGAS TDFSSASAPD QSAPPSLGHA HSEGPAPAYV
     ASGPFREAGF PGQASSPLGR ANGRLFANPR DSFSAMGFQR RFFHQDQSPV GGLTAEDIEK
     ARQAKARPEN KQHKQTLSEH ARERKVPVTR IGRLANFGGL AVGLGFGALA EVAKKSLRSE
     DPSGKKAVLG SSPFLSEANA ERIVRTLCKV RGAALKLGQM LSIQDDAFIN PHLAKIFERV
     RQSADFMPLK QMMKTLNNDL GPNWRDKLEY FEERPFAAAS IGQVHLARMK GGREVAMKIQ
     YPGVAQSINS DVNNLMAVLN MSNMLPEGLF PEHLIDVLRR ELALECDYQR EAACARKFRD
     LLKGHPFFYV PEIVDELCSP HVLTTELVSG FPLDQAEGLS QEIRNEICYN ILVLCLRELF
     EFHFMQTDPN WSNFFYDPQQ HKVALLDFGA TREYDRSFTD LYIQIIRAAA DRDRETVRAK
     SIEMKFLTGY EVKVMEDAHL DAILILGEAF ASDEPFDFGT QSTTEKIHNL IPVMLRHRLV
     PPPEETYSLH RKMGGSFLIC SKLKARFPCK AMFEEAYSNY CKRQAQQ
//
ID   JAG1_HUMAN              Reviewed;        1218 AA.
AC   P78504; A0AV43; B4DYR1; E9PCF9; O14902; O15122; Q15816;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2002, sequence version 3.
DT   22-FEB-2023, entry version 227.
DE   RecName: Full=Protein jagged-1;
DE            Short=Jagged1;
DE            Short=hJ1;
DE   AltName: CD_antigen=CD339;
DE   Flags: Precursor;
GN   Name=JAG1; Synonyms=JAGL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9268641; DOI=10.1006/geno.1997.4820;
RA   Oda T., Elkahloun A.G., Meltzer P.S., Chandrasekharappa S.C.;
RT   "Identification and cloning of the human homolog (JAG1) of the rat Jagged1
RT   gene from the Alagille syndrome critical region at 20p12.";
RL   Genomics 43:376-379(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN ALGS1, AND VARIANT
RP   ALGS1 CYS-184.
RC   TISSUE=Bone marrow;
RX   PubMed=9207788; DOI=10.1038/ng0797-243;
RA   Li L., Krantz I.D., Deng Y., Genin A., Banta A.B., Collins C.C., Qi M.,
RA   Trask B.J., Kuo W.L., Cochran J., Costa T., Pierpont M.E.M., Rand E.B.,
RA   Piccoli D.A., Hood L., Spinner N.B.;
RT   "Alagille syndrome is caused by mutations in human Jagged1, which encodes a
RT   ligand for Notch1.";
RL   Nat. Genet. 16:243-251(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=9462510; DOI=10.1016/s1074-7613(00)80457-4;
RA   Li L., Milner L.A., Deng Y., Iwata M., Banta A.B., Graf L., Marcovina S.,
RA   Friedman C., Trask B.J., Hood L., Torok-Storb B.;
RT   "The human homolog of rat Jagged1 expressed by marrow stroma inhibits
RT   differentiation of 32D cells through interaction with Notch1.";
RL   Immunity 8:43-55(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10329626; DOI=10.1093/emboj/18.10.2803;
RA   Bash J., Zong W.-X., Banga S., Rivera A., Ballard D.W., Ron Y., Gelinas C.;
RT   "Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the
RT   expression of Jagged1, a ligand for Notch receptors.";
RL   EMBO J. 18:2803-2811(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10079256; DOI=10.1016/s0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L., Banks A.,
RA   Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-1218 (ISOFORM 1).
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=8955070; DOI=10.1074/jbc.271.51.32499;
RA   Zimrin A.B., Pepper M.S., McMahon G.A., Nguyen F., Montesano R., Maciag T.;
RT   "An antisense oligonucleotide to the notch ligand Jagged enhances
RT   fibroblast growth factor-induced angiogenesis in vitro.";
RL   J. Biol. Chem. 271:32499-32502(1996).
RN   [10]
RP   DISEASE.
RX   PubMed=9207787; DOI=10.1038/ng0797-235;
RA   Oda T., Elkahloun A.G., Pike B.L., Okajima K., Krantz I.D., Genin A.,
RA   Piccoli D.A., Meltzer P.S., Spinner N.B., Collins F.S.,
RA   Chandrasekharappa S.C.;
RT   "Mutations in the human Jagged1 gene are responsible for Alagille
RT   syndrome.";
RL   Nat. Genet. 16:235-242(1997).
RN   [11]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=10978356; DOI=10.1136/jmg.37.9.658;
RA   Jones E.A., Clement-Jones M., Wilson D.I.;
RT   "JAGGED1 expression in human embryos: correlation with the Alagille
RT   syndrome phenotype.";
RL   J. Med. Genet. 37:658-662(2000).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 185-335, FUNCTION, INTERACTION
RP   WITH NOTCH1, DOMAIN, MUTAGENESIS OF PHE-207, AND DISULFIDE BONDS.
RX   PubMed=18660822; DOI=10.1038/nsmb.1457;
RA   Cordle J., Johnson S., Tay J.Z., Roversi P., Wilkin M.B., de Madrid B.H.,
RA   Shimizu H., Jensen S., Whiteman P., Jin B., Redfield C., Baron M.,
RA   Lea S.M., Handford P.A.;
RT   "A conserved face of the Jagged/Serrate DSL domain is involved in Notch
RT   trans-activation and cis-inhibition.";
RL   Nat. Struct. Mol. Biol. 15:849-857(2008).
RN   [14]
RP   STRUCTURE BY NMR OF 252-295, DOMAIN, AND DISULFIDE BONDS.
RX   PubMed=19586525; DOI=10.1186/1472-6807-9-43;
RA   Pintar A., Guarnaccia C., Dhir S., Pongor S.;
RT   "Exon 6 of human JAG1 encodes a conserved structural unit.";
RL   BMC Struct. Biol. 9:43-43(2009).
RN   [15]
RP   VARIANTS ALGS1 CYS-184 AND HIS-184.
RX   PubMed=9585603; DOI=10.1086/301875;
RA   Krantz I.D., Colliton R.P., Genin A., Rand E.B., Li L., Piccoli D.A.,
RA   Spinner N.B.;
RT   "Spectrum and frequency of Jagged1 (JAG1) mutations in Alagille syndrome
RT   patients and their families.";
RL   Am. J. Hum. Genet. 62:1361-1369(1998).
RN   [16]
RP   VARIANTS ALGS1 HIS-79; THR-127; ARG-129; LEU-163; GLY-184; SER-187;
RP   GLY-229; PHE-284; CYS-288; PHE-438; SER-731 AND ARG-740.
RX   PubMed=10220506; DOI=10.1016/s0016-5085(99)70017-x;
RA   Crosnier C., Driancourt C., Raynaud N., Dhorne-Pollet S., Pollet N.,
RA   Bernard O., Hadchouel M., Meunier-Rotival M.;
RT   "Mutations in JAGGED1 gene are predominantly sporadic in Alagille
RT   syndrome.";
RL   Gastroenterology 116:1141-1148(1999).
RN   [17]
RP   VARIANTS ALGS1 THR-152 AND LEU-184.
RX   PubMed=10533065;
RX   DOI=10.1002/(sici)1098-1004(199911)14:5<394::aid-humu5>3.0.co;2-1;
RA   Pilia G., Uda M., Macis D., Frau F., Crisponi L., Balli F., Barbera C.,
RA   Colombo C., Frediani T., Gatti R., Iorio R., Marazzi M.G., Marcellini M.,
RA   Musumeci S., Nebbia G., Vajro P., Ruffa G., Zancan L., Cao A.,
RA   DeVirgilis S.;
RT   "Jagged-1 mutation analysis in Italian Alagille syndrome patients.";
RL   Hum. Mutat. 14:394-400(1999).
RN   [18]
RP   VARIANTS ALGS1 TYR-229 AND ARG-386.
RX   PubMed=11058898;
RX   DOI=10.1002/1098-1004(200011)16:5<408::aid-humu5>3.0.co;2-9;
RA   Heritage M.L., MacMillan J.C., Colliton R.P., Genin A., Spinner N.B.,
RA   Anderson G.J.;
RT   "Jagged1 (JAG1) mutation detection in an Australian Alagille syndrome
RT   population.";
RL   Hum. Mutat. 16:408-416(2000).
RN   [19]
RP   VARIANT TOF ASP-274.
RX   PubMed=11152664; DOI=10.1093/hmg/10.2.163;
RA   Eldadah Z.A., Hamosh A., Biery N.J., Montgomery R.A., Duke M., Elkins R.,
RA   Dietz H.C.;
RT   "Familial tetralogy of Fallot caused by mutation in the Jagged1 gene.";
RL   Hum. Mol. Genet. 10:163-169(2001).
RN   [20]
RP   VARIANT ALGS1 SER-37.
RX   PubMed=11157803; DOI=10.1093/hmg/10.4.405;
RA   Morrissette J.J.D., Colliton R.P., Spinner N.B.;
RT   "Defective intracellular transport and processing of JAG1 missense
RT   mutations in Alagille syndrome.";
RL   Hum. Mol. Genet. 10:405-413(2001).
RN   [21]
RP   VARIANTS ALGS1 PHE-220 AND ARG-753.
RX   PubMed=11139247; DOI=10.1002/1098-1004(2001)17:1<72::aid-humu11>3.0.co;2-u;
RA   Crosnier C., Driancourt C., Raynaud N., Hadchouel M., Meunier-Rotival M.;
RT   "Fifteen novel mutations in the JAGGED1 gene of patients with Alagille
RT   syndrome.";
RL   Hum. Mutat. 17:72-73(2001).
RN   [22]
RP   VARIANTS ALGS1 ASP-33; SER-37; SER-78; ASN-181; TYR-714 AND SER-902.
RX   PubMed=11180599;
RX   DOI=10.1002/1098-1004(200102)17:2<151::aid-humu8>3.0.co;2-t;
RA   Colliton R.P., Bason L., Lu F.-M., Piccoli D.A., Krantz I.D., Spinner N.B.;
RT   "Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients.";
RL   Hum. Mutat. 17:151-152(2001).
RN   [23]
RP   INVOLVEMENT IN DCHE, AND VARIANT DCHE TYR-234.
RX   PubMed=12022040; DOI=10.1086/341327;
RA   Le Caignec C., Lefevre M., Schott J.J., Chaventre A., Gayet M., Calais C.,
RA   Moisan J.P.;
RT   "Familial deafness, congenital heart defects, and posterior embryotoxon
RT   caused by cysteine substitution in the first epidermal-growth-factor-like
RT   domain of Jagged 1.";
RL   Am. J. Hum. Genet. 71:180-186(2002).
RN   [24]
RP   VARIANTS BILIARY ATRESIA LEU-45; ASP-53; MET-65; LYS-203; ASP-690; ARG-871;
RP   GLN-908; PRO-921 AND GLN-1213.
RX   PubMed=12297837; DOI=10.1053/jhep.2002.35820;
RA   Kohsaka T., Yuan Z.-R., Guo S.-X., Tagawa M., Nakamura A., Nakano M.,
RA   Kawasasaki H., Inomata Y., Tanaka K., Miyauchi J.;
RT   "The significance of human Jagged 1 mutations detected in severe cases of
RT   extrahepatic biliary atresia.";
RL   Hepatology 36:904-912(2002).
RN   [25]
RP   VARIANTS ALGS1 SER-39; HIS-184 AND ARG-913.
RX   PubMed=12442286; DOI=10.1002/humu.9095;
RA   Heritage M.L., MacMillan J.C., Anderson G.J.;
RT   "DHPLC mutation analysis of Jagged1 (JAG1) reveals six novel mutations in
RT   Australian Alagille syndrome patients.";
RL   Hum. Mutat. 20:481-481(2002).
RN   [26]
RP   CHARACTERIZATION OF VARIANT ASP-274.
RX   PubMed=12649809; DOI=10.1086/374386;
RA   Lu F., Morrissette J.J.D., Spinner N.B.;
RT   "Conditional JAG1 mutation shows the developing heart is more sensitive
RT   than developing liver to JAG1 dosage.";
RL   Am. J. Hum. Genet. 72:1065-1070(2003).
RN   [27]
RP   VARIANTS ALGS1 VAL-31; PRO-40; SER-75; SER-123; ARG-163; CYS-224 AND
RP   LEU-269, AND VARIANT GLN-937.
RX   PubMed=12497640; DOI=10.1002/humu.9102;
RA   Roepke A., Kujat A., Graeber M., Giannakudis J., Hansmann I.;
RT   "Identification of 36 novel Jagged1 (JAG1) mutations in patients with
RT   Alagille syndrome.";
RL   Hum. Mutat. 21:100-100(2003).
RN   [28]
RP   VARIANTS ALGS1 ASN-120 AND TYR-187.
RX   PubMed=15712272; DOI=10.1002/humu.9313;
RA   Jurkiewicz D., Popowska E., Glaeser C., Hansmann I., Krajewska-Walasek M.;
RT   "Twelve novel JAG1 gene mutations in Polish Alagille syndrome patients.";
RL   Hum. Mutat. 25:321-321(2005).
RN   [29]
RP   VARIANTS ALGS1 22-CYS--ARG-25 DEL; SER-33; VAL-33; ARG-92; TYR-92; PRO-155;
RP   GLY-252; SER-256; ARG-271; SER-504; TYR-693; GLN-889; TYR-911 AND
RP   1055-VAL-ARG-1056 GLY DELINS, AND VARIANT LYS-818.
RX   PubMed=16575836; DOI=10.1002/humu.20310;
RA   Warthen D.M., Moore E.C., Kamath B.M., Morrissette J.J.D., Sanchez P.,
RA   Piccoli D.A., Krantz I.D., Spinner N.B.;
RT   "Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation
RT   detection rate.";
RL   Hum. Mutat. 27:436-443(2006).
RN   [30]
RP   VARIANT ALGS1 TRP-436.
RX   PubMed=23801938; DOI=10.1159/000347231;
RA   Vozzi D., Licastro D., Martelossi S., Athanasakis E., Gasparini P.,
RA   Fabretto A.;
RT   "Alagille Syndrome: A new missense mutation detected by whole-exome
RT   sequencing in a case previously found to be negative by DHPLC and MLPA.";
RL   Mol. Syndromol. 4:207-210(2013).
RN   [31]
RP   VARIANTS SER-664; GLN-937 AND GLN-1104, CHARACTERIZATION OF VARIANTS
RP   SER-664 AND GLN-937, VARIANT TOF LEU-810, CHARACTERIZATION OF VARIANTS TOF
RP   ASP-274 AND LEU-810, CHARACTERIZATION OF VARIANT ALGS1 SER-37,
RP   CHARACTERIZATION OF VARIANT DCHE TYR-234, AND FUNCTION.
RX   PubMed=20437614; DOI=10.1002/humu.21231;
RA   Bauer R.C., Laney A.O., Smith R., Gerfen J., Morrissette J.J.,
RA   Woyciechowski S., Garbarini J., Loomes K.M., Krantz I.D., Urban Z.,
RA   Gelb B.D., Goldmuntz E., Spinner N.B.;
RT   "Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic
RT   stenosis.";
RL   Hum. Mutat. 31:594-601(2010).
RN   [32]
RP   VARIANTS CMT2HH ARG-577 AND PRO-650, INVOLVEMENT IN CMT2HH, SUBCELLULAR
RP   LOCATION, CHARACTERIZATION OF VARIANT ALGS1 HIS-184, AND CHARACTERIZATION
RP   OF VARIANTS CMT2HH ARG-577 AND PRO-650.
RX   PubMed=32065591; DOI=10.1172/jci128152;
RA   Sullivan J.M., Motley W.W., Johnson J.O., Aisenberg W.H., Marshall K.L.,
RA   Barwick K.E., Kong L., Huh J.S., Saavedra-Rivera P.C., McEntagart M.M.,
RA   Marion M.H., Hicklin L.A., Modarres H., Baple E.L., Farah M.H.,
RA   Zuberi A.R., Lutz C.M., Gaudet R., Traynor B.J., Crosby A.H., Sumner C.J.;
RT   "Dominant mutations of the Notch ligand Jagged1 cause peripheral
RT   neuropathy.";
RL   J. Clin. Invest. 130:1506-1512(2020).
CC   -!- FUNCTION: Ligand for multiple Notch receptors and involved in the
CC       mediation of Notch signaling (PubMed:18660822, PubMed:20437614). May be
CC       involved in cell-fate decisions during hematopoiesis (PubMed:9462510).
CC       Seems to be involved in early and late stages of mammalian
CC       cardiovascular development. Inhibits myoblast differentiation (By
CC       similarity). Enhances fibroblast growth factor-induced angiogenesis (in
CC       vitro). {ECO:0000250, ECO:0000269|PubMed:18660822,
CC       ECO:0000269|PubMed:20437614, ECO:0000269|PubMed:9462510}.
CC   -!- SUBUNIT: Interacts with NOTCH2 and NOTCH3 (By similarity). Interacts
CC       with NOTCH1 (in the presence of calcium ions) (PubMed:18660822).
CC       {ECO:0000250|UniProtKB:Q9QXX0, ECO:0000269|PubMed:18660822}.
CC   -!- INTERACTION:
CC       P78504; P15529: CD46; NbExp=5; IntAct=EBI-2847071, EBI-2623451;
CC       P78504; P46531: NOTCH1; NbExp=6; IntAct=EBI-2847071, EBI-636374;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC       Cell membrane {ECO:0000269|PubMed:32065591}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78504-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78504-2; Sequence=VSP_056532;
CC   -!- TISSUE SPECIFICITY: Widely expressed in adult and fetal tissues. In
CC       cervix epithelium expressed in undifferentiated subcolumnar reserve
CC       cells and squamous metaplasia. Expression is up-regulated in cervical
CC       squamous cell carcinoma. Expressed in bone marrow cell line HS-27a
CC       which supports the long-term maintenance of immature progenitor cells.
CC   -!- DEVELOPMENTAL STAGE: Expressed in 32-52 days embryos in the distal
CC       cardiac outflow tract and pulmonary artery, major arteries, portal
CC       vein, optic vesicle, otocyst, branchial arches, metanephros, pancreas,
CC       mesocardium, around the major bronchial branches, and in the neural
CC       tube. {ECO:0000269|PubMed:10978356}.
CC   -!- DOMAIN: The second EGF-like domain is atypical.
CC       {ECO:0000269|PubMed:18660822, ECO:0000269|PubMed:19586525}.
CC   -!- DISEASE: Alagille syndrome 1 (ALGS1) [MIM:118450]: A form of Alagille
CC       syndrome, an autosomal dominant multisystem disorder. It is clinically
CC       defined by hepatic bile duct paucity and cholestasis in association
CC       with cardiac, skeletal, and ophthalmologic manifestations. There are
CC       characteristic facial features and less frequent clinical involvement
CC       of the renal and vascular systems. {ECO:0000269|PubMed:10220506,
CC       ECO:0000269|PubMed:10533065, ECO:0000269|PubMed:11058898,
CC       ECO:0000269|PubMed:11139247, ECO:0000269|PubMed:11157803,
CC       ECO:0000269|PubMed:11180599, ECO:0000269|PubMed:12442286,
CC       ECO:0000269|PubMed:12497640, ECO:0000269|PubMed:15712272,
CC       ECO:0000269|PubMed:16575836, ECO:0000269|PubMed:20437614,
CC       ECO:0000269|PubMed:23801938, ECO:0000269|PubMed:32065591,
CC       ECO:0000269|PubMed:9207788, ECO:0000269|PubMed:9585603}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Tetralogy of Fallot (TOF) [MIM:187500]: A congenital heart
CC       anomaly which consists of pulmonary stenosis, ventricular septal
CC       defect, dextroposition of the aorta (aorta is on the right side instead
CC       of the left) and hypertrophy of the right ventricle. In this condition,
CC       blood from both ventricles (oxygen-rich and oxygen-poor) is pumped into
CC       the body often causing cyanosis. {ECO:0000269|PubMed:11152664,
CC       ECO:0000269|PubMed:20437614}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, congenital heart defects, and posterior embryotoxon
CC       (DCHE) [MIM:617992]: An autosomal dominant disease characterized by
CC       mild to severe combined hearing loss, congenital heart defects, and
CC       posterior embryotoxon, a corneal abnormality consisting of a central
CC       collagen core surrounded by a thin layer of Descemets membrane and
CC       separated from the anterior chamber by a layer of endothelium.
CC       Congenital heart defects include tetralogy of Fallot, ventricular
CC       septal defect, or isolated peripheral pulmonic stenosis.
CC       {ECO:0000269|PubMed:12022040, ECO:0000269|PubMed:20437614}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2HH (CMT2HH) [MIM:619574]: An
CC       autosomal dominant, axonal form of Charcot-Marie-Tooth disease, a
CC       disorder of the peripheral nervous system characterized by progressive
CC       weakness and atrophy, initially of the peroneal muscles and later of
CC       the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited) and
CC       primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2
CC       group are characterized by signs of axonal degeneration in the absence
CC       of obvious myelin alterations, normal or slightly reduced nerve
CC       conduction velocities, and progressive distal muscle weakness and
CC       atrophy. CMT2HH is characterized by vocal fold paresis that remains
CC       throughout life and may be severe. Additional features include pes
CC       cavus, scoliosis, distal sensory impairment with hyporeflexia, mild
CC       distal muscle weakness and atrophy primarily affecting the lower limbs,
CC       although the upper limbs may also be involved.
CC       {ECO:0000269|PubMed:32065591}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51323.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41029/JAG1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF003837; AAC51731.1; -; mRNA.
DR   EMBL; U73936; AAC52020.1; -; mRNA.
DR   EMBL; AF028593; AAB84053.1; -; mRNA.
DR   EMBL; U61276; AAB39007.1; -; mRNA.
DR   EMBL; AK302554; BAG63823.1; -; mRNA.
DR   EMBL; AL035456; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC126205; AAI26206.1; -; mRNA.
DR   EMBL; BC126207; AAI26208.1; -; mRNA.
DR   EMBL; U77720; AAC51323.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS13112.1; -. [P78504-1]
DR   RefSeq; NP_000205.1; NM_000214.2. [P78504-1]
DR   RefSeq; XP_016883196.1; XM_017027707.1.
DR   PDB; 2KB9; NMR; -; A=252-295.
DR   PDB; 2VJ2; X-ray; 2.50 A; A/B=185-335.
DR   PDB; 4CBZ; X-ray; 2.50 A; A/B=32-335.
DR   PDB; 4CC0; X-ray; 2.32 A; A/B=32-335.
DR   PDB; 4CC1; X-ray; 2.84 A; A/B=32-335.
DR   PDB; 4XI7; X-ray; 2.05 A; C=1120-1130.
DR   PDB; 5BO1; X-ray; 2.56 A; A/B=186-335.
DR   PDBsum; 2KB9; -.
DR   PDBsum; 2VJ2; -.
DR   PDBsum; 4CBZ; -.
DR   PDBsum; 4CC0; -.
DR   PDBsum; 4CC1; -.
DR   PDBsum; 4XI7; -.
DR   PDBsum; 5BO1; -.
DR   AlphaFoldDB; P78504; -.
DR   BMRB; P78504; -.
DR   SMR; P78504; -.
DR   BioGRID; 106689; 38.
DR   DIP; DIP-46371N; -.
DR   IntAct; P78504; 18.
DR   MINT; P78504; -.
DR   STRING; 9606.ENSP00000254958; -.
DR   ChEMBL; CHEMBL3217396; -.
DR   GlyCosmos; P78504; 9 sites, No reported glycans.
DR   GlyGen; P78504; 9 sites.
DR   iPTMnet; P78504; -.
DR   PhosphoSitePlus; P78504; -.
DR   SwissPalm; P78504; -.
DR   BioMuta; JAG1; -.
DR   DMDM; 20455033; -.
DR   EPD; P78504; -.
DR   jPOST; P78504; -.
DR   MassIVE; P78504; -.
DR   MaxQB; P78504; -.
DR   PaxDb; P78504; -.
DR   PeptideAtlas; P78504; -.
DR   ProteomicsDB; 5543; -.
DR   ProteomicsDB; 57626; -. [P78504-1]
DR   ABCD; P78504; 10 sequenced antibodies.
DR   Antibodypedia; 4153; 974 antibodies from 43 providers.
DR   DNASU; 182; -.
DR   Ensembl; ENST00000254958.10; ENSP00000254958.4; ENSG00000101384.12. [P78504-1]
DR   GeneID; 182; -.
DR   KEGG; hsa:182; -.
DR   MANE-Select; ENST00000254958.10; ENSP00000254958.4; NM_000214.3; NP_000205.1.
DR   UCSC; uc002wnw.3; human. [P78504-1]
DR   AGR; HGNC:6188; -.
DR   CTD; 182; -.
DR   DisGeNET; 182; -.
DR   GeneCards; JAG1; -.
DR   GeneReviews; JAG1; -.
DR   HGNC; HGNC:6188; JAG1.
DR   HPA; ENSG00000101384; Low tissue specificity.
DR   MalaCards; JAG1; -.
DR   MIM; 118450; phenotype.
DR   MIM; 187500; phenotype.
DR   MIM; 601920; gene.
DR   MIM; 617992; phenotype.
DR   MIM; 619574; phenotype.
DR   neXtProt; NX_P78504; -.
DR   OpenTargets; ENSG00000101384; -.
DR   Orphanet; 261600; Alagille syndrome due to 20p12 microdeletion.
DR   Orphanet; 261619; Alagille syndrome due to a JAG1 point mutation.
DR   Orphanet; 3303; Tetralogy of Fallot.
DR   PharmGKB; PA29986; -.
DR   VEuPathDB; HostDB:ENSG00000101384; -.
DR   eggNOG; KOG1217; Eukaryota.
DR   GeneTree; ENSGT00940000160148; -.
DR   HOGENOM; CLU_004732_0_0_1; -.
DR   InParanoid; P78504; -.
DR   OMA; GWGGVTC; -.
DR   OrthoDB; 5475408at2759; -.
DR   PhylomeDB; P78504; -.
DR   TreeFam; TF351835; -.
DR   PathwayCommons; P78504; -.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2660826; Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant.
DR   Reactome; R-HSA-2691232; Constitutive Signaling by NOTCH1 HD Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9013507; NOTCH3 Activation and Transmission of Signal to the Nucleus.
DR   Reactome; R-HSA-9013700; NOTCH4 Activation and Transmission of Signal to the Nucleus.
DR   SignaLink; P78504; -.
DR   SIGNOR; P78504; -.
DR   BioGRID-ORCS; 182; 26 hits in 1088 CRISPR screens.
DR   ChiTaRS; JAG1; human.
DR   EvolutionaryTrace; P78504; -.
DR   GeneWiki; JAG1; -.
DR   GenomeRNAi; 182; -.
DR   Pharos; P78504; Tbio.
DR   PRO; PR:P78504; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P78504; protein.
DR   Bgee; ENSG00000101384; Expressed in upper leg skin and 206 other tissues.
DR   ExpressionAtlas; P78504; baseline and differential.
DR   Genevisible; P78504; HS.
DR   GO; GO:0005912; C:adherens junction; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0008083; F:growth factor activity; NAS:UniProtKB.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:DisProt.
DR   GO; GO:0005112; F:Notch binding; IPI:UniProtKB.
DR   GO; GO:0005543; F:phospholipid binding; IMP:CAFA.
DR   GO; GO:0005198; F:structural molecule activity; NAS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; NAS:UniProtKB.
DR   GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003180; P:aortic valve morphogenesis; NAS:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0061309; P:cardiac neural crest cell development involved in outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001709; P:cell fate determination; NAS:UniProtKB.
DR   GO; GO:0061073; P:ciliary body morphogenesis; IEA:Ensembl.
DR   GO; GO:0072017; P:distal tubule development; IEA:Ensembl.
DR   GO; GO:0061444; P:endocardial cushion cell development; ISS:BHF-UCL.
DR   GO; GO:0045446; P:endothelial cell differentiation; NAS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; NAS:UniProtKB.
DR   GO; GO:0002085; P:inhibition of neuroepithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0042491; P:inner ear auditory receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; NAS:UniProtKB.
DR   GO; GO:0072070; P:loop of Henle development; IEA:Ensembl.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IEA:Ensembl.
DR   GO; GO:0045445; P:myoblast differentiation; NAS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0045602; P:negative regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0072006; P:nephron development; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; NAS:UniProtKB.
DR   GO; GO:0061101; P:neuroendocrine cell differentiation; IEA:Ensembl.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEP:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IMP:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:UniProtKB.
DR   GO; GO:0072015; P:podocyte development; ISS:UniProtKB.
DR   GO; GO:0062043; P:positive regulation of cardiac epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0061156; P:pulmonary artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell population proliferation; NAS:UniProtKB.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2000241; P:regulation of reproductive process; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0002456; P:T cell mediated immunity; IMP:UniProtKB.
DR   CDD; cd00054; EGF_CA; 13.
DR   DisProt; DP00418; -.
DR   Gene3D; 2.10.25.140; -; 1.
DR   Gene3D; 2.60.40.3510; -; 1.
DR   Gene3D; 2.10.25.10; Laminin; 15.
DR   IDEAL; IID00203; -.
DR   InterPro; IPR001774; DSL.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR026219; Jagged/Serrate.
DR   InterPro; IPR011651; Notch_ligand_N.
DR   InterPro; IPR001007; VWF_dom.
DR   PANTHER; PTHR12916; CYTOCHROME C OXIDASE POLYPEPTIDE VIC-2; 1.
DR   PANTHER; PTHR12916:SF4; NEUROGENIC LOCUS NOTCH HOMOLOG PROTEIN 1; 1.
DR   Pfam; PF01414; DSL; 1.
DR   Pfam; PF00008; EGF; 10.
DR   Pfam; PF07645; EGF_CA; 1.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF07657; MNNL; 1.
DR   PRINTS; PR00010; EGFBLOOD.
DR   PRINTS; PR02059; JAGGEDFAMILY.
DR   SMART; SM00051; DSL; 1.
DR   SMART; SM00181; EGF; 16.
DR   SMART; SM00179; EGF_CA; 14.
DR   SMART; SM00214; VWC; 1.
DR   SMART; SM00215; VWC_out; 1.
DR   SUPFAM; SSF57196; EGF/Laminin; 4.
DR   SUPFAM; SSF57603; FnI-like domain; 1.
DR   SUPFAM; SSF57184; Growth factor receptor domain; 3.
DR   PROSITE; PS00010; ASX_HYDROXYL; 10.
DR   PROSITE; PS51051; DSL; 1.
DR   PROSITE; PS00022; EGF_1; 16.
DR   PROSITE; PS01186; EGF_2; 12.
DR   PROSITE; PS50026; EGF_3; 15.
DR   PROSITE; PS01187; EGF_CA; 8.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Charcot-Marie-Tooth disease; Deafness; Developmental protein;
KW   Disease variant; Disulfide bond; EGF-like domain; Glycoprotein; Membrane;
KW   Neurodegeneration; Neuropathy; Notch signaling pathway; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000255"
FT   CHAIN           34..1218
FT                   /note="Protein jagged-1"
FT                   /id="PRO_0000007625"
FT   TOPO_DOM        34..1067
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1068..1093
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1094..1218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          185..229
FT                   /note="DSL"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00377"
FT   DOMAIN          230..263
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          264..294
FT                   /note="EGF-like 2; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          296..334
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          336..372
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          374..410
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          412..448
FT                   /note="EGF-like 6; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          450..485
FT                   /note="EGF-like 7; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          487..523
FT                   /note="EGF-like 8; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          525..561
FT                   /note="EGF-like 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          586..627
FT                   /note="EGF-like 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          629..665
FT                   /note="EGF-like 11; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          667..703
FT                   /note="EGF-like 12; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          705..741
FT                   /note="EGF-like 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          744..780
FT                   /note="EGF-like 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          782..818
FT                   /note="EGF-like 15; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          820..856
FT                   /note="EGF-like 16; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REGION          199..207
FT                   /note="Important for interaction with NOTCH1"
FT                   /evidence="ECO:0000269|PubMed:18660822"
FT   REGION          1152..1218
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1152..1169
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1190..1209
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        143
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        217
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        382
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        559
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        745
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        960
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        991
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1045
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1064
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        187..196
FT   DISULFID        200..212
FT   DISULFID        220..229
FT   DISULFID        234..245
FT   DISULFID        238..251
FT   DISULFID        253..262
FT   DISULFID        265..276
FT   DISULFID        271..282
FT   DISULFID        284..293
FT   DISULFID        300..312
FT   DISULFID        306..322
FT   DISULFID        324..333
FT   DISULFID        340..351
FT                   /evidence="ECO:0000250"
FT   DISULFID        345..360
FT                   /evidence="ECO:0000250"
FT   DISULFID        362..371
FT                   /evidence="ECO:0000250"
FT   DISULFID        378..389
FT                   /evidence="ECO:0000250"
FT   DISULFID        383..398
FT                   /evidence="ECO:0000250"
FT   DISULFID        400..409
FT                   /evidence="ECO:0000250"
FT   DISULFID        416..427
FT                   /evidence="ECO:0000250"
FT   DISULFID        421..436
FT                   /evidence="ECO:0000250"
FT   DISULFID        438..447
FT                   /evidence="ECO:0000250"
FT   DISULFID        454..464
FT                   /evidence="ECO:0000250"
FT   DISULFID        458..473
FT                   /evidence="ECO:0000250"
FT   DISULFID        475..484
FT                   /evidence="ECO:0000250"
FT   DISULFID        491..502
FT                   /evidence="ECO:0000250"
FT   DISULFID        496..511
FT                   /evidence="ECO:0000250"
FT   DISULFID        513..522
FT                   /evidence="ECO:0000250"
FT   DISULFID        529..540
FT                   /evidence="ECO:0000250"
FT   DISULFID        534..549
FT                   /evidence="ECO:0000250"
FT   DISULFID        551..560
FT                   /evidence="ECO:0000250"
FT   DISULFID        578..605
FT                   /evidence="ECO:0000250"
FT   DISULFID        599..615
FT                   /evidence="ECO:0000250"
FT   DISULFID        617..626
FT                   /evidence="ECO:0000250"
FT   DISULFID        633..644
FT                   /evidence="ECO:0000250"
FT   DISULFID        638..653
FT                   /evidence="ECO:0000250"
FT   DISULFID        655..664
FT                   /evidence="ECO:0000250"
FT   DISULFID        671..682
FT                   /evidence="ECO:0000250"
FT   DISULFID        676..691
FT                   /evidence="ECO:0000250"
FT   DISULFID        693..702
FT                   /evidence="ECO:0000250"
FT   DISULFID        709..720
FT                   /evidence="ECO:0000250"
FT   DISULFID        714..729
FT                   /evidence="ECO:0000250"
FT   DISULFID        731..740
FT                   /evidence="ECO:0000250"
FT   DISULFID        748..759
FT                   /evidence="ECO:0000250"
FT   DISULFID        753..768
FT                   /evidence="ECO:0000250"
FT   DISULFID        770..779
FT                   /evidence="ECO:0000250"
FT   DISULFID        786..797
FT                   /evidence="ECO:0000250"
FT   DISULFID        791..806
FT                   /evidence="ECO:0000250"
FT   DISULFID        808..817
FT                   /evidence="ECO:0000250"
FT   DISULFID        824..835
FT                   /evidence="ECO:0000250"
FT   DISULFID        829..844
FT                   /evidence="ECO:0000250"
FT   DISULFID        846..855
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..159
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056532"
FT   VARIANT         22..25
FT                   /note="Missing (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026296"
FT   VARIANT         31
FT                   /note="A -> V (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026297"
FT   VARIANT         33
FT                   /note="G -> D (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:11180599"
FT                   /id="VAR_026298"
FT   VARIANT         33
FT                   /note="G -> S (in ALGS1; dbSNP:rs876661123)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026299"
FT   VARIANT         33
FT                   /note="G -> V (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026300"
FT   VARIANT         37
FT                   /note="L -> S (in ALGS1; the mutant is unable to activate
FT                   Notch signaling; dbSNP:rs121918352)"
FT                   /evidence="ECO:0000269|PubMed:11157803,
FT                   ECO:0000269|PubMed:11180599, ECO:0000269|PubMed:20437614"
FT                   /id="VAR_013186"
FT   VARIANT         39
FT                   /note="I -> S (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:12442286"
FT                   /id="VAR_026301"
FT   VARIANT         40
FT                   /note="L -> P (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026302"
FT   VARIANT         45
FT                   /note="V -> L (in biliary atresia; extrahepatic;
FT                   dbSNP:rs183974372)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026303"
FT   VARIANT         53
FT                   /note="N -> D (in biliary atresia; extrahepatic)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026304"
FT   VARIANT         65
FT                   /note="K -> M (in biliary atresia; extrahepatic)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026305"
FT   VARIANT         75
FT                   /note="F -> S (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026306"
FT   VARIANT         78
FT                   /note="C -> S (in ALGS1; dbSNP:rs1555830957)"
FT                   /evidence="ECO:0000269|PubMed:11180599"
FT                   /id="VAR_026307"
FT   VARIANT         79
FT                   /note="L -> H (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013187"
FT   VARIANT         92
FT                   /note="C -> R (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026308"
FT   VARIANT         92
FT                   /note="C -> Y (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026309"
FT   VARIANT         120
FT                   /note="I -> N (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:15712272"
FT                   /id="VAR_026310"
FT   VARIANT         123
FT                   /note="P -> S (in ALGS1; dbSNP:rs1282498658)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026311"
FT   VARIANT         127
FT                   /note="A -> T (in ALGS1; dbSNP:rs930247415)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013188"
FT   VARIANT         129
FT                   /note="P -> R (in ALGS1; dbSNP:rs1032920906)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013189"
FT   VARIANT         146
FT                   /note="V -> I (in dbSNP:rs6040067)"
FT                   /id="VAR_048985"
FT   VARIANT         152
FT                   /note="I -> T (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10533065"
FT                   /id="VAR_013190"
FT   VARIANT         155
FT                   /note="A -> P (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026312"
FT   VARIANT         163
FT                   /note="P -> L (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013191"
FT   VARIANT         163
FT                   /note="P -> R (in ALGS1; dbSNP:rs1555829676)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026313"
FT   VARIANT         181
FT                   /note="Y -> N (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:11180599"
FT                   /id="VAR_026314"
FT   VARIANT         184
FT                   /note="R -> C (in ALGS1; dbSNP:rs121918350)"
FT                   /evidence="ECO:0000269|PubMed:9207788,
FT                   ECO:0000269|PubMed:9585603"
FT                   /id="VAR_013192"
FT   VARIANT         184
FT                   /note="R -> G (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013193"
FT   VARIANT         184
FT                   /note="R -> H (in ALGS1; loss of expression at the cell
FT                   membrane; dbSNP:rs121918351)"
FT                   /evidence="ECO:0000269|PubMed:12442286,
FT                   ECO:0000269|PubMed:32065591, ECO:0000269|PubMed:9585603"
FT                   /id="VAR_013194"
FT   VARIANT         184
FT                   /note="R -> L (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10533065"
FT                   /id="VAR_013195"
FT   VARIANT         187
FT                   /note="C -> S (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013196"
FT   VARIANT         187
FT                   /note="C -> Y (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:15712272"
FT                   /id="VAR_026315"
FT   VARIANT         203
FT                   /note="R -> K (in biliary atresia; extrahepatic)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026316"
FT   VARIANT         220
FT                   /note="C -> F (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:11139247"
FT                   /id="VAR_013197"
FT   VARIANT         224
FT                   /note="W -> C (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026317"
FT   VARIANT         229
FT                   /note="C -> G (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013198"
FT   VARIANT         229
FT                   /note="C -> Y (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:11058898"
FT                   /id="VAR_013199"
FT   VARIANT         234
FT                   /note="C -> Y (in DCHE; the mutant is unable to activate
FT                   Notch signaling; dbSNP:rs121918353)"
FT                   /evidence="ECO:0000269|PubMed:12022040,
FT                   ECO:0000269|PubMed:20437614"
FT                   /id="VAR_026318"
FT   VARIANT         252
FT                   /note="R -> G (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026319"
FT   VARIANT         256
FT                   /note="G -> S (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026320"
FT   VARIANT         269
FT                   /note="P -> L (in ALGS1; dbSNP:rs797044956)"
FT                   /evidence="ECO:0000269|PubMed:12497640"
FT                   /id="VAR_026321"
FT   VARIANT         271
FT                   /note="C -> R (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026322"
FT   VARIANT         274
FT                   /note="G -> D (in TOF; temperature sensitive mutation; the
FT                   protein is abnormally glycosylated and retained
FT                   intracellularly; unable to activate Notch signaling;
FT                   dbSNP:rs28939668)"
FT                   /evidence="ECO:0000269|PubMed:11152664,
FT                   ECO:0000269|PubMed:12649809, ECO:0000269|PubMed:20437614"
FT                   /id="VAR_013200"
FT   VARIANT         284
FT                   /note="C -> F (in ALGS1; dbSNP:rs1555829067)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013201"
FT   VARIANT         288
FT                   /note="W -> C (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013202"
FT   VARIANT         386
FT                   /note="G -> R (in ALGS1; dbSNP:rs863223650)"
FT                   /evidence="ECO:0000269|PubMed:11058898"
FT                   /id="VAR_013203"
FT   VARIANT         436
FT                   /note="C -> W (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:23801938"
FT                   /id="VAR_071513"
FT   VARIANT         438
FT                   /note="C -> F (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013204"
FT   VARIANT         504
FT                   /note="N -> S (in ALGS1; dbSNP:rs527236046)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026323"
FT   VARIANT         577
FT                   /note="S -> R (in CMT2HH; decreased glycosylation;
FT                   decreased expression at the cell membrane due to partial
FT                   retention in the endoplasmic reticulum)"
FT                   /evidence="ECO:0000269|PubMed:32065591"
FT                   /id="VAR_086413"
FT   VARIANT         650
FT                   /note="S -> P (in CMT2HH; decreased glycosylation;
FT                   decreased expression at the cell membrane due to partial
FT                   retention in the endoplasmic reticulum)"
FT                   /evidence="ECO:0000269|PubMed:32065591"
FT                   /id="VAR_086414"
FT   VARIANT         664
FT                   /note="C -> S (found in a patient with pulmonary stenosis;
FT                   unknown pathological significance; the mutant is able to
FT                   activate Notch signaling)"
FT                   /evidence="ECO:0000269|PubMed:20437614"
FT                   /id="VAR_080875"
FT   VARIANT         690
FT                   /note="Y -> D (in biliary atresia; extrahepatic)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026324"
FT   VARIANT         693
FT                   /note="C -> Y (in ALGS1; dbSNP:rs566563238)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026325"
FT   VARIANT         714
FT                   /note="C -> Y (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:11180599"
FT                   /id="VAR_026326"
FT   VARIANT         731
FT                   /note="C -> S (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013205"
FT   VARIANT         740
FT                   /note="C -> R (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:10220506"
FT                   /id="VAR_013206"
FT   VARIANT         753
FT                   /note="C -> R (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:11139247"
FT                   /id="VAR_013207"
FT   VARIANT         810
FT                   /note="P -> L (in TOF; the mutant is unable to activate
FT                   Notch signaling; dbSNP:rs769531968)"
FT                   /evidence="ECO:0000269|PubMed:20437614"
FT                   /id="VAR_080876"
FT   VARIANT         818
FT                   /note="R -> K"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026327"
FT   VARIANT         871
FT                   /note="P -> R (in biliary atresia; extrahepatic;
FT                   dbSNP:rs35761929)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026328"
FT   VARIANT         889
FT                   /note="R -> Q (in ALGS1; unknown pathological significance;
FT                   dbSNP:rs149419694)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026329"
FT   VARIANT         902
FT                   /note="C -> S (in ALGS1; dbSNP:rs876661122)"
FT                   /evidence="ECO:0000269|PubMed:11180599"
FT                   /id="VAR_026330"
FT   VARIANT         908
FT                   /note="H -> Q (in biliary atresia; extrahepatic)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026331"
FT   VARIANT         911
FT                   /note="C -> Y (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:16575836"
FT                   /id="VAR_026332"
FT   VARIANT         913
FT                   /note="S -> R (in ALGS1)"
FT                   /evidence="ECO:0000269|PubMed:12442286"
FT                   /id="VAR_026333"
FT   VARIANT         921
FT                   /note="L -> P (in biliary atresia; extrahepatic;
FT                   dbSNP:rs1305578649)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026334"
FT   VARIANT         937
FT                   /note="R -> Q (likely benign variant; the mutant is able to
FT                   activate Notch signaling; dbSNP:rs145895196)"
FT                   /evidence="ECO:0000269|PubMed:12497640,
FT                   ECO:0000269|PubMed:20437614"
FT                   /id="VAR_026335"
FT   VARIANT         1055..1056
FT                   /note="VR -> G (in ALGS1)"
FT                   /id="VAR_026336"
FT   VARIANT         1104
FT                   /note="H -> Q (found in patient with tetralogy of Fallot
FT                   and pulmonary stenosis; unknown pathological significance;
FT                   dbSNP:rs1250645531)"
FT                   /evidence="ECO:0000269|PubMed:20437614"
FT                   /id="VAR_080877"
FT   VARIANT         1213
FT                   /note="R -> Q (in biliary atresia; extrahepatic;
FT                   dbSNP:rs138007561)"
FT                   /evidence="ECO:0000269|PubMed:12297837"
FT                   /id="VAR_026337"
FT   MUTAGEN         207
FT                   /note="F->A: Strongly reduced NOTCH1 binding."
FT                   /evidence="ECO:0000269|PubMed:18660822"
FT   CONFLICT        117
FT                   /note="R -> P (in Ref. 5; AAB39007)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227
FT                   /note="P -> R (in Ref. 1; AAC51731)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        498
FT                   /note="N -> D (in Ref. 1; AAC51731)"
FT                   /evidence="ECO:0000305"
FT   STRAND          33..43
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          52..57
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   TURN            61..63
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          73..81
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          95..98
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          118..124
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          130..140
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          143..147
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          150..160
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          163..172
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          174..187
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   TURN            193..196
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          203..205
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          208..212
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          218..220
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   TURN            226..229
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   TURN            240..242
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          257..259
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   TURN            268..270
FT                   /evidence="ECO:0007829|PDB:2KB9"
FT   STRAND          273..275
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          277..280
FT                   /evidence="ECO:0007829|PDB:2KB9"
FT   STRAND          286..289
FT                   /evidence="ECO:0007829|PDB:2KB9"
FT   TURN            290..293
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          295..297
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   HELIX           299..303
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          311..316
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          319..323
FT                   /evidence="ECO:0007829|PDB:4CC0"
FT   STRAND          328..330
FT                   /evidence="ECO:0007829|PDB:4CC0"
SQ   SEQUENCE   1218 AA;  133799 MW;  F36EE9FBF64DF162 CRC64;
     MRSPRTRGRS GRPLSLLLAL LCALRAKVCG ASGQFELEIL SMQNVNGELQ NGNCCGGARN
     PGDRKCTRDE CDTYFKVCLK EYQSRVTAGG PCSFGSGSTP VIGGNTFNLK ASRGNDRNRI
     VLPFSFAWPR SYTLLVEAWD SSNDTVQPDS IIEKASHSGM INPSRQWQTL KQNTGVAHFE
     YQIRVTCDDY YYGFGCNKFC RPRDDFFGHY ACDQNGNKTC MEGWMGPECN RAICRQGCSP
     KHGSCKLPGD CRCQYGWQGL YCDKCIPHPG CVHGICNEPW QCLCETNWGG QLCDKDLNYC
     GTHQPCLNGG TCSNTGPDKY QCSCPEGYSG PNCEIAEHAC LSDPCHNRGS CKETSLGFEC
     ECSPGWTGPT CSTNIDDCSP NNCSHGGTCQ DLVNGFKCVC PPQWTGKTCQ LDANECEAKP
     CVNAKSCKNL IASYYCDCLP GWMGQNCDIN INDCLGQCQN DASCRDLVNG YRCICPPGYA
     GDHCERDIDE CASNPCLNGG HCQNEINRFQ CLCPTGFSGN LCQLDIDYCE PNPCQNGAQC
     YNRASDYFCK CPEDYEGKNC SHLKDHCRTT PCEVIDSCTV AMASNDTPEG VRYISSNVCG
     PHGKCKSQSG GKFTCDCNKG FTGTYCHENI NDCESNPCRN GGTCIDGVNS YKCICSDGWE
     GAYCETNIND CSQNPCHNGG TCRDLVNDFY CDCKNGWKGK TCHSRDSQCD EATCNNGGTC
     YDEGDAFKCM CPGGWEGTTC NIARNSSCLP NPCHNGGTCV VNGESFTCVC KEGWEGPICA
     QNTNDCSPHP CYNSGTCVDG DNWYRCECAP GFAGPDCRIN INECQSSPCA FGATCVDEIN
     GYRCVCPPGH SGAKCQEVSG RPCITMGSVI PDGAKWDDDC NTCQCLNGRI ACSKVWCGPR
     PCLLHKGHSE CPSGQSCIPI LDDQCFVHPC TGVGECRSSS LQPVKTKCTS DSYYQDNCAN
     ITFTFNKEMM SPGLTTEHIC SELRNLNILK NVSAEYSIYI ACEPSPSANN EIHVAISAED
     IRDDGNPIKE ITDKIIDLVS KRDGNSSLIA AVAEVRVQRR PLKNRTDFLV PLLSSVLTVA
     WICCLVTAFY WCLRKRRKPG SHTHSASEDN TTNNVREQLN QIKNPIEKHG ANTVPIKDYE
     NKNSKMSKIR THNSEVEEDD MDKHQQKARF AKQPAYTLVD REEKPPNGTP TKHPNWTNKQ
     DNRDLESAQS LNRMEYIV
//
ID   LAMP2_HUMAN             Reviewed;         410 AA.
AC   P13473; A8K4X5; D3DTF0; Q16641; Q6Q3G8; Q96J30; Q99534; Q9UD93;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   22-FEB-2023, entry version 226.
DE   RecName: Full=Lysosome-associated membrane glycoprotein 2;
DE            Short=LAMP-2;
DE            Short=Lysosome-associated membrane protein 2;
DE   AltName: Full=CD107 antigen-like family member B;
DE   AltName: Full=LGP-96 {ECO:0000303|PubMed:8662539};
DE   AltName: CD_antigen=CD107b;
DE   Flags: Precursor;
GN   Name=LAMP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LAMP-2A), AND PROTEIN SEQUENCE OF
RP   29-64; 216-223 AND 238-256.
RX   PubMed=3198605; DOI=10.1016/s0021-9258(18)37370-8;
RA   Fukuda M., Viitala J., Matteson J., Carlsson S.R.;
RT   "Cloning of cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1
RT   and h-lamp-2. Comparison of their deduced amino acid sequences.";
RL   J. Biol. Chem. 263:18920-18928(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM LAMP-2A).
RC   TISSUE=Placenta;
RX   PubMed=8517882; DOI=10.1016/s0021-9258(18)52972-0;
RA   Sawada R., Jardine K.A., Fukuda M.;
RT   "The genes of major lysosomal membrane glycoproteins, lamp-1 and lamp-2.
RT   5'-flanking sequence of lamp-2 gene and comparison of exon organization in
RT   two genes.";
RL   J. Biol. Chem. 268:9014-9022(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LAMP-2B).
RC   TISSUE=Fibroblast;
RX   PubMed=8407947; DOI=10.1016/s0021-9258(19)36899-1;
RA   Fritz G., Dosch J., Thielmann H.W., Kaina B.;
RT   "Molecular and cellular characterization of Mex-/methylation-resistant
RT   phenotype. Gene and cDNA cloning, serum dependence, and tumor suppression
RT   of transfectant strains.";
RL   J. Biol. Chem. 268:21102-21112(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LAMP-2A).
RC   TISSUE=Liver;
RX   PubMed=7999007; DOI=10.1006/bbrc.1994.2620;
RA   Konecki D.S., Foetisch K., Schlotter M., Lichter-Konecki U.;
RT   "Complete cDNA sequence of human lysosome-associated membrane protein-2.";
RL   Biochem. Biophys. Res. Commun. 205:1-5(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LAMP-2B), AND TISSUE SPECIFICITY.
RX   PubMed=7488019; DOI=10.1006/bbrc.1995.2528;
RA   Konecki D.S., Foetisch K., Zimmer K.P., Schlotter M., Lichter-Konecki U.;
RT   "An alternatively spliced form of the human lysosome-associated membrane
RT   protein-2 gene is expressed in a tissue-specific manner.";
RL   Biochem. Biophys. Res. Commun. 215:757-767(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LAMP-2C).
RA   Zhou D., Blum J.S.;
RT   "Lamp-2 isoforms play different roles in lysosomal biogenesis.";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LAMP-2A).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LAMP-2B).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 29-66, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=2912382; DOI=10.1016/0003-9861(89)90597-3;
RA   Mane S.M., Marzella L., Bainton D.F., Holt V.K., Cha Y., Hildreth J.E.K.,
RA   August J.T.;
RT   "Purification and characterization of human lysosomal membrane
RT   glycoproteins.";
RL   Arch. Biochem. Biophys. 268:360-378(1989).
RN   [12]
RP   PROTEIN SEQUENCE OF 29-43.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [13]
RP   POLYLACTOSAMINOGLYCANS, AND GLYCOSYLATION.
RX   PubMed=2243102; DOI=10.1016/s0021-9258(17)30530-6;
RA   Carlsson S.R., Fukuda M.;
RT   "The polylactosaminoglycans of human lysosomal membrane glycoproteins lamp-
RT   1 and lamp-2. Localization on the peptide backbones.";
RL   J. Biol. Chem. 265:20488-20495(1990).
RN   [14]
RP   GLYCOSYLATION OF HINGE REGION, AND PROTEIN SEQUENCE OF 187-215.
RX   PubMed=8323299; DOI=10.1006/abbi.1993.1322;
RA   Carlsson S.R., Lycksell P.-O., Fukuda M.;
RT   "Assignment of O-glycan attachment sites to the hinge-like regions of human
RT   lysosomal membrane glycoproteins lamp-1 and lamp-2.";
RL   Arch. Biochem. Biophys. 304:65-73(1993).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8662539; DOI=10.1126/science.273.5274.501;
RA   Cuervo A.M., Dice J.F.;
RT   "A receptor for the selective uptake and degradation of proteins by
RT   lysosomes.";
RL   Science 273:501-503(1996).
RN   [16]
RP   FUNCTION (ISOFORM LAMP-2A), SUBCELLULAR LOCATION, TOPOLOGY, AND MUTAGENESIS
RP   OF 401-LYS--HIS-404.
RX   PubMed=11082038; DOI=10.1242/jcs.113.24.4441;
RA   Cuervo A.M., Dice J.F.;
RT   "Unique properties of lamp2a compared to other lamp2 isoforms.";
RL   J. Cell Sci. 113:4441-4450(2000).
RN   [17]
RP   GLYCOSYLATION AT ASN-49 AND ASN-101.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-32; ASN-38; ASN-49; ASN-101;
RP   ASN-123 AND ASN-257.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [19]
RP   NOMENCLATURE.
RX   PubMed=16190986; DOI=10.1111/j.1600-0854.2005.00337.x;
RA   Eskelinen E.L., Cuervo A.M., Taylor M.R., Nishino I., Blum J.S., Dice J.F.,
RA   Sandoval I.V., Lippincott-Schwartz J., August J.T., Saftig P.;
RT   "Unifying nomenclature for the isoforms of the lysosomal membrane protein
RT   LAMP-2.";
RL   Traffic 6:1058-1061(2005).
RN   [20]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B., Schaefer H.,
RA   Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=18644871; DOI=10.1128/mcb.02070-07;
RA   Bandyopadhyay U., Kaushik S., Varticovski L., Cuervo A.M.;
RT   "The chaperone-mediated autophagy receptor organizes in dynamic protein
RT   complexes at the lysosomal membrane.";
RL   Mol. Cell. Biol. 28:5747-5763(2008).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-101; ASN-123; ASN-257 AND
RP   ASN-356.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   FUNCTION.
RX   PubMed=20518820; DOI=10.1111/j.1365-2567.2010.03309.x;
RA   Crotzer V.L., Glosson N., Zhou D., Nishino I., Blum J.S.;
RT   "LAMP-2-deficient human B cells exhibit altered MHC class II presentation
RT   of exogenous antigens.";
RL   Immunology 131:318-330(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INTERACTION WITH ABCB9.
RX   PubMed=22641697; DOI=10.1242/jcs.087346;
RA   Demirel O., Jan I., Wolters D., Blanz J., Saftig P., Tampe R., Abele R.;
RT   "The lysosomal polypeptide transporter TAPL is stabilized by interaction
RT   with LAMP-1 and LAMP-2.";
RL   J. Cell Sci. 125:4230-4240(2012).
RN   [26]
RP   INTERACTION WITH MLLT11, AND FUNCTION.
RX   PubMed=24880125; DOI=10.1016/j.yexcr.2014.05.013;
RA   Li P., Ji M., Lu F., Zhang J., Li H., Cui T., Li Wang X., Tang D., Ji C.;
RT   "Degradation of AF1Q by chaperone-mediated autophagy.";
RL   Exp. Cell Res. 327:48-56(2014).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [28]
RP   FUNCTION.
RX   PubMed=27628032; DOI=10.1242/bio.018648;
RA   Hubert V., Peschel A., Langer B., Groeger M., Rees A., Kain R.;
RT   "LAMP-2 is required for incorporating syntaxin-17 into autophagosomes and
RT   for their fusion with lysosomes.";
RL   Biol. Open 5:1516-1529(2016).
RN   [29]
RP   FUNCTION (ISOFORM LAMP-2C), TISSUE SPECIFICITY, AND INDUCTION BY B CELL
RP   STIMULATION.
RX   PubMed=26856698; DOI=10.4049/jimmunol.1501476;
RA   Perez L., McLetchie S., Gardiner G.J., Deffit S.N., Zhou D., Blum J.S.;
RT   "LAMP-2C inhibits MHC class II presentation of cytoplasmic antigens by
RT   disrupting chaperone-mediated autophagy.";
RL   J. Immunol. 196:2457-2465(2016).
RN   [30]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH FURIN, AND INTERACTION
RP   WITH MUMPS VIRURS PROTEIN F (MICROBIAL INFECTION).
RX   PubMed=32295904; DOI=10.1128/jvi.00050-20;
RA   Ueo A., Kubota M., Shirogane Y., Ohno S., Hashiguchi T., Yanagi Y.;
RT   "Lysosome-Associated Membrane Proteins Support the Furin-Mediated
RT   Processing of the Mumps Virus Fusion Protein.";
RL   J. Virol. 94:0-0(2020).
RN   [31]
RP   STRUCTURE BY NMR OF 369-410, INTERACTION WITH HSPA8, AND SUBUNIT.
RX   PubMed=25342746; DOI=10.1074/jbc.m114.609446;
RA   Rout A.K., Strub M.P., Piszczek G., Tjandra N.;
RT   "Structure of transmembrane domain of lysosome-associated membrane protein
RT   type 2a (LAMP-2A) reveals key features for substrate specificity in
RT   chaperone-mediated autophagy.";
RL   J. Biol. Chem. 289:35111-35123(2014).
RN   [32]
RP   VARIANT DAND ARG-321.
RX   PubMed=15673802; DOI=10.1056/nejmoa033349;
RA   Arad M., Maron B.J., Gorham J.M., Johnson W.H. Jr., Saul J.P.,
RA   Perez-Atayde A.R., Spirito P., Wright G.B., Kanter R.J., Seidman C.E.,
RA   Seidman J.G.;
RT   "Glycogen storage diseases presenting as hypertrophic cardiomyopathy.";
RL   N. Engl. J. Med. 352:362-372(2005).
RN   [33]
RP   VARIANT DAND ARG-321.
RX   PubMed=15907287; DOI=10.1016/j.nmd.2005.02.008;
RA   Musumeci O., Rodolico C., Nishino I., Di Guardo G., Migliorato A.,
RA   Aguennouz M., Mazzeo A., Messina C., Vita G., Toscano A.;
RT   "Asymptomatic hyperCKemia in a case of Danon disease due to a missense
RT   mutation in Lamp-2 gene.";
RL   Neuromuscul. Disord. 15:409-411(2005).
CC   -!- FUNCTION: Plays an important role in chaperone-mediated autophagy, a
CC       process that mediates lysosomal degradation of proteins in response to
CC       various stresses and as part of the normal turnover of proteins with a
CC       long biological half-live (PubMed:8662539, PubMed:11082038,
CC       PubMed:18644871, PubMed:24880125, PubMed:27628032). Functions by
CC       binding target proteins, such as GAPDH and MLLT11, and targeting them
CC       for lysosomal degradation (PubMed:8662539, PubMed:11082038,
CC       PubMed:18644871, PubMed:24880125). Plays a role in lysosomal protein
CC       degradation in response to starvation (By similarity). Required for the
CC       fusion of autophagosomes with lysosomes during autophagy
CC       (PubMed:27628032). Cells that lack LAMP2 express normal levels of
CC       VAMP8, but fail to accumulate STX17 on autophagosomes, which is the
CC       most likely explanation for the lack of fusion between autophagosomes
CC       and lysosomes (PubMed:27628032). Required for normal degradation of the
CC       contents of autophagosomes (PubMed:27628032). Required for efficient
CC       MHCII-mediated presentation of exogenous antigens via its function in
CC       lysosomal protein degradation; antigenic peptides generated by
CC       proteases in the endosomal/lysosomal compartment are captured by
CC       nascent MHCII subunits (PubMed:20518820). Is not required for efficient
CC       MHCII-mediated presentation of endogenous antigens (PubMed:20518820).
CC       {ECO:0000250|UniProtKB:P17046, ECO:0000269|PubMed:11082038,
CC       ECO:0000269|PubMed:18644871, ECO:0000269|PubMed:20518820,
CC       ECO:0000269|PubMed:24880125, ECO:0000269|PubMed:27628032,
CC       ECO:0000269|PubMed:8662539}.
CC   -!- FUNCTION: [Isoform LAMP-2C]: Modulates chaperone-mediated autophagy.
CC       Decreases presentation of endogenous antigens by MHCII. Does not play a
CC       role in the presentation of exogenous and membrane-derived antigens by
CC       MHCII. {ECO:0000269|PubMed:26856698}.
CC   -!- FUNCTION: (Microbial infection) Supports the FURIN-mediated cleavage of
CC       mumps virus fusion protein F by interacting with both FURIN and the
CC       unprocessed form but not the processed form of the viral protein F.
CC       {ECO:0000269|PubMed:32295904}.
CC   -!- SUBUNIT: Monomer (PubMed:18644871, PubMed:25342746). Homodimer
CC       (PubMed:25342746). Homotrimer (PubMed:25342746). Forms large
CC       homooligomers (PubMed:18644871). Interacts (via its cytoplasmic region)
CC       with HSPA8 (PubMed:25342746). Interacts with HSP90 in the lysosome
CC       lumen; this enhances LAMP2 stability (By similarity). Interacts with
CC       MLLT11 (PubMed:24880125). Interacts with ABCB9 (PubMed:22641697).
CC       Interacts with FURIN (PubMed:32295904). {ECO:0000250|UniProtKB:P17046,
CC       ECO:0000269|PubMed:18644871, ECO:0000269|PubMed:22641697,
CC       ECO:0000269|PubMed:24880125, ECO:0000269|PubMed:25342746,
CC       ECO:0000269|PubMed:32295904}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein F;
CC       this interaction promotes protein F cleavage by FURIN.
CC       {ECO:0000269|PubMed:32295904}.
CC   -!- INTERACTION:
CC       P13473-2; P45844-6: ABCG1; NbExp=3; IntAct=EBI-21591415, EBI-25873349;
CC       P13473-2; Q7Z5M8-2: ABHD12B; NbExp=3; IntAct=EBI-21591415, EBI-21854797;
CC       P13473-2; Q9Y614: ACTL7B; NbExp=3; IntAct=EBI-21591415, EBI-25835070;
CC       P13473-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-21591415, EBI-18899653;
CC       P13473-2; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-21591415, EBI-10173507;
CC       P13473-2; Q96MA6: AK8; NbExp=3; IntAct=EBI-21591415, EBI-8466265;
CC       P13473-2; Q5T2L2: AKR1C8; NbExp=3; IntAct=EBI-21591415, EBI-22006248;
CC       P13473-2; Q96Q83-2: ALKBH3; NbExp=3; IntAct=EBI-21591415, EBI-9089544;
CC       P13473-2; Q9Y303-2: AMDHD2; NbExp=3; IntAct=EBI-21591415, EBI-12323557;
CC       P13473-2; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-21591415, EBI-8464238;
CC       P13473-2; P09525: ANXA4; NbExp=3; IntAct=EBI-21591415, EBI-2556852;
CC       P13473-2; P02647: APOA1; NbExp=3; IntAct=EBI-21591415, EBI-701692;
CC       P13473-2; P02749: APOH; NbExp=3; IntAct=EBI-21591415, EBI-2114682;
CC       P13473-2; P53365: ARFIP2; NbExp=3; IntAct=EBI-21591415, EBI-638194;
CC       P13473-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-21591415, EBI-5280499;
CC       P13473-2; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-21591415, EBI-10254793;
CC       P13473-2; P18848: ATF4; NbExp=3; IntAct=EBI-21591415, EBI-492498;
CC       P13473-2; Q9H0Y0: ATG10; NbExp=3; IntAct=EBI-21591415, EBI-1048913;
CC       P13473-2; C1IDX9: ATG12; NbExp=3; IntAct=EBI-21591415, EBI-25836940;
CC       P13473-2; O75964: ATP5MG; NbExp=3; IntAct=EBI-21591415, EBI-1044001;
CC       P13473-2; Q14032: BAAT; NbExp=3; IntAct=EBI-21591415, EBI-8994378;
CC       P13473-2; P54687-4: BCAT1; NbExp=3; IntAct=EBI-21591415, EBI-25834445;
CC       P13473-2; P06276: BCHE; NbExp=3; IntAct=EBI-21591415, EBI-7936069;
CC       P13473-2; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-21591415, EBI-10693038;
CC       P13473-2; Q8WZ55: BSND; NbExp=3; IntAct=EBI-21591415, EBI-7996695;
CC       P13473-2; Q96Q07-2: BTBD9; NbExp=3; IntAct=EBI-21591415, EBI-22006737;
CC       P13473-2; Q9H0W9-3: C11orf54; NbExp=3; IntAct=EBI-21591415, EBI-12108466;
CC       P13473-2; Q9NQ89: C12orf4; NbExp=3; IntAct=EBI-21591415, EBI-11090973;
CC       P13473-2; Q13901: C1D; NbExp=3; IntAct=EBI-21591415, EBI-3844053;
CC       P13473-2; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-21591415, EBI-18036948;
CC       P13473-2; Q8N1A6: C4orf33; NbExp=3; IntAct=EBI-21591415, EBI-10264911;
CC       P13473-2; P17655: CAPN2; NbExp=3; IntAct=EBI-21591415, EBI-1028956;
CC       P13473-2; P20807-4: CAPN3; NbExp=3; IntAct=EBI-21591415, EBI-11532021;
CC       P13473-2; P55212: CASP6; NbExp=3; IntAct=EBI-21591415, EBI-718729;
CC       P13473-2; Q5JTY5: CBWD3; NbExp=3; IntAct=EBI-21591415, EBI-723434;
CC       P13473-2; O00257-3: CBX4; NbExp=3; IntAct=EBI-21591415, EBI-4392727;
CC       P13473-2; P24863: CCNC; NbExp=3; IntAct=EBI-21591415, EBI-395261;
CC       P13473-2; Q9UK58-5: CCNL1; NbExp=3; IntAct=EBI-21591415, EBI-25873837;
CC       P13473-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-21591415, EBI-12300031;
CC       P13473-2; P01730: CD4; NbExp=3; IntAct=EBI-21591415, EBI-353826;
CC       P13473-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-21591415, EBI-396137;
CC       P13473-2; P42773: CDKN2C; NbExp=3; IntAct=EBI-21591415, EBI-711290;
CC       P13473-2; O95674: CDS2; NbExp=3; IntAct=EBI-21591415, EBI-3913685;
CC       P13473-2; O15182: CETN3; NbExp=3; IntAct=EBI-21591415, EBI-712959;
CC       P13473-2; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-21591415, EBI-749253;
CC       P13473-2; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-21591415, EBI-744045;
CC       P13473-2; Q8N365: CIART; NbExp=3; IntAct=EBI-21591415, EBI-10265133;
CC       P13473-2; Q9UHD4: CIDEB; NbExp=3; IntAct=EBI-21591415, EBI-7062247;
CC       P13473-2; Q99966: CITED1; NbExp=3; IntAct=EBI-21591415, EBI-2624951;
CC       P13473-2; P09496-2: CLTA; NbExp=3; IntAct=EBI-21591415, EBI-4401010;
CC       P13473-2; Q6PJW8-3: CNST; NbExp=3; IntAct=EBI-21591415, EBI-25836090;
CC       P13473-2; Q96BR5: COA7; NbExp=3; IntAct=EBI-21591415, EBI-6269632;
CC       P13473-2; P02458-1: COL2A1; NbExp=3; IntAct=EBI-21591415, EBI-12375799;
CC       P13473-2; Q8NI60: COQ8A; NbExp=3; IntAct=EBI-21591415, EBI-745535;
CC       P13473-2; Q9UGL9: CRCT1; NbExp=3; IntAct=EBI-21591415, EBI-713677;
CC       P13473-2; P26998: CRYBB3; NbExp=3; IntAct=EBI-21591415, EBI-1965681;
CC       P13473-2; P35222: CTNNB1; NbExp=3; IntAct=EBI-21591415, EBI-491549;
CC       P13473-2; Q53TN4: CYBRD1; NbExp=3; IntAct=EBI-21591415, EBI-8637742;
CC       P13473-2; P10632: CYP2C8; NbExp=3; IntAct=EBI-21591415, EBI-2951522;
CC       P13473-2; P61962: DCAF7; NbExp=3; IntAct=EBI-21591415, EBI-359808;
CC       P13473-2; Q96LJ7: DHRS1; NbExp=3; IntAct=EBI-21591415, EBI-746300;
CC       P13473-2; O60479: DLX3; NbExp=3; IntAct=EBI-21591415, EBI-3908248;
CC       P13473-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-21591415, EBI-11526226;
CC       P13473-2; Q96KC8: DNAJC1; NbExp=3; IntAct=EBI-21591415, EBI-296550;
CC       P13473-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-21591415, EBI-23669343;
CC       P13473-2; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-21591415, EBI-724653;
CC       P13473-2; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-21591415, EBI-10248874;
CC       P13473-2; O00303: EIF3F; NbExp=3; IntAct=EBI-21591415, EBI-711990;
CC       P13473-2; Q13347: EIF3I; NbExp=3; IntAct=EBI-21591415, EBI-354047;
CC       P13473-2; O00472: ELL2; NbExp=3; IntAct=EBI-21591415, EBI-395274;
CC       P13473-2; O00423: EML1; NbExp=3; IntAct=EBI-21591415, EBI-751327;
CC       P13473-2; O95278-6: EPM2A; NbExp=3; IntAct=EBI-21591415, EBI-25836908;
CC       P13473-2; Q6NXG1-3: ESRP1; NbExp=3; IntAct=EBI-21591415, EBI-21567429;
CC       P13473-2; P00748: F12; NbExp=3; IntAct=EBI-21591415, EBI-6378830;
CC       P13473-2; Q49AJ0-4: FAM135B; NbExp=3; IntAct=EBI-21591415, EBI-25835236;
CC       P13473-2; Q96KS9: FAM167A; NbExp=3; IntAct=EBI-21591415, EBI-10290462;
CC       P13473-2; Q8N128-2: FAM177A1; NbExp=3; IntAct=EBI-21591415, EBI-12201693;
CC       P13473-2; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-21591415, EBI-8468186;
CC       P13473-2; Q9NYY8: FASTKD2; NbExp=3; IntAct=EBI-21591415, EBI-1055752;
CC       P13473-2; P02671-2: FGA; NbExp=3; IntAct=EBI-21591415, EBI-9640259;
CC       P13473-2; Q6ZNL6: FGD5; NbExp=3; IntAct=EBI-21591415, EBI-7962481;
CC       P13473-2; Q9NSA1: FGF21; NbExp=3; IntAct=EBI-21591415, EBI-3909329;
CC       P13473-2; P49771-3: FLT3LG; NbExp=3; IntAct=EBI-21591415, EBI-25872794;
CC       P13473-2; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-21591415, EBI-6425864;
CC       P13473-2; Q6P7E6: FUT6; NbExp=3; IntAct=EBI-21591415, EBI-25872807;
CC       P13473-2; P06241: FYN; NbExp=3; IntAct=EBI-21591415, EBI-515315;
CC       P13473-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-21591415, EBI-9088619;
CC       P13473-2; Q9H3K2: GHITM; NbExp=3; IntAct=EBI-21591415, EBI-2868909;
CC       P13473-2; Q8WWP7: GIMAP1; NbExp=3; IntAct=EBI-21591415, EBI-11991950;
CC       P13473-2; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-21591415, EBI-12143817;
CC       P13473-2; Q9HAV0: GNB4; NbExp=3; IntAct=EBI-21591415, EBI-358539;
CC       P13473-2; P32780: GTF2H1; NbExp=3; IntAct=EBI-21591415, EBI-715539;
CC       P13473-2; O75409: H2AP; NbExp=3; IntAct=EBI-21591415, EBI-6447217;
CC       P13473-2; Q6NXT2: H3-5; NbExp=3; IntAct=EBI-21591415, EBI-2868501;
CC       P13473-2; P68431: H3C12; NbExp=3; IntAct=EBI-21591415, EBI-79722;
CC       P13473-2; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-21591415, EBI-2558143;
CC       P13473-2; Q9NRZ9-6: HELLS; NbExp=3; IntAct=EBI-21591415, EBI-12003732;
CC       P13473-2; Q96EW2-2: HSPBAP1; NbExp=3; IntAct=EBI-21591415, EBI-25835621;
CC       P13473-2; Q8N6M8-2: IQCF1; NbExp=3; IntAct=EBI-21591415, EBI-21771049;
CC       P13473-2; Q92613: JADE3; NbExp=3; IntAct=EBI-21591415, EBI-10278909;
CC       P13473-2; P0C870: JMJD7; NbExp=3; IntAct=EBI-21591415, EBI-9090173;
CC       P13473-2; Q9UK76: JPT1; NbExp=3; IntAct=EBI-21591415, EBI-720411;
CC       P13473-2; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-21591415, EBI-743960;
CC       P13473-2; Q8TBB5-2: KLHDC4; NbExp=3; IntAct=EBI-21591415, EBI-21838933;
CC       P13473-2; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-21591415, EBI-8524663;
CC       P13473-2; Q8N4N3-2: KLHL36; NbExp=3; IntAct=EBI-21591415, EBI-10973851;
CC       P13473-2; Q8N1A0: KRT222; NbExp=3; IntAct=EBI-21591415, EBI-8473062;
CC       P13473-2; Q6DKI2: LGALS9C; NbExp=3; IntAct=EBI-21591415, EBI-9088829;
CC       P13473-2; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-21591415, EBI-25835523;
CC       P13473-2; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-21591415, EBI-10264791;
CC       P13473-2; Q9Y234: LIPT1; NbExp=3; IntAct=EBI-21591415, EBI-727376;
CC       P13473-2; Q99732: LITAF; NbExp=3; IntAct=EBI-21591415, EBI-725647;
CC       P13473-2; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-21591415, EBI-2510853;
CC       P13473-2; Q96JB6: LOXL4; NbExp=3; IntAct=EBI-21591415, EBI-749562;
CC       P13473-2; Q8IYG6: LRRC56; NbExp=3; IntAct=EBI-21591415, EBI-14752528;
CC       P13473-2; Q5VYH9: LY9; NbExp=3; IntAct=EBI-21591415, EBI-25872860;
CC       P13473-2; P0DP58-2: LYNX1; NbExp=3; IntAct=EBI-21591415, EBI-21916939;
CC       P13473-2; P43361: MAGEA8; NbExp=3; IntAct=EBI-21591415, EBI-10182930;
CC       P13473-2; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-21591415, EBI-741835;
CC       P13473-2; Q969L2: MAL2; NbExp=3; IntAct=EBI-21591415, EBI-944295;
CC       P13473-2; P27338: MAOB; NbExp=3; IntAct=EBI-21591415, EBI-3911344;
CC       P13473-2; Q8NI22: MCFD2; NbExp=3; IntAct=EBI-21591415, EBI-2689785;
CC       P13473-2; A6NJ78-4: METTL15; NbExp=3; IntAct=EBI-21591415, EBI-10174029;
CC       P13473-2; A0A0A0MR05: MLST8; NbExp=3; IntAct=EBI-21591415, EBI-25835557;
CC       P13473-2; P34949-2: MPI; NbExp=3; IntAct=EBI-21591415, EBI-21823432;
CC       P13473-2; Q9BV20: MRI1; NbExp=3; IntAct=EBI-21591415, EBI-747381;
CC       P13473-2; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-21591415, EBI-25835707;
CC       P13473-2; Q8N387: MUC15; NbExp=3; IntAct=EBI-21591415, EBI-17937277;
CC       P13473-2; A2RUH7: MYBPHL; NbExp=3; IntAct=EBI-21591415, EBI-9088235;
CC       P13473-2; P01106: MYC; NbExp=3; IntAct=EBI-21591415, EBI-447544;
CC       P13473-2; Q9H7X0: NAA60; NbExp=3; IntAct=EBI-21591415, EBI-12260336;
CC       P13473-2; Q15742-2: NAB2; NbExp=3; IntAct=EBI-21591415, EBI-25834665;
CC       P13473-2; Q9UJ70-2: NAGK; NbExp=3; IntAct=EBI-21591415, EBI-11526455;
CC       P13473-2; Q69YL0: NCBP2AS2; NbExp=3; IntAct=EBI-21591415, EBI-10986258;
CC       P13473-2; P25208: NFYB; NbExp=3; IntAct=EBI-21591415, EBI-389728;
CC       P13473-2; Q8NDH3-5: NPEPL1; NbExp=3; IntAct=EBI-21591415, EBI-12329915;
CC       P13473-2; O15130-2: NPFF; NbExp=3; IntAct=EBI-21591415, EBI-25840002;
CC       P13473-2; P36639-4: NUDT1; NbExp=3; IntAct=EBI-21591415, EBI-25834643;
CC       P13473-2; Q8NFH4: NUP37; NbExp=3; IntAct=EBI-21591415, EBI-2563158;
CC       P13473-2; Q8NFH3: NUP43; NbExp=3; IntAct=EBI-21591415, EBI-1059321;
CC       P13473-2; Q7Z3B4: NUP54; NbExp=3; IntAct=EBI-21591415, EBI-741048;
CC       P13473-2; Q6N063-2: OGFOD2; NbExp=3; IntAct=EBI-21591415, EBI-22006224;
CC       P13473-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-21591415, EBI-25830200;
CC       P13473-2; Q99447: PCYT2; NbExp=3; IntAct=EBI-21591415, EBI-750317;
CC       P13473-2; P27815-4: PDE4A; NbExp=3; IntAct=EBI-21591415, EBI-12080840;
CC       P13473-2; A5PLL7: PEDS1; NbExp=3; IntAct=EBI-21591415, EBI-11337896;
CC       P13473-2; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-21591415, EBI-722852;
CC       P13473-2; Q00169: PITPNA; NbExp=3; IntAct=EBI-21591415, EBI-1042490;
CC       P13473-2; P48739: PITPNB; NbExp=3; IntAct=EBI-21591415, EBI-1047143;
CC       P13473-2; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-21591415, EBI-21503705;
CC       P13473-2; O60664: PLIN3; NbExp=3; IntAct=EBI-21591415, EBI-725795;
CC       P13473-2; Q14181: POLA2; NbExp=3; IntAct=EBI-21591415, EBI-712752;
CC       P13473-2; P0DPB6: POLR1D; NbExp=3; IntAct=EBI-21591415, EBI-359498;
CC       P13473-2; P36954: POLR2I; NbExp=3; IntAct=EBI-21591415, EBI-395202;
CC       P13473-2; Q07869: PPARA; NbExp=3; IntAct=EBI-21591415, EBI-78615;
CC       P13473-2; O60927: PPP1R11; NbExp=3; IntAct=EBI-21591415, EBI-1048104;
CC       P13473-2; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-21591415, EBI-25835994;
CC       P13473-2; Q8NCQ7-2: PROCA1; NbExp=3; IntAct=EBI-21591415, EBI-25836043;
CC       P13473-2; P23942: PRPH2; NbExp=3; IntAct=EBI-21591415, EBI-25836834;
CC       P13473-2; P41222: PTGDS; NbExp=3; IntAct=EBI-21591415, EBI-948821;
CC       P13473-2; P29074: PTPN4; NbExp=3; IntAct=EBI-21591415, EBI-710431;
CC       P13473-2; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-21591415, EBI-25835884;
CC       P13473-2; Q5R372-9: RABGAP1L; NbExp=3; IntAct=EBI-21591415, EBI-10699389;
CC       P13473-2; Q9HD47-3: RANGRF; NbExp=3; IntAct=EBI-21591415, EBI-9089733;
CC       P13473-2; Q09028: RBBP4; NbExp=3; IntAct=EBI-21591415, EBI-620823;
CC       P13473-2; Q14498: RBM39; NbExp=3; IntAct=EBI-21591415, EBI-395290;
CC       P13473-2; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-21591415, EBI-14065960;
CC       P13473-2; Q04206: RELA; NbExp=3; IntAct=EBI-21591415, EBI-73886;
CC       P13473-2; P47804-3: RGR; NbExp=3; IntAct=EBI-21591415, EBI-25834767;
CC       P13473-2; Q15382: RHEB; NbExp=4; IntAct=EBI-21591415, EBI-1055287;
CC       P13473-2; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-21591415, EBI-9091816;
CC       P13473-2; Q06587: RING1; NbExp=3; IntAct=EBI-21591415, EBI-752313;
CC       P13473-2; Q8N5U6: RNF10; NbExp=3; IntAct=EBI-21591415, EBI-714023;
CC       P13473-2; Q96IZ7: RSRC1; NbExp=3; IntAct=EBI-21591415, EBI-712189;
CC       P13473-2; Q66K80: RUSC1-AS1; NbExp=3; IntAct=EBI-21591415, EBI-10248967;
CC       P13473-2; O15126: SCAMP1; NbExp=3; IntAct=EBI-21591415, EBI-954338;
CC       P13473-2; P22307-3: SCP2; NbExp=3; IntAct=EBI-21591415, EBI-25834804;
CC       P13473-2; Q9BRK5: SDF4; NbExp=3; IntAct=EBI-21591415, EBI-1389808;
CC       P13473-2; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-21591415, EBI-9089805;
CC       P13473-2; P01011: SERPINA3; NbExp=3; IntAct=EBI-21591415, EBI-296557;
CC       P13473-2; Q9BWM7: SFXN3; NbExp=4; IntAct=EBI-21591415, EBI-1171999;
CC       P13473-2; Q9NR46: SH3GLB2; NbExp=3; IntAct=EBI-21591415, EBI-749607;
CC       P13473-2; Q9BZQ2: SHCBP1L; NbExp=3; IntAct=EBI-21591415, EBI-10818532;
CC       P13473-2; O60902-3: SHOX2; NbExp=3; IntAct=EBI-21591415, EBI-9092164;
CC       P13473-2; O43772: SLC25A20; NbExp=3; IntAct=EBI-21591415, EBI-727085;
CC       P13473-2; Q8IYM2: SLFN12; NbExp=3; IntAct=EBI-21591415, EBI-2822550;
CC       P13473-2; Q86US8: SMG6; NbExp=3; IntAct=EBI-21591415, EBI-3232100;
CC       P13473-2; Q96EX1: SMIM12; NbExp=3; IntAct=EBI-21591415, EBI-2874543;
CC       P13473-2; P37840: SNCA; NbExp=3; IntAct=EBI-21591415, EBI-985879;
CC       P13473-2; Q96H20: SNF8; NbExp=3; IntAct=EBI-21591415, EBI-747719;
CC       P13473-2; Q8N0X7: SPART; NbExp=3; IntAct=EBI-21591415, EBI-2643803;
CC       P13473-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-21591415, EBI-3923692;
CC       P13473-2; Q9NYA1-2: SPHK1; NbExp=3; IntAct=EBI-21591415, EBI-12512419;
CC       P13473-2; Q9BPZ2: SPIN2B; NbExp=3; IntAct=EBI-21591415, EBI-21726245;
CC       P13473-2; Q9C004: SPRY4; NbExp=3; IntAct=EBI-21591415, EBI-354861;
CC       P13473-2; Q96BD6: SPSB1; NbExp=3; IntAct=EBI-21591415, EBI-2659201;
CC       P13473-2; Q9BXA5: SUCNR1; NbExp=3; IntAct=EBI-21591415, EBI-17962797;
CC       P13473-2; Q92797-2: SYMPK; NbExp=3; IntAct=EBI-21591415, EBI-21560407;
CC       P13473-2; O60506-4: SYNCRIP; NbExp=3; IntAct=EBI-21591415, EBI-11123832;
CC       P13473-2; P08247: SYP; NbExp=3; IntAct=EBI-21591415, EBI-9071725;
CC       P13473-2; Q17RD7: SYT16; NbExp=3; IntAct=EBI-21591415, EBI-10238936;
CC       P13473-2; O95947: TBX6; NbExp=3; IntAct=EBI-21591415, EBI-2824328;
CC       P13473-2; O15273: TCAP; NbExp=3; IntAct=EBI-21591415, EBI-954089;
CC       P13473-2; Q86WV5: TEN1; NbExp=3; IntAct=EBI-21591415, EBI-2562799;
CC       P13473-2; P54274-2: TERF1; NbExp=3; IntAct=EBI-21591415, EBI-711018;
CC       P13473-2; P22735: TGM1; NbExp=3; IntAct=EBI-21591415, EBI-2562368;
CC       P13473-2; O43548: TGM5; NbExp=3; IntAct=EBI-21591415, EBI-12027348;
CC       P13473-2; Q9P2T0: THEG; NbExp=3; IntAct=EBI-21591415, EBI-751020;
CC       P13473-2; Q9NQ88: TIGAR; NbExp=3; IntAct=EBI-21591415, EBI-3920747;
CC       P13473-2; O14925: TIMM23; NbExp=3; IntAct=EBI-21591415, EBI-1047996;
CC       P13473-2; Q12893: TMEM115; NbExp=3; IntAct=EBI-21591415, EBI-8633987;
CC       P13473-2; Q8WVE6-2: TMEM171; NbExp=3; IntAct=EBI-21591415, EBI-25874374;
CC       P13473-2; Q3YBM2: TMEM176B; NbExp=3; IntAct=EBI-21591415, EBI-2821479;
CC       P13473-2; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-21591415, EBI-10242677;
CC       P13473-2; Q9NS69: TOMM22; NbExp=3; IntAct=EBI-21591415, EBI-1047508;
CC       P13473-2; P04637: TP53; NbExp=3; IntAct=EBI-21591415, EBI-366083;
CC       P13473-2; Q12888: TP53BP1; NbExp=3; IntAct=EBI-21591415, EBI-396540;
CC       P13473-2; O00463: TRAF5; NbExp=3; IntAct=EBI-21591415, EBI-523498;
CC       P13473-2; P36406: TRIM23; NbExp=3; IntAct=EBI-21591415, EBI-740098;
CC       P13473-2; Q9C035-3: TRIM5; NbExp=3; IntAct=EBI-21591415, EBI-12840050;
CC       P13473-2; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-21591415, EBI-11525489;
CC       P13473-2; Q9H313-4: TTYH1; NbExp=3; IntAct=EBI-21591415, EBI-17671298;
CC       P13473-2; Q9BQE3: TUBA1C; NbExp=3; IntAct=EBI-21591415, EBI-1103245;
CC       P13473-2; P49459: UBE2A; NbExp=3; IntAct=EBI-21591415, EBI-2339348;
CC       P13473-2; P62253: UBE2G1; NbExp=3; IntAct=EBI-21591415, EBI-2340619;
CC       P13473-2; P09936: UCHL1; NbExp=3; IntAct=EBI-21591415, EBI-714860;
CC       P13473-2; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-21591415, EBI-25835297;
CC       P13473-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-21591415, EBI-10316321;
CC       P13473-2; Q6ICG8: WBP2NL; NbExp=3; IntAct=EBI-21591415, EBI-17769315;
CC       P13473-2; Q8NA23-2: WDR31; NbExp=3; IntAct=EBI-21591415, EBI-25835937;
CC       P13473-2; Q9BQA1: WDR77; NbExp=3; IntAct=EBI-21591415, EBI-1237307;
CC       P13473-2; O00755: WNT7A; NbExp=3; IntAct=EBI-21591415, EBI-727198;
CC       P13473-2; O95070: YIF1A; NbExp=3; IntAct=EBI-21591415, EBI-2799703;
CC       P13473-2; Q8IWT0-2: ZBTB8OS; NbExp=3; IntAct=EBI-21591415, EBI-12956041;
CC       P13473-2; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-21591415, EBI-14104088;
CC       P13473-2; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-21591415, EBI-25835471;
CC       P13473-2; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-21591415, EBI-25835852;
CC       P13473-2; Q96LX8: ZNF597; NbExp=3; IntAct=EBI-21591415, EBI-9091553;
CC       P13473-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-21591415, EBI-18036029;
CC       P13473-2; A0A384MDV8; NbExp=3; IntAct=EBI-21591415, EBI-25834468;
CC       P13473-2; B7Z3E8; NbExp=3; IntAct=EBI-21591415, EBI-25831617;
CC       P13473-2; Q86V28; NbExp=3; IntAct=EBI-21591415, EBI-10259496;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17897319,
CC       ECO:0000269|PubMed:2912382}; Single-pass type I membrane protein
CC       {ECO:0000255|PROSITE-ProRule:PRU00740, ECO:0000269|PubMed:17897319}.
CC       Endosome membrane {ECO:0000269|PubMed:17897319}; Single-pass type I
CC       membrane protein {ECO:0000255|PROSITE-ProRule:PRU00740,
CC       ECO:0000269|PubMed:17897319}. Lysosome membrane {ECO:0000255|PROSITE-
CC       ProRule:PRU00740, ECO:0000269|PubMed:11082038,
CC       ECO:0000269|PubMed:17897319, ECO:0000269|PubMed:18644871,
CC       ECO:0000269|PubMed:2912382}; Single-pass type I membrane protein
CC       {ECO:0000255|PROSITE-ProRule:PRU00740, ECO:0000269|PubMed:17897319}.
CC       Cytoplasmic vesicle, autophagosome membrane
CC       {ECO:0000250|UniProtKB:P17047}. Note=This protein shuttles between
CC       lysosomes, endosomes, and the plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=LAMP-2A;
CC         IsoId=P13473-1; Sequence=Displayed;
CC       Name=LAMP-2B;
CC         IsoId=P13473-2; Sequence=VSP_003044;
CC       Name=LAMP-2C;
CC         IsoId=P13473-3; Sequence=VSP_042519;
CC   -!- TISSUE SPECIFICITY: Isoform LAMP-2A is highly expressed in placenta,
CC       lung and liver, less in kidney and pancreas, low in brain and skeletal
CC       muscle (PubMed:7488019, PubMed:26856698). Isoform LAMP-2B is detected
CC       in spleen, thymus, prostate, testis, small intestine, colon, skeletal
CC       muscle, brain, placenta, lung, kidney, ovary and pancreas and liver
CC       (PubMed:7488019, PubMed:26856698). Isoform LAMP-2C is detected in small
CC       intestine, colon, heart, brain, skeletal muscle, and at lower levels in
CC       kidney and placenta (PubMed:26856698). {ECO:0000269|PubMed:26856698,
CC       ECO:0000269|PubMed:7488019}.
CC   -!- INDUCTION: In peripheral blood B cells isoform LAMP-2A, LAMP-2B and
CC       LAMP-2C are up-regulated in response to treatments that stimulate
CC       immune responses via the Toll-like receptors TLR7 or TLR9.
CC       {ECO:0000269|PubMed:26856698}.
CC   -!- PTM: O- and N-glycosylated; some of the 16 N-linked glycans are
CC       polylactosaminoglycans. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:2243102, ECO:0000269|PubMed:2912382,
CC       ECO:0000269|PubMed:8323299}.
CC   -!- DISEASE: Danon disease (DAND) [MIM:300257]: DAND is a lysosomal
CC       glycogen storage disease characterized by the clinical triad of
CC       cardiomyopathy, vacuolar myopathy and intellectual disability. It is
CC       often associated with an accumulation of glycogen in muscle and
CC       lysosomes. {ECO:0000269|PubMed:15673802, ECO:0000269|PubMed:15907287}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the LAMP family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00740}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04183; AAA60383.1; -; mRNA.
DR   EMBL; L09717; AAB41647.1; -; Genomic_DNA.
DR   EMBL; L09709; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09710; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09711; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09712; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09713; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09714; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09715; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; L09716; AAB41647.1; JOINED; Genomic_DNA.
DR   EMBL; X77196; CAA54416.1; -; mRNA.
DR   EMBL; S79873; AAB35426.1; -; mRNA.
DR   EMBL; U36336; AAA91149.1; -; mRNA.
DR   EMBL; AY561849; AAS67876.1; -; mRNA.
DR   EMBL; AK291090; BAF83779.1; -; mRNA.
DR   EMBL; AC002476; AAB67313.1; -; Genomic_DNA.
DR   EMBL; AC002476; AAB67314.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11881.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11882.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11883.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11884.1; -; Genomic_DNA.
DR   EMBL; BC002965; AAH02965.1; -; mRNA.
DR   CCDS; CCDS14599.1; -. [P13473-1]
DR   CCDS; CCDS14600.1; -. [P13473-2]
DR   CCDS; CCDS48159.1; -. [P13473-3]
DR   PIR; JC2414; B31959.
DR   PIR; JC4317; JC4317.
DR   RefSeq; NP_001116078.1; NM_001122606.1. [P13473-3]
DR   RefSeq; NP_002285.1; NM_002294.2. [P13473-1]
DR   RefSeq; NP_054701.1; NM_013995.2. [P13473-2]
DR   PDB; 2MOF; NMR; -; A=369-410.
DR   PDB; 2MOM; NMR; -; A/B/C=369-410.
DR   PDBsum; 2MOF; -.
DR   PDBsum; 2MOM; -.
DR   AlphaFoldDB; P13473; -.
DR   BMRB; P13473; -.
DR   SMR; P13473; -.
DR   BioGRID; 110114; 612.
DR   IntAct; P13473; 304.
DR   MINT; P13473; -.
DR   STRING; 9606.ENSP00000408411; -.
DR   TCDB; 9.A.16.1.2; the lysosomal protein import (lpi) family.
DR   GlyConnect; 356; 115 N-Linked glycans (12 sites), 3 O-Linked glycans.
DR   GlyCosmos; P13473; 26 sites, 142 glycans.
DR   GlyGen; P13473; 28 sites, 24 Asn glycans (6 sites), 129 N-linked glycans (12 sites), 6 O-linked glycans (1 site), 2 Ser glycans (2 sites), 2 Thr glycans (7 sites).
DR   iPTMnet; P13473; -.
DR   PhosphoSitePlus; P13473; -.
DR   SwissPalm; P13473; -.
DR   BioMuta; LAMP2; -.
DR   DMDM; 1708854; -.
DR   CPTAC; CPTAC-1494; -.
DR   CPTAC; CPTAC-689; -.
DR   EPD; P13473; -.
DR   jPOST; P13473; -.
DR   MassIVE; P13473; -.
DR   MaxQB; P13473; -.
DR   PeptideAtlas; P13473; -.
DR   ProteomicsDB; 52910; -. [P13473-1]
DR   ProteomicsDB; 52911; -. [P13473-2]
DR   ProteomicsDB; 52912; -. [P13473-3]
DR   Antibodypedia; 3938; 1327 antibodies from 52 providers.
DR   DNASU; 3920; -.
DR   Ensembl; ENST00000200639.9; ENSP00000200639.4; ENSG00000005893.16. [P13473-1]
DR   Ensembl; ENST00000371335.4; ENSP00000360386.4; ENSG00000005893.16. [P13473-2]
DR   Ensembl; ENST00000434600.6; ENSP00000408411.2; ENSG00000005893.16. [P13473-3]
DR   GeneID; 3920; -.
DR   KEGG; hsa:3920; -.
DR   MANE-Select; ENST00000200639.9; ENSP00000200639.4; NM_002294.3; NP_002285.1.
DR   UCSC; uc004ess.5; human. [P13473-1]
DR   AGR; HGNC:6501; -.
DR   CTD; 3920; -.
DR   DisGeNET; 3920; -.
DR   GeneCards; LAMP2; -.
DR   GeneReviews; LAMP2; -.
DR   HGNC; HGNC:6501; LAMP2.
DR   HPA; ENSG00000005893; Low tissue specificity.
DR   MalaCards; LAMP2; -.
DR   MIM; 300257; phenotype.
DR   MIM; 309060; gene.
DR   neXtProt; NX_P13473; -.
DR   OpenTargets; ENSG00000005893; -.
DR   Orphanet; 34587; Glycogen storage disease due to LAMP-2 deficiency.
DR   PharmGKB; PA30285; -.
DR   VEuPathDB; HostDB:ENSG00000005893; -.
DR   eggNOG; KOG4818; Eukaryota.
DR   GeneTree; ENSGT00950000182899; -.
DR   HOGENOM; CLU_055379_2_0_1; -.
DR   InParanoid; P13473; -.
DR   OMA; NMATGYE; -.
DR   OrthoDB; 5317371at2759; -.
DR   PhylomeDB; P13473; -.
DR   TreeFam; TF316339; -.
DR   PathwayCommons; P13473; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-9613829; Chaperone Mediated Autophagy.
DR   SignaLink; P13473; -.
DR   SIGNOR; P13473; -.
DR   BioGRID-ORCS; 3920; 10 hits in 786 CRISPR screens.
DR   ChiTaRS; LAMP2; human.
DR   GeneWiki; LAMP2; -.
DR   GenomeRNAi; 3920; -.
DR   Pharos; P13473; Tbio.
DR   PRO; PR:P13473; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P13473; protein.
DR   Bgee; ENSG00000005893; Expressed in corpus callosum and 206 other tissues.
DR   ExpressionAtlas; P13473; baseline and differential.
DR   Genevisible; P13473; HS.
DR   GO; GO:0044754; C:autolysosome; IDA:MGI.
DR   GO; GO:0000421; C:autophagosome membrane; IBA:GO_Central.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0061742; C:chaperone-mediated autophagy translocation complex; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005770; C:late endosome; IDA:MGI.
DR   GO; GO:0031902; C:late endosome membrane; IDA:MGI.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:MGI.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0031088; C:platelet dense granule membrane; IDA:MGI.
DR   GO; GO:0005802; C:trans-Golgi network; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0097352; P:autophagosome maturation; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:UniProtKB.
DR   GO; GO:0061684; P:chaperone-mediated autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0072594; P:establishment of protein localization to organelle; IBA:GO_Central.
DR   GO; GO:1905146; P:lysosomal protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0017038; P:protein import; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; ISS:CAFA.
DR   GO; GO:0006605; P:protein targeting; ISS:UniProtKB.
DR   GO; GO:0061740; P:protein targeting to lysosome involved in chaperone-mediated autophagy; IMP:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:ParkinsonsUK-UCL.
DR   Gene3D; 2.40.160.110; -; 2.
DR   InterPro; IPR018134; LAMP_CS.
DR   InterPro; IPR002000; Lysosome-assoc_membr_glycop.
DR   PANTHER; PTHR11506; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN; 1.
DR   PANTHER; PTHR11506:SF6; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN 2; 1.
DR   Pfam; PF01299; Lamp; 1.
DR   PRINTS; PR00336; LYSASSOCTDMP.
DR   PROSITE; PS00310; LAMP_1; 1.
DR   PROSITE; PS00311; LAMP_2; 1.
DR   PROSITE; PS51407; LAMP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autophagy; Cell membrane;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disease variant;
KW   Disulfide bond; Endosome; Glycogen storage disease; Glycoprotein; Lysosome;
KW   Membrane; Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..28
FT                   /evidence="ECO:0000269|PubMed:15340161,
FT                   ECO:0000269|PubMed:2912382, ECO:0000269|PubMed:3198605"
FT   CHAIN           29..410
FT                   /note="Lysosome-associated membrane glycoprotein 2"
FT                   /id="PRO_0000017110"
FT   TOPO_DOM        29..375
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        376..399
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00740"
FT   TOPO_DOM        400..410
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00740"
FT   REGION          29..192
FT                   /note="First lumenal domain"
FT   REGION          193..228
FT                   /note="Hinge"
FT   REGION          199..221
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          229..375
FT                   /note="Second lumenal domain"
FT   REGION          401..404
FT                   /note="Important for binding and subsequent lysosomal
FT                   degradation of target proteins"
FT                   /evidence="ECO:0000269|PubMed:11082038"
FT   CARBOHYD        32
FT                   /note="N-linked (GlcNAc...) (polylactosaminoglycan)
FT                   asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) (polylactosaminoglycan)
FT                   asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        49
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952"
FT   CARBOHYD        58
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        101
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218"
FT   CARBOHYD        123
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        179
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        195
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        196
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        200
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        203
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        204
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        207
FT                   /note="O-linked (GalNAc...) serine; partial"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        209
FT                   /note="O-linked (GalNAc...) threonine; partial"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        210
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        211
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        213
FT                   /note="O-linked (GalNAc...) threonine; partial"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        229
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        242
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        257
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        275
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        300
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        307
FT                   /note="N-linked (GlcNAc...) (polylactosaminoglycan)
FT                   asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        317
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:8323299"
FT   CARBOHYD        356
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   DISULFID        41..79
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00740"
FT   DISULFID        153..189
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00740"
FT   DISULFID        232..265
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00740"
FT   DISULFID        331..368
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00740"
FT   VAR_SEQ         366..410
FT                   /note="QDCSADDDNFLVPIAVGAALAGVLILVLLAYFIGLKHHHAGYEQF -> EEC
FT                   SADSDLNFLIPVAVGVALGFLIIVVFISYMIGRRKSRTGYQSV (in isoform
FT                   LAMP-2C)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_042519"
FT   VAR_SEQ         367..410
FT                   /note="DCSADDDNFLVPIAVGAALAGVLILVLLAYFIGLKHHHAGYEQF -> ECSL
FT                   DDDTILIPIIVGAGLSGLIIVIVIAYVIGRRKSYAGYQTL (in isoform LAMP-
FT                   2B)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7488019, ECO:0000303|PubMed:8407947"
FT                   /id="VSP_003044"
FT   VARIANT         256
FT                   /note="P -> H (in dbSNP:rs1043878)"
FT                   /id="VAR_011992"
FT   VARIANT         321
FT                   /note="W -> R (in DAND; dbSNP:rs104894859)"
FT                   /evidence="ECO:0000269|PubMed:15673802,
FT                   ECO:0000269|PubMed:15907287"
FT                   /id="VAR_026230"
FT   MUTAGEN         401..404
FT                   /note="KHHH->AAAA: Impairs binding and subsequent lysosomal
FT                   degradation of target proteins, such as GAPDH."
FT                   /evidence="ECO:0000269|PubMed:11082038"
FT   CONFLICT        8..13
FT                   /note="PVPGSG -> RFRSGLR (in Ref. 3; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        53
FT                   /note="R -> G (in Ref. 3; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        68
FT                   /note="D -> V (in Ref. 2; AAB41647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        111
FT                   /note="I -> N (in Ref. 2; AAB41647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        143
FT                   /note="I -> Y (in Ref. 2; AAB41647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        220
FT                   /note="A -> P (in Ref. 2; AAB41647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        234
FT                   /note="L -> R (in Ref. 2; AAB41647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        263..269
FT                   /note="GSCRSHT -> AAAVSH (in Ref. 3; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        322..326
FT                   /note="DAPLG -> MPP (in Ref. 1; AAA60383)"
FT                   /evidence="ECO:0000305"
FT   STRAND          374..377
FT                   /evidence="ECO:0007829|PDB:2MOF"
FT   HELIX           380..400
FT                   /evidence="ECO:0007829|PDB:2MOF"
SQ   SEQUENCE   410 AA;  44961 MW;  9E08E3B62D58F454 CRC64;
     MVCFRLFPVP GSGLVLVCLV LGAVRSYALE LNLTDSENAT CLYAKWQMNF TVRYETTNKT
     YKTVTISDHG TVTYNGSICG DDQNGPKIAV QFGPGFSWIA NFTKAASTYS IDSVSFSYNT
     GDNTTFPDAE DKGILTVDEL LAIRIPLNDL FRCNSLSTLE KNDVVQHYWD VLVQAFVQNG
     TVSTNEFLCD KDKTSTVAPT IHTTVPSPTT TPTPKEKPEA GTYSVNNGND TCLLATMGLQ
     LNITQDKVAS VININPNTTH STGSCRSHTA LLRLNSSTIK YLDFVFAVKN ENRFYLKEVN
     ISMYLVNGSV FSIANNNLSY WDAPLGSSYM CNKEQTVSVS GAFQINTFDL RVQPFNVTQG
     KYSTAQDCSA DDDNFLVPIA VGAALAGVLI LVLLAYFIGL KHHHAGYEQF
//
ID   MKKS_HUMAN              Reviewed;         570 AA.
AC   Q9NPJ1; A8K7B0; D3DW18;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   22-FEB-2023, entry version 194.
DE   RecName: Full=Molecular chaperone MKKS {ECO:0000305};
DE   AltName: Full=Bardet-Biedl syndrome 6 protein;
DE   AltName: Full=McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin;
GN   Name=MKKS {ECO:0000312|HGNC:HGNC:7108};
GN   Synonyms=BBS6 {ECO:0000303|PubMed:28753627};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS MKKS CYS-37; TYR-84 AND SER-242, AND
RP   VARIANTS VAL-49 AND CYS-517.
RX   PubMed=10802661; DOI=10.1038/75637;
RA   Stone D.L., Slavotinek A.M., Bouffard G.G., Banerjee-Basu S.,
RA   Baxevanis A.D., Barr M., Biesecker L.G.;
RT   "Mutation of a gene encoding a putative chaperonin causes McKusick-Kaufman
RT   syndrome.";
RL   Nat. Genet. 25:79-82(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS BBS6 ASP-52; LEU-155;
RP   ALA-286; GLU-345 AND SER-499, AND CHARACTERIZATION OF VARIANT PRO-325.
RX   PubMed=15731008; DOI=10.1242/jcs.01676;
RA   Kim J.C., Ou Y.Y., Badano J.L., Esmail M.A., Leitch C.C., Fiedrich E.,
RA   Beales P.L., Archibald J.M., Katsanis N., Rattner J.B., Leroux M.R.;
RT   "MKKS/BBS6, a divergent chaperonin-like protein linked to the obesity
RT   disorder Bardet-Biedl syndrome, is a novel centrosomal component required
RT   for cytokinesis.";
RL   J. Cell Sci. 118:1007-1020(2005).
RN   [7]
RP   INTERACTION WITH CCDC28B.
RX   PubMed=16327777; DOI=10.1038/nature04370;
RA   Badano J.L., Leitch C.C., Ansley S.J., May-Simera H., Lawson S.,
RA   Lewis R.A., Beales P.L., Dietz H.C., Fisher S., Katsanis N.;
RT   "Dissection of epistasis in oligogenic Bardet-Biedl syndrome.";
RL   Nature 439:326-330(2006).
RN   [8]
RP   SUBCELLULAR LOCATION, INTERACTION WITH STUB1, AND CHARACTERIZATION OF
RP   VARIANTS BBS6 CYS-37; ALA-57; SER-242; GLU-345 AND SER-499.
RX   PubMed=18094050; DOI=10.1091/mbc.e07-07-0631;
RA   Hirayama S., Yamazaki Y., Kitamura A., Oda Y., Morito D., Okawa K.,
RA   Kimura H., Cyr D.M., Kubota H., Nagata K.;
RT   "MKKS is a centrosome-shuttling protein degraded by disease-causing
RT   mutations via CHIP-mediated ubiquitination.";
RL   Mol. Biol. Cell 19:899-911(2008).
RN   [9]
RP   FUNCTION, IDENTIFICATION IN A MULTIPROTEIN COMPLEX, INTERACTION WITH BBS2,
RP   AND CHARACTERIZATION OF VARIANTS BBS6 CYS-37; ASP-52; ALA-57; TYR-84;
RP   PRO-236 AND PRO-277.
RX   PubMed=20080638; DOI=10.1073/pnas.0910268107;
RA   Seo S., Baye L.M., Schulz N.P., Beck J.S., Zhang Q., Slusarski D.C.,
RA   Sheffield V.C.;
RT   "BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and
RT   mediate BBSome assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:1488-1493(2010).
RN   [10]
RP   INTERACTION WITH BBS12, VARIANT BBS6 ARG-395, AND CHARACTERIZATION OF
RP   VARIANT BBS6 ARG-395.
RX   PubMed=26900326;
RA   Hulleman J.D., Nguyen A., Ramprasad V.L., Murugan S., Gupta R.,
RA   Mahindrakar A., Angara R., Sankurathri C., Mootha V.V.;
RT   "A novel H395R mutation in MKKS/BBS6 causes retinitis pigmentosa and
RT   polydactyly without other findings of Bardet-Biedl or McKusick-Kaufman
RT   syndrome.";
RL   Mol. Vis. 22:73-81(2016).
RN   [11]
RP   INTERACTION WITH DLEC1.
RX   PubMed=33144677; DOI=10.1038/s41598-020-75957-y;
RA   Okitsu Y., Nagano M., Yamagata T., Ito C., Toshimori K., Dohra H.,
RA   Fujii W., Yogo K.;
RT   "Dlec1 is required for spermatogenesis and male fertility in mice.";
RL   Sci. Rep. 10:18883-18883(2020).
RN   [12]
RP   VARIANT BBS6 ASP-52.
RX   PubMed=10973238; DOI=10.1038/79116;
RA   Slavotinek A.M., Stone E.M., Mykytyn K., Heckenlively J.R., Green J.S.,
RA   Heon E., Musarella M.A., Parfrey P.S., Sheffield V.C., Biesecker L.G.;
RT   "Mutations in MKKS cause Bardet-Biedl syndrome.";
RL   Nat. Genet. 26:15-16(2000).
RN   [13]
RP   VARIANTS BBS6 CYS-37; ALA-57 AND PRO-277.
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=10973251; DOI=10.1038/79201;
RA   Katsanis N., Beales P.L., Woods M.O., Lewis R.A., Green J.S., Parfrey P.S.,
RA   Ansley S.J., Davidson W.S., Lupski J.R.;
RT   "Mutations in MKKS cause obesity, retinal dystrophy and renal malformations
RT   associated with Bardet-Biedl syndrome.";
RL   Nat. Genet. 26:67-70(2000).
RN   [14]
RP   VARIANTS BBS6 MET-32; ALA-57; PRO-236; ALA-286; SER-499; ALA-511 AND
RP   HIS-518, AND VARIANT SER-242.
RX   PubMed=11179009; DOI=10.1086/318794;
RA   Beales P.L., Katsanis N., Lewis R.A., Ansley S.J., Elcioglu N., Raza J.,
RA   Woods M.O., Green J.S., Parfrey P.S., Davidson W.S., Lupski J.R.;
RT   "Genetic and mutational analyses of a large multiethnic Bardet-Biedl cohort
RT   reveal a minor involvement of BBS6 and delineate the critical intervals of
RT   other loci.";
RL   Am. J. Hum. Genet. 68:606-616(2001).
RN   [15]
RP   VARIANTS BBS6 CYS-37; SER-242 AND SER-499.
RX   PubMed=11567139; DOI=10.1126/science.1063525;
RA   Katsanis N., Ansley S.J., Badano J.L., Eichers E.R., Lewis R.A.,
RA   Hoskins B.E., Scambler P.J., Davidson W.S., Beales P.L., Lupski J.R.;
RT   "Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive
RT   disorder.";
RL   Science 293:2256-2259(2001).
RN   [16]
RP   VARIANTS BBS6 LEU-155; SER-242 AND GLU-345, AND VARIANT VAL-339.
RX   PubMed=12107442; DOI=10.1007/s00439-002-0733-3;
RA   Slavotinek A.M., Searby C., Al-Gazali L., Hennekam R.C.M.,
RA   Schrander-Stumpel C., Orcana-Losa M., Pardo-Reoyo S., Cantani A., Kumar D.,
RA   Capellini Q., Neri G., Zackai E., Biesecker L.G.;
RT   "Mutation analysis of the MKKS gene in McKusick-Kaufman syndrome and
RT   selected Bardet-Biedl syndrome patients.";
RL   Hum. Genet. 110:561-567(2002).
RN   [17]
RP   VARIANT BBS6 PRO-236, AND VARIANT PRO-325.
RX   PubMed=12677556; DOI=10.1086/375178;
RA   Beales P.L., Badano J.L., Ross A.J., Ansley S.J., Hoskins B.E., Kirsten B.,
RA   Mein C.A., Froguel P., Scambler P.J., Lewis R.A., Lupski J.R., Katsanis N.;
RT   "Genetic interaction of BBS1 mutations with alleles at other BBS loci can
RT   result in non-Mendelian Bardet-Biedl syndrome.";
RL   Am. J. Hum. Genet. 72:1187-1199(2003).
RN   [18]
RP   VARIANT PRO-325, AND CHARACTERIZATION OF VARIANT PRO-325.
RX   PubMed=12837689; DOI=10.1093/hmg/ddg188;
RA   Badano J.L., Kim J.C., Hoskins B.E., Lewis R.A., Ansley S.J., Cutler D.J.,
RA   Castellan C., Beales P.L., Leroux M.R., Katsanis N.;
RT   "Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic
RT   effect on Bardet-Biedl patients with two mutations at a second BBS locus.";
RL   Hum. Mol. Genet. 12:1651-1659(2003).
RN   [19]
RP   VARIANTS BBS6 PRO-181 AND ASN-492.
RX   PubMed=12920096; DOI=10.1136/jmg.40.8.e104;
RA   Fauser S., Munz M., Besch D.;
RT   "Further support for digenic inheritance in Bardet-Biedl syndrome.";
RL   J. Med. Genet. 40:E104-E104(2003).
RN   [20]
RP   VARIANTS BBS6 PRO-237 AND PRO-460, AND VARIANTS VAL-339; CYS-517 AND
RP   VAL-532.
RX   PubMed=15666242; DOI=10.1086/428679;
RA   Karmous-Benailly H., Martinovic J., Gubler M.-C., Sirot Y., Clech L.,
RA   Ozilou C., Auge J., Brahimi N., Etchevers H., Detrait E., Esculpavit C.,
RA   Audollent S., Goudefroye G., Gonzales M., Tantau J., Loget P., Joubert M.,
RA   Gaillard D., Jeanne-Pasquier C., Delezoide A.-L., Peter M.-O., Plessis G.,
RA   Simon-Bouy B., Dollfus H., Le Merrer M., Munnich A., Encha-Razavi F.,
RA   Vekemans M., Attie-Bitach T.;
RT   "Antenatal presentation of Bardet-Biedl syndrome may mimic Meckel
RT   syndrome.";
RL   Am. J. Hum. Genet. 76:493-504(2005).
RN   [21]
RP   VARIANTS BBS6 ALA-237 AND PRO-237, AND VARIANTS VAL-339; CYS-517 AND
RP   VAL-532.
RX   PubMed=15770229; DOI=10.1038/sj.ejhg.5201372;
RA   Hichri H., Stoetzel C., Laurier V., Caron S., Sigaudy S., Sarda P.,
RA   Hamel C., Martin-Coignard D., Gilles M., Leheup B., Holder M., Kaplan J.,
RA   Bitoun P., Lacombe D., Verloes A., Bonneau D., Perrin-Schmitt F.,
RA   Brandt C., Besancon A.-F., Mandel J.-L., Cossee M., Dollfus H.;
RT   "Testing for triallelism: analysis of six BBS genes in a Bardet-Biedl
RT   syndrome family cohort.";
RL   Eur. J. Hum. Genet. 13:607-616(2005).
RN   [22]
RP   VARIANTS SER-242; CYS-517 AND VAL-532.
RX   PubMed=15483080; DOI=10.1210/jc.2004-0465;
RA   Andersen K.L., Echwald S.M., Larsen L.H., Hamid Y.H., Glumer C.,
RA   Jorgensen T., Borch-Johnsen K., Andersen T., Sorensen T.I., Hansen T.,
RA   Pedersen O.;
RT   "Variation of the McKusick-Kaufman gene and studies of relationships with
RT   common forms of obesity.";
RL   J. Clin. Endocrinol. Metab. 90:225-230(2005).
RN   [23]
RP   VARIANT SER-242, AND DISCUSSION OF THE PATHOLOGICAL ROLE OF VARIANT
RP   SER-242.
RX   PubMed=20120035; DOI=10.1002/humu.21204;
RA   Hjortshoj T.D., Gronskov K., Philp A.R., Nishimura D.Y., Riise R.,
RA   Sheffield V.C., Rosenberg T., Brondum-Nielsen K.;
RT   "Bardet-Biedl syndrome in Denmark -- report of 13 novel sequence variations
RT   in six genes.";
RL   Hum. Mutat. 31:429-436(2010).
RN   [24]
RP   VARIANTS BBS6 ARG-41; ARG-99 AND LEU-299, AND VARIANT THR-488.
RX   PubMed=21344540; DOI=10.1002/humu.21480;
RA   Deveault C., Billingsley G., Duncan J.L., Bin J., Theal R., Vincent A.,
RA   Fieggen K.J., Gerth C., Noordeh N., Traboulsi E.I., Fishman G.A.,
RA   Chitayat D., Knueppel T., Millan J.M., Munier F.L., Kennedy D.,
RA   Jacobson S.G., Innes A.M., Mitchell G.A., Boycott K., Heon E.;
RT   "BBS genotype-phenotype assessment of a multiethnic patient cohort calls
RT   for a revision of the disease definition.";
RL   Hum. Mutat. 32:610-619(2011).
RN   [25]
RP   VARIANT BBS6 ALA-57.
RX   PubMed=22152675; DOI=10.1016/j.ajhg.2011.11.005;
RA   Huang L., Szymanska K., Jensen V.L., Janecke A.R., Innes A.M., Davis E.E.,
RA   Frosk P., Li C., Willer J.R., Chodirker B.N., Greenberg C.R., McLeod D.R.,
RA   Bernier F.P., Chudley A.E., Muller T., Shboul M., Logan C.V., Loucks C.M.,
RA   Beaulieu C.L., Bowie R.V., Bell S.M., Adkins J., Zuniga F.I., Ross K.D.,
RA   Wang J., Ban M.R., Becker C., Nurnberg P., Douglas S., Craft C.M.,
RA   Akimenko M.A., Hegele R.A., Ober C., Utermann G., Bolz H.J., Bulman D.E.,
RA   Katsanis N., Blacque O.E., Doherty D., Parboosingh J.S., Leroux M.R.,
RA   Johnson C.A., Boycott K.M.;
RT   "TMEM237 is mutated in individuals with a Joubert syndrome related disorder
RT   and expands the role of the TMEM family at the ciliary transition zone.";
RL   Am. J. Hum. Genet. 89:713-730(2011).
RN   [26]
RP   VARIANT BBS6 40-SER--ASN-570 DEL.
RX   PubMed=28761321;
RA   Ullah A., Umair M., Yousaf M., Khan S.A., Nazim-Ud-Din M., Shah K.,
RA   Ahmad F., Azeem Z., Ali G., Alhaddad B., Rafique A., Jan A., Haack T.B.,
RA   Strom T.M., Meitinger T., Ghous T., Ahmad W.;
RT   "Sequence variants in four genes underlying Bardet-Biedl syndrome in
RT   consanguineous families.";
RL   Mol. Vis. 23:482-494(2017).
RN   [27]
RP   CHARACTERIZATION OF VARIANTS MKKS CYS-37; TYR-84 AND SER-242, SUBCELLULAR
RP   LOCATION, FUNCTION, MUTAGENESIS OF LEU-454, CHARACTERIZATION OF VARIANT
RP   BBS6 CYS-37, AND INTERACTION WITH SMARCC1.
RX   PubMed=28753627; DOI=10.1371/journal.pgen.1006936;
RA   Scott C.A., Marsden A.N., Rebagliati M.R., Zhang Q., Chamling X.,
RA   Searby C.C., Baye L.M., Sheffield V.C., Slusarski D.C.;
RT   "Nuclear/cytoplasmic transport defects in BBS6 underlie congenital heart
RT   disease through perturbation of a chromatin remodeling protein.";
RL   PLoS Genet. 13:E1006936-E1006936(2017).
CC   -!- FUNCTION: Probable molecular chaperone that assists the folding of
CC       proteins upon ATP hydrolysis (PubMed:20080638). Plays a role in the
CC       assembly of BBSome, a complex involved in ciliogenesis regulating
CC       transports vesicles to the cilia (PubMed:20080638). May play a role in
CC       protein processing in limb, cardiac and reproductive system
CC       development. May play a role in cytokinesis (PubMed:28753627).
CC       {ECO:0000269|PubMed:20080638, ECO:0000269|PubMed:28753627}.
CC   -!- SUBUNIT: Component of a complex composed at least of MKKS, BBS10,
CC       BBS12, TCP1, CCT2, CCT3, CCT4, CCT5 and CCT8 (PubMed:20080638).
CC       Interacts with STUB1 (PubMed:18094050). Interacts with BBS2 (via coiled
CC       coil domain) (PubMed:20080638). Interacts with CCDC28B
CC       (PubMed:16327777). Interacts with BBS12 (PubMed:26900326). Interacts
CC       with SMARCC1, a component of the SWI/SNF complexes; the interaction
CC       takes place predominantly in the cytoplasm and may modulate SMARCC1
CC       location (PubMed:28753627). Interacts with DLEC1 (PubMed:33144677).
CC       {ECO:0000269|PubMed:16327777, ECO:0000269|PubMed:18094050,
CC       ECO:0000269|PubMed:20080638, ECO:0000269|PubMed:26900326,
CC       ECO:0000269|PubMed:28753627, ECO:0000269|PubMed:33144677}.
CC   -!- INTERACTION:
CC       Q9NPJ1; Q6ZW61: BBS12; NbExp=14; IntAct=EBI-721319, EBI-6128352;
CC       Q9NPJ1; Q9BXC9: BBS2; NbExp=4; IntAct=EBI-721319, EBI-748297;
CC       Q9NPJ1; Q01850: CDR2; NbExp=3; IntAct=EBI-721319, EBI-1181367;
CC       Q9NPJ1; O96006: ZBED1; NbExp=3; IntAct=EBI-721319, EBI-740037;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome. Cytoplasm, cytosol {ECO:0000269|PubMed:28753627}.
CC       Nucleus {ECO:0000269|PubMed:28753627}. Note=The majority of the protein
CC       resides within the pericentriolar material (PCM), a proteinaceous tube
CC       surrounding centrioles. During interphase, the protein is confined to
CC       the lateral surfaces of the PCM but during mitosis it relocalizes
CC       throughout the PCM and is found at the intercellular bridge. The MKSS
CC       protein is highly mobile and rapidly shuttles between the cytosol and
CC       centrosome.
CC   -!- TISSUE SPECIFICITY: Widely expressed in adult and fetal tissues.
CC   -!- DOMAIN: The substrate-binding apical domain region is sufficient for
CC       centrosomal association.
CC   -!- DISEASE: McKusick-Kaufman syndrome (MKKS) [MIM:236700]: Autosomal
CC       recessive developmental disorder. It is characterized by
CC       hydrometrocolpos, postaxial polydactyly and congenital heart defects.
CC       {ECO:0000269|PubMed:10802661, ECO:0000269|PubMed:28753627}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Bardet-Biedl syndrome 6 (BBS6) [MIM:605231]: A syndrome
CC       characterized by usually severe pigmentary retinopathy, early-onset
CC       obesity, polydactyly, hypogenitalism, renal malformation and
CC       intellectual disability. Secondary features include diabetes mellitus,
CC       hypertension and congenital heart disease. Bardet-Biedl syndrome
CC       inheritance is autosomal recessive, but three mutated alleles (two at
CC       one locus, and a third at a second locus) may be required for clinical
CC       manifestation of some forms of the disease.
CC       {ECO:0000269|PubMed:10973238, ECO:0000269|PubMed:10973251,
CC       ECO:0000269|PubMed:11179009, ECO:0000269|PubMed:11567139,
CC       ECO:0000269|PubMed:12107442, ECO:0000269|PubMed:12677556,
CC       ECO:0000269|PubMed:12920096, ECO:0000269|PubMed:15666242,
CC       ECO:0000269|PubMed:15731008, ECO:0000269|PubMed:15770229,
CC       ECO:0000269|PubMed:18094050, ECO:0000269|PubMed:20080638,
CC       ECO:0000269|PubMed:21344540, ECO:0000269|PubMed:22152675,
CC       ECO:0000269|PubMed:26900326, ECO:0000269|PubMed:28753627,
CC       ECO:0000269|PubMed:28761321}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TCP-1 chaperonin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Mutations of the MKKS gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/mkksmut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF221992; AAF73872.1; -; mRNA.
DR   EMBL; AF221993; AAF73873.1; -; mRNA.
DR   EMBL; AK291925; BAF84614.1; -; mRNA.
DR   EMBL; AL157427; CAB75652.1; -; mRNA.
DR   EMBL; AL034430; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10344.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10345.1; -; Genomic_DNA.
DR   CCDS; CCDS13111.1; -.
DR   PIR; T46911; T46911.
DR   RefSeq; NP_061336.1; NM_018848.3.
DR   RefSeq; NP_740754.1; NM_170784.2.
DR   AlphaFoldDB; Q9NPJ1; -.
DR   SMR; Q9NPJ1; -.
DR   BioGRID; 113837; 15.
DR   CORUM; Q9NPJ1; -.
DR   DIP; DIP-60349N; -.
DR   IntAct; Q9NPJ1; 11.
DR   STRING; 9606.ENSP00000246062; -.
DR   iPTMnet; Q9NPJ1; -.
DR   PhosphoSitePlus; Q9NPJ1; -.
DR   BioMuta; MKKS; -.
DR   DMDM; 11133565; -.
DR   EPD; Q9NPJ1; -.
DR   MassIVE; Q9NPJ1; -.
DR   PaxDb; Q9NPJ1; -.
DR   PeptideAtlas; Q9NPJ1; -.
DR   ProteomicsDB; 82024; -.
DR   Antibodypedia; 24160; 150 antibodies from 24 providers.
DR   DNASU; 8195; -.
DR   Ensembl; ENST00000347364.7; ENSP00000246062.4; ENSG00000125863.20.
DR   Ensembl; ENST00000399054.6; ENSP00000382008.2; ENSG00000125863.20.
DR   Ensembl; ENST00000651692.1; ENSP00000498849.1; ENSG00000125863.20.
DR   GeneID; 8195; -.
DR   KEGG; hsa:8195; -.
DR   MANE-Select; ENST00000347364.7; ENSP00000246062.4; NM_170784.3; NP_740754.1.
DR   UCSC; uc002wnt.3; human.
DR   AGR; HGNC:7108; -.
DR   CTD; 8195; -.
DR   DisGeNET; 8195; -.
DR   GeneCards; MKKS; -.
DR   GeneReviews; MKKS; -.
DR   HGNC; HGNC:7108; MKKS.
DR   HPA; ENSG00000125863; Low tissue specificity.
DR   MalaCards; MKKS; -.
DR   MIM; 236700; phenotype.
DR   MIM; 604896; gene.
DR   MIM; 605231; phenotype.
DR   neXtProt; NX_Q9NPJ1; -.
DR   OpenTargets; ENSG00000125863; -.
DR   Orphanet; 110; Bardet-Biedl syndrome.
DR   Orphanet; 2473; McKusick-Kaufman syndrome.
DR   PharmGKB; PA30826; -.
DR   VEuPathDB; HostDB:ENSG00000125863; -.
DR   eggNOG; KOG0360; Eukaryota.
DR   GeneTree; ENSGT00390000007214; -.
DR   HOGENOM; CLU_478131_0_0_1; -.
DR   InParanoid; Q9NPJ1; -.
DR   OMA; FVCQKVI; -.
DR   OrthoDB; 3019878at2759; -.
DR   PhylomeDB; Q9NPJ1; -.
DR   TreeFam; TF329106; -.
DR   PathwayCommons; Q9NPJ1; -.
DR   Reactome; R-HSA-5620922; BBSome-mediated cargo-targeting to cilium.
DR   SignaLink; Q9NPJ1; -.
DR   BioGRID-ORCS; 8195; 12 hits in 1156 CRISPR screens.
DR   ChiTaRS; MKKS; human.
DR   GeneWiki; MKKS; -.
DR   GenomeRNAi; 8195; -.
DR   Pharos; Q9NPJ1; Tbio.
DR   PRO; PR:Q9NPJ1; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9NPJ1; protein.
DR   Bgee; ENSG00000125863; Expressed in middle temporal gyrus and 188 other tissues.
DR   Genevisible; Q9NPJ1; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:1902636; C:kinociliary basal body; IBA:GO_Central.
DR   GO; GO:0031514; C:motile cilium; ISS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:MGI.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:ProtInc.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0048854; P:brain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:BHF-UCL.
DR   GO; GO:0051131; P:chaperone-mediated protein complex assembly; IBA:GO_Central.
DR   GO; GO:0060271; P:cilium assembly; IMP:UniProtKB.
DR   GO; GO:0060027; P:convergent extension involved in gastrulation; ISS:BHF-UCL.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; ISS:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; ISS:BHF-UCL.
DR   GO; GO:0032502; P:developmental process; IBA:GO_Central.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0008406; P:gonad development; TAS:ProtInc.
DR   GO; GO:0007507; P:heart development; TAS:ProtInc.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0021766; P:hippocampus development; ISS:BHF-UCL.
DR   GO; GO:0046907; P:intracellular transport; ISS:BHF-UCL.
DR   GO; GO:0032402; P:melanosome transport; ISS:BHF-UCL.
DR   GO; GO:0030837; P:negative regulation of actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0038108; P:negative regulation of appetite by leptin-mediated signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; IEA:Ensembl.
DR   GO; GO:1905515; P:non-motile cilium assembly; IEA:Ensembl.
DR   GO; GO:0045494; P:photoreceptor cell maintenance; ISS:BHF-UCL.
DR   GO; GO:0051877; P:pigment granule aggregation in cell center; ISS:BHF-UCL.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0006457; P:protein folding; TAS:ProtInc.
DR   GO; GO:0060296; P:regulation of cilium beat frequency involved in ciliary motility; ISS:BHF-UCL.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0007608; P:sensory perception of smell; ISS:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; ISS:BHF-UCL.
DR   GO; GO:0007286; P:spermatid development; ISS:BHF-UCL.
DR   GO; GO:0021756; P:striatum development; ISS:BHF-UCL.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   Gene3D; 3.50.7.10; GroEL; 1.
DR   Gene3D; 1.10.560.10; GroEL-like equatorial domain; 1.
DR   Gene3D; 3.30.260.10; TCP-1-like chaperonin intermediate domain; 1.
DR   InterPro; IPR002423; Cpn60/GroEL/TCP-1.
DR   InterPro; IPR027409; GroEL-like_apical_dom_sf.
DR   InterPro; IPR027413; GROEL-like_equatorial_sf.
DR   InterPro; IPR028790; MKKS.
DR   InterPro; IPR027410; TCP-1-like_intermed_sf.
DR   PANTHER; PTHR46787; SYNDROMES PUTATIVE CHAPERONIN-RELATED; 1.
DR   PANTHER; PTHR46787:SF1; SYNDROMES PUTATIVE CHAPERONIN-RELATED; 1.
DR   Pfam; PF00118; Cpn60_TCP1; 1.
DR   SUPFAM; SSF52029; GroEL apical domain-like; 1.
DR   SUPFAM; SSF48592; GroEL equatorial domain-like; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Bardet-Biedl syndrome; Chaperone; Ciliopathy; Cytoplasm;
KW   Cytoskeleton; Disease variant; Intellectual disability; Nucleotide-binding;
KW   Nucleus; Obesity; Reference proteome; Sensory transduction; Vision.
FT   CHAIN           1..570
FT                   /note="Molecular chaperone MKKS"
FT                   /id="PRO_0000128415"
FT   REGION          198..370
FT                   /note="Substrate-binding apical domain"
FT   BINDING         192..199
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255"
FT   VARIANT         32
FT                   /note="I -> M (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:11179009"
FT                   /id="VAR_017035"
FT   VARIANT         37
FT                   /note="Y -> C (in MKKS and BBS6; causes both increased MKKS
FT                   protein degradation and reduced solubility relative to
FT                   wild-type and Tyr-84 mutant; the mutant is immobilized at
FT                   the centrosome even in the absence of proteasome
FT                   inhibition; the mutant is also highly polyubiquitinated; no
FT                   effect on import to the nucleus; dbSNP:rs74315396)"
FT                   /evidence="ECO:0000269|PubMed:10802661,
FT                   ECO:0000269|PubMed:10973251, ECO:0000269|PubMed:11567139,
FT                   ECO:0000269|PubMed:18094050, ECO:0000269|PubMed:20080638,
FT                   ECO:0000269|PubMed:28753627"
FT                   /id="VAR_009864"
FT   VARIANT         40..570
FT                   /note="Missing (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:28761321"
FT                   /id="VAR_080223"
FT   VARIANT         41
FT                   /note="G -> R (in BBS6; dbSNP:rs766132697)"
FT                   /evidence="ECO:0000269|PubMed:21344540"
FT                   /id="VAR_066262"
FT   VARIANT         49
FT                   /note="G -> V (in dbSNP:rs528833454)"
FT                   /evidence="ECO:0000269|PubMed:10802661"
FT                   /id="VAR_009865"
FT   VARIANT         52
FT                   /note="G -> D (in BBS6; fails to associate with centrosome;
FT                   dbSNP:rs28937875)"
FT                   /evidence="ECO:0000269|PubMed:10973238,
FT                   ECO:0000269|PubMed:15731008, ECO:0000269|PubMed:20080638"
FT                   /id="VAR_009882"
FT   VARIANT         57
FT                   /note="T -> A (in BBS6; found in a patient also carrying A-
FT                   155 in TMEM237; causes both increased MKKS protein
FT                   degradation and reduced solubility relative to wild-type
FT                   and Y-84 mutant; greatly reduces the ability to interact
FT                   with BBS12; dbSNP:rs74315399)"
FT                   /evidence="ECO:0000269|PubMed:10973251,
FT                   ECO:0000269|PubMed:11179009, ECO:0000269|PubMed:18094050,
FT                   ECO:0000269|PubMed:20080638, ECO:0000269|PubMed:22152675"
FT                   /id="VAR_009883"
FT   VARIANT         84
FT                   /note="H -> Y (in MKKS; associated with S-242; decreased
FT                   interaction with BBS12; no effect on ciliogenesis; disrupts
FT                   import to the nucleus; no effect on interaction with
FT                   SMARCC1; may affect modulation of SMARCC1 subcellular
FT                   location; dbSNP:rs281797258)"
FT                   /evidence="ECO:0000269|PubMed:10802661,
FT                   ECO:0000269|PubMed:20080638, ECO:0000269|PubMed:28753627"
FT                   /id="VAR_009866"
FT   VARIANT         99
FT                   /note="C -> R (in BBS6; dbSNP:rs1297985227)"
FT                   /evidence="ECO:0000269|PubMed:21344540"
FT                   /id="VAR_066263"
FT   VARIANT         155
FT                   /note="R -> L (in BBS6; increases MKKS protein degradation;
FT                   localizes properly to the centrosome; dbSNP:rs138111422)"
FT                   /evidence="ECO:0000269|PubMed:12107442,
FT                   ECO:0000269|PubMed:15731008"
FT                   /id="VAR_017040"
FT   VARIANT         181
FT                   /note="A -> P (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:12920096"
FT                   /id="VAR_038898"
FT   VARIANT         236
FT                   /note="S -> P (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:11179009,
FT                   ECO:0000269|PubMed:12677556, ECO:0000269|PubMed:20080638"
FT                   /id="VAR_017036"
FT   VARIANT         237
FT                   /note="T -> A (in BBS6; dbSNP:rs760185677)"
FT                   /evidence="ECO:0000269|PubMed:15770229"
FT                   /id="VAR_038899"
FT   VARIANT         237
FT                   /note="T -> P (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:15666242,
FT                   ECO:0000269|PubMed:15770229"
FT                   /id="VAR_038900"
FT   VARIANT         242
FT                   /note="A -> S (in MKKS and BBS6; associated with Y-84 in
FT                   MKKS; unknown pathological significance; increases MKKS
FT                   protein degradation; no effect on ciliogenesis; disrupts
FT                   import to the nucleus; no effect on interaction with
FT                   SMARCC1; may affect modulation of SMARCC1 subcellular
FT                   location; dbSNP:rs74315394)"
FT                   /evidence="ECO:0000269|PubMed:10802661,
FT                   ECO:0000269|PubMed:11179009, ECO:0000269|PubMed:11567139,
FT                   ECO:0000269|PubMed:12107442, ECO:0000269|PubMed:15483080,
FT                   ECO:0000269|PubMed:18094050, ECO:0000269|PubMed:20120035,
FT                   ECO:0000269|PubMed:28753627"
FT                   /id="VAR_009867"
FT   VARIANT         277
FT                   /note="L -> P (in BBS6; moderately affects interaction with
FT                   BBS2; greatly reduces the ability to interact with BBS12;
FT                   dbSNP:rs74315398)"
FT                   /evidence="ECO:0000269|PubMed:10973251,
FT                   ECO:0000269|PubMed:20080638"
FT                   /id="VAR_009884"
FT   VARIANT         286
FT                   /note="D -> A (in BBS6; fails to associate with
FT                   centrosome)"
FT                   /evidence="ECO:0000269|PubMed:11179009,
FT                   ECO:0000269|PubMed:15731008"
FT                   /id="VAR_017037"
FT   VARIANT         299
FT                   /note="P -> L (in BBS6; dbSNP:rs756083063)"
FT                   /evidence="ECO:0000269|PubMed:21344540"
FT                   /id="VAR_066264"
FT   VARIANT         325
FT                   /note="T -> P (has a modifier effect on BBS; causes a
FT                   mislocalization of the protein; fails to associate with
FT                   centrosome; dbSNP:rs137853156)"
FT                   /evidence="ECO:0000269|PubMed:12677556,
FT                   ECO:0000269|PubMed:12837689, ECO:0000269|PubMed:15731008"
FT                   /id="VAR_038901"
FT   VARIANT         339
FT                   /note="I -> V (in dbSNP:rs137853909)"
FT                   /evidence="ECO:0000269|PubMed:12107442,
FT                   ECO:0000269|PubMed:15666242, ECO:0000269|PubMed:15770229"
FT                   /id="VAR_017041"
FT   VARIANT         345
FT                   /note="G -> E (in BBS6; increases MKKS protein degradation;
FT                   fails to associate with centrosome; the mutant is highly
FT                   polyubiquitinated and rapidly degraded by the ubiquitin-
FT                   proteasome protein degradation pathway; dbSNP:rs779116830)"
FT                   /evidence="ECO:0000269|PubMed:12107442,
FT                   ECO:0000269|PubMed:15731008, ECO:0000269|PubMed:18094050"
FT                   /id="VAR_017042"
FT   VARIANT         395
FT                   /note="H -> R (in BBS6; atypical mild phenotype consisting
FT                   of retinitis pigmentosa and polydactyly without other signs
FT                   of Bardet-Biedl syndrome; results in decreased interaction
FT                   with BBS12; dbSNP:rs912923677)"
FT                   /evidence="ECO:0000269|PubMed:26900326"
FT                   /id="VAR_077208"
FT   VARIANT         460
FT                   /note="S -> P (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:15666242"
FT                   /id="VAR_038902"
FT   VARIANT         488
FT                   /note="A -> T (in a patient with Bardet-Biedl syndrome
FT                   compound heterozygote for mutations in BBS12; uncertain
FT                   pathological role; dbSNP:rs61734546)"
FT                   /evidence="ECO:0000269|PubMed:21344540"
FT                   /id="VAR_066265"
FT   VARIANT         492
FT                   /note="D -> N (in BBS6; unknown pathological significance;
FT                   dbSNP:rs142327258)"
FT                   /evidence="ECO:0000269|PubMed:12920096"
FT                   /id="VAR_038903"
FT   VARIANT         499
FT                   /note="C -> S (in BBS6; causes both increased MKKS protein
FT                   degradation and reduced solubility relative to wild-type
FT                   and Tyr-84 mutant; localizes properly to the centrosome;
FT                   dbSNP:rs281797259 and dbSNP:rs137853155)"
FT                   /evidence="ECO:0000269|PubMed:11179009,
FT                   ECO:0000269|PubMed:11567139, ECO:0000269|PubMed:15731008,
FT                   ECO:0000269|PubMed:18094050"
FT                   /id="VAR_013161"
FT   VARIANT         511
FT                   /note="S -> A (in BBS6)"
FT                   /evidence="ECO:0000269|PubMed:11179009"
FT                   /id="VAR_017038"
FT   VARIANT         517
FT                   /note="R -> C (in dbSNP:rs1547)"
FT                   /evidence="ECO:0000269|PubMed:10802661,
FT                   ECO:0000269|PubMed:15483080, ECO:0000269|PubMed:15666242,
FT                   ECO:0000269|PubMed:15770229"
FT                   /id="VAR_009868"
FT   VARIANT         518
FT                   /note="R -> H (in BBS6; dbSNP:rs149051148)"
FT                   /evidence="ECO:0000269|PubMed:11179009"
FT                   /id="VAR_017039"
FT   VARIANT         532
FT                   /note="G -> V (in dbSNP:rs1545)"
FT                   /evidence="ECO:0000269|PubMed:15483080,
FT                   ECO:0000269|PubMed:15666242, ECO:0000269|PubMed:15770229"
FT                   /id="VAR_009869"
FT   MUTAGEN         454
FT                   /note="L->P: No effect on import to the nucleus."
FT                   /evidence="ECO:0000269|PubMed:28753627"
SQ   SEQUENCE   570 AA;  62342 MW;  14BA57FF8AEA0AF7 CRC64;
     MSRLEAKKPS LCKSEPLTTE RVRTTLSVLK RIVTSCYGPS GRLKQLHNGF GGYVCTTSQS
     SALLSHLLVT HPILKILTAS IQNHVSSFSD CGLFTAILCC NLIENVQRLG LTPTTVIRLN
     KHLLSLCISY LKSETCGCRI PVDFSSTQIL LCLVRSILTS KPACMLTRKE TEHVSALILR
     AFLLTIPENA EGHIILGKSL IVPLKGQRVI DSTVLPGILI EMSEVQLMRL LPIKKSTALK
     VALFCTTLSG DTSDTGEGTV VVSYGVSLEN AVLDQLLNLG RQLISDHVDL VLCQKVIHPS
     LKQFLNMHRI IAIDRIGVTL MEPLTKMTGT QPIGSLGSIC PNSYGSVKDV CTAKFGSKHF
     FHLIPNEATI CSLLLCNRND TAWDELKLTC QTALHVLQLT LKEPWALLGG GCTETHLAAY
     IRHKTHNDPE SILKDDECTQ TELQLIAEAF CSALESVVGS LEHDGGEILT DMKYGHLWSV
     QADSPCVANW PDLLSQCGCG LYNSQEELNW SFLRSTRRPF VPQSCLPHEA VGSASNLTLD
     CLTAKLSGLQ VAVETANLIL DLSYVIEDKN
//
ID   PAK5_HUMAN              Reviewed;         719 AA.
AC   Q9P286; A8K5T6; D3DW14; Q5W115; Q8TB93; Q9BX09; Q9ULF6;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   22-FEB-2023, entry version 213.
DE   RecName: Full=Serine/threonine-protein kinase PAK 5 {ECO:0000305};
DE            EC=2.7.11.1;
DE   AltName: Full=p21-activated kinase 5;
DE            Short=PAK-5;
DE   AltName: Full=p21-activated kinase 7;
DE            Short=PAK-7;
GN   Name=PAK5 {ECO:0000312|HGNC:HGNC:15916}; Synonyms=KIAA1264, PAK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=12032833; DOI=10.1038/sj.onc.1205478;
RA   Pandey A., Dan I., Kristiansen T.Z., Watanabe N.M., Voldby J., Kajikawa E.,
RA   Khosravi-Far R., Blagoev B., Mann M.;
RT   "Cloning and characterization of PAK5, a novel member of mammalian p21-
RT   activated kinase-II subfamily that is predominantly expressed in brain.";
RL   Oncogene 21:3939-3948(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-511.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   DOMAIN, AND MUTAGENESIS OF 19-HIS--HIS-22.
RX   PubMed=12860998; DOI=10.1074/jbc.c300234200;
RA   Ching Y.P., Leong V.Y., Wong C.M., Kung H.F.;
RT   "Identification of an autoinhibitory domain of p21-activated protein kinase
RT   5.";
RL   J. Biol. Chem. 278:33621-33624(2003).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12897128; DOI=10.1128/mcb.23.16.5526-5539.2003;
RA   Cotteret S., Jaffer Z.M., Beeser A., Chernoff J.;
RT   "p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits
RT   apoptosis by phosphorylating BAD.";
RL   Mol. Cell. Biol. 23:5526-5539(2003).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH MARK2.
RX   PubMed=16014608; DOI=10.1091/mbc.e05-01-0081;
RA   Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J.,
RA   Mandelkow E., Mandelkow E.M.;
RT   "PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable
RT   microtubules and dynamic actin.";
RL   Mol. Biol. Cell 16:4410-4422(2005).
RN   [10]
RP   INTERACTION WITH RHOD AND RHOH.
RX   PubMed=17064668; DOI=10.1016/j.bbrc.2006.09.172;
RA   Wu X., Frost J.A.;
RT   "Multiple Rho proteins regulate the subcellular targeting of PAK5.";
RL   Biochem. Biophys. Res. Commun. 351:328-335(2006).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16581795; DOI=10.1128/mcb.26.8.3215-3230.2006;
RA   Cotteret S., Chernoff J.;
RT   "Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic
RT   properties.";
RL   Mol. Cell. Biol. 26:3215-3230(2006).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1.
RX   PubMed=18465753; DOI=10.1002/jcb.21809;
RA   Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.;
RT   "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria.";
RL   J. Cell. Biochem. 105:167-175(2008).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF CTNND1.
RX   PubMed=20564219; DOI=10.1002/jcb.22639;
RA   Wong L.E., Reynolds A.B., Dissanayaka N.T., Minden A.;
RT   "p120-catenin is a binding partner and substrate for Group B Pak kinases.";
RL   J. Cell. Biochem. 110:1244-1254(2010).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 425-719.
RX   PubMed=17292838; DOI=10.1016/j.str.2007.01.001;
RA   Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A.,
RA   Fedorov O., Deacon S.W., Peterson J.R., Knapp S.;
RT   "Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6
RT   reveal catalytic domain plasticity of active group II PAKs.";
RL   Structure 15:201-213(2007).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-118; ALA-187; PRO-312; PRO-335;
RP   ASN-511; ASN-538; SER-555; ILE-604 AND SER-704.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell migration, proliferation or cell survival. Activation
CC       by various effectors including growth factor receptors or active CDC42
CC       and RAC1 results in a conformational change and a subsequent
CC       autophosphorylation on several serine and/or threonine residues.
CC       Phosphorylates the proto-oncogene RAF1 and stimulates its kinase
CC       activity. Promotes cell survival by phosphorylating the BCL2 antagonist
CC       of cell death BAD. Phosphorylates CTNND1, probably to regulate
CC       cytoskeletal organization and cell morphology. Keeps microtubules
CC       stable through MARK2 inhibition and destabilizes the F-actin network
CC       leading to the disappearance of stress fibers and focal adhesions.
CC       {ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16014608,
CC       ECO:0000269|PubMed:16581795, ECO:0000269|PubMed:18465753,
CC       ECO:0000269|PubMed:20564219}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21
CC       and RAC1. Interacts with MARK2, leading to inhibit MARK2 independently
CC       of kinase activity. Interacts with RHOD and RHOH.
CC       {ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:17064668}.
CC   -!- INTERACTION:
CC       Q9P286; Q8IW93: ARHGEF19; NbExp=3; IntAct=EBI-741896, EBI-7799822;
CC       Q9P286; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-741896, EBI-742909;
CC       Q9P286; Q8N5M1: ATPAF2; NbExp=7; IntAct=EBI-741896, EBI-1166928;
CC       Q9P286; Q9H257: CARD9; NbExp=5; IntAct=EBI-741896, EBI-751319;
CC       Q9P286; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-741896, EBI-11530605;
CC       Q9P286; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-741896, EBI-744545;
CC       Q9P286; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-741896, EBI-10961624;
CC       Q9P286; P51959: CCNG1; NbExp=4; IntAct=EBI-741896, EBI-3905829;
CC       Q9P286; P60953: CDC42; NbExp=5; IntAct=EBI-741896, EBI-81752;
CC       Q9P286; Q96SW2: CRBN; NbExp=4; IntAct=EBI-741896, EBI-2510250;
CC       Q9P286; P48730: CSNK1D; NbExp=3; IntAct=EBI-741896, EBI-751621;
CC       Q9P286; P26196: DDX6; NbExp=3; IntAct=EBI-741896, EBI-351257;
CC       Q9P286; P50402: EMD; NbExp=3; IntAct=EBI-741896, EBI-489887;
CC       Q9P286; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-741896, EBI-744099;
CC       Q9P286; Q9Y3B2: EXOSC1; NbExp=3; IntAct=EBI-741896, EBI-371892;
CC       Q9P286; Q96CN9: GCC1; NbExp=3; IntAct=EBI-741896, EBI-746252;
CC       Q9P286; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-741896, EBI-14103818;
CC       Q9P286; P42858: HTT; NbExp=3; IntAct=EBI-741896, EBI-466029;
CC       Q9P286; Q96EL1: INKA1; NbExp=5; IntAct=EBI-741896, EBI-10285157;
CC       Q9P286; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-741896, EBI-726510;
CC       Q9P286; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-741896, EBI-739832;
CC       Q9P286; P07196: NEFL; NbExp=3; IntAct=EBI-741896, EBI-475646;
CC       Q9P286; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-741896, EBI-741158;
CC       Q9P286; P16284: PECAM1; NbExp=3; IntAct=EBI-741896, EBI-716404;
CC       Q9P286; Q8WWY3: PRPF31; NbExp=6; IntAct=EBI-741896, EBI-1567797;
CC       Q9P286; Q92530: PSMF1; NbExp=3; IntAct=EBI-741896, EBI-945916;
CC       Q9P286; Q16825: PTPN21; NbExp=3; IntAct=EBI-741896, EBI-2860264;
CC       Q9P286; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-741896, EBI-6285694;
CC       Q9P286; O60504: SORBS3; NbExp=3; IntAct=EBI-741896, EBI-741237;
CC       Q9P286; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-741896, EBI-744794;
CC       Q9P286; Q9UBK9: UXT; NbExp=4; IntAct=EBI-741896, EBI-357355;
CC       Q9P286; O76024: WFS1; NbExp=3; IntAct=EBI-741896, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion. Cytoplasm. Nucleus. Note=Shuttles
CC       between the nucleus and the mitochondria, and mitochondrial
CC       localization is essential for the role in cell survival.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in brain.
CC   -!- DOMAIN: An autoinhibitory domain is present in the N-terminal region of
CC       the protein. {ECO:0000269|PubMed:12860998}.
CC   -!- PTM: Autophosphorylated when activated by CDC42/p21.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86578.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB040812; BAA94194.1; -; mRNA.
DR   EMBL; AB033090; BAA86578.1; ALT_INIT; mRNA.
DR   EMBL; AK291401; BAF84090.1; -; mRNA.
DR   EMBL; AL031652; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL135935; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353612; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10358.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10359.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10360.1; -; Genomic_DNA.
DR   EMBL; BC024179; AAH24179.1; -; mRNA.
DR   CCDS; CCDS13107.1; -.
DR   RefSeq; NP_065074.1; NM_020341.3.
DR   RefSeq; NP_817127.1; NM_177990.2.
DR   RefSeq; XP_016883449.1; XM_017027960.1.
DR   RefSeq; XP_016883450.1; XM_017027961.1.
DR   RefSeq; XP_016883451.1; XM_017027962.1.
DR   RefSeq; XP_016883452.1; XM_017027963.1.
DR   RefSeq; XP_016883453.1; XM_017027964.1.
DR   RefSeq; XP_016883454.1; XM_017027965.1.
DR   PDB; 2F57; X-ray; 1.80 A; A/B=425-719.
DR   PDBsum; 2F57; -.
DR   AlphaFoldDB; Q9P286; -.
DR   SMR; Q9P286; -.
DR   BioGRID; 121402; 94.
DR   IntAct; Q9P286; 104.
DR   MINT; Q9P286; -.
DR   STRING; 9606.ENSP00000367686; -.
DR   BindingDB; Q9P286; -.
DR   ChEMBL; CHEMBL4524; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9P286; -.
DR   GuidetoPHARMACOLOGY; 2138; -.
DR   iPTMnet; Q9P286; -.
DR   PhosphoSitePlus; Q9P286; -.
DR   BioMuta; PAK5; -.
DR   DMDM; 12585290; -.
DR   EPD; Q9P286; -.
DR   jPOST; Q9P286; -.
DR   MassIVE; Q9P286; -.
DR   MaxQB; Q9P286; -.
DR   PaxDb; Q9P286; -.
DR   PeptideAtlas; Q9P286; -.
DR   ProteomicsDB; 83751; -.
DR   Antibodypedia; 8792; 379 antibodies from 39 providers.
DR   DNASU; 57144; -.
DR   Ensembl; ENST00000353224.10; ENSP00000322957.5; ENSG00000101349.17.
DR   Ensembl; ENST00000378423.5; ENSP00000367679.1; ENSG00000101349.17.
DR   Ensembl; ENST00000378429.3; ENSP00000367686.3; ENSG00000101349.17.
DR   GeneID; 57144; -.
DR   KEGG; hsa:57144; -.
DR   MANE-Select; ENST00000353224.10; ENSP00000322957.5; NM_177990.4; NP_817127.1.
DR   UCSC; uc002wnj.3; human.
DR   AGR; HGNC:15916; -.
DR   CTD; 57144; -.
DR   DisGeNET; 57144; -.
DR   GeneCards; PAK5; -.
DR   HGNC; HGNC:15916; PAK5.
DR   HPA; ENSG00000101349; Group enriched (brain, retina).
DR   MIM; 608038; gene.
DR   neXtProt; NX_Q9P286; -.
DR   OpenTargets; ENSG00000101349; -.
DR   PharmGKB; PA32922; -.
DR   VEuPathDB; HostDB:ENSG00000101349; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   GeneTree; ENSGT00940000158656; -.
DR   HOGENOM; CLU_000288_26_6_1; -.
DR   InParanoid; Q9P286; -.
DR   OMA; VDYHAHL; -.
DR   OrthoDB; 460351at2759; -.
DR   PhylomeDB; Q9P286; -.
DR   TreeFam; TF105352; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.12.2; 2681.
DR   PathwayCommons; Q9P286; -.
DR   Reactome; R-HSA-428540; Activation of RAC1.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013405; RHOD GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   SignaLink; Q9P286; -.
DR   SIGNOR; Q9P286; -.
DR   BioGRID-ORCS; 57144; 9 hits in 1193 CRISPR screens.
DR   ChiTaRS; PAK5; human.
DR   EvolutionaryTrace; Q9P286; -.
DR   GeneWiki; PAK7; -.
DR   GenomeRNAi; 57144; -.
DR   Pharos; Q9P286; Tchem.
DR   PRO; PR:Q9P286; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9P286; protein.
DR   Bgee; ENSG00000101349; Expressed in cortical plate and 93 other tissues.
DR   Genevisible; Q9P286; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   CDD; cd06658; STKc_PAK5; 1.
DR   Gene3D; 3.90.810.10; CRIB domain; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR028754; STKc_PAK5.
DR   PANTHER; PTHR48015:SF27; SERINE/THREONINE-PROTEIN KINASE PAK 5; 1.
DR   PANTHER; PTHR48015; SERINE/THREONINE-PROTEIN KINASE TAO; 1.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cytoplasm; Kinase; Mitochondrion;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..719
FT                   /note="Serine/threonine-protein kinase PAK 5"
FT                   /id="PRO_0000086477"
FT   DOMAIN          11..24
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          449..700
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..29
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          25..448
FT                   /note="Linker"
FT   REGION          97..123
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          256..299
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          340..373
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..15
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        97..111
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        270..291
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        354..373
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        568
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         455..463
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         478
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         104
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C015"
FT   MOD_RES         107
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C015"
FT   VARIANT         118
FT                   /note="G -> D (in dbSNP:rs55923311)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040978"
FT   VARIANT         187
FT                   /note="P -> A (in dbSNP:rs34280805)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040979"
FT   VARIANT         312
FT                   /note="S -> P (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs952665081)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040980"
FT   VARIANT         335
FT                   /note="R -> P (in dbSNP:rs11700112)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040981"
FT   VARIANT         511
FT                   /note="S -> N (in dbSNP:rs2297345)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021865"
FT   VARIANT         538
FT                   /note="T -> N (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040982"
FT   VARIANT         555
FT                   /note="A -> S (in dbSNP:rs34102290)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040983"
FT   VARIANT         604
FT                   /note="V -> I (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040984"
FT   VARIANT         704
FT                   /note="G -> S (in a metastatic melanoma sample; somatic
FT                   mutation; dbSNP:rs1484691555)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040985"
FT   MUTAGEN         19..22
FT                   /note="HRVH->LRVL: Complete loss of CDC42 binding and
FT                   CDC42-mediated autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:12860998"
FT   CONFLICT        27
FT                   /note="P -> A (in Ref. 6; AAH24179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        403
FT                   /note="S -> Y (in Ref. 6; AAH24179)"
FT                   /evidence="ECO:0000305"
FT   HELIX           429..437
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           445..447
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          449..457
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          459..468
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   TURN            469..471
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          474..481
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           482..484
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           488..500
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          509..515
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          518..524
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           531..535
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           542..561
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           571..573
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          574..576
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   STRAND          595..597
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           612..615
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           623..638
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   TURN            642..645
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           648..657
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           666..668
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           671..680
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           685..687
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           691..695
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           698..702
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           706..708
FT                   /evidence="ECO:0007829|PDB:2F57"
FT   HELIX           710..712
FT                   /evidence="ECO:0007829|PDB:2F57"
SQ   SEQUENCE   719 AA;  80745 MW;  07A12B1EEC4E2A02 CRC64;
     MFGKKKKKIE ISGPSNFEHR VHTGFDPQEQ KFTGLPQQWH SLLADTANRP KPMVDPSCIT
     PIQLAPMKTI VRGNKPCKET SINGLLEDFD NISVTRSNSL RKESPPTPDQ GASSHGPGHA
     EENGFITFSQ YSSESDTTAD YTTEKYREKS LYGDDLDPYY RGSHAAKQNG HVMKMKHGEA
     YYSEVKPLKS DFARFSADYH SHLDSLSKPS EYSDLKWEYQ RASSSSPLDY SFQFTPSRTA
     GTSGCSKESL AYSESEWGPS LDDYDRRPKS SYLNQTSPQP TMRQRSRSGS GLQEPMMPFG
     ASAFKTHPQG HSYNSYTYPR LSEPTMCIPK VDYDRAQMVL SPPLSGSDTY PRGPAKLPQS
     QSKSGYSSSS HQYPSGYHKA TLYHHPSLQS SSQYISTASY LSSLSLSSST YPPPSWGSSS
     DQQPSRVSHE QFRAALQLVV SPGDPREYLA NFIKIGEGST GIVCIATEKH TGKQVAVKKM
     DLRKQQRREL LFNEVVIMRD YHHDNVVDMY SSYLVGDELW VVMEFLEGGA LTDIVTHTRM
     NEEQIATVCL SVLRALSYLH NQGVIHRDIK SDSILLTSDG RIKLSDFGFC AQVSKEVPKR
     KSLVGTPYWM APEVISRLPY GTEVDIWSLG IMVIEMIDGE PPYFNEPPLQ AMRRIRDSLP
     PRVKDLHKVS SVLRGFLDLM LVREPSQRAT AQELLGHPFL KLAGPPSCIV PLMRQYRHH
//
ID   PDIA1_HUMAN             Reviewed;         508 AA.
AC   P07237; B2RDQ2; P30037; P32079; Q15205; Q6LDE5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 3.
DT   22-FEB-2023, entry version 264.
DE   RecName: Full=Protein disulfide-isomerase;
DE            Short=PDI;
DE            EC=5.3.4.1 {ECO:0000269|PubMed:32149426};
DE   AltName: Full=Cellular thyroid hormone-binding protein;
DE   AltName: Full=Prolyl 4-hydroxylase subunit beta;
DE   AltName: Full=p55;
DE   Flags: Precursor;
GN   Name=P4HB; Synonyms=ERBA2L, PDI, PDIA1, PO4DB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3034602; DOI=10.1002/j.1460-2075.1987.tb04803.x;
RA   Pihlajaniemi T., Helaakoski T., Tasanen K., Myllylae R., Huhtala M.-L.,
RA   Koivu J., Kivirikko K.I.;
RT   "Molecular cloning of the beta-subunit of human prolyl 4-hydroxylase. This
RT   subunit and protein disulphide isomerase are products of the same gene.";
RL   EMBO J. 6:643-649(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3611107; DOI=10.1016/s0021-9258(18)60947-0;
RA   Cheng S.-Y., Gong Q.-H., Parkison C., Robinson E.A., Appella E.,
RA   Merlino G.T., Pastan I.;
RT   "The nucleotide sequence of a human cellular thyroid hormone binding
RT   protein present in endoplasmic reticulum.";
RL   J. Biol. Chem. 262:11221-11227(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=2846539; DOI=10.1016/s0021-9258(18)37581-1;
RA   Tasanen K., Parkkonen T., Chow L.T., Kivirikko K.I., Pihlajaniemi T.;
RT   "Characterization of the human gene for a polypeptide that acts both as the
RT   beta subunit of prolyl 4-hydroxylase and as protein disulfide isomerase.";
RL   J. Biol. Chem. 263:16218-16224(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   PubMed=1597478; DOI=10.1016/s0021-9258(19)49940-7;
RA   Tasanen K., Oikarinen J., Kivirikko K.I., Pihlajaniemi T.;
RT   "Promoter of the gene for the multifunctional protein disulfide isomerase
RT   polypeptide. Functional significance of the six CCAAT boxes and other
RT   promoter elements.";
RL   J. Biol. Chem. 267:11513-11519(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 18-41.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [9]
RP   PROTEIN SEQUENCE OF 18-30.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [10]
RP   PROTEIN SEQUENCE OF 18-29.
RC   TISSUE=Liver;
RA   Frutiger S., Hughes G.J.;
RL   Submitted (FEB-1996) to UniProtKB.
RN   [11]
RP   PROTEIN SEQUENCE OF 18-26.
RX   PubMed=2079031; DOI=10.1002/elps.1150111019;
RA   Ward L.D., Hong J., Whitehead R.H., Simpson R.J.;
RT   "Development of a database of amino acid sequences for human colon
RT   carcinoma proteins separated by two-dimensional polyacrylamide gel
RT   electrophoresis.";
RL   Electrophoresis 11:883-891(1990).
RN   [12]
RP   PRELIMINARY PROTEIN SEQUENCE OF 19-28.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [13]
RP   PROTEIN SEQUENCE OF 19-28.
RX   PubMed=9399589; DOI=10.1093/oxfordjournals.jbchem.a021830;
RA   Urade R., Oda T., Ito H., Moriyama T., Utsumi S., Kito M.;
RT   "Functions of characteristic Cys-Gly-His-Cys (CGHC) and Gln-Glu-Asp-Leu
RT   (QEDL) motifs of microsomal ER-60 protease.";
RL   J. Biochem. 122:834-842(1997).
RN   [14]
RP   PROTEIN SEQUENCE OF 201-207; 223-230; 286-308 AND 402-409, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 293-508.
RX   PubMed=3342239; DOI=10.1016/0167-4781(88)90080-2;
RA   Morris J.I., Varandani P.T.;
RT   "Characterization of a cDNA for human glutathione-insulin transhydrogenase
RT   (protein-disulfide isomerase/oxidoreductase).";
RL   Biochim. Biophys. Acta 949:169-180(1988).
RN   [16]
RP   PROTEIN SEQUENCE OF 317-325; 350-369 AND 401-419.
RX   PubMed=1699755; DOI=10.1002/elps.1150110703;
RA   Bauw G., Rasmussen H.H., van den Bulcke M., van Damme J., Puype M.,
RA   Gesser B., Celis J.E., Vandekerckhove J.;
RT   "Two-dimensional gel electrophoresis, protein electroblotting and
RT   microsequencing: a direct link between proteins and genes.";
RL   Electrophoresis 11:528-536(1990).
RN   [17]
RP   INTERACTION WITH P4HA2.
RX   PubMed=7753822; DOI=10.1073/pnas.92.10.4427;
RA   Helaakoski T., Annunen P., Vuori K., Macneil I.A., Pihlajaniemi T.,
RA   Kivirikko K.I.;
RT   "Cloning, baculovirus expression, and characterization of a second mouse
RT   prolyl 4-hydroxylase alpha-subunit isoform: formation of an alpha 2 beta 2
RT   tetramer with the protein disulfide-isomerase/beta subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:4427-4431(1995).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10636893; DOI=10.1074/jbc.275.3.1920;
RA   Mezghrani A., Courageot J., Mani J.-C., Pugniere M., Bastiani P.,
RA   Miquelis R.;
RT   "Protein-disulfide isomerase (PDI) in FRTL5 cells. pH-dependent
RT   thyroglobulin/PDI interactions determine a novel PDI function in the post-
RT   endoplasmic reticulum of thyrocytes.";
RL   J. Biol. Chem. 275:1920-1929(2000).
RN   [19]
RP   INTERACTION WITH ERO1B.
RX   PubMed=11707400; DOI=10.1093/emboj/20.22.6288;
RA   Mezghrani A., Fassio A., Benham A., Simmen T., Braakman I., Sitia R.;
RT   "Manipulation of oxidative protein folding and PDI redox state in mammalian
RT   cells.";
RL   EMBO J. 20:6288-6296(2001).
RN   [20]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11181151; DOI=10.1086/318823;
RA   Fenouillet E., Barbouche R., Courageot J., Miquelis R.;
RT   "The catalytic activity of protein disulfide isomerase is involved in human
RT   immunodeficiency virus envelope-mediated membrane fusion after CD4 cell
RT   binding.";
RL   J. Infect. Dis. 183:744-752(2001).
RN   [21]
RP   FUNCTION.
RX   PubMed=12485997; DOI=10.1093/emboj/cdf685;
RA   Lumb R.A., Bulleid N.J.;
RT   "Is protein disulfide isomerase a redox-dependent molecular chaperone?";
RL   EMBO J. 21:6763-6770(2002).
RN   [22]
RP   INTERACTION WITH UBQLN1.
RX   PubMed=12095988; DOI=10.1074/jbc.m203412200;
RA   Ko H.S., Uehara T., Nomura Y.;
RT   "Role of ubiquilin associated with protein-disulfide isomerase in the
RT   endoplasmic reticulum in stress-induced apoptotic cell death.";
RL   J. Biol. Chem. 277:35386-35392(2002).
RN   [23]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=12218051; DOI=10.1074/jbc.m204547200;
RA   Gallina A., Hanley T.M., Mandel R., Trahey M., Broder C.C., Viglianti G.A.,
RA   Ryser H.J.;
RT   "Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide
RT   bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry.";
RL   J. Biol. Chem. 277:50579-50588(2002).
RN   [24]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=12218052; DOI=10.1074/jbc.m205467200;
RA   Barbouche R., Miquelis R., Jones I.M., Fenouillet E.;
RT   "Protein-disulfide isomerase-mediated reduction of two disulfide bonds of
RT   HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for
RT   fusion.";
RL   J. Biol. Chem. 278:3131-3136(2003).
RN   [25]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K., Valencia J.,
RA   Muller J., Vieira W.D., Watabe H., Shabanowitz J., Hearing V.J., Hunt D.F.,
RA   Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [26]
RP   REVIEW.
RX   PubMed=15158710; DOI=10.1016/j.bbapap.2004.02.017;
RA   Wilkinson B., Gilbert H.F.;
RT   "Protein disulfide isomerase.";
RL   Biochim. Biophys. Acta 1699:35-44(2004).
RN   [27]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=14592831; DOI=10.1182/blood-2003-05-1390;
RA   Markovic I., Stantchev T.S., Fields K.H., Tiffany L.J., Tomic M.,
RA   Weiss C.D., Broder C.C., Strebel K., Clouse K.A.;
RT   "Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1
RT   envelope-mediated T-cell fusion during viral entry.";
RL   Blood 103:1586-1594(2004).
RN   [28]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=15644496; DOI=10.1124/mol.104.008276;
RA   Barbouche R., Lortat-Jacob H., Jones I.M., Fenouillet E.;
RT   "Glycosaminoglycans and protein disulfide isomerase-mediated reduction of
RT   HIV Env.";
RL   Mol. Pharmacol. 67:1111-1118(2005).
RN   [29]
RP   INTERACTION WITH MTTP.
RX   PubMed=16478722; DOI=10.1074/jbc.m512823200;
RA   Rava P., Ojakian G.K., Shelness G.S., Hussain M.M.;
RT   "Phospholipid transfer activity of microsomal triacylglycerol transfer
RT   protein is sufficient for the assembly and secretion of apolipoprotein B
RT   lipoproteins.";
RL   J. Biol. Chem. 281:11019-11027(2006).
RN   [30]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION AS RECEPTOR FOR LGALS9, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=21670307; DOI=10.1073/pnas.1017954108;
RA   Bi S., Hong P.W., Lee B., Baum L.G.;
RT   "Galectin-9 binding to cell surface protein disulfide isomerase regulates
RT   the redox environment to enhance T-cell migration and HIV entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:10650-10655(2011).
RN   [33]
RP   INTERACTION WITH MTTP, AND SUBCELLULAR LOCATION.
RX   PubMed=23475612; DOI=10.1194/jlr.m031658;
RA   Khatun I., Walsh M.T., Hussain M.M.;
RT   "Loss of both phospholipid and triglyceride transfer activities of
RT   microsomal triglyceride transfer protein in abetalipoproteinemia.";
RL   J. Lipid Res. 54:1541-1549(2013).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   PHOSPHORYLATION AT SER-357.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [36]
RP   INVOLVEMENT IN CLCRP1, VARIANT CLCRP1 CYS-393, AND CHARACTERIZATION OF
RP   VARIANT CLCRP1 CYS-393.
RX   PubMed=25683117; DOI=10.1016/j.ajhg.2014.12.027;
RA   Rauch F., Fahiminiya S., Majewski J., Carrot-Zhang J., Boudko S.,
RA   Glorieux F., Mort J.S., Baechinger H.P., Moffatt P.;
RT   "Cole-Carpenter syndrome is caused by a heterozygous missense mutation in
RT   P4HB.";
RL   Am. J. Hum. Genet. 96:425-431(2015).
RN   [37]
RP   INTERACTION WITH MTTP.
RX   PubMed=26224785; DOI=10.1161/circgenetics.115.001106;
RA   Walsh M.T., Iqbal J., Josekutty J., Soh J., Di Leo E., Oezaydin E.,
RA   Guenduez M., Tarugi P., Hussain M.M.;
RT   "A novel abetalipoproteinemia missense mutation highlights the importance
RT   of N-Terminal beta-barrel in microsomal triglyceride transfer protein
RT   function.";
RL   Circ. Cardiovasc. Genet. 8:677-687(2015).
RN   [38]
RP   CLEAVAGE OF SIGNAL PEPTIDE [LARGE SCALE ANALYSIS] AFTER ALA-17, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [39]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH ERN1, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-331; SER-357 AND SER-427, AND MUTAGENESIS OF
RP   TRP-128; SER-331; SER-357; LEU-403 AND SER-427.
RX   PubMed=32149426; DOI=10.15252/embj.2019103841;
RA   Yu J., Li T., Liu Y., Wang X., Zhang J., Wang X., Shi G., Lou J., Wang L.,
RA   Wang C.C., Wang L.;
RT   "Phosphorylation switches protein disulfide isomerase activity to maintain
RT   proteostasis and attenuate ER stress.";
RL   EMBO J. 39:e103841-e103841(2020).
RN   [40]
RP   STRUCTURE BY NMR OF 18-137.
RX   PubMed=8580850; DOI=10.1002/pro.5560041216;
RA   Kemmink J., Darby N.J., Dijkstra K., Scheek R.M., Creighton T.E.;
RT   "Nuclear magnetic resonance characterization of the N-terminal thioredoxin-
RT   like domain of protein disulfide isomerase.";
RL   Protein Sci. 4:2587-2593(1995).
RN   [41]
RP   STRUCTURE BY NMR OF 18-137, AND DISULFIDE BOND.
RX   PubMed=8672469; DOI=10.1021/bi960335m;
RA   Kemmink J., Darby N.J., Dijkstra K., Nilges M., Creighton T.E.;
RT   "Structure determination of the N-terminal thioredoxin-like domain of
RT   protein disulfide isomerase using multidimensional heteronuclear 13C/15N
RT   NMR spectroscopy.";
RL   Biochemistry 35:7684-7691(1996).
RN   [42]
RP   STRUCTURE BY NMR OF 136-245.
RX   PubMed=10383197; DOI=10.1023/a:1008341820489;
RA   Kemmink J., Dijkstra K., Mariani M., Scheek R.M., Penka E., Nilges M.,
RA   Darby N.J.;
RT   "The structure in solution of the B domain of protein disulfide
RT   isomerase.";
RL   J. Biomol. NMR 13:357-368(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 368-477.
RG   RIKEN structural genomics initiative (RSGI);
RT   "The solution structure of the second thioredoxin-like domain of human
RT   protein disulfide-isomerase.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: This multifunctional protein catalyzes the formation,
CC       breakage and rearrangement of disulfide bonds. At the cell surface,
CC       seems to act as a reductase that cleaves disulfide bonds of proteins
CC       attached to the cell. May therefore cause structural modifications of
CC       exofacial proteins. Inside the cell, seems to form/rearrange disulfide
CC       bonds of nascent proteins. At high concentrations and following
CC       phosphorylation by FAM20C, functions as a chaperone that inhibits
CC       aggregation of misfolded proteins (PubMed:32149426). At low
CC       concentrations, facilitates aggregation (anti-chaperone activity). May
CC       be involved with other chaperones in the structural modification of the
CC       TG precursor in hormone biogenesis. Also acts as a structural subunit
CC       of various enzymes such as prolyl 4-hydroxylase and microsomal
CC       triacylglycerol transfer protein MTTP. Receptor for LGALS9; the
CC       interaction retains P4HB at the cell surface of Th2 T helper cells,
CC       increasing disulfide reductase activity at the plasma membrane,
CC       altering the plasma membrane redox state and enhancing cell migration
CC       (PubMed:21670307). {ECO:0000269|PubMed:10636893,
CC       ECO:0000269|PubMed:12485997, ECO:0000269|PubMed:21670307,
CC       ECO:0000269|PubMed:32149426}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Catalyzes the rearrangement of -S-S- bonds in proteins.;
CC         EC=5.3.4.1; Evidence={ECO:0000269|PubMed:32149426};
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with the protein microsomal
CC       triglyceride transfer MTTP (PubMed:23475612, PubMed:26224785,
CC       PubMed:16478722). Homodimer. Monomers and homotetramers may also occur.
CC       Interacts with P4HA2, forming a heterotetramer consisting of 2 alpha
CC       subunits (P4HA2) and 2 beta (P4HB), where P4HB plays the role of a
CC       structural subunit; this tetramer catalyzes the formation of 4-
CC       hydroxyproline in collagen (PubMed:7753822). Also constitutes the
CC       structural subunit of the microsomal triacylglycerol transfer protein
CC       MTTP in mammalian cells. Stabilizes both enzymes and retain them in the
CC       ER without contributing to the catalytic activity (By similarity).
CC       Binds UBQLN1 (PubMed:12095988). Interacts with ERO1B (PubMed:11707400).
CC       Binds to CD4, and upon HIV-1 binding to the cell membrane, is part of a
CC       P4HB/PDI-CD4-CXCR4-gp120 complex. Interacts with ILDR2 (By similarity).
CC       Interacts with ERN1/IRE1A (via N-terminus); the interaction is enhanced
CC       by phosphorylation of P4HB by FAM20C in response to endoplasmic
CC       reticulum stress and results in attenuation of ERN1 activity
CC       (PubMed:32149426). {ECO:0000250, ECO:0000250|UniProtKB:P09103,
CC       ECO:0000269|PubMed:11707400, ECO:0000269|PubMed:12095988,
CC       ECO:0000269|PubMed:16478722, ECO:0000269|PubMed:23475612,
CC       ECO:0000269|PubMed:26224785, ECO:0000269|PubMed:32149426,
CC       ECO:0000269|PubMed:7753822}.
CC   -!- INTERACTION:
CC       P07237; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-395883, EBI-8464238;
CC       P07237; Q96RK4: BBS4; NbExp=3; IntAct=EBI-395883, EBI-1805814;
CC       P07237; O43521: BCL2L11; NbExp=3; IntAct=EBI-395883, EBI-526406;
CC       P07237; P17655: CAPN2; NbExp=3; IntAct=EBI-395883, EBI-1028956;
CC       P07237; Q8TAB7: CCDC26; NbExp=3; IntAct=EBI-395883, EBI-10271580;
CC       P07237; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-395883, EBI-742887;
CC       P07237; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-395883, EBI-11953200;
CC       P07237; Q9Y6H1: CHCHD2; NbExp=3; IntAct=EBI-395883, EBI-2321769;
CC       P07237; Q8NE01: CNNM3; NbExp=3; IntAct=EBI-395883, EBI-741032;
CC       P07237; P09228: CST2; NbExp=3; IntAct=EBI-395883, EBI-8832659;
CC       P07237; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-395883, EBI-742054;
CC       P07237; Q96HE7: ERO1A; NbExp=2; IntAct=EBI-395883, EBI-2564539;
CC       P07237; Q53R41: FASTKD1; NbExp=3; IntAct=EBI-395883, EBI-3957005;
CC       P07237; Q9ULW2: FZD10; NbExp=3; IntAct=EBI-395883, EBI-8803802;
CC       P07237; Q8NEG0: GARIN6; NbExp=3; IntAct=EBI-395883, EBI-752049;
CC       P07237; P62873: GNB1; NbExp=3; IntAct=EBI-395883, EBI-357130;
CC       P07237; P28799: GRN; NbExp=4; IntAct=EBI-395883, EBI-747754;
CC       P07237; Q8TCT9: HM13; NbExp=3; IntAct=EBI-395883, EBI-347472;
CC       P07237; Q8N4N3-2: KLHL36; NbExp=3; IntAct=EBI-395883, EBI-10973851;
CC       P07237; Q9P2K6: KLHL42; NbExp=3; IntAct=EBI-395883, EBI-739890;
CC       P07237; P02538: KRT6A; NbExp=3; IntAct=EBI-395883, EBI-702198;
CC       P07237; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-395883, EBI-11953334;
CC       P07237; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-395883, EBI-11953846;
CC       P07237; Q9BYQ6: KRTAP4-11; NbExp=3; IntAct=EBI-395883, EBI-10302392;
CC       P07237; P26371: KRTAP5-9; NbExp=3; IntAct=EBI-395883, EBI-3958099;
CC       P07237; Q9BYQ0: KRTAP9-8; NbExp=3; IntAct=EBI-395883, EBI-11958364;
CC       P07237; Q5T7P3: LCE1B; NbExp=3; IntAct=EBI-395883, EBI-10245913;
CC       P07237; Q5TA82: LCE2D; NbExp=3; IntAct=EBI-395883, EBI-10246750;
CC       P07237; Q5TA78: LCE4A; NbExp=3; IntAct=EBI-395883, EBI-10246358;
CC       P07237; P80188: LCN2; NbExp=3; IntAct=EBI-395883, EBI-11911016;
CC       P07237; Q6PJG9: LRFN4; NbExp=3; IntAct=EBI-395883, EBI-7910762;
CC       P07237; Q92692-2: NECTIN2; NbExp=3; IntAct=EBI-395883, EBI-6979889;
CC       P07237; O94818-2: NOL4; NbExp=3; IntAct=EBI-395883, EBI-10190763;
CC       P07237; Q9P121-3: NTM; NbExp=3; IntAct=EBI-395883, EBI-12027160;
CC       P07237; Q14990: ODF1; NbExp=3; IntAct=EBI-395883, EBI-10234557;
CC       P07237; O15534: PER1; NbExp=3; IntAct=EBI-395883, EBI-2557276;
CC       P07237; Q63HM9: PLCXD3; NbExp=3; IntAct=EBI-395883, EBI-12105500;
CC       P07237; O00444: PLK4; NbExp=3; IntAct=EBI-395883, EBI-746202;
CC       P07237; Q13162: PRDX4; NbExp=2; IntAct=EBI-395883, EBI-2211957;
CC       P07237; Q09028: RBBP4; NbExp=3; IntAct=EBI-395883, EBI-620823;
CC       P07237; Q96B97: SH3KBP1; NbExp=3; IntAct=EBI-395883, EBI-346595;
CC       P07237; Q86WV1-2: SKAP1; NbExp=3; IntAct=EBI-395883, EBI-11995314;
CC       P07237; Q8WUG5: SLC22A17; NbExp=3; IntAct=EBI-395883, EBI-11722858;
CC       P07237; Q03518: TAP1; NbExp=4; IntAct=EBI-395883, EBI-747259;
CC       P07237; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-395883, EBI-12833746;
CC       P07237; P01137: TGFB1; NbExp=3; IntAct=EBI-395883, EBI-779636;
CC       P07237; Q9UC07-2: ZNF69; NbExp=3; IntAct=EBI-395883, EBI-12310821;
CC       P07237; Q2GL86: APH_0248; Xeno; NbExp=3; IntAct=EBI-395883, EBI-26435798;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:23475612, ECO:0000269|PubMed:32149426}. Endoplasmic
CC       reticulum lumen {ECO:0000269|PubMed:10636893,
CC       ECO:0000269|PubMed:23475612}. Melanosome {ECO:0000269|PubMed:12643545,
CC       ECO:0000269|PubMed:17081065}. Cell membrane
CC       {ECO:0000269|PubMed:21670307}; Peripheral membrane protein
CC       {ECO:0000305}. Note=Highly abundant. In some cell types, seems to be
CC       also secreted or associated with the plasma membrane, where it
CC       undergoes constant shedding and replacement from intracellular sources
CC       (Probable). Localizes near CD4-enriched regions on lymphoid cell
CC       surfaces (PubMed:11181151). Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV (PubMed:10636893).
CC       Colocalizes with MTTP in the endoplasmic reticulum (PubMed:23475612).
CC       {ECO:0000269|PubMed:10636893, ECO:0000269|PubMed:11181151,
CC       ECO:0000269|PubMed:23475612, ECO:0000305}.
CC   -!- PTM: Phosphorylation of Ser-357 by FAM20C is induced by endoplasmic
CC       reticulum stress and results in a functional switch from oxidoreductase
CC       to molecular chaperone (PubMed:32149426). It also promotes interaction
CC       with ERN1 (PubMed:32149426). {ECO:0000269|PubMed:32149426}.
CC   -!- DISEASE: Cole-Carpenter syndrome 1 (CLCRP1) [MIM:112240]: A form of
CC       Cole-Carpenter syndrome, a disorder characterized by features of
CC       osteogenesis imperfecta such as bone deformities and severe bone
CC       fragility with frequent fractures, in association with
CC       craniosynostosis, ocular proptosis, hydrocephalus, growth failure and
CC       distinctive facial features. Craniofacial findings include marked
CC       frontal bossing, midface hypoplasia, and micrognathia. Despite the
CC       craniosynostosis and hydrocephalus, intellectual development is normal.
CC       CLCRP1 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:25683117}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Reduces and may activate fusogenic properties of HIV-1
CC       gp120 surface protein, thereby enabling HIV-1 entry into the cell.
CC   -!- SIMILARITY: Belongs to the protein disulfide isomerase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X05130; CAA28775.1; -; mRNA.
DR   EMBL; J02783; AAA61169.1; -; mRNA.
DR   EMBL; M22806; AAC13652.1; -; Genomic_DNA.
DR   EMBL; M22803; AAC13652.1; JOINED; Genomic_DNA.
DR   EMBL; M22804; AAC13652.1; JOINED; Genomic_DNA.
DR   EMBL; M22805; AAC13652.1; JOINED; Genomic_DNA.
DR   EMBL; AK315631; BAG37999.1; -; mRNA.
DR   EMBL; CH471099; EAW89690.1; -; Genomic_DNA.
DR   EMBL; BC010859; AAH10859.1; -; mRNA.
DR   EMBL; BC029617; AAH29617.1; -; mRNA.
DR   EMBL; BC071892; AAH71892.1; -; mRNA.
DR   EMBL; S37207; AAB22262.2; -; Genomic_DNA.
DR   EMBL; X07077; CAA30112.1; -; mRNA.
DR   CCDS; CCDS11787.1; -.
DR   PIR; A31913; ISHUSS.
DR   RefSeq; NP_000909.2; NM_000918.3.
DR   PDB; 1BJX; NMR; -; A=136-245.
DR   PDB; 1MEK; NMR; -; A=18-137.
DR   PDB; 1X5C; NMR; -; A=368-475.
DR   PDB; 2BJX; NMR; -; A=136-245.
DR   PDB; 2K18; NMR; -; A=135-357.
DR   PDB; 3BJ5; X-ray; 2.20 A; A=230-368.
DR   PDB; 3UEM; X-ray; 2.29 A; A=137-479.
DR   PDB; 4EKZ; X-ray; 2.51 A; A=18-479.
DR   PDB; 4EL1; X-ray; 2.88 A; A/B=18-479.
DR   PDB; 4JU5; X-ray; 2.28 A; A/B=135-367.
DR   PDB; 6I7S; X-ray; 2.50 A; A/B=18-508.
DR   PDB; 7ZSC; X-ray; 3.85 A; C/D=18-508.
DR   PDBsum; 1BJX; -.
DR   PDBsum; 1MEK; -.
DR   PDBsum; 1X5C; -.
DR   PDBsum; 2BJX; -.
DR   PDBsum; 2K18; -.
DR   PDBsum; 3BJ5; -.
DR   PDBsum; 3UEM; -.
DR   PDBsum; 4EKZ; -.
DR   PDBsum; 4EL1; -.
DR   PDBsum; 4JU5; -.
DR   PDBsum; 6I7S; -.
DR   PDBsum; 7ZSC; -.
DR   AlphaFoldDB; P07237; -.
DR   BMRB; P07237; -.
DR   SMR; P07237; -.
DR   BioGRID; 111073; 378.
DR   CORUM; P07237; -.
DR   DIP; DIP-32979N; -.
DR   IntAct; P07237; 191.
DR   MINT; P07237; -.
DR   STRING; 9606.ENSP00000327801; -.
DR   BindingDB; P07237; -.
DR   ChEMBL; CHEMBL5422; -.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB03615; Ribostamycin.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   GlyGen; P07237; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P07237; -.
DR   MetOSite; P07237; -.
DR   PhosphoSitePlus; P07237; -.
DR   SwissPalm; P07237; -.
DR   BioMuta; P4HB; -.
DR   DMDM; 2507460; -.
DR   DOSAC-COBS-2DPAGE; P07237; -.
DR   OGP; P07237; -.
DR   REPRODUCTION-2DPAGE; IPI00010796; -.
DR   REPRODUCTION-2DPAGE; P07237; -.
DR   SWISS-2DPAGE; P07237; -.
DR   EPD; P07237; -.
DR   jPOST; P07237; -.
DR   MassIVE; P07237; -.
DR   MaxQB; P07237; -.
DR   PaxDb; P07237; -.
DR   PeptideAtlas; P07237; -.
DR   PRIDE; P07237; -.
DR   ProteomicsDB; 51976; -.
DR   TopDownProteomics; P07237; -.
DR   Antibodypedia; 3250; 571 antibodies from 43 providers.
DR   DNASU; 5034; -.
DR   Ensembl; ENST00000331483.9; ENSP00000327801.4; ENSG00000185624.16.
DR   GeneID; 5034; -.
DR   KEGG; hsa:5034; -.
DR   MANE-Select; ENST00000331483.9; ENSP00000327801.4; NM_000918.4; NP_000909.2.
DR   UCSC; uc002kbn.2; human.
DR   AGR; HGNC:8548; -.
DR   CTD; 5034; -.
DR   DisGeNET; 5034; -.
DR   GeneCards; P4HB; -.
DR   HGNC; HGNC:8548; P4HB.
DR   HPA; ENSG00000185624; Tissue enhanced (liver, pancreas).
DR   MalaCards; P4HB; -.
DR   MIM; 112240; phenotype.
DR   MIM; 176790; gene.
DR   neXtProt; NX_P07237; -.
DR   OpenTargets; ENSG00000185624; -.
DR   Orphanet; 2050; Cole-Carpenter syndrome.
DR   Orphanet; 216796; Osteogenesis imperfecta type 1.
DR   PharmGKB; PA32876; -.
DR   VEuPathDB; HostDB:ENSG00000185624; -.
DR   eggNOG; KOG0190; Eukaryota.
DR   GeneTree; ENSGT00940000157351; -.
DR   InParanoid; P07237; -.
DR   OMA; FCDRFLE; -.
DR   OrthoDB; 5399045at2759; -.
DR   PhylomeDB; P07237; -.
DR   TreeFam; TF106381; -.
DR   BioCyc; MetaCyc:HS06845-MON; -.
DR   BRENDA; 5.3.4.1; 2681.
DR   PathwayCommons; P07237; -.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-HSA-8866423; VLDL assembly.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-8963888; Chylomicron assembly.
DR   Reactome; R-HSA-8964041; LDL remodeling.
DR   Reactome; R-HSA-9020591; Interleukin-12 signaling.
DR   Reactome; R-HSA-9020933; Interleukin-23 signaling.
DR   SignaLink; P07237; -.
DR   SIGNOR; P07237; -.
DR   BioGRID-ORCS; 5034; 26 hits in 1172 CRISPR screens.
DR   ChiTaRS; P4HB; human.
DR   EvolutionaryTrace; P07237; -.
DR   GeneWiki; P4HB; -.
DR   GenomeRNAi; 5034; -.
DR   Pharos; P07237; Tchem.
DR   PRO; PR:P07237; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P07237; protein.
DR   Bgee; ENSG00000185624; Expressed in stromal cell of endometrium and 205 other tissues.
DR   ExpressionAtlas; P07237; baseline and differential.
DR   Genevisible; P07237; HS.
DR   GO; GO:0005856; C:cytoskeleton; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:ARUK-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0034663; C:endoplasmic reticulum chaperone complex; IEA:Ensembl.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:ARUK-UCL.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016222; C:procollagen-proline 4-dioxygenase complex; IDA:MGI.
DR   GO; GO:0032991; C:protein-containing complex; IDA:ARUK-UCL.
DR   GO; GO:0003779; F:actin binding; IPI:ARUK-UCL.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0004656; F:procollagen-proline 4-dioxygenase activity; TAS:ProtInc.
DR   GO; GO:0003756; F:protein disulfide isomerase activity; IDA:CACAO.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0015035; F:protein-disulfide reductase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0016972; F:thiol oxidase activity; IDA:FlyBase.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0098761; P:cellular response to interleukin-7; IEA:Ensembl.
DR   GO; GO:0006888; P:endoplasmic reticulum to Golgi vesicle-mediated transport; IEA:Ensembl.
DR   GO; GO:0030070; P:insulin processing; IEA:Ensembl.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038155; P:interleukin-23-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0018401; P:peptidyl-proline hydroxylation to 4-hydroxy-L-proline; IDA:MGI.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:ARUK-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:ARUK-UCL.
DR   GO; GO:0046598; P:positive regulation of viral entry into host cell; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:0034975; P:protein folding in endoplasmic reticulum; IDA:FlyBase.
DR   GO; GO:1902175; P:regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:BHF-UCL.
DR   CDD; cd02961; PDI_a_family; 1.
DR   CDD; cd02995; PDI_a_PDI_a'_C; 1.
DR   CDD; cd02982; PDI_b'_family; 1.
DR   CDD; cd02981; PDI_b_family; 1.
DR   DisProt; DP02637; -.
DR   Gene3D; 3.40.30.10; Glutaredoxin; 4.
DR   InterPro; IPR005788; Disulphide_isomerase.
DR   InterPro; IPR005792; Prot_disulphide_isomerase.
DR   InterPro; IPR036249; Thioredoxin-like_sf.
DR   InterPro; IPR017937; Thioredoxin_CS.
DR   InterPro; IPR013766; Thioredoxin_domain.
DR   PANTHER; PTHR18929; PROTEIN DISULFIDE ISOMERASE; 1.
DR   PANTHER; PTHR18929:SF101; PROTEIN DISULFIDE-ISOMERASE; 1.
DR   Pfam; PF00085; Thioredoxin; 2.
DR   Pfam; PF13848; Thioredoxin_6; 1.
DR   PRINTS; PR00421; THIOREDOXIN.
DR   SUPFAM; SSF52833; Thioredoxin-like; 4.
DR   TIGRFAMs; TIGR01130; ER_PDI_fam; 1.
DR   TIGRFAMs; TIGR01126; pdi_dom; 2.
DR   PROSITE; PS00014; ER_TARGET; 1.
DR   PROSITE; PS00194; THIOREDOXIN_1; 2.
DR   PROSITE; PS51352; THIOREDOXIN_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Chaperone; Craniosynostosis;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   Endoplasmic reticulum; Isomerase; Membrane; Osteogenesis imperfecta;
KW   Phosphoprotein; Redox-active center; Reference proteome; Repeat; Signal.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0000269|PubMed:2079031, ECO:0000269|PubMed:9150948,
FT                   ECO:0000269|Ref.10, ECO:0007744|PubMed:25944712"
FT   CHAIN           18..508
FT                   /note="Protein disulfide-isomerase"
FT                   /id="PRO_0000034195"
FT   DOMAIN          18..134
FT                   /note="Thioredoxin 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00691"
FT   DOMAIN          349..475
FT                   /note="Thioredoxin 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00691"
FT   REGION          471..508
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           505..508
FT                   /note="Prevents secretion from ER"
FT   COMPBIAS        476..508
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        53
FT                   /note="Nucleophile"
FT   ACT_SITE        56
FT                   /note="Nucleophile"
FT   ACT_SITE        397
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        400
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250"
FT   SITE            54
FT                   /note="Contributes to redox potential value"
FT   SITE            55
FT                   /note="Contributes to redox potential value"
FT   SITE            120
FT                   /note="Lowers pKa of C-terminal Cys of first active site"
FT   SITE            398
FT                   /note="Contributes to redox potential value"
FT                   /evidence="ECO:0000250"
FT   SITE            399
FT                   /note="Contributes to redox potential value"
FT                   /evidence="ECO:0000250"
FT   SITE            461
FT                   /note="Lowers pKa of C-terminal Cys of second active site"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         200
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09103"
FT   MOD_RES         222
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09103"
FT   MOD_RES         271
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09103"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   MOD_RES         357
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0000269|PubMed:32149426"
FT   MOD_RES         427
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   DISULFID        53..56
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00691,
FT                   ECO:0000269|PubMed:8672469"
FT   DISULFID        397..400
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00691"
FT   VARIANT         393
FT                   /note="Y -> C (in CLCRP1; impairs ability to act as a
FT                   disulfide isomerase enzyme; dbSNP:rs786204843)"
FT                   /evidence="ECO:0000269|PubMed:25683117"
FT                   /id="VAR_073440"
FT   MUTAGEN         128
FT                   /note="W->I: Reduced interaction with ERN1. Abolishes
FT                   interaction with ERN1; when associated with W-403."
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   MUTAGEN         331
FT                   /note="S->E: Phosphomimetic mutant. Does not affect enzyme
FT                   or chaperone activity."
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   MUTAGEN         357
FT                   /note="S->A: Abolishes phosphorylation at this site but
FT                   protein is still phosphorylated at other sites. No changes
FT                   in chaperone or enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   MUTAGEN         357
FT                   /note="S->E: Phosphomimetic mutant. Reduced resistance to
FT                   protease digestion, sugesting adoption of an open
FT                   conformation. Increased chaperone activity. Decreased
FT                   enzyme activity. Increased binding to ERN1."
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   MUTAGEN         403
FT                   /note="L->W: Reduced interaction with ERN1. Abolishes
FT                   interaction with ERN1; when associated with I-128."
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   MUTAGEN         427
FT                   /note="S->E: Phosphomimetic mutant. Does not affect enzyme
FT                   or chaperone activity. Does not increase binding to ERN1."
FT                   /evidence="ECO:0000269|PubMed:32149426"
FT   CONFLICT        10..11
FT                   /note="AV -> PW (in Ref. 1; CAA28775)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        21
FT                   /note="E -> D (in Ref. 13; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        24
FT                   /note="D -> V (in Ref. 13; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        44..45
FT                   /note="LL -> PP (in Ref. 1; CAA28775)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        49
FT                   /note="Y -> H (in Ref. 1; CAA28775)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141
FT                   /note="P -> R (in Ref. 2; AAA61169)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        360..362
FT                   /note="LPE -> RAG (in Ref. 2; AAA61169)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        372
FT                   /note="L -> P (in Ref. 2; AAA61169)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        439
FT                   /note="S -> G (in Ref. 1; CAA28775)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        444
FT                   /note="K -> G (in Ref. 1; CAA28775)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        460
FT                   /note="E -> Q (in Ref. 15; CAA30112)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        481
FT                   /note="D -> V (in Ref. 1; CAA28775)"
FT                   /evidence="ECO:0000305"
FT   STRAND          21..23
FT                   /evidence="ECO:0007829|PDB:4EKZ"
FT   STRAND          26..28
FT                   /evidence="ECO:0007829|PDB:4EKZ"
FT   TURN            31..33
FT                   /evidence="ECO:0007829|PDB:4EL1"
FT   HELIX           34..40
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   STRAND          42..49
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   HELIX           54..71
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   STRAND          76..83
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   TURN            84..86
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   HELIX           88..93
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   STRAND          98..105
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   STRAND          110..112
FT                   /evidence="ECO:0007829|PDB:4EL1"
FT   STRAND          114..116
FT                   /evidence="ECO:0007829|PDB:4EL1"
FT   HELIX           122..133
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   STRAND          137..139
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   HELIX           143..151
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          153..160
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          164..166
FT                   /evidence="ECO:0007829|PDB:6I7S"
FT   HELIX           167..178
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          184..187
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   HELIX           190..195
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          199..209
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          212..215
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   HELIX           222..232
FT                   /evidence="ECO:0007829|PDB:4JU5"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   TURN            242..244
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   HELIX           245..249
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          250..252
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          255..260
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          265..267
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   HELIX           268..280
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   TURN            281..285
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          287..291
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   HELIX           296..298
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   HELIX           299..304
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   HELIX           309..311
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          313..319
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          330..332
FT                   /evidence="ECO:0007829|PDB:4EKZ"
FT   HELIX           336..347
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          353..355
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   HELIX           362..364
FT                   /evidence="ECO:0007829|PDB:3BJ5"
FT   STRAND          367..372
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   TURN            374..376
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   HELIX           377..381
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   STRAND          387..393
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   HELIX           398..413
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   TURN            414..416
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   STRAND          418..426
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   TURN            427..429
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   STRAND          439..446
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   STRAND          448..451
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   HELIX           463..470
FT                   /evidence="ECO:0007829|PDB:3UEM"
FT   TURN            471..473
FT                   /evidence="ECO:0007829|PDB:3UEM"
SQ   SEQUENCE   508 AA;  57116 MW;  906CE6D9900B8FCE CRC64;
     MLRRALLCLA VAALVRADAP EEEDHVLVLR KSNFAEALAA HKYLLVEFYA PWCGHCKALA
     PEYAKAAGKL KAEGSEIRLA KVDATEESDL AQQYGVRGYP TIKFFRNGDT ASPKEYTAGR
     EADDIVNWLK KRTGPAATTL PDGAAAESLV ESSEVAVIGF FKDVESDSAK QFLQAAEAID
     DIPFGITSNS DVFSKYQLDK DGVVLFKKFD EGRNNFEGEV TKENLLDFIK HNQLPLVIEF
     TEQTAPKIFG GEIKTHILLF LPKSVSDYDG KLSNFKTAAE SFKGKILFIF IDSDHTDNQR
     ILEFFGLKKE ECPAVRLITL EEEMTKYKPE SEELTAERIT EFCHRFLEGK IKPHLMSQEL
     PEDWDKQPVK VLVGKNFEDV AFDEKKNVFV EFYAPWCGHC KQLAPIWDKL GETYKDHENI
     VIAKMDSTAN EVEAVKVHSF PTLKFFPASA DRTVIDYNGE RTLDGFKKFL ESGGQDGAGD
     DDDLEDLEEA EEPDMEEDDD QKAVKDEL
//
ID   PR40A_HUMAN             Reviewed;         957 AA.
AC   O75400; O43856; O75404; Q8TBQ1; Q9H782; Q9NWU9; Q9P0Q2; Q9Y5A8;
DT   22-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   22-AUG-2003, sequence version 2.
DT   22-FEB-2023, entry version 209.
DE   RecName: Full=Pre-mRNA-processing factor 40 homolog A;
DE   AltName: Full=Fas ligand-associated factor 1;
DE   AltName: Full=Formin-binding protein 11;
DE   AltName: Full=Formin-binding protein 3;
DE   AltName: Full=Huntingtin yeast partner A;
DE   AltName: Full=Huntingtin-interacting protein 10;
DE            Short=HIP-10;
DE   AltName: Full=Huntingtin-interacting protein A;
DE   AltName: Full=Renal carcinoma antigen NY-REN-6;
GN   Name=PRPF40A; Synonyms=FBP11, FLAF1, FNBP3, HIP10, HYPA; ORFNames=HSPC225;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 710-957 (ISOFORM 1).
RC   TISSUE=Smooth muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-448 (ISOFORM 1), NUCLEOTIDE SEQUENCE [MRNA]
RP   OF 1-423 (ISOFORM 2), INTERACTION WITH HTT, AND TISSUE SPECIFICITY.
RC   TISSUE=Frontal cortex;
RX   PubMed=9700202; DOI=10.1093/hmg/7.9.1463;
RA   Faber P.W., Barnes G.T., Srinidhi J., Chen J., Gusella J.F.,
RA   MacDonald M.E.;
RT   "Huntingtin interacts with a family of WW domain proteins.";
RL   Hum. Mol. Genet. 7:1463-1474(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-449 AND 743-957 (ISOFORM 2).
RC   TISSUE=Lymphoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-374 (ISOFORM 3).
RC   TISSUE=Placenta;
RA   Hachiya T., Kobayasi A., Touji S., Tamai K.;
RT   "A Fas-ligand associated factor 1, FLAF1, potentiates Fas-ligand
RT   stability.";
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 542-957, AND IDENTIFICATION AS A RENAL CANCER
RP   ANTIGEN.
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 646-957.
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for 300
RT   previously undefined genes expressed in CD34+ hematopoietic stem/progenitor
RT   cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [8]
RP   INTERACTION WITH POLR2A, AND STRUCTURE BY NMR OF 381-450.
RX   PubMed=12381297; DOI=10.1016/s0022-2836(02)00968-3;
RA   Allen M., Friedler A., Schon O., Bycroft M.;
RT   "The structure of an FF domain from human HYPA/FBP11.";
RL   J. Mol. Biol. 323:411-416(2002).
RN   [9]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16391387; DOI=10.1385/nmm:7:4:297;
RA   Sayer J.A., Manczak M., Akileswaran L., Reddy P.H., Coghlan V.M.;
RT   "Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin:
RT   implications for nuclear toxicity in Huntington's disease pathogenesis.";
RL   NeuroMolecular Med. 7:297-310(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-373; SER-883; SER-885;
RP   SER-888 AND SER-938, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-932; SER-933; SER-935 AND
RP   SER-938, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-196, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; THR-373; SER-933 AND
RP   SER-938, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   FUNCTION.
RX   PubMed=21834987; DOI=10.1186/1741-7007-9-54;
RA   Bai S.W., Herrera-Abreu M.T., Rohn J.L., Racine V., Tajadura V.,
RA   Suryavanshi N., Bechtel S., Wiemann S., Baum B., Ridley A.J.;
RT   "Identification and characterization of a set of conserved and new
RT   regulators of cytoskeletal organisation, cell morphology and migration.";
RL   BMC Biol. 9:54-54(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-883; SER-888; SER-933 AND
RP   SER-938, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34; SER-151; THR-373;
RP   SER-723; SER-787; SER-883; SER-885; SER-888 AND SER-938, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-345; THR-373 AND SER-938, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-17; ARG-24 AND ARG-47 (ISOFORMS 2
RP   AND 5), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-241, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-191; LYS-241; LYS-375 AND
RP   LYS-376, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [24]
RP   STRUCTURE BY NMR OF 743-806.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the FF domain of human formin-binding protein 3.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: Binds to WASL/N-WASP and suppresses its translocation from
CC       the nucleus to the cytoplasm, thereby inhibiting its cytoplasmic
CC       function (By similarity). Plays a role in the regulation of cell
CC       morphology and cytoskeletal organization. Required in the control of
CC       cell shape and migration. May play a role in cytokinesis. May be
CC       involved in pre-mRNA splicing. {ECO:0000250,
CC       ECO:0000269|PubMed:21834987}.
CC   -!- SUBUNIT: Interacts with the N-terminus of HTT. Interacts with the
CC       phosphorylated C-terminal domain of POLR2A. Interacts with AKAP8L, SF1,
CC       SRPK1, ENAH, ATBF1 and MECP2 (By similarity). Interacts through the WW
CC       domains with formin proline-rich regions and with WASL/N-WASP (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       O75400; Q12873: CHD3; NbExp=2; IntAct=EBI-473291, EBI-523590;
CC       O75400; P42858: HTT; NbExp=15; IntAct=EBI-473291, EBI-466029;
CC       O75400; Q8N5F7: NKAP; NbExp=2; IntAct=EBI-473291, EBI-721539;
CC       O75400; Q15637: SF1; NbExp=3; IntAct=EBI-473291, EBI-744603;
CC       O75400; Q15459: SF3A1; NbExp=2; IntAct=EBI-473291, EBI-1054743;
CC       O75400-2; P45844-6: ABCG1; NbExp=3; IntAct=EBI-5280197, EBI-25873349;
CC       O75400-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-5280197, EBI-18899653;
CC       O75400-2; Q5T2L2: AKR1C8; NbExp=3; IntAct=EBI-5280197, EBI-22006248;
CC       O75400-2; Q96Q83-2: ALKBH3; NbExp=3; IntAct=EBI-5280197, EBI-9089544;
CC       O75400-2; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-5280197, EBI-8464238;
CC       O75400-2; P09525: ANXA4; NbExp=3; IntAct=EBI-5280197, EBI-2556852;
CC       O75400-2; P53365: ARFIP2; NbExp=3; IntAct=EBI-5280197, EBI-638194;
CC       O75400-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-5280197, EBI-5280499;
CC       O75400-2; P18848: ATF4; NbExp=3; IntAct=EBI-5280197, EBI-492498;
CC       O75400-2; Q9H0Y0: ATG10; NbExp=3; IntAct=EBI-5280197, EBI-1048913;
CC       O75400-2; Q14032: BAAT; NbExp=3; IntAct=EBI-5280197, EBI-8994378;
CC       O75400-2; P54687-4: BCAT1; NbExp=3; IntAct=EBI-5280197, EBI-25834445;
CC       O75400-2; P06276: BCHE; NbExp=3; IntAct=EBI-5280197, EBI-7936069;
CC       O75400-2; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-5280197, EBI-10181188;
CC       O75400-2; Q9NQ89: C12orf4; NbExp=3; IntAct=EBI-5280197, EBI-11090973;
CC       O75400-2; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-5280197, EBI-18036948;
CC       O75400-2; Q96LM5: C4orf45; NbExp=3; IntAct=EBI-5280197, EBI-12020542;
CC       O75400-2; P17655: CAPN2; NbExp=3; IntAct=EBI-5280197, EBI-1028956;
CC       O75400-2; P20807-4: CAPN3; NbExp=3; IntAct=EBI-5280197, EBI-11532021;
CC       O75400-2; O00257-3: CBX4; NbExp=3; IntAct=EBI-5280197, EBI-4392727;
CC       O75400-2; P24863: CCNC; NbExp=3; IntAct=EBI-5280197, EBI-395261;
CC       O75400-2; Q9UK58: CCNL1; NbExp=3; IntAct=EBI-5280197, EBI-2836773;
CC       O75400-2; Q9UK58-5: CCNL1; NbExp=3; IntAct=EBI-5280197, EBI-25873837;
CC       O75400-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-5280197, EBI-12300031;
CC       O75400-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-5280197, EBI-396137;
CC       O75400-2; P42773: CDKN2C; NbExp=3; IntAct=EBI-5280197, EBI-711290;
CC       O75400-2; O95674: CDS2; NbExp=3; IntAct=EBI-5280197, EBI-3913685;
CC       O75400-2; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-5280197, EBI-11953200;
CC       O75400-2; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-5280197, EBI-744045;
CC       O75400-2; P09496-2: CLTA; NbExp=3; IntAct=EBI-5280197, EBI-4401010;
CC       O75400-2; Q96BR5: COA7; NbExp=3; IntAct=EBI-5280197, EBI-6269632;
CC       O75400-2; P02458-1: COL2A1; NbExp=3; IntAct=EBI-5280197, EBI-12375799;
CC       O75400-2; Q9UGL9: CRCT1; NbExp=3; IntAct=EBI-5280197, EBI-713677;
CC       O75400-2; Q9UKG9-2: CROT; NbExp=3; IntAct=EBI-5280197, EBI-25835363;
CC       O75400-2; P26998: CRYBB3; NbExp=3; IntAct=EBI-5280197, EBI-1965681;
CC       O75400-2; P68400: CSNK2A1; NbExp=2; IntAct=EBI-5280197, EBI-347804;
CC       O75400-2; Q5HYN5: CT45A1; NbExp=3; IntAct=EBI-5280197, EBI-12051833;
CC       O75400-2; P35222: CTNNB1; NbExp=3; IntAct=EBI-5280197, EBI-491549;
CC       O75400-2; Q53TN4: CYBRD1; NbExp=3; IntAct=EBI-5280197, EBI-8637742;
CC       O75400-2; P10632: CYP2C8; NbExp=3; IntAct=EBI-5280197, EBI-2951522;
CC       O75400-2; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-5280197, EBI-742054;
CC       O75400-2; Q96LJ7: DHRS1; NbExp=3; IntAct=EBI-5280197, EBI-746300;
CC       O75400-2; O60479: DLX3; NbExp=3; IntAct=EBI-5280197, EBI-3908248;
CC       O75400-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-5280197, EBI-11526226;
CC       O75400-2; Q96BY6: DOCK10; NbExp=3; IntAct=EBI-5280197, EBI-748520;
CC       O75400-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-5280197, EBI-23669343;
CC       O75400-2; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-5280197, EBI-724653;
CC       O75400-2; Q86YF9: DZIP1; NbExp=3; IntAct=EBI-5280197, EBI-998108;
CC       O75400-2; Q8IYY4: DZIP1L; NbExp=3; IntAct=EBI-5280197, EBI-10264440;
CC       O75400-2; O00303: EIF3F; NbExp=3; IntAct=EBI-5280197, EBI-711990;
CC       O75400-2; O00472: ELL2; NbExp=3; IntAct=EBI-5280197, EBI-395274;
CC       O75400-2; Q49AJ0-4: FAM135B; NbExp=3; IntAct=EBI-5280197, EBI-25835236;
CC       O75400-2; Q96KS9: FAM167A; NbExp=3; IntAct=EBI-5280197, EBI-10290462;
CC       O75400-2; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-5280197, EBI-8468186;
CC       O75400-2; Q6ZNL6: FGD5; NbExp=3; IntAct=EBI-5280197, EBI-7962481;
CC       O75400-2; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-5280197, EBI-12143817;
CC       O75400-2; P32780: GTF2H1; NbExp=3; IntAct=EBI-5280197, EBI-715539;
CC       O75400-2; Q9NRZ9-6: HELLS; NbExp=3; IntAct=EBI-5280197, EBI-12003732;
CC       O75400-2; Q96EW2-2: HSPBAP1; NbExp=3; IntAct=EBI-5280197, EBI-25835621;
CC       O75400-2; P42858: HTT; NbExp=9; IntAct=EBI-5280197, EBI-466029;
CC       O75400-2; P0C870: JMJD7; NbExp=3; IntAct=EBI-5280197, EBI-9090173;
CC       O75400-2; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-5280197, EBI-743960;
CC       O75400-2; Q8TBB5-2: KLHDC4; NbExp=3; IntAct=EBI-5280197, EBI-21838933;
CC       O75400-2; Q8N4N3-2: KLHL36; NbExp=3; IntAct=EBI-5280197, EBI-10973851;
CC       O75400-2; Q5JUW0-3: KRBOX4; NbExp=3; IntAct=EBI-5280197, EBI-12893625;
CC       O75400-2; Q6DKI2: LGALS9C; NbExp=3; IntAct=EBI-5280197, EBI-9088829;
CC       O75400-2; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-5280197, EBI-25835523;
CC       O75400-2; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-5280197, EBI-2510853;
CC       O75400-2; P27338: MAOB; NbExp=3; IntAct=EBI-5280197, EBI-3911344;
CC       O75400-2; A0A0A0MR05: MLST8; NbExp=3; IntAct=EBI-5280197, EBI-25835557;
CC       O75400-2; P34949-2: MPI; NbExp=3; IntAct=EBI-5280197, EBI-21823432;
CC       O75400-2; Q9BV20: MRI1; NbExp=3; IntAct=EBI-5280197, EBI-747381;
CC       O75400-2; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-5280197, EBI-25835707;
CC       O75400-2; P01106: MYC; NbExp=3; IntAct=EBI-5280197, EBI-447544;
CC       O75400-2; Q9H7X0: NAA60; NbExp=3; IntAct=EBI-5280197, EBI-12260336;
CC       O75400-2; Q6ZUT1: NKAPD1; NbExp=3; IntAct=EBI-5280197, EBI-3920396;
CC       O75400-2; Q8NFH3: NUP43; NbExp=3; IntAct=EBI-5280197, EBI-1059321;
CC       O75400-2; Q6N063-2: OGFOD2; NbExp=3; IntAct=EBI-5280197, EBI-22006224;
CC       O75400-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-5280197, EBI-25830200;
CC       O75400-2; Q99447: PCYT2; NbExp=3; IntAct=EBI-5280197, EBI-750317;
CC       O75400-2; P27815-4: PDE4A; NbExp=3; IntAct=EBI-5280197, EBI-12080840;
CC       O75400-2; O15534: PER1; NbExp=3; IntAct=EBI-5280197, EBI-2557276;
CC       O75400-2; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-5280197, EBI-79165;
CC       O75400-2; P48739: PITPNB; NbExp=3; IntAct=EBI-5280197, EBI-1047143;
CC       O75400-2; O60664: PLIN3; NbExp=3; IntAct=EBI-5280197, EBI-725795;
CC       O75400-2; Q14181: POLA2; NbExp=3; IntAct=EBI-5280197, EBI-712752;
CC       O75400-2; P36954: POLR2I; NbExp=3; IntAct=EBI-5280197, EBI-395202;
CC       O75400-2; P02775: PPBP; NbExp=3; IntAct=EBI-5280197, EBI-718973;
CC       O75400-2; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-5280197, EBI-25835994;
CC       O75400-2; P54619: PRKAG1; NbExp=3; IntAct=EBI-5280197, EBI-1181439;
CC       O75400-2; P23942: PRPH2; NbExp=3; IntAct=EBI-5280197, EBI-25836834;
CC       O75400-2; P29074: PTPN4; NbExp=3; IntAct=EBI-5280197, EBI-710431;
CC       O75400-2; Q5R372-9: RABGAP1L; NbExp=3; IntAct=EBI-5280197, EBI-10699389;
CC       O75400-2; Q14498: RBM39; NbExp=6; IntAct=EBI-5280197, EBI-395290;
CC       O75400-2; Q04206: RELA; NbExp=3; IntAct=EBI-5280197, EBI-73886;
CC       O75400-2; Q15382: RHEB; NbExp=3; IntAct=EBI-5280197, EBI-1055287;
CC       O75400-2; Q8N5U6: RNF10; NbExp=3; IntAct=EBI-5280197, EBI-714023;
CC       O75400-2; Q96IZ7: RSRC1; NbExp=3; IntAct=EBI-5280197, EBI-712189;
CC       O75400-2; O15126: SCAMP1; NbExp=3; IntAct=EBI-5280197, EBI-954338;
CC       O75400-2; P22307-3: SCP2; NbExp=3; IntAct=EBI-5280197, EBI-25834804;
CC       O75400-2; O00560: SDCBP; NbExp=3; IntAct=EBI-5280197, EBI-727004;
CC       O75400-2; Q9H190: SDCBP2; NbExp=6; IntAct=EBI-5280197, EBI-742426;
CC       O75400-2; Q9BRK5: SDF4; NbExp=3; IntAct=EBI-5280197, EBI-1389808;
CC       O75400-2; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-5280197, EBI-9089805;
CC       O75400-2; Q7L8J4: SH3BP5L; NbExp=3; IntAct=EBI-5280197, EBI-747389;
CC       O75400-2; Q9BZQ2: SHCBP1L; NbExp=3; IntAct=EBI-5280197, EBI-10818532;
CC       O75400-2; O60902-3: SHOX2; NbExp=3; IntAct=EBI-5280197, EBI-9092164;
CC       O75400-2; Q8IYM2: SLFN12; NbExp=3; IntAct=EBI-5280197, EBI-2822550;
CC       O75400-2; Q86US8: SMG6; NbExp=3; IntAct=EBI-5280197, EBI-3232100;
CC       O75400-2; Q96EX1: SMIM12; NbExp=3; IntAct=EBI-5280197, EBI-2874543;
CC       O75400-2; P37840: SNCA; NbExp=3; IntAct=EBI-5280197, EBI-985879;
CC       O75400-2; Q96H20: SNF8; NbExp=3; IntAct=EBI-5280197, EBI-747719;
CC       O75400-2; Q13573: SNW1; NbExp=3; IntAct=EBI-5280197, EBI-632715;
CC       O75400-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-5280197, EBI-3923692;
CC       O75400-2; Q9C004: SPRY4; NbExp=3; IntAct=EBI-5280197, EBI-354861;
CC       O75400-2; Q5W111-2: SPRYD7; NbExp=3; IntAct=EBI-5280197, EBI-12408727;
CC       O75400-2; Q8WXA9: SREK1; NbExp=3; IntAct=EBI-5280197, EBI-1044237;
CC       O75400-2; Q8N9Q2: SREK1IP1; NbExp=3; IntAct=EBI-5280197, EBI-10268630;
CC       O75400-2; Q92797-2: SYMPK; NbExp=3; IntAct=EBI-5280197, EBI-21560407;
CC       O75400-2; O15273: TCAP; NbExp=3; IntAct=EBI-5280197, EBI-954089;
CC       O75400-2; Q86WV5: TEN1; NbExp=3; IntAct=EBI-5280197, EBI-2562799;
CC       O75400-2; P22735: TGM1; NbExp=3; IntAct=EBI-5280197, EBI-2562368;
CC       O75400-2; O43548: TGM5; NbExp=3; IntAct=EBI-5280197, EBI-12027348;
CC       O75400-2; Q9UIK5-2: TMEFF2; NbExp=3; IntAct=EBI-5280197, EBI-25835153;
CC       O75400-2; Q8WVE6-2: TMEM171; NbExp=3; IntAct=EBI-5280197, EBI-25874374;
CC       O75400-2; Q12888: TP53BP1; NbExp=3; IntAct=EBI-5280197, EBI-396540;
CC       O75400-2; Q9H313-4: TTYH1; NbExp=3; IntAct=EBI-5280197, EBI-17671298;
CC       O75400-2; Q9BQE3: TUBA1C; NbExp=3; IntAct=EBI-5280197, EBI-1103245;
CC       O75400-2; P49459: UBE2A; NbExp=3; IntAct=EBI-5280197, EBI-2339348;
CC       O75400-2; P62253: UBE2G1; NbExp=3; IntAct=EBI-5280197, EBI-2340619;
CC       O75400-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-5280197, EBI-10316321;
CC       O75400-2; O43829: ZBTB14; NbExp=3; IntAct=EBI-5280197, EBI-10176632;
CC       O75400-2; Q8IWT0-2: ZBTB8OS; NbExp=3; IntAct=EBI-5280197, EBI-12956041;
CC       O75400-2; Q96LX8: ZNF597; NbExp=3; IntAct=EBI-5280197, EBI-9091553;
CC       O75400-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-5280197, EBI-18036029;
CC       O75400-2; B7Z3E8; NbExp=3; IntAct=EBI-5280197, EBI-25831617;
CC       O75400-2; Q86V28; NbExp=3; IntAct=EBI-5280197, EBI-10259496;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000250}. Nucleus matrix
CC       {ECO:0000269|PubMed:16391387}. Note=Colocalizes with AKAP8L in the
CC       nuclear matrix. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O75400-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75400-2; Sequence=VSP_040781, VSP_008047;
CC       Name=3;
CC         IsoId=O75400-3; Sequence=VSP_008048;
CC       Name=5;
CC         IsoId=O75400-5; Sequence=VSP_040781, VSP_008047, VSP_040782,
CC                                  VSP_040783;
CC   -!- TISSUE SPECIFICITY: Expressed in the brain cortex (at protein level).
CC       Widely expressed. {ECO:0000269|PubMed:16391387,
CC       ECO:0000269|PubMed:9700202}.
CC   -!- DOMAIN: The WW domains are essential for localization to nuclear
CC       speckles. {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Probable target of nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the PRPF40 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC27501.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC27502.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC27506.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD42862.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAF36145.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAH11788.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 409.; Evidence={ECO:0000305};
CC       Sequence=BAA91277.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB15016.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC012443; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079344; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK000592; BAA91277.1; ALT_INIT; mRNA.
DR   EMBL; AK024810; BAB15016.1; ALT_SEQ; mRNA.
DR   EMBL; AF049523; AAC27501.1; ALT_INIT; mRNA.
DR   EMBL; AF049524; AAC27502.1; ALT_INIT; mRNA.
DR   EMBL; AF049528; AAC27506.1; ALT_INIT; mRNA.
DR   EMBL; BC011788; AAH11788.1; ALT_SEQ; mRNA.
DR   EMBL; BC027178; AAH27178.1; -; mRNA.
DR   EMBL; U70667; AAB93495.1; -; mRNA.
DR   EMBL; AF155096; AAD42862.1; ALT_FRAME; mRNA.
DR   EMBL; AF151059; AAF36145.1; ALT_FRAME; mRNA.
DR   RefSeq; NP_060362.3; NM_017892.3. [O75400-2]
DR   PDB; 1UZC; NMR; -; A=381-450.
DR   PDB; 1YWI; NMR; -; A=142-173.
DR   PDB; 1YWJ; NMR; -; A=142-173.
DR   PDB; 1ZR7; NMR; -; A=146-173.
DR   PDB; 2CQN; NMR; -; A=743-806.
DR   PDB; 2DYF; NMR; -; A=146-173.
DR   PDB; 2KZG; NMR; -; A=381-450.
DR   PDB; 2L5F; NMR; -; A=133-220.
DR   PDB; 2L9V; NMR; -; A=381-450.
DR   PDB; 2LKS; NMR; -; A=391-439.
DR   PDBsum; 1UZC; -.
DR   PDBsum; 1YWI; -.
DR   PDBsum; 1YWJ; -.
DR   PDBsum; 1ZR7; -.
DR   PDBsum; 2CQN; -.
DR   PDBsum; 2DYF; -.
DR   PDBsum; 2KZG; -.
DR   PDBsum; 2L5F; -.
DR   PDBsum; 2L9V; -.
DR   PDBsum; 2LKS; -.
DR   AlphaFoldDB; O75400; -.
DR   BMRB; O75400; -.
DR   SMR; O75400; -.
DR   BioGRID; 120792; 414.
DR   CORUM; O75400; -.
DR   IntAct; O75400; 252.
DR   MINT; O75400; -.
DR   STRING; 9606.ENSP00000386458; -.
DR   MoonDB; O75400; Predicted.
DR   GlyCosmos; O75400; 1 site, 1 glycan.
DR   GlyGen; O75400; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O75400; -.
DR   PhosphoSitePlus; O75400; -.
DR   SwissPalm; O75400; -.
DR   BioMuta; PRPF40A; -.
DR   EPD; O75400; -.
DR   jPOST; O75400; -.
DR   MassIVE; O75400; -.
DR   MaxQB; O75400; -.
DR   PaxDb; O75400; -.
DR   PeptideAtlas; O75400; -.
DR   ProteomicsDB; 49972; -. [O75400-1]
DR   ProteomicsDB; 49973; -. [O75400-2]
DR   ProteomicsDB; 49974; -. [O75400-3]
DR   ProteomicsDB; 49975; -. [O75400-5]
DR   Antibodypedia; 33687; 96 antibodies from 18 providers.
DR   DNASU; 55660; -.
DR   Ensembl; ENST00000354363.11; ENSP00000346332.7; ENSG00000196504.21. [O75400-5]
DR   Ensembl; ENST00000696381.1; ENSP00000512591.1; ENSG00000196504.21. [O75400-1]
DR   GeneID; 55660; -.
DR   KEGG; hsa:55660; -.
DR   UCSC; uc002tyh.5; human. [O75400-1]
DR   AGR; HGNC:16463; -.
DR   CTD; 55660; -.
DR   DisGeNET; 55660; -.
DR   GeneCards; PRPF40A; -.
DR   HGNC; HGNC:16463; PRPF40A.
DR   HPA; ENSG00000196504; Low tissue specificity.
DR   MIM; 612941; gene.
DR   neXtProt; NX_O75400; -.
DR   OpenTargets; ENSG00000196504; -.
DR   PharmGKB; PA28195; -.
DR   eggNOG; KOG0152; Eukaryota.
DR   GeneTree; ENSGT00930000150980; -.
DR   HOGENOM; CLU_005825_0_0_1; -.
DR   InParanoid; O75400; -.
DR   OrthoDB; 25674at2759; -.
DR   PhylomeDB; O75400; -.
DR   TreeFam; TF318732; -.
DR   PathwayCommons; O75400; -.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   SignaLink; O75400; -.
DR   BioGRID-ORCS; 55660; 760 hits in 1162 CRISPR screens.
DR   ChiTaRS; PRPF40A; human.
DR   EvolutionaryTrace; O75400; -.
DR   GeneWiki; PRPF40A; -.
DR   GenomeRNAi; 55660; -.
DR   Pharos; O75400; Tbio.
DR   PRO; PR:O75400; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O75400; protein.
DR   Bgee; ENSG00000196504; Expressed in secondary oocyte and 213 other tissues.
DR   ExpressionAtlas; O75400; baseline and differential.
DR   Genevisible; O75400; HS.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005685; C:U1 snRNP; IBA:GO_Central.
DR   GO; GO:0071004; C:U2-type prespliceosome; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0045292; P:mRNA cis splicing, via spliceosome; IEA:InterPro.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; IBA:GO_Central.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IMP:UniProtKB.
DR   CDD; cd00201; WW; 2.
DR   Gene3D; 2.20.70.10; -; 2.
DR   Gene3D; 1.10.10.440; FF domain; 5.
DR   InterPro; IPR002713; FF_domain.
DR   InterPro; IPR036517; FF_domain_sf.
DR   InterPro; IPR039726; Prp40-like.
DR   InterPro; IPR001202; WW_dom.
DR   InterPro; IPR036020; WW_dom_sf.
DR   PANTHER; PTHR11864:SF20; PRE-MRNA-PROCESSING FACTOR 40 HOMOLOG A; 1.
DR   PANTHER; PTHR11864; PRE-MRNA-PROCESSING PROTEIN PRP40; 1.
DR   Pfam; PF01846; FF; 5.
DR   Pfam; PF00397; WW; 2.
DR   SMART; SM00441; FF; 5.
DR   SMART; SM00456; WW; 2.
DR   SUPFAM; SSF81698; FF domain; 5.
DR   SUPFAM; SSF51045; WW domain; 2.
DR   PROSITE; PS51676; FF; 6.
DR   PROSITE; PS01159; WW_DOMAIN_1; 2.
DR   PROSITE; PS50020; WW_DOMAIN_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division;
KW   Isopeptide bond; Methylation; mRNA processing; mRNA splicing; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..957
FT                   /note="Pre-mRNA-processing factor 40 homolog A"
FT                   /id="PRO_0000076085"
FT   DOMAIN          140..173
FT                   /note="WW 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00224"
FT   DOMAIN          181..214
FT                   /note="WW 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00224"
FT   DOMAIN          393..447
FT                   /note="FF 1"
FT   DOMAIN          460..514
FT                   /note="FF 2"
FT   DOMAIN          527..587
FT                   /note="FF 3"
FT   DOMAIN          607..667
FT                   /note="FF 4"
FT   DOMAIN          672..727
FT                   /note="FF 5"
FT   DOMAIN          742..799
FT                   /note="FF 6"
FT   REGION          1..36
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          243..263
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          337..386
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          803..957
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        249..263
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        337..367
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        368..386
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        807..827
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        828..866
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        867..881
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        882..927
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        937..957
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         9
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1C7"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         196
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         345
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         373
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         723
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         787
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         883
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         885
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         888
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         932
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         933
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         935
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         938
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   CROSSLNK        191
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        241
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        375
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        376
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1
FT                   /note="M -> MCSGSGRRRSSLSPTM (in isoform 2 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9700202"
FT                   /id="VSP_040781"
FT   VAR_SEQ         14..55
FT                   /note="Missing (in isoform 2 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9700202"
FT                   /id="VSP_008047"
FT   VAR_SEQ         127..128
FT                   /note="PG -> LN (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040782"
FT   VAR_SEQ         129..957
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040783"
FT   VAR_SEQ         220..237
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_008048"
FT   CONFLICT        372..373
FT                   /note="FT -> LL (in Ref. 5; AAB93495)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        433
FT                   /note="K -> N (in Ref. 3; AAC27501/AAC27506)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        787
FT                   /note="S -> P (in Ref. 1; BAA91277)"
FT                   /evidence="ECO:0000305"
FT   STRAND          136..138
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   TURN            142..145
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   STRAND          146..151
FT                   /evidence="ECO:0007829|PDB:1YWI"
FT   TURN            152..154
FT                   /evidence="ECO:0007829|PDB:1YWI"
FT   STRAND          155..160
FT                   /evidence="ECO:0007829|PDB:1YWI"
FT   TURN            161..164
FT                   /evidence="ECO:0007829|PDB:1YWI"
FT   STRAND          165..169
FT                   /evidence="ECO:0007829|PDB:1YWI"
FT   HELIX           172..174
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   HELIX           177..183
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   STRAND          186..191
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   STRAND          197..201
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   TURN            202..205
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   STRAND          206..209
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   HELIX           213..216
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   STRAND          218..220
FT                   /evidence="ECO:0007829|PDB:2L5F"
FT   HELIX           393..406
FT                   /evidence="ECO:0007829|PDB:1UZC"
FT   STRAND          411..413
FT                   /evidence="ECO:0007829|PDB:2LKS"
FT   HELIX           415..423
FT                   /evidence="ECO:0007829|PDB:1UZC"
FT   HELIX           426..430
FT                   /evidence="ECO:0007829|PDB:1UZC"
FT   HELIX           434..447
FT                   /evidence="ECO:0007829|PDB:1UZC"
FT   HELIX           743..755
FT                   /evidence="ECO:0007829|PDB:2CQN"
FT   HELIX           767..774
FT                   /evidence="ECO:0007829|PDB:2CQN"
FT   HELIX           778..781
FT                   /evidence="ECO:0007829|PDB:2CQN"
FT   HELIX           786..804
FT                   /evidence="ECO:0007829|PDB:2CQN"
FT   MOD_RES         O75400-2:17
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         O75400-2:24
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         O75400-2:47
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         O75400-5:17
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         O75400-5:24
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         O75400-5:47
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
SQ   SEQUENCE   957 AA;  108805 MW;  8874D0C1CE1FCDAF CRC64;
     MRPGTGAERG GLMVSEMESH PPSQGPGDGE RRLSGSSLCS GSWVSADGFL RRRPSMGHPG
     MHYAPMGMHP MGQRANMPPV PHGMMPQMMP PMGGPPMGQM PGMMSSVMPG MMMSHMSQAS
     MQPALPPGVN SMDVAAGTAS GAKSMWTEHK SPDGRTYYYN TETKQSTWEK PDDLKTPAEQ
     LLSKCPWKEY KSDSGKPYYY NSQTKESRWA KPKELEDLEG YQNTIVAGSL ITKSNLHAMI
     KAEESSKQEE CTTTSTAPVP TTEIPTTMST MAAAEAAAAV VAAAAAAAAA AAAANANAST
     SASNTVSGTV PVVPEPEVTS IVATVVDNEN TVTISTEEQA QLTSTPAIQD QSVEVSSNTG
     EETSKQETVA DFTPKKEEEE SQPAKKTYTW NTKEEAKQAF KELLKEKRVP SNASWEQAMK
     MIINDPRYSA LAKLSEKKQA FNAYKVQTEK EEKEEARSKY KEAKESFQRF LENHEKMTST
     TRYKKAEQMF GEMEVWNAIS ERDRLEIYED VLFFLSKKEK EQAKQLRKRN WEALKNILDN
     MANVTYSTTW SEAQQYLMDN PTFAEDEELQ NMDKEDALIC FEEHIRALEK EEEEEKQKSL
     LRERRRQRKN RESFQIFLDE LHEHGQLHSM SSWMELYPTI SSDIRFTNML GQPGSTALDL
     FKFYVEDLKA RYHDEKKIIK DILKDKGFVV EVNTTFEDFV AIISSTKRST TLDAGNIKLA
     FNSLLEKAEA REREREKEEA RKMKRKESAF KSMLKQAAPP IELDAVWEDI RERFVKEPAF
     EDITLESERK RIFKDFMHVL EHECQHHHSK NKKHSKKSKK HHRKRSRSRS GSDSDDDDSH
     SKKKRQRSES RSASEHSSSA ESERSYKKSK KHKKKSKKRR HKSDSPESDA EREKDKKEKD
     RESEKDRTRQ RSESKHKSPK KKTGKDSGNW DTSGSELSEG ELEKRRRTLL EQLDDDQ
//
ID   SHLB1_HUMAN             Reviewed;         365 AA.
AC   Q9Y371; B4E182; Q5H8U5; Q9H3Z0; Q9NR47; Q9NYA9;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   22-FEB-2023, entry version 193.
DE   RecName: Full=Endophilin-B1;
DE   AltName: Full=Bax-interacting factor 1;
DE            Short=Bif-1;
DE   AltName: Full=SH3 domain-containing GRB2-like protein B1;
GN   Name=SH3GLB1; Synonyms=KIAA0491; ORFNames=CGI-61;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS OF VAL-8, INTERACTION
RP   WITH BAX AND SH3GLB2, AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=11161816; DOI=10.1006/geno.2000.6378;
RA   Pierrat B., Simonen M., Cueto M., Mestan J., Ferrigno P., Heim J.;
RT   "SH3GLB, a new endophilin-related protein family featuring an SH3 domain.";
RL   Genomics 71:222-234(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH BAX, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=11259440; DOI=10.1074/jbc.m101527200;
RA   Cuddeback S.M., Yamaguchi H., Komatsu K., Miyashita T., Yamada M., Wu C.,
RA   Singh S., Wang H.-G.;
RT   "Molecular cloning and characterization of Bif-1. A novel Src homology 3
RT   domain-containing protein that associates with Bax.";
RL   J. Biol. Chem. 276:20559-20565(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=12456676; DOI=10.1074/jbc.m208568200;
RA   Modregger J., Schmidt A.A., Ritter B., Huttner W.B., Plomann M.;
RT   "Characterization of endophilin B1b, a brain-specific membrane-associated
RT   lysophosphatidic acid acyl transferase with properties distinct from
RT   endophilin A1.";
RL   J. Biol. Chem. 278:4160-4167(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9455484; DOI=10.1093/dnares/4.5.345;
RA   Seki N., Ohira M., Nagase T., Ishikawa K., Miyajima N., Nakajima D.,
RA   Nomura N., Ohara O.;
RT   "Characterization of cDNA clones in size-fractionated cDNA libraries from
RT   human brain.";
RL   DNA Res. 4:345-349(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=10810093; DOI=10.1101/gr.10.5.703;
RA   Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
RT   "Identification of novel human genes evolutionarily conserved in
RT   Caenorhabditis elegans by comparative proteomics.";
RL   Genome Res. 10:703-713(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Kidney, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=11604418; DOI=10.1083/jcb.200107075;
RA   Farsad K., Ringstad N., Takei K., Floyd S.R., Rose K., De Camilli P.;
RT   "Generation of high curvature membranes mediated by direct endophilin
RT   bilayer interactions.";
RL   J. Cell Biol. 155:193-200(2001).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15452144; DOI=10.1083/jcb.200407046;
RA   Karbowski M., Jeong S.-Y., Youle R.J.;
RT   "Endophilin B1 is required for the maintenance of mitochondrial
RT   morphology.";
RL   J. Cell Biol. 166:1027-1039(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=16227588; DOI=10.1128/mcb.25.21.9369-9382.2005;
RA   Takahashi Y., Karbowski M., Yamaguchi H., Kazi A., Wu J., Sebti S.M.,
RA   Youle R.J., Wang H.G.;
RT   "Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial
RT   apoptosis.";
RL   Mol. Cell. Biol. 25:9369-9382(2005).
RN   [12]
RP   FUNCTION, INTERACTION WITH UVRAG AND BECN1, SUBCELLULAR LOCATION, AND
RP   DOMAIN.
RX   PubMed=17891140; DOI=10.1038/ncb1634;
RA   Takahashi Y., Coppola D., Matsushita N., Cualing H.D., Sun M., Sato Y.,
RA   Liang C., Jung J.U., Cheng J.Q., Mule J.J., Pledger W.J., Wang H.G.;
RT   "Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and
RT   tumorigenesis.";
RL   Nat. Cell Biol. 9:1142-1151(2007).
RN   [13]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=20643123; DOI=10.1016/j.yexcr.2010.07.008;
RA   Thoresen S.B., Pedersen N.M., Liestol K., Stenmark H.;
RT   "A phosphatidylinositol 3-kinase class III sub-complex containing VPS15,
RT   VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative
RT   endocytic traffic.";
RL   Exp. Cell Res. 316:3368-3378(2010).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21068542; DOI=10.4161/auto.7.1.14015;
RA   Takahashi Y., Meyerkord C.L., Hori T., Runkle K., Fox T.E., Kester M.,
RA   Loughran T.P., Wang H.G.;
RT   "Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi
RT   membranes during autophagy.";
RL   Autophagy 7:61-73(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION AT THR-145, AND MUTAGENESIS OF THR-145.
RX   PubMed=21499257; DOI=10.1038/ncb2217;
RA   Wong A.S., Lee R.H., Cheung A.Y., Yeung P.K., Chung S.K., Cheung Z.H.,
RA   Ip N.Y.;
RT   "Cdk5-mediated phosphorylation of endophilin B1 is required for induced
RT   autophagy in models of Parkinson's disease.";
RL   Nat. Cell Biol. 13:568-579(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: May be required for normal outer mitochondrial membrane
CC       dynamics (PubMed:15452144). Required for coatomer-mediated retrograde
CC       transport in certain cells (By similarity). May recruit other proteins
CC       to membranes with high curvature. May promote membrane fusion
CC       (PubMed:11604418). Involved in activation of caspase-dependent
CC       apoptosis by promoting BAX/BAK1 activation (PubMed:16227588). Isoform 1
CC       acts proapoptotic in fibroblasts (By similarity). Involved in caspase-
CC       independent apoptosis during nutrition starvation and involved in the
CC       regulation of autophagy. Activates lipid kinase activity of PIK3C3
CC       during autophagy probably by associating with the PI3K complex II
CC       (PI3KC3-C2) (PubMed:17891140). Associated with PI3KC3-C2 during
CC       autophagy may regulate the trafficking of ATG9A from the Golgi complex
CC       to the peripheral cytoplasm for the formation of autophagosomes by
CC       inducing Golgi membrane tubulation and fragmentation (PubMed:21068542).
CC       Involved in regulation of degradative endocytic trafficking and
CC       cytokinesis, probably in the context of PI3KC3-C2 (PubMed:20643123).
CC       Isoform 2 acts antiapoptotic in neuronal cells; involved in maintenance
CC       of mitochondrial morphology and promotes neuronal viability (By
CC       similarity). {ECO:0000250|UniProtKB:Q9JK48,
CC       ECO:0000269|PubMed:11604418, ECO:0000269|PubMed:15452144,
CC       ECO:0000269|PubMed:17891140, ECO:0000269|PubMed:20643123,
CC       ECO:0000269|PubMed:21068542}.
CC   -!- SUBUNIT: Homodimer, and heterodimer with SH3GLB2 (PubMed:11161816).
CC       Binds BAX; induction of apoptosis augments BAX binding
CC       (PubMed:11161816, PubMed:11259440). Binds DNM1, HTT, AMPH, BIN1 and
CC       ARFGAP1 (By similarity). Interacts with UVRAG; UVRAG bridges the
CC       interaction to BECN1 indicative for an association with the PI3K
CC       complex II (PI3KC3-C2) (PubMed:17891140, PubMed:20643123).
CC       {ECO:0000250|UniProtKB:Q9JK48, ECO:0000269|PubMed:11161816,
CC       ECO:0000269|PubMed:11259440, ECO:0000269|PubMed:17891140}.
CC   -!- INTERACTION:
CC       Q9Y371; P45844-6: ABCG1; NbExp=3; IntAct=EBI-2623095, EBI-25873349;
CC       Q9Y371; Q7Z5M8-2: ABHD12B; NbExp=3; IntAct=EBI-2623095, EBI-21854797;
CC       Q9Y371; Q8WTS1: ABHD5; NbExp=3; IntAct=EBI-2623095, EBI-2813554;
CC       Q9Y371; Q96CM8: ACSF2; NbExp=3; IntAct=EBI-2623095, EBI-2876502;
CC       Q9Y371; O95994: AGR2; NbExp=3; IntAct=EBI-2623095, EBI-712648;
CC       Q9Y371; Q6RW13-2: AGTRAP; NbExp=3; IntAct=EBI-2623095, EBI-11522760;
CC       Q9Y371; Q96MA6: AK8; NbExp=3; IntAct=EBI-2623095, EBI-8466265;
CC       Q9Y371; Q5T2L2: AKR1C8; NbExp=3; IntAct=EBI-2623095, EBI-22006248;
CC       Q9Y371; Q96Q83-2: ALKBH3; NbExp=3; IntAct=EBI-2623095, EBI-9089544;
CC       Q9Y371; Q9NU02: ANKEF1; NbExp=3; IntAct=EBI-2623095, EBI-8464238;
CC       Q9Y371; P02647: APOA1; NbExp=3; IntAct=EBI-2623095, EBI-701692;
CC       Q9Y371; P06727: APOA4; NbExp=3; IntAct=EBI-2623095, EBI-1222447;
CC       Q9Y371; P02749: APOH; NbExp=3; IntAct=EBI-2623095, EBI-2114682;
CC       Q9Y371; P53365: ARFIP2; NbExp=6; IntAct=EBI-2623095, EBI-638194;
CC       Q9Y371; P18848: ATF4; NbExp=3; IntAct=EBI-2623095, EBI-492498;
CC       Q9Y371; C1IDX9: ATG12; NbExp=3; IntAct=EBI-2623095, EBI-25836940;
CC       Q9Y371; O75964: ATP5MG; NbExp=3; IntAct=EBI-2623095, EBI-1044001;
CC       Q9Y371; Q14032: BAAT; NbExp=3; IntAct=EBI-2623095, EBI-8994378;
CC       Q9Y371; Q8WZ55: BSND; NbExp=3; IntAct=EBI-2623095, EBI-7996695;
CC       Q9Y371; Q9NQ89: C12orf4; NbExp=3; IntAct=EBI-2623095, EBI-11090973;
CC       Q9Y371; Q13901: C1D; NbExp=6; IntAct=EBI-2623095, EBI-3844053;
CC       Q9Y371; Q8N1A6: C4orf33; NbExp=3; IntAct=EBI-2623095, EBI-10264911;
CC       Q9Y371; Q9UGQ2: CACFD1; NbExp=3; IntAct=EBI-2623095, EBI-8652492;
CC       Q9Y371; P20807-4: CAPN3; NbExp=3; IntAct=EBI-2623095, EBI-11532021;
CC       Q9Y371; P24863: CCNC; NbExp=3; IntAct=EBI-2623095, EBI-395261;
CC       Q9Y371; Q9UK58-5: CCNL1; NbExp=3; IntAct=EBI-2623095, EBI-25873837;
CC       Q9Y371; P01730: CD4; NbExp=3; IntAct=EBI-2623095, EBI-353826;
CC       Q9Y371; O15182: CETN3; NbExp=3; IntAct=EBI-2623095, EBI-712959;
CC       Q9Y371; Q9UHD4: CIDEB; NbExp=3; IntAct=EBI-2623095, EBI-7062247;
CC       Q9Y371; P09496-2: CLTA; NbExp=3; IntAct=EBI-2623095, EBI-4401010;
CC       Q9Y371; Q96DZ9: CMTM5; NbExp=3; IntAct=EBI-2623095, EBI-2548702;
CC       Q9Y371; Q96DZ9-2: CMTM5; NbExp=3; IntAct=EBI-2623095, EBI-11522780;
CC       Q9Y371; Q8NI60: COQ8A; NbExp=11; IntAct=EBI-2623095, EBI-745535;
CC       Q9Y371; Q9UGL9: CRCT1; NbExp=3; IntAct=EBI-2623095, EBI-713677;
CC       Q9Y371; Q53TN4: CYBRD1; NbExp=3; IntAct=EBI-2623095, EBI-8637742;
CC       Q9Y371; P10632: CYP2C8; NbExp=3; IntAct=EBI-2623095, EBI-2951522;
CC       Q9Y371; Q9BSY9: DESI2; NbExp=3; IntAct=EBI-2623095, EBI-12878374;
CC       Q9Y371; Q96LJ7: DHRS1; NbExp=3; IntAct=EBI-2623095, EBI-746300;
CC       Q9Y371; Q96KC8: DNAJC1; NbExp=3; IntAct=EBI-2623095, EBI-296550;
CC       Q9Y371; Q96BY6: DOCK10; NbExp=3; IntAct=EBI-2623095, EBI-748520;
CC       Q9Y371; O00303: EIF3F; NbExp=3; IntAct=EBI-2623095, EBI-711990;
CC       Q9Y371; O00472: ELL2; NbExp=3; IntAct=EBI-2623095, EBI-395274;
CC       Q9Y371; O95278-6: EPM2A; NbExp=3; IntAct=EBI-2623095, EBI-25836908;
CC       Q9Y371; Q9NRY5: FAM114A2; NbExp=3; IntAct=EBI-2623095, EBI-10973142;
CC       Q9Y371; Q8N128-2: FAM177A1; NbExp=3; IntAct=EBI-2623095, EBI-12201693;
CC       Q9Y371; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-2623095, EBI-8468186;
CC       Q9Y371; Q9NYY8: FASTKD2; NbExp=3; IntAct=EBI-2623095, EBI-1055752;
CC       Q9Y371; P02671-2: FGA; NbExp=3; IntAct=EBI-2623095, EBI-9640259;
CC       Q9Y371; P49771-3: FLT3LG; NbExp=3; IntAct=EBI-2623095, EBI-25872794;
CC       Q9Y371; Q8IVP5: FUNDC1; NbExp=3; IntAct=EBI-2623095, EBI-3059266;
CC       Q9Y371; Q6P7E6: FUT6; NbExp=3; IntAct=EBI-2623095, EBI-25872807;
CC       Q9Y371; P24522: GADD45A; NbExp=2; IntAct=EBI-2623095, EBI-448167;
CC       Q9Y371; Q9H3K2: GHITM; NbExp=3; IntAct=EBI-2623095, EBI-2868909;
CC       Q9Y371; Q8WWP7: GIMAP1; NbExp=3; IntAct=EBI-2623095, EBI-11991950;
CC       Q9Y371; Q9HAV0: GNB4; NbExp=3; IntAct=EBI-2623095, EBI-358539;
CC       Q9Y371; P32780: GTF2H1; NbExp=3; IntAct=EBI-2623095, EBI-715539;
CC       Q9Y371; O75409: H2AP; NbExp=3; IntAct=EBI-2623095, EBI-6447217;
CC       Q9Y371; Q6NXT2: H3-5; NbExp=3; IntAct=EBI-2623095, EBI-2868501;
CC       Q9Y371; P68431: H3C12; NbExp=3; IntAct=EBI-2623095, EBI-79722;
CC       Q9Y371; P53701: HCCS; NbExp=3; IntAct=EBI-2623095, EBI-10763431;
CC       Q9Y371; Q9BUP3-3: HTATIP2; NbExp=3; IntAct=EBI-2623095, EBI-12937691;
CC       Q9Y371; P0C870: JMJD7; NbExp=3; IntAct=EBI-2623095, EBI-9090173;
CC       Q9Y371; Q9UK76: JPT1; NbExp=3; IntAct=EBI-2623095, EBI-720411;
CC       Q9Y371; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-2623095, EBI-743960;
CC       Q9Y371; Q6DKI2: LGALS9C; NbExp=3; IntAct=EBI-2623095, EBI-9088829;
CC       Q9Y371; Q5VYH9: LY9; NbExp=3; IntAct=EBI-2623095, EBI-25872860;
CC       Q9Y371; P43361: MAGEA8; NbExp=3; IntAct=EBI-2623095, EBI-10182930;
CC       Q9Y371; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-2623095, EBI-741835;
CC       Q9Y371; Q969L2: MAL2; NbExp=6; IntAct=EBI-2623095, EBI-944295;
CC       Q9Y371; P27338: MAOB; NbExp=3; IntAct=EBI-2623095, EBI-3911344;
CC       Q9Y371; Q8NI22: MCFD2; NbExp=3; IntAct=EBI-2623095, EBI-2689785;
CC       Q9Y371; Q96C03-3: MIEF2; NbExp=3; IntAct=EBI-2623095, EBI-11988931;
CC       Q9Y371; Q9BV20: MRI1; NbExp=3; IntAct=EBI-2623095, EBI-747381;
CC       Q9Y371; Q8N387: MUC15; NbExp=3; IntAct=EBI-2623095, EBI-17937277;
CC       Q9Y371; P01106: MYC; NbExp=3; IntAct=EBI-2623095, EBI-447544;
CC       Q9Y371; Q9H7X0: NAA60; NbExp=3; IntAct=EBI-2623095, EBI-12260336;
CC       Q9Y371; Q9UJ70-2: NAGK; NbExp=3; IntAct=EBI-2623095, EBI-11526455;
CC       Q9Y371; Q69YL0: NCBP2AS2; NbExp=3; IntAct=EBI-2623095, EBI-10986258;
CC       Q9Y371; P25208: NFYB; NbExp=3; IntAct=EBI-2623095, EBI-389728;
CC       Q9Y371; O15130-2: NPFF; NbExp=3; IntAct=EBI-2623095, EBI-25840002;
CC       Q9Y371; P27815-4: PDE4A; NbExp=3; IntAct=EBI-2623095, EBI-12080840;
CC       Q9Y371; A5PLL7: PEDS1; NbExp=3; IntAct=EBI-2623095, EBI-11337896;
CC       Q9Y371; Q00169: PITPNA; NbExp=3; IntAct=EBI-2623095, EBI-1042490;
CC       Q9Y371; P48739: PITPNB; NbExp=3; IntAct=EBI-2623095, EBI-1047143;
CC       Q9Y371; O60664: PLIN3; NbExp=3; IntAct=EBI-2623095, EBI-725795;
CC       Q9Y371; Q14181: POLA2; NbExp=3; IntAct=EBI-2623095, EBI-712752;
CC       Q9Y371; P02775: PPBP; NbExp=3; IntAct=EBI-2623095, EBI-718973;
CC       Q9Y371; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-2623095, EBI-25835994;
CC       Q9Y371; P23942: PRPH2; NbExp=3; IntAct=EBI-2623095, EBI-25836834;
CC       Q9Y371; P25786: PSMA1; NbExp=3; IntAct=EBI-2623095, EBI-359352;
CC       Q9Y371; P41222: PTGDS; NbExp=3; IntAct=EBI-2623095, EBI-948821;
CC       Q9Y371; Q9UI14: RABAC1; NbExp=3; IntAct=EBI-2623095, EBI-712367;
CC       Q9Y371; Q09028: RBBP4; NbExp=3; IntAct=EBI-2623095, EBI-620823;
CC       Q9Y371; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-2623095, EBI-14065960;
CC       Q9Y371; Q6ZWK4: RHEX; NbExp=3; IntAct=EBI-2623095, EBI-18304046;
CC       Q9Y371; Q9NPQ8-4: RIC8A; NbExp=8; IntAct=EBI-2623095, EBI-9091816;
CC       Q9Y371; P62701: RPS4X; NbExp=3; IntAct=EBI-2623095, EBI-354303;
CC       Q9Y371; O15126: SCAMP1; NbExp=3; IntAct=EBI-2623095, EBI-954338;
CC       Q9Y371; Q9BRK5: SDF4; NbExp=3; IntAct=EBI-2623095, EBI-1389808;
CC       Q9Y371; P01011: SERPINA3; NbExp=3; IntAct=EBI-2623095, EBI-296557;
CC       Q9Y371; Q9BWM7: SFXN3; NbExp=3; IntAct=EBI-2623095, EBI-1171999;
CC       Q9Y371; Q7L8J4: SH3BP5L; NbExp=3; IntAct=EBI-2623095, EBI-747389;
CC       Q9Y371; Q9Y371: SH3GLB1; NbExp=8; IntAct=EBI-2623095, EBI-2623095;
CC       Q9Y371; Q9NR46: SH3GLB2; NbExp=20; IntAct=EBI-2623095, EBI-749607;
CC       Q9Y371; Q9BZQ2: SHCBP1L; NbExp=3; IntAct=EBI-2623095, EBI-10818532;
CC       Q9Y371; H3BQL7: SIN3A; NbExp=3; IntAct=EBI-2623095, EBI-13384308;
CC       Q9Y371; Q96EX1: SMIM12; NbExp=3; IntAct=EBI-2623095, EBI-2874543;
CC       Q9Y371; Q71RC9: SMIM5; NbExp=3; IntAct=EBI-2623095, EBI-12334905;
CC       Q9Y371; O60906: SMPD2; NbExp=3; IntAct=EBI-2623095, EBI-12828299;
CC       Q9Y371; Q13573: SNW1; NbExp=3; IntAct=EBI-2623095, EBI-632715;
CC       Q9Y371; Q13596: SNX1; NbExp=3; IntAct=EBI-2623095, EBI-2822329;
CC       Q9Y371; O95219: SNX4; NbExp=3; IntAct=EBI-2623095, EBI-724909;
CC       Q9Y371; Q8N0X7: SPART; NbExp=3; IntAct=EBI-2623095, EBI-2643803;
CC       Q9Y371; Q9NYA1-2: SPHK1; NbExp=3; IntAct=EBI-2623095, EBI-12512419;
CC       Q9Y371; Q9BPZ2: SPIN2B; NbExp=3; IntAct=EBI-2623095, EBI-21726245;
CC       Q9Y371; Q9BXA5: SUCNR1; NbExp=3; IntAct=EBI-2623095, EBI-17962797;
CC       Q9Y371; O60506-4: SYNCRIP; NbExp=3; IntAct=EBI-2623095, EBI-11123832;
CC       Q9Y371; O43761: SYNGR3; NbExp=6; IntAct=EBI-2623095, EBI-11321949;
CC       Q9Y371; P08247: SYP; NbExp=6; IntAct=EBI-2623095, EBI-9071725;
CC       Q9Y371; Q17RD7: SYT16; NbExp=3; IntAct=EBI-2623095, EBI-10238936;
CC       Q9Y371; P54274-2: TERF1; NbExp=3; IntAct=EBI-2623095, EBI-711018;
CC       Q9Y371; Q9UBB9: TFIP11; NbExp=7; IntAct=EBI-2623095, EBI-1105213;
CC       Q9Y371; P22735: TGM1; NbExp=3; IntAct=EBI-2623095, EBI-2562368;
CC       Q9Y371; Q9NQ88: TIGAR; NbExp=3; IntAct=EBI-2623095, EBI-3920747;
CC       Q9Y371; O14925: TIMM23; NbExp=3; IntAct=EBI-2623095, EBI-1047996;
CC       Q9Y371; Q12893: TMEM115; NbExp=3; IntAct=EBI-2623095, EBI-8633987;
CC       Q9Y371; Q8WVE6-2: TMEM171; NbExp=3; IntAct=EBI-2623095, EBI-25874374;
CC       Q9Y371; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-2623095, EBI-10242677;
CC       Q9Y371; Q9NS69: TOMM22; NbExp=3; IntAct=EBI-2623095, EBI-1047508;
CC       Q9Y371; P55327-2: TPD52; NbExp=3; IntAct=EBI-2623095, EBI-12124194;
CC       Q9Y371; O43399: TPD52L2; NbExp=3; IntAct=EBI-2623095, EBI-782604;
CC       Q9Y371; Q6FGS1: TPD52L2; NbExp=3; IntAct=EBI-2623095, EBI-10327230;
CC       Q9Y371; Q9C035-3: TRIM5; NbExp=3; IntAct=EBI-2623095, EBI-12840050;
CC       Q9Y371; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-2623095, EBI-11525489;
CC       Q9Y371; P49638: TTPA; NbExp=3; IntAct=EBI-2623095, EBI-10210710;
CC       Q9Y371; Q9H313-4: TTYH1; NbExp=3; IntAct=EBI-2623095, EBI-17671298;
CC       Q9Y371; Q9BQE3: TUBA1C; NbExp=3; IntAct=EBI-2623095, EBI-1103245;
CC       Q9Y371; P62253: UBE2G1; NbExp=3; IntAct=EBI-2623095, EBI-2340619;
CC       Q9Y371; Q9P2Y5: UVRAG; NbExp=11; IntAct=EBI-2623095, EBI-2952704;
CC       Q9Y371; O95070: YIF1A; NbExp=3; IntAct=EBI-2623095, EBI-2799703;
CC       Q9Y371; O43829: ZBTB14; NbExp=3; IntAct=EBI-2623095, EBI-10176632;
CC       Q9Y371; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-2623095, EBI-14104088;
CC       Q9Y371; Q9H609: ZNF576; NbExp=6; IntAct=EBI-2623095, EBI-3921014;
CC       Q9Y371; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-2623095, EBI-18036029;
CC       Q9Y371-1; Q07812: BAX; NbExp=2; IntAct=EBI-5291808, EBI-516580;
CC       Q9Y371-2; Q9Y371-2: SH3GLB1; NbExp=3; IntAct=EBI-5282812, EBI-5282812;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15452144}. Golgi
CC       apparatus membrane {ECO:0000269|PubMed:21068542}; Peripheral membrane
CC       protein {ECO:0000250}. Mitochondrion outer membrane
CC       {ECO:0000269|PubMed:15452144}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:15452144}. Cytoplasmic vesicle, autophagosome
CC       membrane {ECO:0000269|PubMed:17891140}. Midbody
CC       {ECO:0000269|PubMed:20643123}. Note=Association with the Golgi
CC       apparatus depends on the cell type (By similarity). Following
CC       starvation colocalizes with ATG5 and LC3 autophagy-related protein(s)on
CC       autophagosomal membranes (PubMed:17891140). {ECO:0000250,
CC       ECO:0000269|PubMed:17891140}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q9Y371-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y371-2; Sequence=VSP_009276;
CC       Name=3;
CC         IsoId=Q9Y371-3; Sequence=VSP_044895;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle, kidney
CC       and placenta. Detected at lower levels in brain, colon, thymus, spleen,
CC       liver, small intestine, lung and peripheral blood leukocytes.
CC       {ECO:0000269|PubMed:11161816, ECO:0000269|PubMed:11259440}.
CC   -!- DOMAIN: An N-terminal amphipathic helix, the BAR domain and a second
CC       amphipathic helix inserted into helix 1 of the BAR domain (N-BAR
CC       domain) induce membrane curvature and bind curved membranes.
CC       {ECO:0000269|PubMed:11604418}.
CC   -!- DOMAIN: The SH3 domain is required and sufficient for the interaction
CC       with UVRAG. {ECO:0000269|PubMed:17891140}.
CC   -!- PTM: Phosphorylated at Thr-145 by CDK5; this phosphorylation is
CC       required for autophagy induction in starved neurons and facilitates
CC       homodimerization. {ECO:0000269|PubMed:21499257}.
CC   -!- MISCELLANEOUS: HeLa cells lacking SH3GLB1 show dissociation of outer
CC       and inner mitochondrial membrane as well as abnormal mitochondrial
CC       morphology. Cells overexpressing SH3GLB1 lacking an N-terminal
CC       amphipathic helix show a similar phenotype.
CC   -!- MISCELLANEOUS: SH3GLB1 binds liposomes and induces formation of tubules
CC       from liposomes. SH3GLB1 lacking the N-terminal amphipathic helix fails
CC       to induce liposome tubulation.
CC   -!- SIMILARITY: Belongs to the endophilin family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to have lysophosphatidic acid
CC       acyltransferase activity, but by homology with SH3GL2/endophilin A1 is
CC       unlikely to have this activity. {ECO:0000305|PubMed:12456676}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF81225.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAD88797.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF257318; AAF81225.1; ALT_INIT; mRNA.
DR   EMBL; AF350371; AAK27365.1; -; mRNA.
DR   EMBL; AF263293; AAF73017.1; -; mRNA.
DR   EMBL; AB007960; BAD88797.1; ALT_INIT; mRNA.
DR   EMBL; AF151819; AAD34056.1; -; mRNA.
DR   EMBL; AK001954; BAA91999.1; -; mRNA.
DR   EMBL; AK303710; BAG64694.1; -; mRNA.
DR   EMBL; AL049597; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007455; AAH07455.1; -; mRNA.
DR   CCDS; CCDS55612.1; -. [Q9Y371-2]
DR   CCDS; CCDS55613.1; -. [Q9Y371-3]
DR   CCDS; CCDS710.1; -. [Q9Y371-1]
DR   RefSeq; NP_001193580.1; NM_001206651.1.
DR   RefSeq; NP_001193581.1; NM_001206652.1. [Q9Y371-2]
DR   RefSeq; NP_001193582.1; NM_001206653.1. [Q9Y371-3]
DR   RefSeq; NP_057093.1; NM_016009.4. [Q9Y371-1]
DR   PDB; 6UP6; EM; 9.00 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/V/W/a/b/c/d/e/f/g/h=1-365.
DR   PDB; 6UPN; EM; 10.00 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/V/W/X/Y/a/b/c/d/e/f=1-365.
DR   PDBsum; 6UP6; -.
DR   PDBsum; 6UPN; -.
DR   AlphaFoldDB; Q9Y371; -.
DR   SMR; Q9Y371; -.
DR   BioGRID; 119289; 116.
DR   DIP; DIP-41970N; -.
DR   IntAct; Q9Y371; 189.
DR   MINT; Q9Y371; -.
DR   STRING; 9606.ENSP00000479919; -.
DR   TCDB; 8.A.34.1.4; the endophilin (endophilin) family.
DR   GlyGen; Q9Y371; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Y371; -.
DR   PhosphoSitePlus; Q9Y371; -.
DR   BioMuta; SH3GLB1; -.
DR   DMDM; 41018158; -.
DR   REPRODUCTION-2DPAGE; IPI00006558; -.
DR   EPD; Q9Y371; -.
DR   jPOST; Q9Y371; -.
DR   MassIVE; Q9Y371; -.
DR   MaxQB; Q9Y371; -.
DR   PeptideAtlas; Q9Y371; -.
DR   ProteomicsDB; 5734; -.
DR   ProteomicsDB; 85978; -. [Q9Y371-1]
DR   ProteomicsDB; 85979; -. [Q9Y371-2]
DR   Antibodypedia; 2824; 562 antibodies from 37 providers.
DR   DNASU; 51100; -.
DR   Ensembl; ENST00000370558.8; ENSP00000473267.1; ENSG00000097033.15. [Q9Y371-1]
DR   Ensembl; ENST00000482504.1; ENSP00000418744.1; ENSG00000097033.15. [Q9Y371-2]
DR   Ensembl; ENST00000535010.5; ENSP00000441355.1; ENSG00000097033.15. [Q9Y371-3]
DR   GeneID; 51100; -.
DR   KEGG; hsa:51100; -.
DR   MANE-Select; ENST00000370558.8; ENSP00000473267.1; NM_016009.5; NP_057093.1.
DR   UCSC; uc001dlw.4; human. [Q9Y371-1]
DR   AGR; HGNC:10833; -.
DR   CTD; 51100; -.
DR   DisGeNET; 51100; -.
DR   GeneCards; SH3GLB1; -.
DR   HGNC; HGNC:10833; SH3GLB1.
DR   HPA; ENSG00000097033; Low tissue specificity.
DR   MIM; 609287; gene.
DR   neXtProt; NX_Q9Y371; -.
DR   OpenTargets; ENSG00000097033; -.
DR   PharmGKB; PA35739; -.
DR   VEuPathDB; HostDB:ENSG00000097033; -.
DR   eggNOG; KOG3725; Eukaryota.
DR   GeneTree; ENSGT00940000155667; -.
DR   HOGENOM; CLU_043817_1_0_1; -.
DR   InParanoid; Q9Y371; -.
DR   OMA; ETTYYAQ; -.
DR   OrthoDB; 3494067at2759; -.
DR   PhylomeDB; Q9Y371; -.
DR   TreeFam; TF313281; -.
DR   PathwayCommons; Q9Y371; -.
DR   SignaLink; Q9Y371; -.
DR   SIGNOR; Q9Y371; -.
DR   BioGRID-ORCS; 51100; 14 hits in 1159 CRISPR screens.
DR   ChiTaRS; SH3GLB1; human.
DR   GeneWiki; SH3GLB1; -.
DR   GenomeRNAi; 51100; -.
DR   Pharos; Q9Y371; Tbio.
DR   PRO; PR:Q9Y371; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9Y371; protein.
DR   Bgee; ENSG00000097033; Expressed in tibialis anterior and 207 other tissues.
DR   ExpressionAtlas; Q9Y371; baseline and differential.
DR   Genevisible; Q9Y371; HS.
DR   GO; GO:0000421; C:autophagosome membrane; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:HGNC-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048102; P:autophagic cell death; IMP:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IMP:UniProtKB.
DR   GO; GO:0090148; P:membrane fission; IMP:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; IBA:GO_Central.
DR   GO; GO:2000786; P:positive regulation of autophagosome assembly; IMP:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:1903527; P:positive regulation of membrane tubulation; IMP:UniProtKB.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:1903778; P:protein localization to vacuolar membrane; IMP:UniProtKB.
DR   GO; GO:0032801; P:receptor catabolic process; IMP:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0031647; P:regulation of protein stability; HMP:ParkinsonsUK-UCL.
DR   CDD; cd07616; BAR_Endophilin_B1; 1.
DR   CDD; cd11945; SH3_Endophilin_B1; 1.
DR   Gene3D; 1.20.1270.60; Arfaptin homology (AH) domain/BAR domain; 1.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR004148; BAR_dom.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR035695; SH3GLB1_BAR.
DR   PANTHER; PTHR14167:SF52; ENDOPHILIN-B1; 1.
DR   PANTHER; PTHR14167; SH3 DOMAIN-CONTAINING; 1.
DR   Pfam; PF03114; BAR; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   SMART; SM00721; BAR; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF103657; BAR/IMD domain-like; 1.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS51021; BAR; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; Autophagy;
KW   Coiled coil; Cytoplasm; Cytoplasmic vesicle; Golgi apparatus;
KW   Lipid-binding; Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   Phosphoprotein; Reference proteome; SH3 domain.
FT   CHAIN           1..365
FT                   /note="Endophilin-B1"
FT                   /id="PRO_0000146753"
FT   DOMAIN          27..261
FT                   /note="BAR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00361"
FT   DOMAIN          305..365
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   REGION          1..37
FT                   /note="Required for membrane binding"
FT                   /evidence="ECO:0000269|PubMed:21068542"
FT   REGION          1..30
FT                   /note="Membrane-binding amphipathic helix"
FT   COILED          155..195
FT                   /evidence="ECO:0000255"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         145
FT                   /note="Phosphothreonine; by CDK5"
FT                   /evidence="ECO:0000269|PubMed:21499257"
FT   VAR_SEQ         1..100
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044895"
FT   VAR_SEQ         190
FT                   /note="S -> SQLNSARLEGDNIMIWAEEVTK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12456676"
FT                   /id="VSP_009276"
FT   MUTAGEN         8
FT                   /note="V->M: Abolishes interaction with BAX."
FT                   /evidence="ECO:0000269|PubMed:11161816"
FT   MUTAGEN         145
FT                   /note="T->A: Reduced CDK5-mediated phosphorylation and
FT                   impaired dimerization."
FT                   /evidence="ECO:0000269|PubMed:21499257"
FT   MUTAGEN         145
FT                   /note="T->E: Spontaneous dimerization."
FT                   /evidence="ECO:0000269|PubMed:21499257"
SQ   SEQUENCE   365 AA;  40796 MW;  42C2AEA57A0B350E CRC64;
     MNIMDFNVKK LAADAGTFLS RAVQFTEEKL GQAEKTELDA HLENLLSKAE CTKIWTEKIM
     KQTEVLLQPN PNARIEEFVY EKLDRKAPSR INNPELLGQY MIDAGTEFGP GTAYGNALIK
     CGETQKRIGT ADRELIQTSA LNFLTPLRNF IEGDYKTIAK ERKLLQNKRL DLDAAKTRLK
     KAKAAETRNS SEQELRITQS EFDRQAEITR LLLEGISSTH AHHLRCLNDF VEAQMTYYAQ
     CYQYMLDLQK QLGSFPSNYL SNNNQTSVTP VPSVLPNAIG SSAMASTSGL VITSPSNLSD
     LKECSGSRKA RVLYDYDAAN STELSLLADE VITVFSVVGM DSDWLMGERG NQKGKVPITY
     LELLN
//
ID   SNP25_HUMAN             Reviewed;         206 AA.
AC   P60880; B2RAU4; D3DW16; D3DW17; P13795; P36974; P70557; P70558; Q53EM2;
AC   Q5U0B5; Q8IXK3; Q96FM2; Q9BR45;
DT   13-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-APR-2004, sequence version 1.
DT   22-FEB-2023, entry version 187.
DE   RecName: Full=Synaptosomal-associated protein 25;
DE            Short=SNAP-25;
DE   AltName: Full=Super protein;
DE            Short=SUP;
DE   AltName: Full=Synaptosomal-associated 25 kDa protein;
GN   Name=SNAP25; Synonyms=SNAP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Fetal brain, and Temporal cortex;
RX   PubMed=8112622; DOI=10.1016/0378-1119(94)90773-0;
RA   Bark I.C., Wilson M.C.;
RT   "Human cDNA clones encoding two different isoforms of the nerve terminal
RT   protein SNAP-25.";
RL   Gene 139:291-292(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Frontal cortex;
RX   PubMed=8056350; DOI=10.1016/0378-1119(94)90027-2;
RA   Zhao N., Hashida H., Takahashi N., Sakaki Y.;
RT   "Cloning and sequence analysis of the human SNAP25 cDNA.";
RL   Gene 145:313-314(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8760387; DOI=10.1042/bj3170945;
RA   Jagadish M.N., Fernandez C.S., Hewish D.R., Macaulay S.L., Gough K.H.,
RA   Grusovin J., Verkuylen A., Cosgrove L., Alafaci A., Frenkel M.J.,
RA   Ward C.W.;
RT   "Insulin-responsive tissues contain the core complex protein SNAP-25
RT   (synaptosomal-associated protein 25) A and B isoforms in addition to
RT   syntaxin 4 and synaptobrevins 1 and 2.";
RL   Biochem. J. 317:945-954(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION) BY C.BOTULINUM NEUROTOXIN TYPES
RP   A; C AND E.
RX   PubMed=9886085; DOI=10.1046/j.1471-4159.1999.0720327.x;
RA   Vaidyanathan V.V., Yoshino K., Jahnz M., Doerries C., Bade S.,
RA   Nauenburg S., Niemann H., Binz T.;
RT   "Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E:
RT   domains and amino acid residues controlling the formation of enzyme-
RT   substrate complexes and cleavage.";
RL   J. Neurochem. 72:327-337(1999).
RN   [11]
RP   PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION) BY C.BOTULINUM NEUROTOXIN TYPE
RP   C, AND MUTAGENESIS OF GLN-152; ILE-156; ASP-166 AND ALA-199.
RX   PubMed=17718519; DOI=10.1021/bi701162d;
RA   Jin R., Sikorra S., Stegmann C.M., Pich A., Binz T., Brunger A.T.;
RT   "Structural and biochemical studies of botulinum neurotoxin serotype C1
RT   light chain protease: implications for dual substrate specificity.";
RL   Biochemistry 46:10685-10693(2007).
RN   [12]
RP   PUTATIVE IRON-SULFUR CLUSTER.
RX   PubMed=18375205; DOI=10.1016/j.febslet.2008.03.028;
RA   Huang Q., Hong X., Hao Q.;
RT   "SNAP-25 is also an iron-sulfur protein.";
RL   FEBS Lett. 582:1431-1436(2008).
RN   [13]
RP   ASSOCIATION WITH THE BLOC-1 COMPLEX, AND INTERACTION WITH BLOC1S6.
RX   PubMed=19546860; DOI=10.1038/mp.2009.58;
RA   Ghiani C.A., Starcevic M., Rodriguez-Fernandez I.A., Nazarian R.,
RA   Cheli V.T., Chan L.N., Malvar J.S., de Vellis J., Sabatti C.,
RA   Dell'Angelica E.C.;
RT   "The dysbindin-containing complex (BLOC-1) in brain: developmental
RT   regulation, interaction with SNARE proteins and role in neurite
RT   outgrowth.";
RL   Mol. Psychiatry 15:204-215(2010).
RN   [14]
RP   INTERACTION WITH ALPHA-SYNUCLEIN/SNCA.
RX   PubMed=20798282; DOI=10.1126/science.1195227;
RA   Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Suedhof T.C.;
RT   "Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.";
RL   Science 329:1663-1667(2010).
RN   [15]
RP   INTERACTION WITH PRRT2.
RX   PubMed=22832103; DOI=10.1016/j.celrep.2011.11.001;
RA   Lee H.Y., Huang Y., Bruneau N., Roll P., Roberson E.D., Hermann M.,
RA   Quinn E., Maas J., Edwards R., Ashizawa T., Baykan B., Bhatia K.,
RA   Bressman S., Bruno M.K., Brunt E.R., Caraballo R., Echenne B., Fejerman N.,
RA   Frucht S., Gurnett C.A., Hirsch E., Houlden H., Jankovic J., Lee W.L.,
RA   Lynch D.R., Mohammed S., Mueller U., Nespeca M.P., Renner D., Rochette J.,
RA   Rudolf G., Saiki S., Soong B.W., Swoboda K.J., Tucker S., Wood N.,
RA   Hanna M., Bowcock A.M., Szepetowski P., Fu Y.H., Ptacek L.J.;
RT   "Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with
RT   infantile convulsions.";
RL   Cell Rep. 1:2-12(2012).
RN   [16]
RP   INTERACTION WITH PRRT2.
RX   PubMed=25915028; DOI=10.3390/ijms16059134;
RA   Li M., Niu F., Zhu X., Wu X., Shen N., Peng X., Liu Y.;
RT   "PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling.";
RL   Int. J. Mol. Sci. 16:9134-9151(2015).
RN   [17]
RP   INTERACTION WITH ZDHHC17.
RX   PubMed=28882895; DOI=10.1074/jbc.m117.799650;
RA   Lemonidis K., MacLeod R., Baillie G.S., Chamberlain L.H.;
RT   "Peptide array based screening reveals a large number of proteins
RT   interacting with the ankyrin repeat domain of the zDHHC17 S-
RT   acyltransferase.";
RL   J. Biol. Chem. 292:17190-17202(2017).
RN   [18]
RP   INVOLVEMENT IN CMS18, VARIANT CMS18 ASN-67, AND CHARACTERIZATION OF VARIANT
RP   CMS18 ASN-67.
RX   PubMed=25381298; DOI=10.1212/wnl.0000000000001079;
RA   Shen X.M., Selcen D., Brengman J., Engel A.G.;
RT   "Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and
RT   intellectual disability.";
RL   Neurology 83:2247-2255(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 11-81 AND 141-202 IN COMPLEX WITH
RP   STX1A; CPLX1 AND VAMP2, AND STRUCTURE BY NMR.
RX   PubMed=11832227; DOI=10.1016/s0896-6273(02)00583-4;
RA   Chen X., Tomchick D.R., Kovrigin E., Arac D., Machius M., Suedhof T.C.,
RA   Rizo J.;
RT   "Three-dimensional structure of the complexin/SNARE complex.";
RL   Neuron 33:397-409(2002).
RN   [20] {ECO:0007744|PDB:1XTG}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 146-204 IN COMPLEX WITH INACTIVE
RP   C.BOTULINUM NEUROTOXIN A LIGHT CHAIN, PROTEOLYTIC CLEAVAGE (MICROBIAL
RP   INFECTION) BY C.BOTULINUM NEUROTOXIN TYPE A, AND MUTAGENESIS OF ILE-156;
RP   MET-167 AND MET-202.
RX   PubMed=15592454; DOI=10.1038/nature03123;
RA   Breidenbach M.A., Brunger A.T.;
RT   "Substrate recognition strategy for botulinum neurotoxin serotype A.";
RL   Nature 432:925-929(2004).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 111-120 IN COMPLEX WITH ZDHHC17,
RP   PALMITOYLATION, AND MUTAGENESIS OF VAL-112; VAL-113; SER-115; GLN-116;
RP   PRO-117 AND ARG-119.
RX   PubMed=28757145; DOI=10.1016/j.str.2017.06.018;
RA   Verardi R., Kim J.S., Ghirlando R., Banerjee A.;
RT   "Structural basis for substrate recognition by the ankyrin repeat domain of
RT   human DHHC17 palmitoyltransferase.";
RL   Structure 0:0-0(2017).
CC   -!- FUNCTION: t-SNARE involved in the molecular regulation of
CC       neurotransmitter release. May play an important role in the synaptic
CC       function of specific neuronal systems. Associates with proteins
CC       involved in vesicle docking and membrane fusion. Regulates plasma
CC       membrane recycling through its interaction with CENPF. Modulates the
CC       gating characteristics of the delayed rectifier voltage-dependent
CC       potassium channel KCNB1 in pancreatic beta cells.
CC       {ECO:0000250|UniProtKB:P60881}.
CC   -!- SUBUNIT: Part of the SNARE core complex containing SNAP25, VAMP2 and
CC       STX1A; this complex binds CPLX1 (PubMed:11832227). Found in a complex
CC       containing SYT1, SV2B and syntaxin-1 (By similarity). Found in a
CC       ternary complex with STX1A and VAMP8 (By similarity). Interacts with
CC       HSC70 and with SYT9, forming a complex with DNAJC5 (By similarity). The
CC       interaction with SYT9 is inhibited in presence of calcium (By
CC       similarity). Isoform 1 and isoform 2 interact with BLOC1S6
CC       (PubMed:19546860). Interacts with CENPF (By similarity). Interacts with
CC       EQTN (By similarity). Interacts with HGS (By similarity). Interacts
CC       with KCNB1 (via N-terminus); reduces the voltage-dependent potassium
CC       channel KCNB1 activity in pancreatic beta cells (By similarity).
CC       Interacts with OTOF (By similarity). Interacts with RIMS1 (By
CC       similarity). Interacts with SNAPIN (By similarity). Interacts with
CC       STXBP6 (By similarity). Interacts with TRIM9 (By similarity). Interacts
CC       with ZDHHC13 (via ANK repeats) (By similarity). Interacts with ZDHHC17
CC       (via ANK repeats) (PubMed:28882895, PubMed:28757145). Associates with
CC       the BLOC-1 complex (PubMed:19546860). Interacts with PLCL1 (via C2
CC       domain) (By similarity). Interacts with PRRT2; this interaction may
CC       impair the formation of the SNARE complex (PubMed:22832103,
CC       PubMed:25915028). Interacts with alpha-synuclein/SNCA
CC       (PubMed:20798282). Interacts with PRPH2 (By similarity). Interacts with
CC       ROM1 (By similarity). Interacts with STX3 (By similarity).
CC       {ECO:0000250|UniProtKB:P60879, ECO:0000250|UniProtKB:P60881,
CC       ECO:0000269|PubMed:11832227, ECO:0000269|PubMed:19546860,
CC       ECO:0000269|PubMed:20798282, ECO:0000269|PubMed:22832103,
CC       ECO:0000269|PubMed:25915028, ECO:0000269|PubMed:28757145,
CC       ECO:0000269|PubMed:28882895}.
CC   -!- INTERACTION:
CC       P60880; Q16623: STX1A; NbExp=3; IntAct=EBI-524785, EBI-712466;
CC       P60880; Q8IUH5: ZDHHC17; NbExp=3; IntAct=EBI-524785, EBI-524753;
CC       P60880; PRO_0000449622 [P0DTD1]: rep; Xeno; NbExp=3; IntAct=EBI-524785, EBI-25475862;
CC       P60880-2; O14810: CPLX1; NbExp=6; IntAct=EBI-12177361, EBI-2691813;
CC       P60880-2; P42858: HTT; NbExp=9; IntAct=EBI-12177361, EBI-466029;
CC       P60880-2; O75558: STX11; NbExp=3; IntAct=EBI-12177361, EBI-714135;
CC       P60880-2; Q8N4C7: STX19; NbExp=3; IntAct=EBI-12177361, EBI-8484990;
CC       P60880-2; Q16623: STX1A; NbExp=5; IntAct=EBI-12177361, EBI-712466;
CC       P60880-2; Q9BRT2: UQCC2; NbExp=3; IntAct=EBI-12177361, EBI-1054584;
CC       P60880-2; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-12177361, EBI-12272076;
CC       P60880-2; P32851: Stx1a; Xeno; NbExp=4; IntAct=EBI-12177361, EBI-539720;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:P60879}. Cell membrane
CC       {ECO:0000250|UniProtKB:P60881}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:P60879}. Synapse, synaptosome
CC       {ECO:0000250|UniProtKB:P60879}. Photoreceptor inner segment
CC       {ECO:0000250|UniProtKB:P60879}. Note=Membrane association requires
CC       palmitoylation. Expressed throughout cytoplasm, concentrating at the
CC       perinuclear region. Colocalizes with KCNB1 at the cell membrane (By
CC       similarity). Colocalizes with PLCL1 at the cell membrane (By
CC       similarity). {ECO:0000250|UniProtKB:P60879,
CC       ECO:0000250|UniProtKB:P60881}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Isoforms differ by the usage of two alternative homologous
CC         exons (5a and 5b) which code for positions 56 to 94 and differ only
CC         in 9 positions out of 39.;
CC       Name=1; Synonyms=SNAP-25b;
CC         IsoId=P60880-1, P13795-1;
CC         Sequence=Displayed;
CC       Name=2; Synonyms=SNAP-25a;
CC         IsoId=P60880-2, P13795-2;
CC         Sequence=VSP_006186;
CC   -!- TISSUE SPECIFICITY: Neurons of the neocortex, hippocampus, piriform
CC       cortex, anterior thalamic nuclei, pontine nuclei, and granule cells of
CC       the cerebellum.
CC   -!- PTM: Palmitoylated (PubMed:28757145). Cys-85 appears to be the main
CC       site, and palmitoylation is required for membrane association (By
CC       similarity). {ECO:0000250|UniProtKB:P60879,
CC       ECO:0000269|PubMed:28757145}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.botulinum
CC       neurotoxin type A (BoNT/A, botA) which hydrolyzes the 197-Gln-|-Arg-198
CC       bond and inhibits neurotransmitter release (PubMed:15592454,
CC       PubMed:9886085). {ECO:0000269|PubMed:9886085,
CC       ECO:0000305|PubMed:15592454}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.botulinum
CC       neurotoxin type C (BoNT/C) which hydrolyzes the 198-Arg-|-Ala-199 bond
CC       and inhibits neurotransmitter release (PubMed:9886085,
CC       PubMed:17718519). C.botulinum type C only rarely infects humans.
CC       {ECO:0000269|PubMed:17718519, ECO:0000269|PubMed:9886085}.
CC   -!- PTM: (Microbial infection) Targeted and hydrolyzed by C.botulinum
CC       neurotoxin type E (BoNT/E) which hydrolyzes the 180-Arg-|-Ile-181 bond
CC       and inhibits neurotransmitter release (PubMed:9886085).
CC       {ECO:0000269|PubMed:9886085}.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 18 (CMS18) [MIM:616330]: A
CC       form of congenital myasthenic syndrome, a group of disorders
CC       characterized by failure of neuromuscular transmission, including pre-
CC       synaptic, synaptic, and post-synaptic disorders that are not of
CC       autoimmune origin. Clinical features are easy fatigability and muscle
CC       weakness affecting the axial and limb muscles (with hypotonia in early-
CC       onset forms), the ocular muscles (leading to ptosis and
CC       ophthalmoplegia), and the facial and bulbar musculature (affecting
CC       sucking and swallowing, and leading to dysphonia). The symptoms
CC       fluctuate and worsen with physical effort. CMS18 is an autosomal
CC       dominant presynaptic disorder clinically characterized by early-onset
CC       muscle weakness and easy fatigability associated with delayed
CC       psychomotor development and ataxia. {ECO:0000269|PubMed:25381298}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: When cloned and expressed in E.coli, where protein
CC       palmitoylation does not occur, Cys-85, Cys-88, Cys-90 and Cys-92 in the
CC       protein sequence readily form an iron-sulfur cluster.
CC       {ECO:0000269|PubMed:18375205}.
CC   -!- SIMILARITY: Belongs to the SNAP-25 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L19760; AAC37545.1; -; mRNA.
DR   EMBL; L19761; AAC37546.1; -; mRNA.
DR   EMBL; D21267; BAA22370.1; -; mRNA.
DR   EMBL; BT019684; AAV38490.1; -; mRNA.
DR   EMBL; AK223617; BAD97337.1; -; mRNA.
DR   EMBL; AK289647; BAF82336.1; -; mRNA.
DR   EMBL; AK314359; BAG36991.1; -; mRNA.
DR   EMBL; AL023913; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10346.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10349.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10350.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10352.1; -; Genomic_DNA.
DR   EMBL; BC010647; AAH10647.1; -; mRNA.
DR   CCDS; CCDS13109.1; -. [P60880-2]
DR   CCDS; CCDS13110.1; -.
DR   PIR; I53735; I53735.
DR   PIR; I67823; I67823.
DR   RefSeq; NP_001309831.1; NM_001322902.1. [P60880-2]
DR   RefSeq; NP_001309832.1; NM_001322903.1. [P60880-1]
DR   RefSeq; NP_001309833.1; NM_001322904.1. [P60880-1]
DR   RefSeq; NP_001309834.1; NM_001322905.1. [P60880-1]
DR   RefSeq; NP_001309835.1; NM_001322906.1. [P60880-1]
DR   RefSeq; NP_001309836.1; NM_001322907.1. [P60880-1]
DR   RefSeq; NP_001309837.1; NM_001322908.1. [P60880-1]
DR   RefSeq; NP_001309838.1; NM_001322909.1. [P60880-1]
DR   RefSeq; NP_001309839.1; NM_001322910.1. [P60880-1]
DR   RefSeq; NP_003072.2; NM_003081.4. [P60880-2]
DR   RefSeq; NP_570824.1; NM_130811.3. [P60880-1]
DR   RefSeq; XP_005260865.1; XM_005260808.4. [P60880-1]
DR   RefSeq; XP_016883510.1; XM_017028021.1. [P60880-2]
DR   RefSeq; XP_016883511.1; XM_017028022.1. [P60880-2]
DR   PDB; 1KIL; X-ray; 2.30 A; C=10-81, D=139-204.
DR   PDB; 1XTG; X-ray; 2.10 A; B=146-204.
DR   PDB; 2N1T; NMR; -; C=7-83, D=131-204.
DR   PDB; 3DDA; X-ray; 1.50 A; B=197-202.
DR   PDB; 3DDB; X-ray; 1.60 A; B=198-202.
DR   PDB; 3RK2; X-ray; 2.20 A; C/G=7-82, D/H=141-203.
DR   PDB; 3RK3; X-ray; 3.50 A; C=7-82, D=141-203.
DR   PDB; 3RL0; X-ray; 3.80 A; C/G/K/O/S/W/a/e=7-82, D/H/L/P/T/X/b/f=141-203.
DR   PDB; 3ZUR; X-ray; 2.71 A; A/B=145-206.
DR   PDB; 5W7I; X-ray; 2.10 A; B/D=111-120.
DR   PDB; 5W7J; X-ray; 2.20 A; B/D=111-120.
DR   PDB; 6JLH; X-ray; 2.37 A; B/D=154-170.
DR   PDBsum; 1KIL; -.
DR   PDBsum; 1XTG; -.
DR   PDBsum; 2N1T; -.
DR   PDBsum; 3DDA; -.
DR   PDBsum; 3DDB; -.
DR   PDBsum; 3RK2; -.
DR   PDBsum; 3RK3; -.
DR   PDBsum; 3RL0; -.
DR   PDBsum; 3ZUR; -.
DR   PDBsum; 5W7I; -.
DR   PDBsum; 5W7J; -.
DR   PDBsum; 6JLH; -.
DR   AlphaFoldDB; P60880; -.
DR   BMRB; P60880; -.
DR   SMR; P60880; -.
DR   BioGRID; 112500; 54.
DR   CORUM; P60880; -.
DR   DIP; DIP-34554N; -.
DR   IntAct; P60880; 62.
DR   MINT; P60880; -.
DR   STRING; 9606.ENSP00000254976; -.
DR   ChEMBL; CHEMBL2364159; -.
DR   DrugBank; DB00083; Botulinum toxin type A.
DR   DrugCentral; P60880; -.
DR   TCDB; 1.F.1.1.1; the synaptosomal vesicle fusion pore (svf-pore) family.
DR   iPTMnet; P60880; -.
DR   PhosphoSitePlus; P60880; -.
DR   SwissPalm; P60880; -.
DR   BioMuta; SNAP25; -.
DR   DMDM; 46397726; -.
DR   EPD; P60880; -.
DR   jPOST; P60880; -.
DR   MassIVE; P60880; -.
DR   MaxQB; P60880; -.
DR   PaxDb; P60880; -.
DR   PeptideAtlas; P60880; -.
DR   ProteomicsDB; 57231; -.
DR   ProteomicsDB; 57232; -. [P60880-2]
DR   Antibodypedia; 713; 1236 antibodies from 48 providers.
DR   DNASU; 6616; -.
DR   Ensembl; ENST00000254976.7; ENSP00000254976.3; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000304886.6; ENSP00000307341.2; ENSG00000132639.15. [P60880-2]
DR   Ensembl; ENST00000685131.1; ENSP00000508837.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000687785.1; ENSP00000510219.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000689757.1; ENSP00000509312.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000689858.1; ENSP00000510663.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000690812.1; ENSP00000509287.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000691161.1; ENSP00000510109.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000691353.1; ENSP00000509759.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000691665.1; ENSP00000508541.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000692411.1; ENSP00000508939.1; ENSG00000132639.15. [P60880-1]
DR   Ensembl; ENST00000693325.1; ENSP00000510558.1; ENSG00000132639.15. [P60880-1]
DR   GeneID; 6616; -.
DR   KEGG; hsa:6616; -.
DR   MANE-Select; ENST00000254976.7; ENSP00000254976.3; NM_130811.4; NP_570824.1.
DR   UCSC; uc002wnq.3; human.
DR   AGR; HGNC:11132; -.
DR   CTD; 6616; -.
DR   DisGeNET; 6616; -.
DR   GeneCards; SNAP25; -.
DR   HGNC; HGNC:11132; SNAP25.
DR   HPA; ENSG00000132639; Group enriched (brain, retina).
DR   MalaCards; SNAP25; -.
DR   MIM; 600322; gene.
DR   MIM; 616330; phenotype.
DR   neXtProt; NX_P60880; -.
DR   OpenTargets; ENSG00000132639; -.
DR   Orphanet; 98914; Presynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA35980; -.
DR   VEuPathDB; HostDB:ENSG00000132639; -.
DR   eggNOG; KOG3065; Eukaryota.
DR   GeneTree; ENSGT00950000182843; -.
DR   HOGENOM; CLU_096939_0_0_1; -.
DR   InParanoid; P60880; -.
DR   OMA; WKASEDG; -.
DR   OrthoDB; 388796at2759; -.
DR   PhylomeDB; P60880; -.
DR   TreeFam; TF315125; -.
DR   PathwayCommons; P60880; -.
DR   Reactome; R-HSA-181429; Serotonin Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-210500; Glutamate Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-212676; Dopamine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-264642; Acetylcholine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-449836; Other interleukin signaling.
DR   Reactome; R-HSA-5250968; Toxicity of botulinum toxin type A (botA).
DR   Reactome; R-HSA-5250971; Toxicity of botulinum toxin type C (botC).
DR   Reactome; R-HSA-5250992; Toxicity of botulinum toxin type E (botE).
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-888590; GABA synthesis, release, reuptake and degradation.
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   SignaLink; P60880; -.
DR   SIGNOR; P60880; -.
DR   BioGRID-ORCS; 6616; 7 hits in 1152 CRISPR screens.
DR   ChiTaRS; SNAP25; human.
DR   EvolutionaryTrace; P60880; -.
DR   GeneWiki; SNAP25; -.
DR   GenomeRNAi; 6616; -.
DR   Pharos; P60880; Tclin.
DR   PRO; PR:P60880; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P60880; protein.
DR   Bgee; ENSG00000132639; Expressed in pons and 147 other tissues.
DR   ExpressionAtlas; P60880; baseline and differential.
DR   Genevisible; P60880; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; ISS:HGNC-UCL.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:HGNC-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0001917; C:photoreceptor inner segment; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0098794; C:postsynapse; IEA:Ensembl.
DR   GO; GO:0042734; C:presynaptic membrane; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0097470; C:ribbon synapse; IEA:Ensembl.
DR   GO; GO:0031201; C:SNARE complex; IDA:UniProtKB.
DR   GO; GO:0036477; C:somatodendritic compartment; IEA:Ensembl.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0070032; C:synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex; IBA:GO_Central.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0005802; C:trans-Golgi network; IEA:Ensembl.
DR   GO; GO:0048306; F:calcium-dependent protein binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0008289; F:lipid binding; EXP:DisProt.
DR   GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt.
DR   GO; GO:0005484; F:SNAP receptor activity; IBA:GO_Central.
DR   GO; GO:0019905; F:syntaxin binding; IBA:GO_Central.
DR   GO; GO:0017075; F:syntaxin-1 binding; IPI:UniProtKB.
DR   GO; GO:0008306; P:associative learning; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; NAS:UniProtKB.
DR   GO; GO:0098967; P:exocytic insertion of neurotransmitter receptor to postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0006887; P:exocytosis; IBA:GO_Central.
DR   GO; GO:0051179; P:localization; EXP:DisProt.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0099590; P:neurotransmitter receptor internalization; IEA:Ensembl.
DR   GO; GO:0001504; P:neurotransmitter uptake; NAS:UniProtKB.
DR   GO; GO:0099525; P:presynaptic dense core vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:UniProtKB.
DR   GO; GO:0010975; P:regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0016081; P:synaptic vesicle docking; NAS:UniProtKB.
DR   GO; GO:0016079; P:synaptic vesicle exocytosis; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0031629; P:synaptic vesicle fusion to presynaptic active zone membrane; IBA:GO_Central.
DR   GO; GO:0016082; P:synaptic vesicle priming; IBA:GO_Central.
DR   GO; GO:0006906; P:vesicle fusion; IBA:GO_Central.
DR   CDD; cd15885; SNARE_SNAP25C; 1.
DR   CDD; cd15894; SNARE_SNAP25N; 1.
DR   DisProt; DP02561; -.
DR   Gene3D; 1.20.5.110; -; 2.
DR   InterPro; IPR039077; chord_SNAP-25_N_SNARE.
DR   InterPro; IPR000928; SNAP-25_dom.
DR   InterPro; IPR000727; T_SNARE_dom.
DR   PANTHER; PTHR19305; SYNAPTOSOMAL ASSOCIATED PROTEIN; 1.
DR   PANTHER; PTHR19305:SF5; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; 1.
DR   Pfam; PF00835; SNAP-25; 1.
DR   SMART; SM00397; t_SNARE; 2.
DR   SUPFAM; SSF58038; SNARE fusion complex; 2.
DR   PROSITE; PS50192; T_SNARE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Coiled coil;
KW   Congenital myasthenic syndrome; Cytoplasm; Disease variant;
KW   Intellectual disability; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Reference proteome; Repeat; Synapse; Synaptosome.
FT   CHAIN           1..206
FT                   /note="Synaptosomal-associated protein 25"
FT                   /id="PRO_0000213587"
FT   DOMAIN          19..81
FT                   /note="t-SNARE coiled-coil homology 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00202"
FT   DOMAIN          140..202
FT                   /note="t-SNARE coiled-coil homology 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00202"
FT   REGION          1..75
FT                   /note="Interaction with CENPF"
FT                   /evidence="ECO:0000250"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          111..120
FT                   /note="Interaction with ZDHHC17"
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   SITE            180..181
FT                   /note="(Microbial infection) Cleavage; by C.botulinum
FT                   neurotoxin type E (BoNT/E)"
FT                   /evidence="ECO:0000269|PubMed:9886085"
FT   SITE            197..198
FT                   /note="(Microbial infection) Cleavage; by C.botulinum
FT                   neurotoxin type A (BoNT/A, botA)"
FT                   /evidence="ECO:0000269|PubMed:9886085,
FT                   ECO:0000305|PubMed:15592454"
FT   SITE            198..199
FT                   /note="(Microbial infection) Cleavage; by C.botulinum
FT                   neurotoxin type C (BoNT/C)"
FT                   /evidence="ECO:0000269|PubMed:9886085,
FT                   ECO:0000305|PubMed:15592454"
FT   MOD_RES         138
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   MOD_RES         154
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   MOD_RES         187
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   LIPID           85
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   LIPID           88
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   LIPID           90
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   LIPID           92
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P60879"
FT   VAR_SEQ         58..89
FT                   /note="ERIEEGMDQINKDMKEAEKNLTDLGKFCGLCV -> DRVEEGMNHINQDMKE
FT                   AEKNLKDLGKCCGLFI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8056350,
FT                   ECO:0000303|PubMed:8112622, ECO:0000303|Ref.4"
FT                   /id="VSP_006186"
FT   VARIANT         67
FT                   /note="I -> N (in CMS18; interfers with calcium-induced
FT                   fusion; inhibits exocytosis of catecholamine-containing
FT                   vesicles; dbSNP:rs1555794286)"
FT                   /evidence="ECO:0000269|PubMed:25381298"
FT                   /id="VAR_073698"
FT   MUTAGEN         112
FT                   /note="V->A: Mildly decreased binding affinity for
FT                   ZDHHC17."
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   MUTAGEN         113
FT                   /note="V->A: Mildly decreased binding affinity for
FT                   ZDHHC17."
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   MUTAGEN         115
FT                   /note="S->A: No effect on ZDHHC17 binding."
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   MUTAGEN         116
FT                   /note="Q->A: Decreased binding affinity for ZDHHC17."
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   MUTAGEN         117
FT                   /note="P->A: Decreased binding affinity for ZDHHC17."
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   MUTAGEN         119
FT                   /note="R->A: No effect on ZDHHC17 binding."
FT                   /evidence="ECO:0000269|PubMed:28757145"
FT   MUTAGEN         152
FT                   /note="Q->A: Decreased cleavage by C.botulinum BoNT/C, no
FT                   change in cleavage by C.botulinum BoNT/A (botA)."
FT                   /evidence="ECO:0000269|PubMed:17718519"
FT   MUTAGEN         156
FT                   /note="I->E: Small decrease in affinity for C.botulinum
FT                   BoNT/A, increased efficiency of BoNT/C cleavage."
FT                   /evidence="ECO:0000269|PubMed:15592454,
FT                   ECO:0000269|PubMed:17718519"
FT   MUTAGEN         166
FT                   /note="D->A: Decreased cleavage by BoNT/C, no change in
FT                   cleavage by BoNT/A."
FT                   /evidence="ECO:0000269|PubMed:17718519"
FT   MUTAGEN         167
FT                   /note="M->E: Small decrease in affinity for C.botulinum
FT                   BoNT/A."
FT                   /evidence="ECO:0000269|PubMed:15592454"
FT   MUTAGEN         199
FT                   /note="A->R: Not cleaved by BoNT/C."
FT                   /evidence="ECO:0000269|PubMed:17718519"
FT   MUTAGEN         202
FT                   /note="M->Y: Slight decrease in affinity for BoNT/A,
FT                   increases kcat for BoNT/A."
FT                   /evidence="ECO:0000269|PubMed:15592454"
FT   CONFLICT        44
FT                   /note="I -> V (in Ref. 5; BAD97337)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..80
FT                   /evidence="ECO:0007829|PDB:3RK2"
FT   HELIX           148..167
FT                   /evidence="ECO:0007829|PDB:1XTG"
FT   STRAND          191..193
FT                   /evidence="ECO:0007829|PDB:1XTG"
SQ   SEQUENCE   206 AA;  23315 MW;  FBED2B082A4CB6A6 CRC64;
     MAEDADMRNE LEEMQRRADQ LADESLESTR RMLQLVEESK DAGIRTLVML DEQGEQLERI
     EEGMDQINKD MKEAEKNLTD LGKFCGLCVC PCNKLKSSDA YKKAWGNNQD GVVASQPARV
     VDEREQMAIS GGFIRRVTND ARENEMDENL EQVSGIIGNL RHMALDMGNE IDTQNRQIDR
     IMEKADSNKT RIDEANQRAT KMLGSG
//
